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Abstract 
Cancer is a group a diseases that involves abnormal cell growth with potential to invade or 
spread to other parts of the body, and it represents the second leading cause of death in developed 
countries.  
Cisplatin is one of the most chemotherapeutic drug. In spite of its great efficacy, it shows several 
side effects and most patients develop a resistance to cisplatin. To overcome the cisplatin resistance, 
drugs are often administered in combination in order to exploit the drug synergy. After discovery of 
cisplatin, the research focused on metal complexes less toxic, more effective and that exploit 
synergistic effect when used in combination.  
In this work I studied new copper, zinc and vanadium complexes with biological activity. I tested 
in vitro the studied compounds alone and in combination with drug currently in use against a panel 
of wild type tumour cell lines and their cisplatin-resistant sublines. I applied chemometric tools 
such as experimental design (ED) and artificial neural networks (ANNs) to the biochemical data 
collected. Finally, I used the artificial neural networks to evaluate the cell culture cross-
contamination. 
I selected a new family of copper(II) complexes with 1,10-phenanthroline (phen), 
1,10-phenanthrolin-5,6-dione (phendione), and 1,10-phenanthrolin-5,6-diol (phendiol) for the 
synthesis of new antiproliferative agents. Considering that the DNA is an important target for 
several cytotoxic metal complexes, I studied the interaction of these Cu(II) complexes with DNA. I 
tested the ligands and complexes against normal and tumour derived human cell lines.  
I tested combinations of the studied complexes and cisplatin for their potential synergistic effect 
against a panel of wild type tumour cell lines and their cisplatin-resistant sublines. I evaluated the 
selectivity of drug combinations testing the compounds also against ex vivo cultures of human 
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normal cell lines. Considering that the synergy may arise from a chemical reaction among the 
drugs, I studied the possible formation of new adducts between cisplatin, copper(II) complexes and 
glutathione. 
I studied the phospholipid profile of wild type human cancer cell lines and their 
cisplatin-resistant sublines, given that changes in lipid composition and distribution on the cell 
membranes have been observed in cancer cells. 
The in vitro cultured cell lines are widely used as model in biomedical research and the 
cross-contamination of cell lines represents a highly relevant problem. The ex-post discovery of 
erroneous results and conclusions led to paper retraction and many high-impact journals started to 
adopt a zero-tolerance policy requiring confirmation of cell line identity as prerequisite for 
publication. On the base of these considerations, I decided to develop and validate a method for 
evaluation of cell culture cross-contamination. 
I also studied zinc and vanadium complexes. Zinc is an essential metal ion involved in a wide 
variety of biological processes and several proteins bind zinc for their proper functioning. I studied 
zinc complexes with the drug methimazole (MeImHS) and its anion (MeImS) in order to provide 
information for the structure prediction and reactivity of Zn-metalloproteins and -metalloenzymes.  
Vanadium plays a number of roles in biological systems and vanadocene dichloride was the first 
discovered vanadium species with antitumour activity. Considering that the mechanism of the 
anticancer agent vanadocene dichloride is closely related to the biotransformation in the blood 
plasma, I studied the speciation of vanadocene dichloride in the plasma under physiological 
conditions. 
In order to prepare new metal complexes, I also synthesized and characterized a new group of 
Schiff base ligands derived from salicyladehyde and six natural amino acids. 
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For the analysis of the collected data, I used the ED to set up the experiments for the evaluation 
of the synergistic effect of drug combinations, and for the study of the possible formation of new 
adducts between cisplatin, glutathione and studied complexes. I used ANNs for predict and quantify 
the synergism of drugs, and for the evaluation of cell culture cross-contamination levels. 
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1 L-Salicylidenealanine  
2 L-Salicylidenevaline 
3 L-Salicylidenecysteine  
4 L-Salicylideneserine  
5 L-Salicylidenearginine  
6 L-Salicylidenehistidine  
A2780 Human ovarian carcinoma 
A2780-res Cisplatin-resistant subline of human ovarian carcinoma 
A2780-wt Wild type human ovarian carcinoma 
AE Addictive effect  
ANNs Artificial neural networks 
ATR-IR Attenuated Total Reflectance Infrared Spectroscopy 
C0  [Cu(phen)2(H2O)](ClO4)2 
C1 [Cu(phen)2(H2dit)](ClO4)2   
C10 [Cu(phen)(H2O)2(ClO4)2] 
CCRF-CEM Human acute T-lymphoblastic leukemia 
CCRF-CEM-res Cisplatin-resistant subline of human acute T-lymphoblastic leukemia 
CCRF-CEM-wt Wild type human acute T-lymphoblastic leukemia 
CCRF-SB Human acute B-lymphoblastic leukemia 
CDDP Cisplatin or cis-diammineplatinum(II) dichloride 
ct-DNA Calf thymus DNA  
DMSO Dimethyl sulfoxide 
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DMSO-d6 Hexadeuterodimethyl sulfoxide 
DU-145 Human prostate carcinoma  
E
0
 Electrode standard potential 
ED Experimental design 
ESI-MS Electro-Spray Ionisation at Atmospheric-Pressure Mass Spectrometry 
GSH Gluthathione 
GSSG Gluthathione disulfide 
H2dit Imidazolidine-2-thione 
hCtr1 Human copper transport protein 
Hep-G2 Human hepatocellular carcinoma  
hESCs Human embryonic stem cells 
His Histidine 
HLA Human leukocyte antigen 
hOCT2 Human organic cation transporter 2 
HTFA Trifluoroacetic acid 
I1 [Cu(phendiol)(H2O)2(ClO4)2]   
I2 [Cu(phendiol)2(H2O)](ClO4)2   
IC50 Concentration of compound required to reduce the viability of the tested cells by 50% 
K1 [Cu(phendione)(H2O)2(ClO4)2]   
K2 [Cu(phendione)2(H2O)(OClO3)](ClO4)   
Kb Binding constant 
MDT Multidrug therapy 
mEFs Mouse embryonic fibroblasts cells 
MeImHS Methimazole (1-methyl-3H-imidazole-2-thione) 
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mESCs mouse embryonic stem cells  
mp Melting points  
MTT 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-tetrazolium bromide  
NAAE Non-algebraic additive effect 
NMDEI Net multi-drug effect index 
NMR Nuclear Magnetic Resonance 
phen 1,10-phenanthroline 
phendione 1,10-phenanthrolin-5,6-dione  
phendiol 1,10-phenanthrolin-5,6-diol  
PIPES 1,4-piperazinediethanesulfonic acid 
pKw Water ionic product 
PL phospholipid 
RMS Root mean square 
ROS Reactive oxygen species  
SK-MES-1 Human squamous cell lung carcinoma 
SPE Solid phase extraction 
STR Short tandem repeat 
UV-vis  Ultraviolet-visible  
VDC or [Cp2VCl2] Vanadocene dichloride  
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Essential metal ions 
The study of the metal ions in biological systems represents a link between chemistry and living 
world (Figure 1). Given the importance of this topic, a programme on “the Chemistry of Metals in 
Biological Systems” was founded by the European Science Foundation in the 1990s.[1] Some metal 
ions are essential since they are involved in vital functions like respiration, circulation, 
reproduction, and are integral part of metabolic and biochemical enzymatic processes. The human 
body provides a complex series of homeostatic mechanisms that increase or decrease metal uptake 
and excretion in order to maintain its concentrations in physiological levels. In fact, at high 
concentration also essential  metal ions can became toxic.   
 
Figure 1. Metal ions as connection between chemistry and living world. 
 
Metals in medicine 
Metal ions and their compounds play an important role in medicine as therapeutic agents. Metals 
have been used to treat different human diseases since antiquity. Nowadays the number of metal-
based drugs is in continuous growing, involving a broad spectrum of metals. For example, several 
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platinum compounds are used to treat various types of cancers; zinc compounds are used as 
chelating agents; silver and its compounds are used as antimicrobial agents; and finally various gold 
compounds and lithium salts are used in the treatment of rheumatoid arthritis and bipolar disorder, 
respectively.  
 
Antitumor chemotherapy  
Cancer is a group of diseases that involves abnormal cell growth with the potential to invade or 
spread to other parts of the body. This disease represents the second leading cause of death in 
developed countries. Chemotherapy, surgery, radiation, hormonal and immune-therapy represent 
the most used treatments for cancer, depending on type, location, severity, and person’s health. The 
chemotherapy is the treatment of cancer with one or more cytotoxic anti-neoplastic drugs able to 
kill cancer cells or to inhibit their proliferation. The antitumor properties of 
cis-diammineplatinum(II) dichloride, cisplatin or CDDP (Figure 2), were discovered fortuitously in 
1965 by Rosenberg and colleagues
1
. 
[2]
  
 
Figure 2. Cisplatin (cis-diammineplatinum(II) dichloride or CDDP) was introduce in clinical 
practice in 1978. 
                                                 
1
 The “accidental” discovery of cisplatin was made when Barnett Rosenberg used platinum electrodes to apply an 
alternating electric field across a chamber in which bacteria E. coli were growing. Although bacterial cell growth 
continued, cell division was arrested. Additional studies were required to understand that the effective agent in blocking 
cell division in the bacteria was a platinum complex in solution, the cisplatin, electrolytically formed by the applied 
electric field. 
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In 1978, with the introduction of cisplatin in clinical practice, the real use of metal complexes in 
cancer therapy actually started. Many complexes with metal ions, such as ruthenium, gold, copper, 
silver or vanadium, have been designed, synthesized and tested in order to develop effective and not 
toxic drugs.
[3]
 
 
Cytotoxic activity of a drug 
In order to experimentally estimate the cytotoxic activity of a drug, the percentage of living cells 
after drug treatment is measured for each solution with respect to the control (untreated cells). This 
value represents the vitality but usually the data are expressed as mortality, i.e. 100% minus vitality. 
To compare the antiproliferative activities of different drugs, the concentration required to inhibit 
cell proliferation by 50%, with respect to untreated cells, is used (IC50). The IC50 values are 
determined from the dose-response curve by non-linear regression of the mortality % as a function 
of the drug concentration (Figure 3).   
 
 
Figure 3. Example of dose-response curves. 
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Cisplatin 
Cisplatin is one of the most powerful metal based chemotherapeutic agent, used alone or in 
combination for the treatment of several cancers, including testicular, ovarian, bladder, head and 
neck, esophageal, small and non-small cell lung, breast, cervical, stomach, and prostate cancers.
[4]
 
Cisplatin is administered intravenously due to its low chemical stability. It interacts with plasma 
proteins and 1 day after administration, is bound for 95% to different plasmatic proteins containing 
thiolic groups, thanks to the great affinity of platinum for the sulfur atom.
[5]–[7]
 The molecules of 
cisplatin enter the cells by passive diffusion and by active protein-mediated transport systems, in 
particular by human copper transport protein (hCtr1) and human organic cation transporter 2 
(hOCT2).
[8],[9]
 In cytoplasm, one chloride ligand is displaced by a water molecule to form the 
[Pt(Cl)(H2O)(NH3)2]
+
, this species interacts with DNA in the N7 position of guanine and adenine 
and in the N3 of cytosine, and forms the monofunctional adduct [Pt(Cl)(DNA)(NH3)2]
+
 (Figure 4). 
This last can hydrolyze to form the species [Pt(H2O)(DNA)(NH3)2]
+
. Both the monofunctional 
adduct and its hydrated form may re-interact with DNA by crosslinking forming the bifunctional 
adduct [Pt(NH3)2DNA]
+
. This last acts  triggering cellular apoptosis.
[10]
 Cisplatin can interact with 
DNA in several modes: 1,2-intrastrand cross-linking with two adjacent guanines (1,2-d(GpG));  
1,2-intrastrand cross-linking with an adenine and an adjacent guanine (1,2-d(ApG)); 1,3-intrastrand 
cross-linking with nonadjacent guanines, and finally by interstrand adducts.    
Despite the great efficacy of cisplatin, it shows high cytotoxicity also for normal tissues and 
causes several side-effects, as nausea and vomiting, neuro- and nephrotoxicity.
[11]
 Moreover, the 
efficacy of cisplatin therapy is often limited by the development of drug resistance. In fact, cancer 
cells may show an inherited or acquired resistance, and, in order to reach the therapeutic 
effectiveness, higher doses of the drug are required with a higher incidence of the side effects 
related to the doses. Among the main identified mechanisms of cisplatin resistance there are: 
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reduced cisplatin influx due to decreased levels of hCtr1
[12]
; an increased cisplatin efflux due to 
overexpression of copper-transporting protein ATP7B or multidrug resistance protein MRP-2
[13],[14]
; 
a higher deactivation by thiol-containing biomolecules, as glutathione (GSH) or thioredoxin
[15]–[17]
; 
and an increased capacity of DNA repair or inhibition of the apoptotic pathway.
[18]
 
 
 
Figure 4. Interaction of cisplatin with DNA. 
 
Glutathione 
One of the most abundant thiol-containing molecules in the human body is the glutathione, a 
tripeptide of the sequence γ-Glu-Cys-Gly. GSH is ubiquitous in biological fluids and prevents 
cellular damage caused by reactive oxygen species (ROS). GSH is in equilibrium with its oxidized 
 Introduction 
7 
 
form (GSSG) formed by two glutathione molecules bound with a disulfide bridge between the 
cysteine residuals (Scheme 1).  
 
 
 
GSH GSSG 
(2S)-2-amino-4-{[(1R)-1-
[(carboxymethyl)carbamoyl]-2-
sulfanylethyl]carbamoyl}butanoic acid 
(2S)-2-amino-5-[[(2R)-3-[(2R)-2-[[(4S)-4-
amino-5-hydroxy-5-oxopentanoyl]amino]-
3-(carboxymethylamino)-3-
oxopropyl]disulfanyl-1- 
(carboxymethylamino)-1-oxopropan-2-
yl]amino]-5-oxopentanoic acid 
 
Scheme 1. Formula and acronyms of glutathione (GSH) and its oxidized form (GSSG).   
 
In physiological conditions, the intracellular concentrations of GSSG is 1/10 of that of GSH. The 
GSSG is reduced to GSH by glutathione reductase. The glutathione depletion, i.e. the decrease of 
the normal ratio GSH/GSSG, is often correlated with cancer. It has been shown that in some kinds 
of cancer the level of GSH is lower than the physiological one.
[4]
 GSH is involved also in the 
elimination of xenobiotics and in the intra-, inter- and extracellular metal ion transport. GSH 
presents eight coordination sites (two carboxyls, one thiol, one amino and two pairs of carbonyls 
and amide donors within the peptide chain), and having N, O and S donor atoms, it is able to 
interact with both soft and hard metal ions.
[19]
 Since Pt(II) is a soft ion, it has more affinity towards 
a soft donor such as the sulfur atom of GSH than toward a hard one such as the nitrogen atoms of 
DNA bases. The cisplatin can react with GSH, resulting deactivated as drug.
[4]
 Actually, CDDP 
N
H
HOOC
NH2
O
H
N
O
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COOH
N
H
HOOC
NH2
O
H
N
O
S
COOH
H
N
COOH
NH2
O
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forms with GSH the bis-(glutathionato)-platinum [Pt(GS)2]
[20]
, however the formation of adducts 
with GSH is a controversial issue in literature.
[21]
 Since the increasing of GSH level is not 
associated to a decreasing in Pt(II)-DNA adducts in the tumor cells, it has been supposed that GSH 
plays a role in apoptotic regulatory pathways.
[22]
 Moreover, the increase of the GSH level inside the 
cells could enhance the sensibility of cancer cells to the CDDP, by increasing the number of copper 
transporters and then the drug uptake within the cell.
[23]
 
 
Copper complexes 
Copper-based complexes have been selected for the synthesis of new antitumour agents on the 
assumption that complexes with essential metal ions may be less toxic for normal cells than toward 
cancer ones.
[24]
 In human, copper concentration is regulated by the homeostatic system and in blood 
stream, it is transported by ceruloplasmin as Cu(I) and Cu(II) or by albumins and small molecules 
like histidine. Copper enters the cells via the hCtr1 (the same carrier protein exploited by 
cisplatin
[25],[26]
), and, inside the cell, copper is bound to a variety of ligands
[27]
 that prevent the 
interaction of the free copper ion with DNA, proteins or cellular membranes. Actually, the 
concentration of free Cu is kept < 10
-18
 M. The majority of the copper is complexed by GSH as 
Cu(I). The complex Cu(I)-GSH can donate copper to proteins such as metallothionein (proteins 
involved in metal detoxification) or chaperones (molecules involved in copper delivery).    
The study of Cu(II) complexes with nitrogen-containing ligands, such as 1,10-phenanthroline 
(phen) and 2,2’-bipyridine, started with the discovery of the antitumour properties of the 
[Cu(phen)2]
2+
 complex.
[28]
 This complex is able to cleave DNA and has been tested against several 
tumour cell lines.
[29],[30]
 Several copper-phen complexes have been then tested in vitro and in vivo, 
showing cytotoxic
[31]
, genotoxic
[32]
 and antitumoural activity.
[33]
 In the research group where I 
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prepared my PhD thesis, several copper(II) complexes containing two phenanthrolinic units and 
N,N’-substituted imidalidine-2-thione as auxiliary ligands, have been studied.[30],[34] The studied 
complexes exhibit IC50 values in the µM range against human acute T-lymphoblastic leukemia 
(CCRF-CEM), human acute B-lymphoblastic leukemia (CCRF-SB), human squamous cell lung 
carcinoma (SK-MES-1), and human prostate carcinoma (DU-145). For the SK-MES-1 cell line 
these copper complexes are more toxic than cisplatin, while for the other cell lines they are almost 
equally cytotoxic as cisplatin. It has been found a correlation between the polarity of the complexes 
and their citotoxic activity toward solid or liquid tumors. In fact, complexes with higher dipole 
moments resulted more active against the hematological cancer cells, while complexes with lower 
dipole moments, were more active against solid cancer cells. These results lead us also to assess that 
cultured cancer cells may reflect the physiological environment of the original organ from which 
they are derived.  
 
Multidrug therapy 
The multidrug therapy (MDT) was introduced as a modern approach in order to defeat the drug 
resistance, reduce the required dose and therefore the side effects. In MDT, two or more drugs are 
administered simultaneously to exploit their synergism. The combined drugs might show equal or 
different effects with respect to those of the individual drugs (addictive effect, AE). When the 
therapeutic effect of the drug combination is enhanced, the drugs act synergistically, when the 
overall effect is decreased, the drugs act antagonistically. The final effect of MDT depends on the 
kind of drugs and on their doses. The AE of two drugs was described at first by Webb and Bliss as 
algebraic summation of drug activities and a third term that takes into account the sequence of 
drugs.
[35][36]
 A new definition of AE, that is the non-algebraic additive effect (NAAE), was 
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introduced in 2013.
[37]
 The NAAE is a operational definition of the additive effect, not related to the 
number of drugs or to the action mechanism. The occurrence of synergism or antagonism of drugs 
is defined by the Net Multi-drug Effect Index (NMDEI). When the NMDEI assumes positive 
values, the net multidrug effect is synergistic. Otherwise, when the NMDEI assumes negative 
values, the net multidrug effect is antagonistic. The NMDEI can be also equal to zero, in this case 
the experimental activity of the multidrug mixture is equal to NAAE. 
 
Artificial neural network 
Artificial neural networks (ANNs) represent a robust and versatile mathematical tool for many 
applications in various fields. ANNs mimic the structure of the human brain as well as its 
“learning” and “generalization” ability. The basic units of ANNs are called “nodes” or “neurons”. 
They are organized in one “input” layer, in one or more “hidden” layers, and in one “output” layer. 
The i-th neuron in a layer is linked to all the j-th neurons in the next layer. Each connection is 
weighted with a weight wij. The ANN architecture is usually written as (a, b, c), where a, b, and c 
represent the number of neurons in the input, hidden, and output layer, respectively. An example of 
ANN architecture is given in Figure 5. 
The role of the neurons in the input layer is to receive the input data and transfer them to the 
neurons in the hidden layer through the weighed connections. The neurons in the hidden layer(s) 
perform mathematical operations on the incoming data (summation, addition of a “bias” term and 
transformation by a suitable mathematical function). The result is then transferred to the neurons in 
the output layer where the ANN output is calculated.  
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Figure 5. Example of ANN architecture (1 input layer, 1 hidden layer with three neurons, and 1 
output layer). The wij are weights assigned to each connection between the nodes (neurons). 
    
   The ANN “learning” is achieved by adjusting iteratively the values of connection weights in 
order to minimize the difference between ANN calculated output value (o
*
pk) and the experimental 
one (opk). This is done using a suitable mathematical rule called “training algorithm”. After each 
iteration, the root mean square of the sum of (opk - o
*
pk)
2
 residuals (RMS) is calculated. The weights 
are altered in order to minimize the RMS value (for a given ANN architecture). However, also the 
optimal ANN architecture must be searched for. It means that the optimal number of hidden layers 
and that of neurons therein have to be found too. The most common approach to find the optimal 
ANN architecture is to plot the RMS value vs. the number of neurons in the hidden layer(s). At first, 
as the number of neurons increases, the RMS value decreases. However, when an “optimal” number 
of neurons is reached, the RMS value is reduced and further increase of the number of neurons has 
no or little effect on it.  
The “generalization” ability of the network is its ability to predict the correct value of the output 
for input data not used for training. Such ability should be checked performing the so called 
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“verification” step. Most of the modern software tools allow to perform training and verification 
steps simultaneously. The “verification” step is stopped when acceptably low RMS value for the 
verification set is achieved. Afterwards, the network can be used for “predict” the response for 
“unknown” data sets.  
In order to obtain good results, the choice of the experimental data is fundamental. Besides, for 
practical reasons, the number of experiments should be as low as possible while providing a high 
content of information. Experimental design (ED) techniques can be useful for this purpose.
[38]
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Aim of the work 
The aim of the present work was to prepare and study new metal complexes with biological 
activity. In particular, I synthesized and characterized new copper, zinc and vanadium complexes. I 
tested in vitro the studied compounds alone and in combination with drug currently in use against a 
panel of tumour cell lines. I applied chemometric tools such as experimental design and artificial 
neural networks to the biochemical data achieved in the previous steps. Moreover, I used the 
artificial neural networks to evaluate the cell culture cross-contamination. 
I selected a new family of copper(II) complexes with 1,10-phenanthroline (phen), 1,10-
phenanthrolin-5,6-dione (phendione), and 1,10-phenanthrolin-5,6-diol (phendiol) for the synthesis 
of new antitumour agents. I studied the interaction of these Cu(II) complexes with DNA given that 
the DNA is an important target for several cytotoxic metal complexes. I tested the ligands and 
complexes against normal and cancer derived human cell lines.  
I tested combinations of the studied complexes and chemotherapeutic drugs currently in use for 
their potential synergistic effect against a panel of wild type cancer cell lines and their 
cisplatin-resistant sublines. I evaluated the selectivity of drug combinations testing the compounds 
also against human normal cell lines. I studied the possible formation of new adducts between 
cisplatin, copper(II) complexes and glutathione given that the synergy may arise from a chemical 
reaction among the drugs.  
Considering that changes in lipid composition and distribution on the cell membranes have been 
observed in cancer cells, I studied the phospholipid profile of wild type human cancer cell lines and 
their cisplatin-resistant sublines. 
Cross-contamination of cell lines represents a highly relevant problem in biomedical research. 
After the ex-post discovery of erroneous results and conclusions that led to paper retraction, many 
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high-impact journals started to adopt a zero-tolerance policy requiring confirmation of cell 
line identity as prerequisite for publication. On the base of these considerations, I decided to 
develop a rapid and routinely applicable method for evaluation of cell culture cross contamination. 
I studied complexes of zinc and vanadium. Zinc is an essential metal ion involved in a wide 
variety of biological processes, and several proteins bind zinc for their proper functioning. In order 
to provide information for the structure prediction and reactivity of Zn-metalloproteins and 
-metalloenzymes, I studied zinc complexes with (N,S)-donor molecules.  
Vanadium plays a number of roles in biological systems and vanadocene dichloride was the first 
discovered vanadium species with anticancer activity. I studied the speciation of vanadocene 
dichloride in the plasma under physiological conditions because the mechanism of the antitumour 
agent vanadocene dichloride is closely related to the biotransformation in the blood plasma. 
In order to prepare new metal complexes, I also synthesized and characterized a new group of 
Schiff base ligands derived from salicyladehyde and six natural amino acids. 
For the analysis of the acquired data, I used many chemometric tools. In particular I used the ED 
to set up the experiments for the determination of the synergistic effect of drug combinations, and 
for the study of the possible formation of new adducts between cisplatin, glutathione and studied 
complexes. I used ANNs for predict and quantify the synergism of drugs, and for the evaluation of 
cell culture cross-contamination levels.  
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Abstract 
Copper-based complexes have been selected for the synthesis of new antitumour agents on the 
assumption that complexes with essential metal ions, thanks to the homeostatic regulatory system, 
may be less toxic for normal cells than toward cancer cells. Copper(II) complexes containing 
1,10-phenanthroline (phen) and its derivatives show antitumour activity against several human 
derived tumour cell lines. The antiproliferative activity and the DNA binding of these complexes 
can be also modified by substitution in the phen backbone. From these considerations and results, I 
decided to study the antitumour activity and the DNA affinity of a new family of copper(II) 
complexes with phen, 1,10-phenanthrolin-5,6-dione (phendione), and 1,10-phenanthrolin-5,6-diol 
(phendiol). This study is reported in Chapter 1 - Article I. The formulas, names and abbreviations 
of the studied ligands and complexes are reported in Figure 6 and Table 1.  
 
 
Figure 6. Formulas, names and abbreviations of the studied ligands. 
 
The cytotoxic activity of the studied ligands and complexes have been tested
1
 in vitro against a 
panel of tumour and normal human cell lines. It was found that the studied compounds present 
antitumour activity higher than that of cisplatin towards the human hepatocellular carcinoma 
                                                 
1
 In collaboration with professor Alessandra Pani (Dipartimento di Scienze Biomediche, Università degli Studi di 
Cagliari). 
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(HEP-G2), squamous cell lung carcinoma (SK-MES-1), human acute T-lymphoblastic leukaemia 
(CCRF-CEM), and human acute B-lymphoblastic leukaemia (CCRF-SB). In particular, C0 and K2 
are promising for the treatment of SK-MES-1 and HEP-G2 cell line, respectively. These two 
complexes, in fact, show an IC50 value 37 and 18 times lower than that of cisplatin (Figure 7).  
 
Compound Abbreviations 
[Cu(phen)(OH2)2(OClO3)2] C10 
[Cu(phen)2(OH2)](ClO4)2 C0 
[Cu(phendione)(OH2)2(ClO4)2] K1 
[Cu(phendione)2(OH2)(OClO3)](ClO4) K2 
[Cu(phendiol)(OH2)2(ClO4)2] I1 
[Cu(phendiol)2(OH2)](ClO4)2 I2 
Table 1. Formulas and abbreviations of the studied complexes. 
 
 
Figure 7. Comparison of the cytotoxic activity of [Cu(phendiol)2(OH2)](ClO4)2 (I2), 
[Cu(phendione)2(OH2)(ClO3)](ClO4) (K2) and cisplatin against SK-MES-1 and HEP-G2 cell line. 
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The ligand cytotoxicity, although measured in vitro, appears related to the cellular 
microenvironment of the original organ, i.e. its lipophilicity or hydrophilicity. To discriminate the 
polarity and lipophilicity/hydrophilicity of the ligands, dipole moments in aqueous medium were 
calculated by quantomechanical calculations. It has been found that phendiol, the less lipophilic 
ligand, appears as the most active on cells surrounded by an hydrophilic environment, while 
phendione, the most lipophilic, is more effective against cells in a lipophilic environment 
(Figure 8). 
 
 
 
Figure 8. Relation between ligand cytotoxicity measured in vitro and cellular microenvironment 
(lipophilicity or hydrophilicity) of the original organ. 
 
Considering that the DNA is an important target for several cytotoxic metal complexes, that can 
bind DNA by covalent or non-covalent interactions, the reactivity of Cu(II) complexes towards 
DNA has been studied by UV-vis spectroscopy. It has been found that the prepared complexes 
interact with DNA by groove binding or electrostatic interactions. The most important result was 
that the DNA binding constants resulted directly correlated with IC50 values and then inversely 
correlated with the antitumour activity (Figure 9). In fact, the complexes with the highest DNA 
affinity show the lowest antitumour activity. In particular, C10, that presents the highest DNA 
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binding constant, shows the lowest cytotoxicity, while I2, that presents the lowest DNA binding 
constant, shows the highest antitumour activity. This behavior can be explained assuming that the 
copper complexes exhibit their antiproliferative activity with mechanisms different from the DNA 
binding. 
 
 
Figure 9. Trend of IC50 versus logarithm of the DNA-binding constant for CCRF-CEM (left) and 
CCRF-SB (right) cell lines.  
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DNA bindingThe cytotoxic properties of copper(II) complexes with 1,10-phenanthroline (phen) can bemodiﬁed by substitu-
tion in the phen backbone. For this purpose, Cu(II) complexes with phen, 1,10-phenanthrolin-5,6-dione
(phendione) and 1,10-phenanthrolin-5,6-diol (phendiol) have been synthesised and characterised. The crystal
structure of [Cu(phendione)2(OH2)(OClO3)](ClO4) is discussed. The complex formation equilibria between
Cu(II) and phen or phendione were studied by potentiometric measurements at 25 and 37 °C in 0.1 M ionic
strength (NaCl). The antitumour activity of the compounds has been tested in vitro against a panel of tumour
(DU-145, HEP-G2, SK-MES-1, CCRF-CEM, CCRF-SB) and normal (CRL-7065) human cell lines. The studied com-
pounds generally present an antiproliferative effect greater than that of cisplatin. The phen and phendione li-
gands present a similar antiproliferative effect against all the tested cells. Phendiol presents an antiproliferative
effect 1.3 to 18 times greater than that of phen or phendione for leukemic, lung, prostatic and ﬁbroblast cells,
while it presents less activity towards hepatic cells. Complexes with two ligands are more cytotoxic towards
all the tested cell lines than complexes with one ligand and are generally more cytotoxic than the ligand alone.
Complexes [Cu(phendiol)2(OH2)](ClO4)2 and [Cu(phendione)2(OH2)(OClO3)](ClO4) appear to be the most ac-
tive compounds for the treatment of SK-MES-1 and HEP-G2 cells, respectively, being at least 18 times more cy-
totoxic than cisplatin. The studied Cu(II) complexes are characterised by a strong DNA afﬁnity and were found
to interact with DNA mainly by groove binding or electrostatic interactions. The complexes appear to act on
cells with a mechanism different from that of cisplatin.
© 2014 Elsevier Inc. All rights reserved.1. Introduction
Copper is ametal ion essential for aerobicmicroorganisms, plants and
animals. It bindsmolecular oxygen in oxygen-transport proteins and par-
ticipates in electron transport [1]. In the human body the copper concen-
tration level is regulated by the homeostatic system. Copper has been
selected for the synthesis of new antitumour drugs since complexes con-
taining essentialmetal ions, thanks to the homeostatic regulatory system,
may produce less systemic toxicity than complexes with exogenous
metal ions. Copper(II) complexes with nitrogen ligands such as 1,10-
phenanthroline (phen) show cytotoxic activity against a panel of
human tumour cell lines [2–4]. Also complexes of 1,10-phenanthroline-
5,6-dione (phendione) with copper(II) show interesting cytotoxic activ-
ity against human kidney adenocarcinoma and human hepatocellular
carcinoma cell lines [5,6]. Many other phen derivatives, alone or in com-
plexes, have been tested for antitumour activity towards human ovariancarcinoma, melanoma and breast, colon, ovarian, renal and non-small-
cell lung cancers [7–10].
Being the DNA an important target for several cytotoxic agents, the
interaction of metal complexes containing phenanthroline derivatives
with DNA has also been studied. In fact, DNA offers multiple binding
sites and modes for covalent and non-covalent interactions. Cisplatin
binds covalently DNA [11], but most of the metal complexes bind DNA
by non-covalent interactions, i.e. by intercalation, groove bindings, elec-
trostatic forces and hydrogen bonds [12,13]. Some ruthenium com-
plexes with phenanthroline ligands cleave DNA via a proton-coupled
electron transfer mechanism [14]. The DNA-interaction modes can be
studied by UV–visible (UV–vis) absorption study as the intercalation is
associated with hypochromism and red shifting of the DNA adduct ab-
sorption bands, while groove binding and electrostatic interactions are
associated with hyperchromism [15]. The cytotoxic properties and the
DNA binding of copper(II) complexes with phen may be inﬂuenced
also by the substituents eventually present on the phen backbone.
In this work, a new family of copper(II) complexes with phendione
and 1,10-phenanthroline-5,6-diol (phendiol) has been synthesised
104 T. Pivetta et al. / Journal of Inorganic Biochemistry 141 (2014) 103–113and characterised by determining their chemical speciation in aqueous
media, as well as their cytotoxicity and their DNA binding properties.
Analogue series of complexes with phen was also prepared and studied
for comparison.
2. Experimental section
2.1. Reagents
Calf thymus DNA sodium salt, chloridric acid standard solutions,
copper(II) carbonate basic (Cu2(CO3)(OH)2), copper(II) chloride, di-
chloromethane, dimethyl sulphoxyde (DMSO), dithiooxamide, ethanol,
ethyl ether, ethylenediaminetetraacetic acid, isopropanol, nitric acid,
petroleum ether, perchloric acid, 1,10-phenanthroline monohydrate,
1,4-piperazinediethanesulfonic acid (PIPES), potassium bromide, potas-
sium hydroxide, sodium chloride, sodium hydroxide, sodium perchlo-
rate, sodium sulphate anhydrous and sulphuric acid were purchased
from Sigma-Aldrich and used without any further puriﬁcation. Caution:
perchlorate complexes are potentially explosive. Handle these com-
pounds in small quantities with care.
2.2. Synthesis
2.2.1. Preparation of 1,10-phenanthroline-5,6-dione (phendione)
An ice-cold solution of concentrated HNO3 (18 mL) and H2SO4
(35 mL) was added drop-wise to a mixture of phen (3.6 g, 18 mmol)
and KBr (3.2 g, 27 mmol) in an ice bath (Scheme 1). The mixture was
then reﬂuxed until dark-red vapours disappeared (approx. 4 h). The
light yellow solution was poured over 200 mL of ice and then neutral-
ized by addition of a saturated solution of KOH. The presence of a
white precipitate of inorganic salts was observed depending on solution
concentration. The solids were ﬁltered off and repeatedly washed with
CH2Cl2. The desired product was extracted from the aqueous solution
with fresh CH2Cl2. The extracted phases were combined with the por-
tions of CH2Cl2 used for washing. The remaining water was removed
with anhydrous Na2SO4. The yellow product phendione was recovered
by solvent evaporation under vacuum. Yield 82%. I.R. selected bands
(cm−1): 2959, 2927, 2874 C\H stretching (broad, medium strong);
1688 C_O stretching (sharp, medium); 1567, 1461, 1415 C_C
stretching (sharp, medium strong); and 813, 739, 623 C_C\H bendingScheme 1. Synthetic route for the preparation of 1,10-phenanthroline-5(sharp, medium). Elemental analysis: calc. C% 68.57, H% 2.88, N% 13.33,
found C% 68.65, H% 2.92, and N% 13.36.
2.2.2. Preparation of 1,10-phenanthroline-5,6-diol (phendiol)
An ethanol solution (15 mL) of phendione (0.1 g, 0.48 mmol) and
dithiooxamide (0.58 g, 0.48 mmol) was reﬂuxed for 16 h. The resulting
yellow solid was recovered by ﬁltration, washed in sequence with eth-
anol, CH2Cl2 and petroleum ether and air dried. Yield 82%. I.R. selected
bands (cm−1): 2966, 2927, 2718, 2622 C\H stretching (broad, strong);
1575, 1497, 1426 C_C stretching (sharp, medium strong); and 806,
739, 629 C_C\H bending (sharp, medium). Elemental analysis: calc.
C% 67.92, H% 3.80, N% 13.20, found C% 67.54, H% 3.84, N% 13.18.
2.2.3. Preparation of Cu(phendione)(OH2)2(ClO4)2 (K1)
Concentrated perchloric acid was added to an isopropanolic suspen-
sion of Cu2(CO3)(OH)2 (0.110 g, 0.50 mmol of copper, 10 mL) warming
under stirring till the complete dissolution of the salt was achieved. The
light blue solutionwas cooled at room temperature and an isopropanolic
solution of phendione (0.050 g, 0.24 mmol, 10mL)was added drop-wise
under stirring. The resulting light blue solution was left at room temper-
ature and a light blue product was recovered after solvent evaporation.
Yield 79%. I.R. selected bands (cm−1): 3400 O\H stretching (broad,
weak); 2955, 2927, 2853 C\H stretching (broad, weak); 1585, 1521,
1418 C_C stretching (sharp, medium strong); 1146, 1111, 1086 Cl\O
stretching of coordinating perchlorate group (broad, very strong); 852,
717 C_C\H bending (sharp, medium strong), 627 C_C\H bending
and OClO deforming (sharp, medium strong). Elemental analysis: calc.
C% 28.33, H% 1.98, N% 5.51, found C% 29.22, H% 2.01, and N% 5.48.
2.2.4. Preparation of [Cu(phendione)2(OH2)(OClO3)](ClO4) (K2)
Concentrated perchloric acid was added to an isopropanolic suspen-
sion of Cu2(CO3)(OH)2 (0.044 g, 0.20 mmol of copper, 10 mL) warming
under stirring till the complete dissolution of the salt was achieved. The
light blue solutionwas cooled at room temperature and an isopropanolic
solution of phendione (0.084 g, 0.40 mmol, 10mL)was added drop-wise
under stirring. The green precipitate of K2 was ﬁltered, washed with
isopropanol and dried under vacuum. The solid was dissolved in ethanol
and allowed to crystallise at room temperature. After four days green
crystals suitable for X-ray analysiswere recovered. Yield 81%. I.R. selected
bands (cm−1): 3450 O\H stretching (broad, weak); 2923, 2856 C\H,6-dione (phendione) and 1,10-phenanthroline-5,6-diol (phendiol).
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dium); 1146, 1093 Cl\O stretching non coordinating perchlorate group
(broad, very strong); 856, 725 C_C\Hbending (sharp,mediumstrong),
625 C_C\H bending and OClO deforming (sharp, medium strong). Ele-
mental analysis: calc. C% 41.13, H% 2.01, N%7.99, foundC%41.44, H%2.04,
and N% 7.95.
2.2.5. Preparation of Cu(phendiol)(OH2)2(ClO4)2 (I1)
Concentrated perchloric acid was added to an isopropanolic suspen-
sion of Cu2(CO3)(OH)2 (0.104 g, 0.47 mmol of copper, 10 mL) warming
under stirring till the complete dissolution of the salt was achieved. The
light blue solution was cooled at room temperature and an ethanolic
suspension of phendiol (0.100 g, 0.47 mmol, 10 mL) was added. The
dark green solution was reﬂuxed for half an hour and cooled at room
temperature. The dark green precipitate of I1was ﬁltered under vacu-
um, washed with isopropanol and petroleum ether and air dried. Yield
46%. I.R. selected bands (cm−1): 3400 O\H stretching (broad, strong);
3079, 2923, 2852 C\H stretching (broad, weak); 1086, 1070 Cl\O
stretching of coordinating perchlorate group (broad, very strong);
834, 809, 718 C_C\H bending (sharp, medium strong), 626 C_C\H
bending andOClO deforming (sharp,medium strong). Elemental analy-
sis: calc. C% 28.22, H% 2.37, N% 5.49, found C% 28.78, H% 2.22, and N%
5.42.
2.2.6. Preparation of Cu(phendiol)2(OH2)(ClO4)2 (I2)
Concentrated perchloric acid was added to an isopropanolic suspen-
sion of Cu2(CO3)(OH)2 (0.051 g, 0.23 mmol of copper, 10 mL) warming
under stirring till the complete dissolution of the salt was achieved. The
light blue solution was cooled at room temperature and an isopropanolic
suspensionof phendiol (0.098 g, 0.46 mmol, 10mL)was addeddropwise
under stirring. The dark green product obtained was ﬁltered under vacu-
um,washedwith isopropanol, and air dried. Yield 75%. I.R. selected bands
(cm−1): 2958, 2930, 2874 C\H stretching (broad, medium); 1606, 1514,
1432 C_C stretching (medium broad, medium); 1117, 1090 Cl\O
stretching non coordinating perchlorate group (broad, very strong);
820, 728 C_C\H bending (sharp, medium strong), 628 C_C\H bend-
ing and OClO deforming (sharp, medium strong). Elemental analysis:
calc. C% 40.90, H% 2.57, N% 7.95, found C% 41.25, H% 2.66, and N% 7.99.
2.2.7. Preparation of [Cu(phen)2(OH2)](ClO4)2 (C0) and [Cu(phen)(OH2)
2(OClO3)2] (C10)
The synthesis of C0 and C10were previously reported [2].
2.3. Determination of the crystal structure of K2
C24H14Cl2CuN4O13,M= 700.83 g/mol, orthorhombic, a= 14.174(3),
b= 16.440(3), c= 22.350(5) Å,U= 5208(2) Å3, T=293K, space group
Pbca (no. 61), Z = 8, μ = (Mo–Kα) 1.125 mm−1. 52,523 reﬂections
(8383 unique; Rint = 0.0282) were collected at room temperature in
the range 3.64° b 2ϑ b 63.30°, employing a 0.30 × 0.15 × 0.12mm crystal
mounted on a Bruker APEX II CCD diffractometer and using graphite-
monochromatized Mo–Kα radiation (λ= 0.71073 Å). Final R1 [wR2]
values are 0.0584 [0.2055] on I N 2σ(I) (all data). Datasetswere corrected
for Lorentz polarization effects and for absorption (SADABS, Siemens
Area-Detector ABSorption correction program, Bruker AXS Inc. Madison,
WI, USA 2000). The structure was solved by direct methods [16] and
was completed by iterative cycles of full-matrix least squares reﬁnement
on Fo2 and ΔF synthesis using the SHELXL-97 [17,18]. Hydrogen atoms,
with the exception of those of the water molecule, were located on the
ΔF maps and allowed to ride on the carbon atoms of the phendione li-
gand. Crystallographic data for compound K2 (excluding structure fac-
tors) have been deposited with the Cambridge Crystallographic Data
Centre as supplementary publication no. CCDC-977445. These data can
be obtained free of charge viawww.ccdc.cam.ac.uk/conts/retrieving.html.2.4. Biological assays
2.4.1. Compounds
Stock solutions of test compounds were prepared in DMSO at
100mMand stored at 4 °C in the dark. For evaluation of the cytotoxicity,
stocks were serially diluted in the growth media speciﬁc for each cell
line. In all experiments, the highest concentration of DMSO on cells
was 0.1%, corresponding to the maximum non-toxic dose of DMSO for
all cell lines.
2.4.2. Cell lines
All cell lines used in this study were purchased from the American
Type Culture Collection (ATCC, USA), and were stored in aliquots in liq-
uid nitrogen between the third to the fourth passage in culture. Cell
lines derived from human lung squamous carcinoma (SK-MES-1),
human prostate carcinoma (DU-145), and human hepatocellular carci-
noma (Hep-G2), were used as representative cells of solid cancers.
Human acute T-lymphoblastic leukaemia (CCRF-CEM) and human
acute B-lymphoblastic leukaemia (CCRF-SB) cell lines were used as rep-
resentative cells of hematologic tumours. A cell line established from
human normal skin ﬁbroblasts (CRL-7065) was used as a control cell
line to determine the degree of selectivity of each compound towards
neoplastic cells. All cell lines were cultured at 37 °C in a 5% CO2 atmo-
sphere in their speciﬁc media according to ATCC instructions, with 5–
10% foetal bovine serum (FBS), antibiotic, and, unless otherwise indicat-
ed, sodium pyruvate. Cell cultures were maintained in exponential
growth by periodically (one to two times/week) diluting high density
non-adherent cells (i.e. 106 cell/mL), or when monolayers of adherent
cells reached sub-conﬂuency (70–90% conﬂuence). All cell lines were
replaced every three–four months by freshly thawed cells from liquid
nitrogen collections. The absence of mycoplasma contamination was
checked periodically by the Hoechst staining method [19].
2.4.3. Cytotoxic assays
The cytotoxic effect of test compounds was evaluated in exponen-
tially growing cells. For adherent cells (i.e. SK-MES, DU-145, Hep-G2,
CRL-7065), 100 μL of cell suspensions at a density of 5 × 104 cells/mL
was seeded in each well of 96-well ﬂat bottomed plates. Cell cultures
were incubated overnight before the addition of 100 μL of growthmedi-
um (controls) or of 2× the ﬁnal concentrations of test compounds (four
replicates/concentration). For non-adherent cells (i.e. CCRF-CEM and
CCRF-SB), 100 μL of cell suspensions at a density of 1 × 105 cells/mL
was seeded in 96-well ﬂat bottomed plates, and equal volumes of
growth medium (controls) or of 2× the ﬁnal concentrations of each
compound (four replicates/concentration) were immediately added.
Cell viability was determined after 96 h (approximately three to four
cell divisions) of incubation at 37 °C, 5% CO2, by the 3-(4,5-dimethyl-
thiazol-2-yl)-2,5-diphenyl-tetrazolium bromide (MTT) method as pre-
viously described [20]. Cisplatin was used as reference drug [21–23].
The extent of cell viability at each drug concentration tested was
expressed as percentage of untreated controls. Dose–response curves
and concentrations resulting in 50% of cell viability of cells, compared
to the controls, were determined for each compound by non-linear
curve ﬁtting. All data reported represent the mean values ± SD of
three to four independent experiments.
2.5. DNA binding
The binding constants (Kb) between ct-DNA and the phen,
phendione and Cu(II) complexes were determined at 25 °C by spectro-
photometric titrationswith ct-DNA, in PIPES buffer 0.01Mat pH7.0. The
UV–vismeasurementswere carried out on anAgilent Cary 60 spectrom-
eter equipped with a ﬁbre optic dip probe (1 cm path length). A stock
solution of ct-DNA in 0.01 M PIPES buffer at pH 7.0 was stored at 4 °C
and used within four days. The concentration of DNA per nucleotide
was determined by UV absorption at 260 nmusing its molar absorption
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by monitoring the ratio of the absorbance at 260 nm to that at
280 nm. A ratio higher than 1.8 indicated a DNA sufﬁciently protein-
free [25].
Two sets of solutions were prepared: i) thirty solutions containing a
ﬁxed amount of ligand or metal complex (ranging from≈ 1.5 × 10−6
to≈ 8 × 10−5 mmol, according to compound absorptivity) and variable
amounts of DNA (ranging from 4.5 × 10−5 to 2.4 × 10−4 mmol, DNA/
complex molar ratio from 0 to 3); ii) twenty solutions containing a
ﬁxed amount of ligand or metal complex (ranging from≈ 6.5 × 10−6
to≈ 3.6 × 10−5 mmol, according to compound absorptivity) and vari-
able amounts of DNA (ranging from 6.5 × 10−5 to 3.6 × 10−4 mmol,
DNA/complex molar ratio from 0 to 10). All the solutions were stored
in the dark at room temperature. The hydrolysis of the copper com-
plexes as well as the interaction between DNA and ligands were slow
processes. Therefore, spectra in the 200–400 nm range were recorded
after equilibration was reached. This was checked spectrophotometri-
cally, by determining the time after which further changes in UV–vis
spectra were not observed (≈15 h).
The number of linearly independent absorbing specieswas obtained
by applying the eigenvalues analysis on the absorbance datamatrix [26,
27]. Binding constants were obtained by using the Hyperquad 2003
program [28].
2.6. Potentiometric study
Potentiometric titrations were carried out in a thermostatted vessel
with a Mettler-Toledo Seven Compact pH/Ion-meter equipped with a
Mettler-Toledo InLab Micro Pro combined glass electrode with an inte-
grated temperature probe. Potentiometric titrations were performed at
25 and 37 °C in 0.1 M ionic strength (NaCl) under N2 atmosphere. The
glass electrode was calibrated daily by titration of a known amount of
HCl with carbonate-free NaOH solution prepared according to Albert
[29]. Electrode standard potential (E0), water ionic product (pKw), elec-
trode response and carbonate content of the titrant solution were
checked with Gran's procedure [30] using the Glee program [31].
The copper(II) stock solution was prepared by dissolving the proper
amount of CuCl2 salt in 0.01MHCl aqueous solution (pH≈ 2, copper(II)
concentration≈ 5 × 10−3 M). Themetal content was determined by ti-
tration with EDTA [32]. A solution of phendione was prepared daily by
dissolving the proper amount of the compound in freshly distilled
water (concentration of phendione ≈ 4 × 10−3 M). Due to its low
water solubility, phen (≈0.03 g) was dissolved in 20 μL of DMSO. The
resulting solution was diluted with freshly distilled water up to 20 mL.
The mixing of the two solvents was favoured by gentle shaking and
heating (avoiding sonication to prevent emulsion formation). For the
potentiometric titration, approx. 3 mL of this stock solution was diluted
up to 20 mL with aqueous solution, so that the DMSO content in the ti-
tration vessel was never higher than 0.015% (ﬁnal concentration of
phen≈ 5 × 10−3 M).
Ligand protonation constants were determined by titrating solu-
tions containing a known amount of ligand and three (for phen) or
ﬁve (for phendione) equivalents of HCl permole of ligand. Complex for-
mation constants between phen or phendione with Cu(II) were deter-
mined by titrating solutions with 3:1, 2:1 and 1:1 ligand:metal molar
ratios. The hydrolysis of the metal ion was studied at 1.0 × 10−3 M,
5.0 × 10−4 M and 3.3 × 10−4 M concentrations. The reversibility of all
the studied equilibria was checked by back-titration with standard
HCl. The overall stability constants were determined with the
Hyperquad2003 program [28].
2.7. Computation
The quantomechanical calculations were performed on a dual core
INTEL i-7 CPU with the “SPARTAN'06” program for Windows
(Wavefunction Inc); geometries were optimized using ab-initiomethods with 6–31G++ Gaussian basis sets [33,34]; dipole moments
were calculated using semi-empirical methods with AM1/SM2 basis
sets [35].
3. Results and discussion
3.1. Synthesis
The ligands phendione and phendiol were synthesised (Scheme 1)
by slight modiﬁcations of previously reported syntheses [36,37]. A less
toxic solvent was preferred for the extraction and washing steps. Com-
pound phendiol is slightly soluble in themost common solvents such as
CH3CN, CH2Cl2, DMSO, dimethylformamide, ethanol, isopropanol, pe-
troleum ether and water. Despite the presence of two hydroxyl groups,
its solubility in polar solvents is reduced due to the formation of poly-
mers. Phendiol is water soluble at basic pH but is rapidly and irrevers-
ibly oxidised.
Complexes Cu(phen)(OH2)2(ClO4)2 (K1), [Cu(phendione)2(OH2)
(OClO3)](ClO4) (K2), Cu(phendione)(OH2)2(ClO4)2 (I1), and
Cu(phendione)2(OH2)(ClO4)2 (I2) are novel. No polynuclear com-
plexes with phendione or phendiol were obtained, not even in an ex-
cess of Cu(II) salt. All the complexes are stable in the solid state at
room temperature. Suspensions of I1 and I2 are stable in the dark
at 4 °C for one week. In compounds K1 and I1, one ligand is present
like in C10, while two ligands are present in compound I2, as in C0.
The I.R. spectra of K1 and I1 show the signals of coordinating perchlo-
rate groups, while the I.R. spectrum of I2 shows the signals of uncoordi-
nated perchlorate groups. By analogy with the reported structures of
C10 and C0 [2], the molecular formulas [Cu(phendione)(OH2)
2(OClO3)2], [Cu(phendiol)(OH2)2(OClO3)2] and [Cu(phendiol)2(OH2)]
(ClO4)2 for K1, I1 and I2 are proposed.
3.2. Crystal structure
The asymmetric unit of K2 contains Cu(phendione)2(OH2)(OClO3)+
cations with the copper atoms in a distorted tetragonal bypiramidal co-
ordination and an additional perchlorate anion (Fig. 1). Selected bond
lengths and angles are reported in Table 1. The Cu\O2 distance in the
perchlorate coordinated at the apical position is longer than typical
Cu\O bond lengths of about 1.95 Å, but lies in the 2.3–2.8 Å range ob-
served for complexes with Jahn–Teller distortion (mean axial Cu\O
bond lengths for Jahn–Teller distorted complexes are about 2.48 Å).
The axially-coordinated perchlorate displays an additional intramolecu-
lar hydrogen bond with the equatorial water molecule [O4⋯Ow
3.076(9) Å]. The other perchlorate interacts with the water molecule
only through an intramolecular hydrogen bond O8⋯Ow of 2.698(8) Å.
No other interactions below the sum of the van der Waals radii are ob-
served. One of the two phendione ligands occupies two equatorial posi-
tions of the octahedronwith atomsN1 andN2, whereas the other one is
coordinated at one equatorial position through N4 and at one apical po-
sition through N3. The copper atom is about 0.20 Å displaced from the
average coordination plane deﬁned by atoms N1, N2, N4 and Ow, to-
wards the apical position N3. The dihedral angle between the two nitro-
gen ligands is 78.6°. A comparison can be donewith the structure of the
similar complex [Cu(phen)2(H2O)](ClO4)2 [2,38], where instead the co-
ordination of the copper ion is closer to a trigonal bipyramidal geometry
and no perchlorate anion interacts with the metal ion. With respect to
this compound the Cu\Ow distance is deﬁnitely shorter in our case
(2.026(3) Å vs. 2.245(4) Å), whereas the Cu\N distances are larger
[range 2.003(2)–2.187(3) 1.993(2) Å vs. 1.980(4)–2.032(3) Å)]. A
structure similar to that of K2 was reported for [Co(phendione)2Cl2]Cl
where the central Co(III) ion is hexacoordinated with distorted octahe-
dral geometry. The mean Co\N bond length is 1.944(3) Å which is
shorter than the Cu\Nbond length inK2 [39]. Differently, in the crystal
structures of [Cu(phendione)2(NO3)]NO3·CH3CN or [Cu(phendione)
2Br]Br·2CH3CN, the copper ion is coordinated by two phendione
Table 2
Antiproliferative activity of the test compounds against six different cell lines. The stan-
dard deviation on the last signiﬁcant ﬁgure is given in parentheses.
Compound IC50[a] (μM)
CRL-
7065[b]
DU-
145[c]
HEP-
G2[d]
SK-MES-
1[e]
CCRF-
CEM[f]
CCRF-
SB[g]
Phen 2.3 (1) 2.30 (5) 1.7 (2) 2.60 (4) 2.70 (2) 1.20 (1)
Phendione 1.90 (2) 2.16 (2) 1.60 (2) 1.90 (1) 2.90 (1) 0.95 (1)
Phendiol 1.80 (2) 0.79 (1) 2.90 (1) 0.47 (1) 0.15 (1) 0.145 (4)
C10 N5 2.6[i] 2.90 (3) 1.9[j] 3.2[j] 1.4[i]
K1 6.30 (1) 4.10 (1) 1.70 (2) 3.10 (1) 3.80 (2) 1.21 (1)
I1 3.10 (1) 4.00 (2) 3.60 (1) 2.25 (2) 0.18 (1) 0.20 (1)
C0 2.20 (3) 1.6[i] 1.05 (1) 0.93[i] 1.25[i] 0.50[i]
K2 2.47 (2) 1.16 (2) 0.67 (2) 1.20 (1) 0.80 (2) 0.42 (1)
I2 1.34 (3) 0.93 (1) 1.20 (1) 0.54 (1) 0.090 (4) 0.070 (3)
6-MP[h] – 2.0 (1) – N 100 2.0 (2) 0.70 (8)
Cisplatin – 2.0[k] 12.0[l] 20.0[m] 0.95 1.38
[a] compound concentration required to reduce the viability by 50%, as determined by
the MTT method.
[b] CRL-7065 skin ﬁbroblasts.
[c] DU-145 human prostate carcinoma.
[d] HEP-G2 human hepatocellular carcinoma.
[e] SK-MES-1 squamous cell lung carcinoma.
[f] CCRF-CEM human acute T-lymphoblastic leukaemia.
[g] CCRF-SB human acute B-lymphoblastic leukaemia.
[h] 6-MP 6-mercaptopurine.
[i] From Ref. [2].
[j] From Ref. [4].
[k] from Ref. [21].
[l] From Ref. [22].
[m] From Ref. [23]. Values represent the mean ± SD of at least three independent
experiments.
Fig. 1. Crystal structure of K2 complex.
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ramidal geometry [40]. An example of crystal structure of a metal
complex with phendiol is [(di-tert-butylbipyridine)2Ru(phendiol)Pt(di-
tert-butylbipyridine)](PF6)2, where phendiol molecule acts as a linker
between Ru(di-tert-butylbipyridine)2- and Pt(di-tert-butylbipyridine)-
units [37].
3.3. Dipole moments of ligands
The low water solubility of phendiol prevents accurate determina-
tion of its octanol/water partition coefﬁcient. Thus, to discriminate the
polarity and lipophilicity/hydrophilicity of the ligands, dipole momentsTable 1
Selected bond lengths (Å) and angles (deg) for K2. In parenthesis the standard deviation
on the last signiﬁcant ﬁgure is reported.
Atom1 Atom2 Length
Cu N1 2.040 (2)
Cu N2 2.003 (2)
Cu N3 2.187 (3)
Cu N4 2.019 (2)
Cu OW 2.026 (3)
Cu O2 2.667 (4)
Atom1 Atom2 Atom3 Angle
N1 Cu N2 81.6 (1)
N1 Cu N3 101.28 (9)
N1 Cu N4 97.7 (1)
N1 Cu OW 160.2 (1)
N1 Cu O2 77.0 (1)
N2 Cu N3 106.11 (9)
N2 Cu N4 175.4 (1)
N2 Cu OW 89.9 (1)
N2 Cu O2 85.9 (1)
N3 Cu N4 78.5 (1)
N3 Cu OW 98.2 (1)
N3 Cu O2 167.6 (1)
N4 Cu OW 89.3 (1)
N4 Cu O2 89.5 (1)
OW Cu O2 84.6 (1)in aqueous medium were calculated by quantum mechanical calcula-
tions. The calculated dipole moments for the three ligands are in the
following order: phendiol (3.52 Debye) N phen (3.42 Debye) N
phendione (3.11 Debye).
3.4. Cytotoxic activities
The antiproliferative activities of the studied ligands and complexes
are expressed as IC50, i.e. the concentration of compound required to re-
duce the viability of the tested cells by 50% (Table 2).
3.4.1. Phen, phendione and phendiol ligands
The phen and phendione ligands present very similar antiprolifera-
tive effects against all the tested cells (Fig. 2). For phen the IC50 value
ranges from 1.20 to 2.70 μM, while for phendione it ranges from 0.95
to 2.90 μM. Both compounds are more active against CCRF-SB leukemic
cells. The phendiol compound presents an antiproliferative effect from
1.3 to 18 times greater than that of phen or phendione for leukemic,
lung, prostatic andﬁbroblast cells, while it presents less activity towards
hepatic cells. The cellular microenvironment appears related to the cy-
totoxicity shown by the ligands. In fact, their different activities on
solid and/or haematological cancer cells can be explained in terms of
the lipophilicity or hydrophilicity of the compound and the target cells.
The tested cells are derived from human organs characterised by dif-
ferent physical–chemical conditions. In prostate, blood and lungs themi-
croenvironment is mainly hydrophilic while in liver and ﬁbroblasts it is
mainly lipophilic.1 However, the phenotype, metabolic reactions and1 Prostatic cells produce a slightly acidic solution containing citric acid, spermine and
spermidine, acid phosphatase, protease serum, prostate-speciﬁc antigen, calcium, zinc, so-
dium and dihydrotestosterone. Liver is involved with carbohydrate and lipid metabolism,
cholesterol synthesis and triglyceride production. Plasma (55 % of blood ﬂuid) contains
water, dissipated proteins, glucose, mineral ions, hormones, and blood cells themselves.
Lungs, involved in the CO2/O2 exchange, contain blood and aqueous vapour. Fibroblasts
produce collagen, glycosaminoglycan, ﬁbres and glycoproteins that are constituents of
the extracellular material.
Fig. 2. Doses (IC50 values, μM) of the studied complexes required to reduce the viability by 50%, as determined by the MTT method. CRL-7065 skin ﬁbroblasts; DU-145 human prostate
carcinoma; HEP-G2 human hepatocellular carcinoma; SK-MES-1 squamous cell lung carcinoma; CCRF-CEM human acute T-lymphoblastic leukaemia; CCRF-SB: human acute B-
lymphoblastic leukaemia.
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cultured cells. In our case, the experimental results, i.e. the different activ-
ities shown by the ligands, indicate that microenvironmental conditions
in the cell lines reﬂect those of the original organ from which they were
derived. This phenomenon has also been observed in other studies, for
example in terms of pH and vacuolar-H-ATPase expression [41]. The
less lipophilic ligand, phendiol, is preferentially active against cells in a
hydrophilic environment, while the most lipophilic ligand phendione is
more effective than phendiol against cells in a lipophilic one.
3.4.2. Copper(II) complexes
The cytotoxicity of the studied copper(II) complexes (Fig. 2) ismain-
ly due to the presence of the nitrogen containing ligands, the metal ionbeing devoid of relevant antiproliferative activity (IC50 N 100 μM). Com-
plexeswith one ligand (C10, K1 and I1) exhibit an antiproliferative
activity generally lower than that of the ligand alone (phen,
phendione and phendiol, respectively) on all tested cell lines. The
C10, K1 and I1 compounds present the highest cytotoxic activity
against CCRF-SB cells and the lowest towards CRL-7065 and DU-
145 cells. Complexes with two ligands (C0, K2 and I2) are more
cytotoxic towards all the tested cell lines than the related com-
plexes with one ligand (C10, K1 and I1, respectively) and are gen-
erally more cytotoxic than the ligand alone (phen, phendione and
phendiol, respectively). The C0, K2 and I2 compounds present the
highest cytotoxic activity against CCRF-SB and the lowest towards
CRL-7065 cells.
Fig. 3. Absorptivity spectra of adducts formed between DNA and the studied compounds
(25 °C, 0.01 M PIPES buffer, pH = 7.0).
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antiproliferative activities against normal and cancerous cells that be-
long to different lineages, the parallel could be useful in estimating the
possible selectivity of a compound, i.e. the ability of the drug to discrim-
inate between normal and cancerous cells. The potential selectivity, cal-
culated with respect to the normal ﬁbroblasts, varies from 1.7 to 3.6 for
C10, from 1.4 to 4.4 for C0, from 1.5 to 5.2 for K1, from 2.1 to 5.9 for K2,
from 0.78 to 17.2 for I1 and from 1.1 to 19.1 for I2. From all these results
I2 appears as the most active compound for the treatment of leukemic
(CCRF-CEM and CCRF-SB), lung (SK-MES-1) and prostatic (DU-145)
cancer cells, while K2 is eligible for the treatment of hepatic (HEP-G2)
ones.
3.5. DNA binding constants
The intrinsic binding constants of the adducts formed by ct-DNA and
the studied compounds were evaluated by spectrophotometric titra-
tions. The binding constants of phendiol were not studied because of
the poor solubility of the ligand in PIPES. The UV–vis spectra of the syn-
thesised copper(II) complexes exhibit bands at≈800 nm (d–d transi-
tions, ε≈ 100 M−1 cm−1) and at ≈270 nm (ligand-to-metal charge
transfer (LMCT) transitions, ε≈ 50,000M−1 cm−1). Due to the low ab-
sorption at 800 nm, only the changes in the LMCT bands were followed
during the titrationswith DNA. In the absorbance spectra of C10,K1 and
C0 two peaks (at≈ 225 and 275 nm) and a shoulder (at≈ 295 nm) are
present. In the spectrum of K2 two pairs of overlapping peaks (at 260
and 272 nm and at 226 and 232 nm) and a shoulder (at 295 nm) are
evident.
In the absorbance spectrum of I1 a wide band is present at 267 nm
and, ﬁnally, in the spectrum of I2 two partially overlapping bands are
present at 258 and 280 nm. The UV spectra of phen and phendione
show peaks at 266 nm and 254 nm, respectively.
By titrating the ligands and Cu(II) compounds with DNA, the follow-
ing trends were shown:
• the absorbance increases without a signiﬁcant shift in the maximum
wavelength for phen and phendione;
• for DNA:Cu(II) molar ratios in 0–3 range:
o the absorbance increases without a signiﬁcant shift in the maxi-
mum wavelength for C10, K1, K2 and I2;
o the absorbance increases with a signiﬁcant shift in the maximum
wavelength for I1 (from 267 to 259 nm);
o the absorbance decreases without a signiﬁcant shift in the maxi-
mum wavelength for C0;
• for Cu(II):DNA molar ratios N 3:
o the absorbance increases with a signiﬁcant shift in the maximum
wavelength for all the complexes (from≈270 to 260 nm).
Selected spectra recorded during the titrations are reported in
Supporting Information (Fig. S1).
For the studied systems, hyperchromism is evident for all the com-
pounds except for C0. However, the extent of the hyperchromism/
hypochromism noted and the shift towards higher wavelengths is af-
fected by the presence of excess DNA, whose spectrum is characterised
by a wide band centred at 260 nm. For this reason direct inspection of
the experimental spectra to determine if hyper- or hypochromism is re-
ally present may lead to inaccurate results. Therefore, to assign the cor-
rect interaction mode, the pure spectra of the involved species were
compared.
From eigenvalue analysis of spectrophotometric data, three signiﬁ-
cant eigenvalues were found. These can be interpreted as the number
of linearly independent absorbing species [27]. In our case, such species
are the free DNA, the free ligand or copper complex, and the related
DNA adduct. The absorbance data were ﬁtted supposing a model taking
into account the 1:1 DNA:ligand or DNA:copper complex adduct, and
the pure spectra of all the absorbing species were calculated (Fig. 3).
The obtained absorptivity spectra show hyperchromism in all thetitrations, suggesting that ligands and complexes interact with DNA
principally by groove binding or electrostatic interaction. A blue shift
in the absorbance maximum is revealed for K2 (from 272 nm to
261 nm), while for the other complexes no signiﬁcant shift is evident
(Table 3).
The extent of the hyperchromism is related to the kind of DNA inter-
action [42,43] and varies along the series: K2–DNA (135%) N C10–DNA
(108%) N I1–DNA (58%) ≈ I2–DNA (56%) N K1–DNA (47%) N phen
(36%) N C0–DNA (28%) N phendione (22%). In particular, K2 and C10
present the highest DNA afﬁnity through groove binding or electrostatic
interaction, while I2, K1 and I1 exhibit lower afﬁnities. The high
Table 3
DNA binding constants and spectral data for the studied compounds (25 °C, in PIPES buffer 0.01 M, pH = 7.0).
Compound DNA binding constants
(M−1)
λmax
(nm)
εmax
(M−1 L−1)
Ref.
Phen – 266 20,524 This work
Phen–DNA 2.29 (1) × 106 266 27,861 "
Phendione – 256 22,975 "
phendione–DNA 7.76 (1) × 104 256 28,019 "
C10 – 272 13,114 "
C10–DNA 1.9 (1) × 105 270 27,236 "
K1 – 273 14,943 "
K1–DNA 1.8 (2) × 105 273 21,902 "
I1 – 267 10,876 "
I1–DNA 5.5 (1) × 104 263 17,145 "
C0 – 273 43,916 "
C0–DNA 8.3 (1) × 104 273 56,432 "
K2 – 272 32,373 "
K2–DNA 7.2 (1) × 104 261 75,980 "
I2 – 256 23,901 "
I2–DNA 2.8 (1) × 104 258 37,329 "
[Cu(phen)2(branched polyethyleneimine)]Cl2. 4H2O 5.95 × 105 – – [49]
Cu(phen)2Cl2 2.75 × 103 – – [50]
Cu2(phen)2Cl4 4.79 × 104 – – [51]
[Cu(L-phenylalanine) (phen)(H2O)](NO3) 3.6 (1) × 105 – – [52]
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not intercalate or intercalate just partially. This is in agreementwith the
results reported by Chikira and co-workers [44] for C10. The low per-
centage of hyperchromism shown for phen and phendione is due to
their ability to intercalate. The low hyperchromism shown by C0 could
be due to a possible partial DNA intercalation. In fact, it has been report-
ed that bis(1,10-phenanthroline) copper(II) complexes apparently bind
to DNA by intercalation but the correct binding mode is still controver-
sial [45,46]. Furthermore, in the copper(I) complex [Cu(phen)2]+ the
phen ligands are roughly perpendicular to each other, so complete in-
tercalation of the phen ring between a set of adjacent base pairs is steri-
cally impossible, but some type of partial intercalation involving one of
the ligands can be presumed [47]. Similar considerations may also be
proposed for C0, [Cu(phen)2(OH2)]2+, where a trigonal bypiramidal co-
ordination around Cu(II) is present. It is worthwhile remarking that the
action of the [Cu(phen)2(OH2)]2+ complex on DNA, besides intercala-
tion, is due to an oxidative attack on the deoxyribose units that cleaves
the DNA strand leading to cell death [48].
The magnitude of the DNA binding constants is related to the
strength of the interaction, independently of the bindingmode. The cal-
culated constants (Table 3) vary along the series: C10–DNA ≈ K1–
DNA N I1–DNA N C0–DNA N K2–DNA N I2–DNA. The obtained values
are in agreement with binding constants reported in the literature for
similar compounds [49–52].
The DNA binding constants for the studied copper(II) complexes ap-
pear directly correlatedwith the IC50 values and then inversely correlat-
ed to the cytotoxic activity. This behaviour is particularly relevant on the
CCRF-CEM and CCRF-SB cell lines (Fig. 4). As can be seen, C10 presents
the highest DNA binding constant but the lowest antiproliferative activ-
ity, while I2 presents the lowest binding constant and the highest bio-
logical activity. These results indicate that different reaction
mechanisms with respect to DNA-binding are responsible for the anti-
cancer activities of these complexes.3.6. Potentiometric measurements
The protonation constants of phendiol and the complex formation
constants of the phendiol-copper(II) system were not studied because
of the poor solubility of the ligand in water or in water-DMSO solution
(less than 1 × 10−5 M).3.6.1. Protonation constants of phen and phendione
At acidic pH all the nitrogen and oxygen atoms of the ligands may
hypothetically be protonated. Actually, in the 2–11 pH range only one
protonation equilibrium was in evidence during the potentiometric ti-
tration. The protonation of the second nitrogen atom of phen and
phendione and also that of the oxygen atoms of phendione should hap-
pen at more acidic pH, outside the working range of the glass electrode.
The calculated log β and the related log K values are reported in Table 4.
For both ligands the log K value decreases with temperature, and the
difference is double in the case of phendione (0.31 and 0.15 log K
units for phendione and phen, respectively). Besides the presence in
phendione of the two oxygen atoms that exert a negative inductive ef-
fect, no signiﬁcant differences between the log K values of the two li-
gands are evident.3.6.2. Copper(II) hydrolysis
The formation constants of copper(II) hydrolysed species were deter-
mined by titrating several solutions containing Cu(II) at three different
molar concentrations (1 × 10−3 M, 5.0 × 10−4 M and 3.3 × 10-4 M).
The copper(II) concentrationwas varied to verify the presence of polynu-
clear species. All the solutions titrated with NaOH were back-titrated
withHCl. The overlapping of the acidic andbasic titration curves indicates
the reversibility of the involved equilibria although it is slow to be
reached. In fact, the time delay between additions necessary to reach
equilibrium ranged from 1 to 30 min. A colloidal phase occurred after
pH≈ 6 or after pH≈ 5 at 25 and 37 °C, respectively. At the end of the
basic titrations (pH N 10) the solutions appeared slightly turbid. The po-
tentiometric data for all the titrations carried out at the same temperature
were ﬁtted simultaneously. At the studied temperatures the formations
of the Cu(OH)2, [Cu(OH)3]− and the polynuclear [Cu2(OH)]3+ species
were evident.
The hydrolysis equilibria of copper(II) have been studied by sev-
eral authors but under different experimental conditions, mainly at
25 °C and in the presence of nitrate or perchlorate ions as the back-
ground electrolyte [53–56]. The [Cu(OH)]+, [Cu2(OH)2]2+,
[Cu2(OH)]3+ and [Cu3(OH)4]2+ species were observed. A direct
comparison between our data and those reported in the literature
is problematic since most of the stability constants are expressed
using different deﬁnitions and conventions. However, we observe
that, after proper conversion, our values are slightly lower. These
Fig. 4. Trend of IC50 versus logarithm of the DNA-binding constant. (y = 4.99x2− 44.29x + 98.22, r2 = 0.9332 for CCRF-CEM; y = 1.92x2− 17.14x + 38.28, r2 = 0.9970 for CCRF-SB;
DNA binding constants were determined at 25 °C in 0.01 M PIPES buffer, pH 7.0).
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[Cu(OH)]+, [Cu2(OH)2]2+ and [Cu3(OH)4]2+ species were not found
suitable to ﬁt our experimental data. The calculated stability constants
of hydroxo-complexes of Cu(II) are reported in Table 4.
3.6.3. Cu(II)–phen system
Complex formation equilibria between Cu(II) and the phen ligand
were studied by potentiometric titrations. It was not possible to simul-
taneously record the UV–vis spectrum due to the absorption being too
low in the visible region (d–d bands, ε b 100 M−1 cm−1) and too high
in the UV region (charge transfer bands, ε N 100,000 M−1 cm−1). In
fact, molar concentrations of complexes equal to 10−2 M or 10−5 M,
not suitable for potentiometric measurements, had to be used. Some ti-
tration curves for phen:Cu(II) at molar ratios of 1:0, 3:1, 2:1 and 1:1 are
reported in the Supplementary Materials (Fig. S2A and S2B). At a 3:1 li-
gand:metal molar ratio, variously protonated CuL2 and CuL3 complexes
are formed. At pH b 4 the species [CuL3H]3+ is present. In this complex,
the nitrogen atom of one ligand is still protonated and does not coordi-
nate themetal ion. At a 2:1 phen:Cu(II) molar ratio, variously protonat-
ed CuL2 and CuL forms are present. At a 1:1 molar ratio, CuL is the
predominant species. At every molar ratio, the neutral CuL2H−2 speciesTable 4
Overall stability constants for the studied systems, in 0.1 M ionic strength (NaCl) at 25 °C
and 37 °C temperatures (the standard deviations on the last signiﬁcantﬁgure are reported
in parentheses).
System Species Overall stability constants
25 °C 37 °C
Log β Log K Log β Log K
phen HL+ 5.08 (1) 5.08 4.93 (1) 4.93
phendione HL+ 5.14 (1) 5.14 4.83 (1) 4.83
Cu(II) Cu(OH)2 −8.42 (1) – −7.08 (2) –
[Cu(OH)3]− −19.07 (3) 10.65 −17.27 (3) 10.19
[Cu2(OH)]3+ 4.92 (3) – 5.39 (4) –
Cu(II)–phen [CuL3H]3+ 36.7 (1) – 36.5 (1) –
[CuL3]2+ 32.3 (1) 4.4 32.7 (1) 3.8
[CuL2]2+ 25.5 (1) – 27.58 (4) –
[CuL2H−1]+ 17.72 (5) 7.78 19.41 (4) 8.17
CuL2H−2 7.54 (4) 10.18 8.6 (1) 10.8
[CuL]2+ 16.98 (2) – 17.24 (2) –
[CuLH−1]+ 10.20 (2) 6.78 10.33 (5) 6.91
[CuLH−3]− – – −9.3 (1) 9.8
Cu(II)–phendione [CuL3H]3+ 34.3 (1) – 35.0 (1) –
[CuL3]2+ 29.6 (1) 4.7 30.84 (5) 4.2
[CuL2H]3+ 28.0 (1) – 30.2 (1) –
[CuL2]2+ 24.0 (1) 4.0 24.34 (3) 5.9
[CuL2H−1]+ 13.9 (1) 10.1 – –
[CuL2H−3]− – – −2.85 (4) 9.1
[CuL]2+ 15.51 (2) – 15.71 (3) –
[CuLH−1]+ 8.54 (2) 6.97 8.8 (1) 6.9
CuLH−2 – – 1.19 (2) 7.6
[CuLH−3]− −13.40 (1) 10.97 −8.91 (4) 10.10is formed beyond pH = 10 (the term H-i means that iwater molecules
coordinated to the metal ion have lost a proton). A colourless colloidal
species is present after pH = 10 at a 1:1 molar ratio, probably due to
the formation of the CuH−2 species.
The complex formation constants are reported in Table 4. In all the
complexes the coordination sphere is completed by water molecules.
Taking into account the solid state structures for Cu(phen)(OH2)
2(OClO3)2 and [Cu(phen)2(OH2)](ClO4)2, and their visible absorption
spectra [3], the hypothesised structures in solution for [Cu(phen)2]2+,
Cu(phen)2H−2, and [Cu(phen)3H]3+ are reported in Fig. 5. The distribu-
tion curves at 25 and 37 °C are shown in Fig. S3. The complex formation
constants obtained in thiswork are higher than those reported in the lit-
erature for this system [57–60]. However, in most of the previous stud-
ies, the constants were determined under different experimental
conditions, and no protonated species were considered for ﬁtting the
experimental data.
3.6.4. Cu(II)–phendione system
As for the phen–Cu(II) system, complex formation equilibria between
Cu(II) and the phendione ligand were studied by potentiometric titra-
tions. Titration curves for 1:0, 3:1, 2:1 and1:1 phendione:Cu(II)molar ra-
tios are reported in Fig. S2C and S2D. Similarly to phen, phendione forms
variously protonated CuL, CuL2 and CuL3 complexes with Cu(II). At a 3:1
ligand:metal molar ratio, CuL2 and CuL3 complexes are the predominant
species. At pH b 4 the protonated species [CuL3H]3+ and [CuL2H]3+ are
present. In these complexes, the nitrogen atom of one ligand is still pro-
tonated, and does not coordinate themetal ion. At a 2:1 phendione:Cu(II)
molar ratio, CuL2 and CuL are present. At a 1:1 molar ratio the predomi-
nant species is CuL. Unlike the phen–Cu(II) system, the neutral CuL2H−2
species is formed only at 37 °C and 1:1 molar ratio. A colourless colloidal
species is present after pH = 10 at 1:1 molar ratio, probably due to the
formation of the CuH−2 species.
The complex formation constants are reported in Table 4. In all the
complexes the coordination sphere is completed by water molecules.
Taking into account the solid state structure for [Cu(phendione)
2(OH2)(OClO3)](ClO4) and on the basis of the visible absorption spectra,
the hypothesised structures in solution for [Cu(phendione)2]2+ and
[Cu(phendione)3]2+ are reported in Fig. 5. The distribution curves for
the phendione–Cu(II) system at 25 and 37 °C are shown in Fig. S4.
3.6.5. Stability of the copper(II) complexes
The complex formation constants depend on ligand protonation
constants and on metal hydrolysis; therefore, they cannot be directly
compared to evaluate the relative complex stability. Then, in order to
properly compare the stabilities of the formed complexes, the minus
logarithm of the equilibrium concentration of the free metal ion
(− log [Mefree] = pMe), in a solution at speciﬁed pH, total metal and
total ligand concentrations, might be calculated. In this way, a smaller
freemetal ion concentration, i.e. a larger pMe, indicates amore effective
Fig. 5. Hypothesised structures for [Cu(phendione)2]2+ (A), [Cu(phen)2]2+ (B), Cu(phen)2H−2 (C), [Cu(phen)3H]3+ (D) and [Cu(phendione)3]2+ (E).
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volved equilibria, and can be directly compared to state deﬁnitely
which ligand forms the most stable complex under the chosen experi-
mental conditions. The pCu(II) values for the phen–Cu(II) system are
22.8 (25 °C) and 23.7 (37 °C), while for the phendione–Cu(II) system
they are 20.3 (25 °C) and 21.4 (37 °C), respectively. From these results
it is evident that the formed complexes are more stable at physiological
temperature and the complexes formed with phen are the most stable
at both temperatures.
A direct correlation between the results obtained through potentio-
metric measurements and DNA binding study, could be misleading be-
cause of the different experimental conditions such as ionic strength,
pH, temperature, and, in particular, concentration range. However some
information could be translated. From the potentiometric study, it results
that the predominant species, at pH 7.0 and 25 °C, are (L = phen or
phendione): i) [CuL3]2+ when ligand and metal are present in 3:1
molar ratio; ii) [CuL2(OH2)2]2+ when ligand and metal are present in
2:1molar ratio; iii) [CuL(OH2)(OH)]+when ligand andmetal are present
1:1 inmolar ratio; and iv) L when only ligand is present. Then, dissolving
C10, C0, K1 and K2 in PIPES buffer, the species in solution that react with
DNA are supposed to be [CuL(OH2)(OH)]+ for C10 and K1, [CuL2(OH2)2]
2+ for C0 and K2. Regarding I1 and I2, in the absence of potentiometric
data, it is possible to suppose a behaviour similar to that shown by the
other complexes. Then the species in solution supposed to react with
DNA, are [CuL(OH2)(OH)]+ for I1 and [CuL2(OH2)2]2+ for I2. Among
the species present in solution, only L for phen and phendione and
[Cu(phen)2(OH2)2]2+ are able to partially intercalate.
4. Conclusion
Copper(II) formwith 1,10-phenanthroline, 1,10-phenanthrolin-5,6-
dione, and 1,10-phenanthrolin-5,6-diol, complexes with 1:1, 2:1 and
3:1 ligand:metal stoichiometry.
The studied ligands and complexes generally present a higher anti-
proliferative effect than that of cisplatin. Complexes with two ligands
aremore cytotoxic towards all the tested cell lines than the related com-
plexeswith one ligand and are generally more cytotoxic than the ligand
alone. The [Cu(1,10-phenanthrolin-5,6-diol)2(OH2)](ClO4)2 complex
appears as the most active compound for the treatment of CCRF-CEM,
CCRF-SB, SK-MES-1 and DU-145 human tumour cell lines. In particular
this compound is very promising for the treatment of SK-MES-1, having
a IC50 value 37 times lower than that of cisplatin. The [Cu(1,10-
phenanthrolin-5,6-dione)2(OH2)(OClO3)](ClO4) complex is eligible for
treatment of the HEP-G2 cell line, having a IC50 value 18 times lower
than that of cisplatin. The cytotoxic activity of the ligands was found
to be correlated to the cellular microenvironment. Compound 1,10-
phenanthrolin-5,6-diol appears the most active ligand on cells
surrounded by a hydrophilic environment.
The studied copper(II) complexes are characterised by a DNA afﬁnity
in the range 3 × 104–2 × 105 M−1, andwere found to interact with DNA
mainly by groove binding or electrostatic interactions. The DNA com-
plexes formed with [Cu(1,10-phenanthrolin-5,6-dione)(OH2)2(OClO3)
2] or [Cu(1,10-phenanthroline)(OH2)2(OClO3)2] are characterised bygreater DNA binding constants than the analogous ones formed with
[Cu(1,10-phenanthrolin-5,6-dione)2(OH2)(OClO3)](ClO4) or [Cu(1,10-
phenanthroline)2(OH2)(OClO3)](ClO4). The lower stability of these lat-
ter complexes may be due to the steric hindrance of two ligand mole-
cules. It is interesting to notice that the Cu(II) complexes that present
the highest DNA afﬁnity show also the lowest cytotoxicity. The correla-
tion found between cytotoxicity and DNA binding constants for copper
complexes shows that DNA afﬁnity cannot be considered a reliable uni-
versal indicator of the cytotoxic activity of a drug, giving only a sugges-
tion of the involved action mechanism. Our complexes appear to act
via a mechanism different from that of cisplatin. Therefore, they might
be exploited for the treatment of cisplatin resistant cancer cells. Conclud-
ing, the results provide valuable information for the development of
novel copper(II) complexes, as anticancer drugs with wider spectrum
of action.
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SUPPLEMENTARY MATERIALS 
 
 
 
 
 
 
Fig. S1. Selected UV-Vis spectra recorded during titration with at least 10 equivalents of DNA 
and 2.65 x 10
-5  
mmoles of C10 (A), 3.04 x 10
-5  
mmoles of K1 (B), 3.61 x 10
-5  
mmoles of I1 (C), 
6.54 x 10
-6  
mmoles of C0 (D), 1.69 x 10
-5  
mmoles of K2 (E) and 1.20 x    10
-5  
mmoles of I2 (F), 
and with, at maximum 3 equivalents of DNA of 3.5 x 10
-5 
mmoles of C10 (G),  1.5 x 10
-5  
mmoles of C0 (H), 7.8 x 10
-5 
mmoles of K1 (I); at 25 °C, 0.01 M PIPES buffer, pH = 7.0, 1 cm 
optical path length. 
2  
 
 
Fig. S2.Titration curves for Cu(II)-phen at 25 (A) and 37 °C (B), Cu(II)-phendione at 25 (C) and 
37 °C (D); 1:0 (•), 3:1 (■), 2:1 (◆) and 1:1 (★) ligand:Cu(II) molar ratios, ligand  concentration 
≈ 1 mM, 0.1 M NaCl ionic strength, NaOH ≈ 0.1 M. 
3  
 
 
 
 
 
 
 
 
Fig. S3. Distribution curves at 0.1 M NaCl ionic strength and 25 °C (upper) and 37 °C (bottom) 
for 3:1 (A and D), 2:1 (B and E) and 1:1 (C and F) 1,10-phenanthroline:Cu(II) molar ratios. 
4  
 
 
 
Fig. S4. Distribution curves at 0.1 M NaCl ionic strength and 25 °C (upper) and 37 °C (bottom) 
for 3:1 (A and D), 2:1 (B and E) and 1:1 (C and F) 1,10-phenanthroline-5,6-dione:Cu(II) molar 
ratios. 
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Abstract 
Cisplatin is one of the most powerful chemotherapeutic drug. In spite of the great efficacy of this 
drug, it shows several side effects and most patients develop a resistance to cisplatin. To overcome 
the cisplatin resistance, drugs are often administered in combination (multi-drug therapy) in order to 
exploit the drug synergy. In the research group where I prepared my PhD thesis, it has been found 
that binary combinations of cisplatin and three copper complexes, [Cu(phen)(OH2)2(OClO3)2] 
(C10), [Cu(phen)2(OH2)](ClO4)2 (C0), and [Cu(phen)2(H2dit)](ClO4)2  (C1) (phen = 
1,10-phenanthroline, H2dit = imidazolidine-2-thione) (Figure 10), present in vitro a synergistic 
effect against the wild type human acute T-lymphoblastic leukaemia cell line (CCRF-CEM-wt). 
From these results, I decided to study the cytotoxic activity of cisplatin in combination with C0 
against the cisplatin-resistant sublines of CCRF-CEM (CCRF-CEM-res) and ovarian (A2780-res) 
cancer cell lines.  
The three copper complexes have been re-synthesized using new synthetic route with less-toxic 
solvent and/or with higher yields. In particular, the new synthesis method of C10 led to a crystalline 
product with higher purity (95%) and yield. In the synthesis method of C1, the solvent H2O was 
used instead of CH3CN.  
The cytotoxic activity of C0 and cisplatin, both alone and in binary combinations, were 
evaluated against cisplatin-resistant sublines of leukemic and ovarian cancer cell lines
1
. Copper 
complex C0 showed an IC50 values of 0.75 and 0.24 µM in CCRF-CEM-res and A2780-res, 
respectively. Cisplatin showed an IC50 values of 6.98 and 5.3 µM in CCRF-CEM-res and 
A2780-res, respectively. The combinatorial treatment against cisplatin-resistant cell lines, gave rise 
to a synergistic antiproliferative effect between cisplatin and the studied copper complex in vitro.  
                                                 
1
 In collaboration with professor Alessandra Pani (Dipartimento di Scienze Biomediche, Università degli Studi di 
Cagliari). 
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Figure 10. Formulas and acronyms of the studied molecules. Complex C10 is 
Cu(phen)(OH2)2(OClO3)2, C0 is [Cu(phen)2(OH2)](ClO4)2, C1 is [Cu(phen)2(H2dit)](ClO4)2, and 
cisplatin is cis-diammineplatinum(II) dichloride (phen = 1,10-phenanthroline, H2dit = 
imidazolidine-2-thione). 
 
Considering that the synergy may arise from the interaction of the drugs with different targets, 
from the shielding effect or from a chemical reaction among the drugs, I decided to study the 
possible formation of new adducts between cisplatin and copper(II) complexes by mass 
spectrometry. This study is reported in Chapter 2- Article II.  
A mixed complex containing copper and platinum with a stoichiometry of 
[Cu(phen)(OH)µ-(Cl)2Pt(NH3)(H2O)]
+
 was detected (Figure 11) regardless of the copper complex 
used. 
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 Figure 11. Formula of the detected mixed copper-platinum complex.  
 
 The detected mixed complex is able to hydrolyze to form [Cu(phen)(OH)µ-(Cl)2Pt(H2O)2]
+
, 
species that could be responsible of the synergistic effect shown by the studied mixtures and it is 
likely to interfere with one or more of the mechanisms that lead to cisplatin resistance. Given that 
the determining step in the interaction of cisplatin with DNA are the slow hydrolysis processes and 
considering that the hydrolyzed complexes [Cu(phen)(OH)µ-(Cl)2Pt(NH3)(H2O)]
+
 and 
[Cu(phen)(OH)µ-(Cl)2Pt(H2O)2]
+
 are formed within a few minutes, this mixed copper-platinum 
complex is supposed to be able to react with DNA more readily than cisplatin (Figure 12).  
 
Figure 12. Comparison between the determining step in the interaction of cisplatin with DNA and 
that hypothesized for the mixed complex [Cu(phen)(OH)µ-(Cl)2Pt(NH3)(H2O)]
+
, species that could 
be responsible of the synergistic effect shown by studied mixtures. 
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Cisplatin-resistant cellsCisplatin, cis-diammineplatinum(II) dichloride, is a metal complex used in clinical practice for the treatment of
cancer. Despite its great efﬁcacy, it causes adverse reactions and most patients develop a resistance to cisplatin.
To overcome these issues, a multi-drug therapy was introduced as amodern approach to exploit the drug syner-
gy. A synergistic effect had been previously foundwhen testing binary combinations of cisplatin and three copper
complexes in vitro, namely, Cu(phen)(OH2)2(OClO3)2, [Cu(phen)2(OH2)](ClO4)2 and [Cu(phen)2(H2dit)]
(ClO4)2,(phen = 1,10-phenanthroline, H2dit = imidazolidine-2-thione), against the human acute T-
lymphoblastic leukaemia cell line (CCRF-CEM). In this work [Cu(phen)2(OH2)](ClO4)2 was also tested in combi-
nation with cisplatin against cisplatin-resistant sublines of CCRF-CEM (CCRF-CEM-res) and ovarian (A2780-res)
cancer cell lines. The tested combinations show a synergistic effect against both the types of resistant cells. The
possibility that this effect was caused by the formation of new adducts was considered andmass spectra of solu-
tions containing cisplatin and one of the three copper complexes at a time were measured using electrospray
ionisation at atmospheric-pressure mass spectrometry (ESI–MS). A mixed complex was detected and its stoichi-
ometry was assessed on the basis of the isotopic pattern and the results of tandem mass spectrometry experi-
ments. The formed complex was found to be [Cu(phen)(OH)μ-(Cl)2Pt(NH3)(H2O)]+.
© 2015 Elsevier Inc. All rights reserved.1. Introduction
Cisplatin, cis-diammineplatinum(II) dichloride, is a metal complex
widely used in clinical practice for the treatment of cancer. Cisplatin is
able to enter the cells through passive diffusion and with protein-
mediated transport systems such as human organic cation transporter
T2 and copper transporter Ctr1[1–3]. Cisplatin exerts its biological activ-
ity by interacting with DNA through hydrolysis. In fact, once inside the
cell, one chloride ligand of the complex is displaced by awatermolecule
to form the aquo-complex [Pt(NH3)2(H2O)Cl]+. This species binds
DNA, losing the water molecule, and forming the mono-functional
adduct [PtCl(DNA)(NH3)2]+. The second chloride of this species is
now displaced by a water molecule, forming another aquo-complex
[Pt(H2O)(DNA)(NH3)2]2+. This species interacts with DNA to form the
bi-functional adduct [Pt(DNA)(NH3)2]2+ [4–7]. The principal bi-
functional adduct with DNA is the 1,2-intra-strand cross-linking with
two adjacent guanines, which is supposed to be responsible for the39 070 584597.cytotoxic activity of the drug [7]. Despite its great efﬁcacy against deadly
types of tumour, such as breast, ovarian, prostate, testes, and non-small
cell lung cancers [8–11], it causes adverse reactions with dose-
dependent side effects. Furthermore, after some treatment, most pa-
tients develop resistance to cisplatin [12], and, in order to reach the
same therapeutic efﬁcacy, higher doses of the drug are required with a
higher incidence of side effects related to the dose. Cisplatin resistance
could be caused by several mechanisms, such as a decreased inﬂux in-
side the cell, an increased deactivation by biomolecules present in the
cytosol, an increased capacity of DNA repair and an increased efﬂux out-
side the cell [13,14]. To defeat the drug resistance and reduce the side
effects, a multi-drug (MD) therapy was introduced as a modern ap-
proach. Under theMD regimen, two or more drugs are administered si-
multaneously to exploit their synergism, achieving several advantages
[15]. Synergism arises when the mixture of drugs shows a cytotoxic
activity higher than the pure additive effect of the single drugs. In
synergistic drug combinations, lower doses of each drug can be ad-
ministered, achieving equal or higher therapeutic effectswhile reducing
side effects and lowering resistance development. With this pur-
pose, cisplatin has often been proposed in combinatorial therapies
with other drugs or with natural products [16–22]. We tested, in a
Fig. 1. Formulas and acronyms of the molecules studied in this work. Complex 1 is
Cu(phen)(OH2)2(OClO3)2, 2 is [Cu(phen)2(OH2)](ClO4)2, C1 is [Cu(phen)2(H2dit)](ClO4)2
and cisplatin is cis-diammineplatinum(II) dichloride (phen = 1,10-phenanthroline,
H2dit = the imidazolidine-2-thione).
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[Cu(phen)(OH2)2(OClO3)2] (1), [Cu(phen)2(OH2)](ClO4)2 (2) and
[Cu(phen)2(H2dit)](ClO4)2 (C1) (phen = 1,10-phenanthroline,
H2dit = imidazolidine-2-thione) in vitro against the wild type human
acute T-lymphoblastic leukaemia cell line (CCRF-CEM-wt), ﬁnding a
synergistic effect. Especially, the maximum of synergistic effect was ob-
served for particular combinations of copper complexes and cisplatin,
i.e. 5:1 for 1 and cisplatin, 1:1 for 2 and cisplatin and 1:2 for C1 and cis-
platin [15]. In this work, we extended the study of the cytotoxic activity
of the most promising copper complex 2 as a leader compound, on
cisplatin-resistant sublines of leukemic (CCRF-CEM-res) and ovarian
(A2780-res) cancer cell lines. The CCRF-CEM-res cells were purposely
selected in order to verify whether the synergistic effect shown by 2
and cisplatin in the CCRF-CEM-wt cell line [15] was maintained in a
cisplatin-resistant counterpart, even if cisplatin is not used in the
chemotherapic treatment of leukaemia. The A2780-res cells were se-
lected since they are derived from the ovarian cancer forwhich cisplatin
is still now one of the chemotherapic agent of choice. This kind of cancer
is actually sensitive to cisplatin but becomes resistant to this drug dur-
ing chemotherapy cycles or in recurrences [23].
Copper(II) complexes are supposed to act against cancer cells in dif-
ferent ways with respect to cisplatin, but the real mechanisms are not
completely clariﬁed to date [24]. Furthermore, as both copper(I) and
copper(II) are involved in several biological functions, it is not univer-
sally accepted that the cytotoxic properties of copper complexes are re-
lated to a speciﬁc oxidation state of the metal ion. In most studies, cell
apoptosis and enzyme inhibition (proteasome, topoisomerase I and II,
tyrosin protein kinase) are involved [25,26], whereas DNA appears to
be the target of copper complexes containing nitrogen chelators, such
as phen [27]. The synergistic effect shown by cisplatin and our copper
complexes containing one or two phen molecules may then arise from
several mechanisms, that is, simultaneous involvement of the same or
different targets, such as DNA, proteins, enzymes, biomolecules, but
also through the formation of new adducts. According to the Pearson
acid–base concept [28], platinum(II) and copper(I) are both soft ions,
whereas copper(II) has a hard–soft intermediate character. These ions
present an afﬁnity for the same ligands, which may lead to the forma-
tion of polynuclear complexes containing both platinum and copper.
Starting from the above considerations, we decided to verify the forma-
tion ofmixed complexes, acquiringmass spectra of solutions containing
cisplatin and copper complexes, using electrospray ionisation in
atmospheric-pressure mass (ESI–MS). This ionisation system limits
fragmentation processes, allowing the additional detection of com-
plexes that fragment readily. The ESI–MS technique is, in fact, suitable
for the study of various complexes [29] and was successfully
applied for the study of copper and platinum complexes [30–36]. Pre-
liminary measurements made using stronger ionisation systems, such
as laser desorption ionisation (LDI) or matrix-assisted laser desorption
ionisation (MALDI), only showed evidence of signals deriving from the
platinum ion and from copper–phen complexes [15]. Instead, using
ESI–MS, polynuclear complexes containing copper and platinum were
found, and their stoichiometry was assessed on the basis of isotopic
patterns and fragmentation results of tandem mass spectrometry
(MS–MS). The molecules studied in this work are reported in Fig. 1.
2. Experimental section
2.1. Reagents and apparatus
Methanol (CH3OH), propanol (CH3(CH2)2OH), isopropanol
((CH3)2CHOH), CH3CN, DMSO, H2dit, phen and triﬂuoroacetic acid
(HTFA) were purchased from Sigma-Aldrich. Cis-diammineplatinum(II)
dichloride (cisplatin) was purchased from Alfa-Aesar. The commercial
reagents were used as received, without any further puriﬁcation. Ultra-
pure water obtained with MilliQ Millipore was used for all experiments.
Mass spectra in positive-ion mode were obtained on a triple quadrupleQqQ Varian 310-MS mass spectrometer using the atmospheric-
pressure ESI technique. The sample solutions were infused directly into
the ESI source using a programmable syringe pump at a ﬂow rate of
1.50 ml/h. A dwell time of 14 s was used and the spectra were accumu-
lated for at least 10 min in order to increase the signal-to-noise ratio.
Tandem MS–MS experiments were performed with argon as the colli-
sion gas (1.8 PSI) using a needle voltage of 6000 V, shield voltage of
800 V, housing temperature of 60 °C, drying gas temperature of 120 °C,
nebuliser gas pressure of 40 PSI, drying gas pressure of 20 PSI and a de-
tector voltage of 2000 V. The collision energy was varied from 2 to 45 V.
The isotopic patterns of the measured peaks in the mass spectra were
analysed using mMass 5.5.0 software package [37–39]. The assignments
were based on the copper-63 and platinum-195 isotopes.
2.2. Preparation of 1, 2 and C1
The synthesismethods for 1, 2 andC1 have previously been reported
[40,41]. However, in this work, we report new synthetic routes with
less-toxic solvents and/or with higher yields.
[Cu(phen)(OH2)2(OClO3)2] (1): The basic carbonate of copper(II)
Cu2(CO3)(OH)2 (1.0 g, 4.54 mmol) was suspended in isopropanol
(50ml), and the suspensionwaswarmed to boiling point. Concentrated
perchloric acidwas slowly added to the suspension,whilst stirring, until
a clear-blue solutionwas obtained. The solutionwas boiled for 10min to
remove all carbon dioxide that was formed, and then it was cooled to
room temperature. An isopropanolic solution of phen (0.4 g,
2.22 mmol) was slowly added drop-wise whilst stirring. In presence
of opalescence, the addition of phen was interrupted and the solution
was left stirring until the precipitate disappeared, and phen addition
was then resumed. The entire process required 3 h. The resulting blue
solution was ﬁltered, concentrated under vacuum (10 ml) and left to
crystallise. Blue crystals were obtained after 12 h. The percentage yield
was 95% (calculated on the basis of the amount of phen). The product
was re-crystallised from CH3CN. The ﬁnal yield was 98%. Anal. Calcd.
for Cu(phen)(OH2)2(ClO4)2: C 30.11, H 2.53, N 5.85, found: C 30.87, H
2.66, N 5.79.
[Cu(phen)2(OH2)](ClO4)2 (2): The basic carbonate of copper(II)
Cu2(CO3)(OH)2 (1.0 g, 2.22 mmol) was suspended in isopropanol
(50 ml) and the suspension waswarmed to boiling point. Concentrated
perchloric acidwas slowly added to the suspension,whilst stirring, until
a clear-blue solutionwas obtained. The solutionwas boiled for 10min to
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room temperature and an isopropanolic solution of phen (1.64 g,
4.44 mmol) was slowly added. The resulting turquoise precipitate was
ﬁltered off under vacuum, washed with isopropanol and dried at
room temperature. The percentage yield was 88%. The product was re-
crystallised from CH3CN. The ﬁnal yield was 99%. Anal. Calcd. for
Cu(phen)2(OH2)(ClO4)2: C 44.98, H 2.84, N 8.74, found: C 44.30, H
2.96, N 8.91.
[Cu(phen)2(H2dit)](ClO4)2 (C1): A portion of 2 (0.30 g, 0.41 mmol)
and H2dit (0.048 g, colourless) were suspended in distilled water
(50 ml). The suspension was stirred for 12 h at room temperature,
after which a green powder was recovered by ﬁltration under vacuum.
The product was washed with water and dried at room temperature.
Yield: 80%. The product was re-crystallised from CH3CN. The ﬁnal
yield was 97%. Anal. Calcd. for Cu(phen)2(H2dit)(ClO4)2: C 44.73, H
3.06, N 11.59, found: C 45.01, H 2.98, N 11.30.
2.3. ESI–MS measurements
2.3.1. Copper complexes
A solution of 1was prepared by dissolving an appropriate amount of
the compound in water containing 0.05% of HTFA (v/v). Solutions of 2
and C1, which are both insoluble in water, were prepared by dissolving
an appropriate amount of the compounds inDMSO (100 μl) and diluting
to 50 ml with water containing 0.05% of HTFA (v/v). The stability of the
compounds in DMSOor in DMSO/water/HTFA solutionswas checked by
measuring the UV–visible (UV–Vis) absorbance of the resulting solu-
tions during the time. No changes in the UV–Vis absorbance were evi-
denced in 14 days.
All sample solutions were mixed with methanol in 1:1 H2O/CH3OH
volume ratio immediately before the mass measurements in order to
improve the quality of the spectra. Mass spectra of 1, 2 and C1were re-
corded in the m/z range 100–1000 at a ﬁnal concentration of 0.5 mM.
The same experimental conditions were used for the three compounds
(needle voltage 4500 V, shield voltage 600 V, housing temperature
60 °C, drying gas temperature 120 °C, nebuliser gas pressure 40 PSI, dry-
ing gas pressure 20 PSI, and detector voltage 1450 V).
2.3.2. Cisplatin
A solution of cisplatin was prepared by dissolving an appropriate
amount of the compound in water containing 0.05% of HTFA (v/v).
The solution was mixed with methanol in 1:1 H2O/CH3OH volume
ratio immediately before the mass measurements in order to improve
the quality of the spectra. The mass spectrum of cisplatin was recorded
in the m/z range 100–1000 at a ﬁnal concentration of 0.5 mM. The ex-
perimental conditions were: needle voltage 6000 V, shield voltage
600 V, housing temperature 60 °C, drying gas temperature 120 °C,
nebuliser gas pressure 40 PSI, drying gas pressure 20 PSI, and detector
voltage 2000 V.
2.3.3. Binary combinations
Solutions containing a copper complex and cisplatin in 10:1, 5:1 and
1:1 Pt/Cu molar ratios were prepared, keeping the cisplatin concentra-
tion constant (1.0 mM). Sample solutions were mixed with methanol
in 1:1 H2O/CH3OH volume ratio in order to improve the quality of the
spectra. So as not to alter the complex formation equilibria, methanol
was added immediately before the mass spectra were recorded. Solu-
tions containing cisplatin and the copper complex were analysed at
4500, 600 and 1500 V as needle, shield and detector voltages, respec-
tively, for studying masses in them/z range 100–450, and at 6000, 800
and 2000 V as needle, shield and detector voltages, respectively, for
studying masses in the m/z range 450–1000. All other parameters
were kept constant during the experiments (housing temperature
60 °C, drying gas temperature 120 °C, nebuliser gas pressure 40 PSI,
and drying gas pressure 20 PSI).2.4. Biological assays
2.4.1. Cell lines
The cisplatin-resistant subline of human acute T-lymphoblastic leu-
kaemia (CCRF-CEM-res) and cisplatin-resistant subline of human ovar-
ian carcinoma (A2780-res) were used in the study. The CCRF-CEM-res
subline was obtained by us (see Section 2.4.2); the cell line was main-
tained in culture between 1 × 105 cells/ml and 1 × 106 cells/ml in
RPMI medium 10% foetal bovine serum (FBS) with 1% kanamycin
(growth medium). To the growth medium for CCRF-CEM-res cell cul-
tures, we also added cisplatin (5 μM). A2780-res cells were a generous
gift by Dr. Eva Fischer (Tumor Biology Laboratory, The Ion Chiricuta
Oncology Institute, Cluj-Napoca, Romania) and were grown in RPMI
medium with 2 mM glutamine and 10% FBS. Cell monolayers were
sub-cultivated when they reached 70% conﬂuency (every 3–4 days)
by a 1:3 ratio. In order to keep the cisplatin resistance, A2780-res
were cultured in the presence of 1 μM cisplatin every two to three pas-
sages. All cell lines were periodically checked for micoplasma contami-
nation. For the experiments, each cell line was replaced every 3 months
with freshly-towed cells from the cell stores in liquid nitrogen.
2.4.2. Selection of the cisplatin-resistant CCRF-CEM subline
A CCRF-CEM subline able to grow at the same extent in the absence
and in the presence of 5 μM cisplatin (CCRF-CEM-res) was obtained by
serial passages of wild-type cells in the presence of increasing cisplatin
concentrations, starting from a sub-inhibitory concentration (0.5 μM).
At each cell passage (every 3–4 days), the number of viable cells of
cisplatin-treated cultures was compared to that of duplicate untreated
cultures. The cisplatin concentration was increased at each cell passage
up to 1.50 μM; from then on, cisplatin-treated cultures grew poorly and
much slower than their untreated counterparts and had to be kept
(5–10 passages) at the same cisplatin concentration until the cell popu-
lation had regained original growth timing and viability. At intervals
during the selection process, the level of cisplatin resistance was
checked by the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-tetrazolium
bromide (MTT) method in cells that had grown without the drug for
one passage; doxorubicin was used as a reference compound to evalu-
ate the cisplatin-resistance speciﬁcity. Given that cell cultures never
survived at concentrations over 5 μM, the cell population was stabilised
by 15 further passages at 5 μM cisplatin, and then grown without the
drug for one passage, checked for the level of resistance as described
above, and ﬁnally stored in aliquots in liquid nitrogen for further use.
2.4.3. Cytotoxic assays
Stock solutions of the copper complexes were prepared in DMSO
(1 mM) and stored at 4 °C in the dark. The biological stability of these
solutions was checked verifying the cytotoxic activity measured by
using the same solutions over more than 6 months. The tested com-
pounds maintained the same IC50 (concentration required to inhibit
cell proliferation by 50% with respect to untreated cells) in all the per-
formed experiments. The DMSO solutions of cisplatin (1000× of the
highest concentration to be used on the cell culture), being stable only
for few hours and showing a decreasing of the cytotoxic potency during
the time, were prepared in DMSO and diluted to the necessary concen-
tration each time immediately before the experiments.
Dilutions of the drug stocks for biologic investigations were made
in RPMI medium at 2× the ﬁnal concentration for single drug evalua-
tions, or at 4× the ﬁnal concentration for evaluation of dual drug com-
binations. The concentration of DMSO in the cells was never higher
than 0.1%. The effects of the drugs and drug combinations were evaluat-
ed in cultures of exponentially growing cells; for experiments in
cisplatin-resistant cell cultures, both CCRF-CEM-res and A2780-res
cells were allowed to grow in the absence of the drug for 1 passage.
CCRF-CEM-res cells were seeded at a density of 1 × 105 cells/ml of
growthmedium inﬂat-bottomed96-well plates and simultaneously ex-
posed to the drugs or drug combinations. A2780-res cells were seeded
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here overnight before of the addition of the drugs or the drug combina-
tions. Cell growth in the absence and presence of drugs was determined
after 96 h of incubation at 37 °C and 5% CO2 (corresponding to three to
four duplication rounds of untreated cells), through both the viable cell
counting, with the trypan blue exclusion method, and the MTTmethod
[42,43]. Values obtained in drug-treated samples were expressed as
percentages of those of their respective controls. Dose–response curves
for each drug were determined and the IC50s of single drugs and drug
combinations were calculated.3. Results and discussion
3.1. Synthesis
The synthesised compounds were characterised, in addition to ele-
mental analysis, by infrared (IR) and UV–Vis spectroscopy, ﬁnding
results in agreement with the previously reported data [40,41]. The
new synthesis method of 1 led to a crystalline product with a higher
purity (≥95%) and yield. The obtained compound, whichmust be stored
under vacuum, is hygroscopic and deliquescent. It is stable for a number
ofmonths at room temperature in a desiccator, but if warmed, its colour
changes from blue to turquoise. The turquoise product was
characterised by elemental analysis and IR spectroscopy and it resulted
to be 2. In the synthesis method of C1, the previously used solvent
CH3CN was changed to H2O.3.2. Cytotoxicity measurements
The cytotoxic activities of 2 and cisplatin, both alone and in dual drug
combinations, were evaluated against CCFR-CEM-res and A2780-res
human cell lines. Dose–response curves for 2 and cisplatin were obtain-
ed, and the IC50 values were determined. Copper complex 2 showed
IC50 values of 0.75 and 0.24 μM in CCFR-CEM-res and A2780-res cells,
respectively. Cisplatin showed IC50 values of 6.98 and 5.3 μM for
CCFR-CEM-res and A2780-res cells, respectively. Dose–response curves
of 2 and cisplatin in cisplatin-resistant cell lines are reported in the
Supplementary Information (Fig. S1). The effects of single drugs and
dual drug combinations on the tested cell lines are reported in Table 1
as a percentage of the untreated controls. In all cases, combinatorial
treatment gave rise to a synergistic interaction between cisplatin
and the studied copper complex. In particular, it is worth mentioning
the synergistic effect shown by combinatorial treatments against
cisplatin-resistant cell lines, which has evident potential in the clinic
of cisplatin-resistant cancers.Table 1
Antiproliferative activity (%) against cisplatin-resistant leukemic cancer cells (CCRF-CEM-
res), cisplatin-resistant ovarian cancer cells (A2780-res) exhibited by copper complex 2,
cisplatin and their binary combinations.
2
(μM)
Cisplatin
(μM)
Antiproliferative
activity (%)
Cell line Effect Index of
synergy⁎
0.67 40.0 CCRF-CEM-res
5.0 28.2
0.67 5.0 88.0 synergism 31%
0.60 24.0
4.0 17.5
0.60 4.0 59.5 synergism 22%
0.20 32.7 A2780-res
4.0 6.0
0.20 4.0 58.4 synergism 22%
0.10 6.0
0.10 4.0 20.0 synergism 8%
⁎ Calculated as in Ref. [15].3.3. ESI–MS results
3.3.1. Copper complexes
In the mass spectra of 1, 2 and C1, only mono-charged species con-
taining copper(II) or copper(I) were evidenced. Reduction of Cu(II) to
Cu(I) is commonly observed in the ESI phase for solutions of Cu(II)
salts [44]. Characteristic isotopic peaks for copper- and copper–chlo-
rine-containing ions were clearly seen, and the isotopic patterns of
these peaks conﬁrmed the elemental composition of the observed
ions. The most relevant peaks are assigned in the shown spectra
(Fig. 2), whereas calculated and experimental isotopic patterns for se-
lected peaks are reported in the Supplementary Information (Fig. S2).
In the spectrum of 1 (Fig. 2A), the most important signals correspond
to [Cu(II)(phen)(ClO4)]+ (m/z 342), [Cu(II)(phen)Cl]+ (m/z 278) and
[Cu(I)(phen)]+ (m/z 243) species. The last two species derive from frag-
mentation–recombination reactions occurring during theMS–MS of the
parent compound [Cu(II)(phen)(ClO4)]+. In the insert the peaks falling
in the m/z range 340–350 are reported. Also other complexes were
recognised, but theywere identiﬁed as adducts with TFA or as the prod-
ucts of exchange reactions with ﬂuorine carried out by the TFA. These
complexes were [Cu(II)(phen)(TFA)]+ (m/z 356), [Cu(II)(phen)F]+ (m/z
262), and [Cu(II)(phen)2(TFA)]+ (m/z 536). In the spectrum of 2
(Fig. 2B), some species observed in the spectrum of 1 are present
([Cu(II)(phen)Cl]+ (m/z 278), [Cu(II)(phen)(TFA)]+ (m/z 356),
[Cu(II)(phen)2(TFA)]+ (m/z 536)) together with [phen+H]+( m/z
181), [Cu(I)(phen)2]+ (m/z 423), [Cu(II)(phen)2Cl]+ (m/z 458), and
[Cu(II)(phen)2(ClO4)]+ (m/z 522). The species [phen+H]+,
[Cu(I)(phen)2]+ and [Cu(II)(phen)2Cl]+ are fragmentation products
of the parent compound [Cu(II)(phen)2(ClO4)]+. In the spectrum of
C1 (Fig. 2C), some species observed in the spectrum of 1 and 2 areFig. 2. ESImass spectra (+) of 1 (A), 2 (B) and C1 (C); 0.5mM, 50:50methanol/waterwith
0.05% of triﬂuroacetic acid (phen = 1,10-phenanthroline, H2dit = the imidazolidine-2-
thione, TFA = triﬂuroacetate ion).
Fig. 3. ESI–MS (+) spectrum of cisplatin in them/z 200–315 range; 0.5 mM, 50:50 meth-
anol/water with 0.05% of triﬂuroacetic acid.
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[Cu(II)(phen)Cl]+ (m/z 278), [Cu(II)(phen)(TFA)]+ (m/z 356),
[Cu(II)(phen)2Cl]+ (m/z 458), [Cu(II)(phen)2(ClO4)]+ (m/z 522),
[Cu(II)(phen)2(TFA)]+ (m/z 536)) together with species containing
the thionic ligand H2dit, that is, [Cu(II)(phen)2(Hdit)]+ (m/z 524),
[Cu(II)(phen)(Hdit)]+ (m/z 344), and [H2dit+H]+ (m/z 103). In the
inserts are reported the peaks falling in the m/z ranges 340–350
and 520–530. The presence of the [phen+H]+ signal in the spectra
of 2 and C1, is due to the fragmentation of the Cu–phen complexes.
The species [Cu(I)(phen)]+ , [Cu(II)(phen)Cl]+, [Cu(II)(phen)(TFA)]+,
[Cu(II)(phen)2(TFA)]+ are detectable in all the spectra, as fragmenta-
tion products of the parent compounds. The species [Cu(II)(phen)
(Hdit)]+ and [H2dit+H]+ are fragmentationproducts of the parent com-
pound [Cu(II)(phen)2(Hdit)]+. The occurrence of [Cu(phen)2(TFA)]+
also in the spectrum of 1, is due to a reaction in ESI phase between the
monochelate complex Cu–phen and the freed phen (the intensity of
the related signal atm/z 536, lowers directly with the needle potential).
All the fragmentation processes were studied by tandem MS-MS. The
assignments are tabulated with calculated m/z values in Table 2 (rows
1–18).
It is interesting to remark that, although the copper complexes have
been measured at the same molar concentration, their mass spectra
presented different intensities, from 4.5 × 109 (for 1) to 1.75 × 109 a.u.
(for 2).
3.3.2. Cisplatin
The ESI–MS spectrum of cisplatin is reported fromm/z 200 to 315 in
Fig. 3 and from 300 to 600 in Fig. S3. Due to the number of the isotopic
peaks of the metal ion and to the limited resolving power of the instru-
ment, the peaks in the spectrum appear broad. The signal related to the
protonated cisplatin, [Pt(NH3)2Cl2+H]+, appears atm/z 300. Other sig-
nals related to [Pt(NH3)2Cl]+, [Pt(NH3)Cl]+ and [Pt(NH2)]+ are present
atm/z 264, 247, and 211, respectively. A signal interpreted as a mixture
of [Pt(NH3)3(H2O)2Cl]+ (78%) and [Pt(NH3)2(H2O)3Cl]+ (22%) isTable 2
Species identiﬁed from the ESI–MS studies.
Row Ion Composition Exp.
m/z⁎
Calc.
m/z⁎
1 [Cu2(phen)2(TFA)2(ClO4)]+ C28H16ClCu2F6N4O8 810.94 810.91
2 [Cu2(phen)2(TFA)2Cl]+ C28H16ClCu2F6N4O4 746.90 746.94
3 [Cu3(phen)2(TFA)(OH)(H2O)2]+ C26H21Cu3F3N4O5 714.86 714.93
4 [Cu2(phen)2(TFA)Cl2]+ C26H16Cl2Cu2F3N4O2 668.87 668.92
5 [Cu(phen)2(TFA)]+ C26H16CuF3N4O2 536.11 536.05
6 [Cu(phen)2(Hdit)]+ C27H21CuN6S 522.02 524.08
7 [Cu(phen)2(ClO4)]+ C24H16ClCuN4O4 521.95 522.01
8 [Cu(phen)2Cl]+ C24H16ClCuN4 458.03 458.04
9 [Cu(phen)2]+ C24H16CuN4 423.05 423.07
10 [Cu(phen)(TFA)]+ C14H8CuF3N2O2 355.94 355.98
11 [Cu(phen)(Hdit)]+ C15H13CuN4S 343.99 344.02
12 [Cu(phen)(ClO4)]+ C12H8ClCuN2O4 341.88 341.95
13 [Cu(phen)Cl]+ C12H8ClCuN2 277.92 277.97
14 [Cu(phen)F]+ C12H8CuFN2 261.95 262.00
15 [Cu(phen)(H2O)]+ C12H10CuN2O 260.94 261.01
16 [Cu(phen)]+ C12H8CuN2 242.96 243.00
17 [phen+H]+ C12H9N2 181.05 181.08
18 [H2dit+H]+ C3H7N2S 102.99 103.03
19 [Pt2(NH3)4Cl3]+ H12Cl3N4Pt2 562.79 562.94
20 [Pt2(NH3)3Cl3]+ H9Cl3N3Pt2 545.80 545.92
21 [Pt(NH3)2(H2O)3Cl]+ H12ClN2O3Pt 318.88 318.02
22 [Pt(NH3)3(H2O)2Cl]+ H13ClN3O2Pt 317.84 317.03
23 [Pt(NH3)2Cl2+H]+ H7Cl2N2Pt 300.84 299.96
24 [Pt(NH3)2Cl]+ H6ClN2Pt 263.88 263.99
25 [Pt(NH3)Cl]+ H3ClNPt 246.85 246.96
26 [Pt(NH2)]+ H2NPt 210.88 210.98
27 [CuPt(phen)(H2O)2(OH)Cl2]+ C12H13Cl2CuN2O3Pt 560.90 560.92
28 [CuPt(phen)(H2O)(NH3)(OH)Cl2]+ C12H14Cl2CuN3O2Pt 559.90 559.94
29 [CuPt(phen)(H2O)2Cl2]+ C12H12Cl2CuN2O2Pt 543.95 543.92
⁎ The experimental and calculatedm/z values refer to the peak representative of the
monoisotopic mass.present at m/z 317-318. At m/z 546 and 563, signals of the di-nuclear
complexes [Pt2(NH3)3Cl3]+ and [Pt2(NH3)4Cl3]+ can be seen. Calculated
and experimental isotopic patterns for selected peaks are reported in
the Supplementary Information (Fig. S4). In the species containing plat-
inum and NH2−, a double bond between platinum and nitrogen ion is
present, which has already been reported [36,45]. It is important to re-
mark that the mass-spectral proﬁle of cisplatin solutions begins to
change 1 h after preparation, as the compound undergoes hydrolysis.
In fact, the signals atm/z 300, 264 and 247 decrease in intensity and ad-
ducts with water and methanol are formed. The assignments are tabu-
lated with calculatedm/z values in Table 2 (rows 19–26).
3.3.3. Binary combinations
Several binarymixtures of cisplatin and copper complexeswere pre-
pared and theirmass spectrawere acquired in order to verify the forma-
tion of a mixed complex.
3.3.3.1. Cisplatin and copper complexes. The number and the aspect of the
signals present in the spectra are strongly dependent on the chosen ex-
perimental conditions of needle, shield and detector voltages. Generally,
increasing the voltage of the needle, shield and detectors causes the
fragmentation processes to increase. The fragmentations are helpful,
as they are characteristic of the molecule and provide structural infor-
mation. However, as the fragments themselves can undergo to a further
fragmentation, the resulting spectra could become difﬁcult to under-
stand. On the other hand, a voltage that is too low determines a fall in
the overall ion current, leading to a reduction in the ionisation efﬁcien-
cy. These issues could determine non-reliable signals [46].
Themass spectra of the binary combinationswere collected by vary-
ing the voltage values in order to ﬁnd the optimal conditions. In all the
experiments, signals with isotopic pattern characteristic of species
containing both copper and platinum were observed. However, at nee-
dle, shield, and detector voltages of 4500, 600, and 1500 V, respectively,
the signals with reliable intensities (109magnitude) were characteristic
of species containing only copper as the metal ion. In particular, signals
of the species [Cu(II)(phen)(TFA)]+ (m/z 356), [Cu(I)(phen)(H2O)]+ (m/z
261), and [Cu(I)(phen)]+ (m/z 243) were present. To observe signals of
the other ions with sufﬁcient intensity, needle, shield, and detector
voltages of 6000, 800, and 2000 V, respectively, were used. The binary
combinations were tested at 1:1, 5:1 and 10:1 platinum/copper molar
ratios. In the spectra of the equimolar mixtures, the signals originating
from the copper complexes were more intense than those originating
from cisplatin. The measured mass spectra of the solutions containing
cisplatin and 2 at the three different molar ratios are reported as an ex-
ample in Fig. S5. The signals of the mixed complexes containing both
copper and platinum appeared at all molar ratios for all of the studied
systems; however, at 1:1 platinum/copper, the more intense signals
(marked with “*” in Fig. S5) were attributed to mono- and poly-
nuclear copper complexes. The stoichiometry of these complexes
were identiﬁed from the m/z value and from the isotopic pattern as
[Cu(II)2(phen)2(TFA)Cl2]+ (m/z 669), [Cu(I)3(phen)2(TFA)(OH)(H2O)2]+
Fig. 5. TandemMS–MS spectrum of the signals atm/z 561. The isotopic pattern was par-
tially lost for the low signal intensity and for the little range ofm/z isolated (collision en-
ergy 20 V, charges are omitted for clarity, the two nitrogen connected by a curved line
represent the phen molecule).
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(TFA)2(ClO4)]+ (m/z 811).
At 10:1 platinum/coppermolar ratio, togetherwith signals of copper
and mixed copper–platinum complexes, signals of poly-nuclear com-
plexes containing two or more platinum ions and a variable number
of chlorine, ammonia and water molecules, were present in the m/z
range 800–1000. The lack of a good pattern resolution prevented the de-
termination of their exact stoichiometry. From these results, it followed
that the combination at 5:1 platinum/copper molar ratio was the best
one to study mixed platinum–copper complexes.
In Fig. 4, themass spectra of solutions containing cisplatin and 1, cis-
platin and 2 as well as cisplatin and C1, at 5:1 platinum/copper molar
ratio, are reported (signals from the copper complexes are marked
with “*”). As can be seen, the mass spectra of all systems present a sim-
ilar proﬁle, even if they have different intensities, indicating that the
same mixed complexes were formed. In particular, the signals with
the isotopic pattern typical of mixed platinum–copper complexes fall
in them/z range 540–660. As for the copper complexes, the stoichiom-
etry of these mixed complexes was identiﬁed from the m/z value and
from the isotopic pattern. In many cases, convoluted signals were
observed, owing to the simultaneous presence of complexes with simi-
lar masses. In this case, the experimental pattern was attributed to a
weighted combination of the isotopic pattern of the differentmolecules.
The weights, that is, the percentage in which each molecule was pres-
ent, were obtained by multivariate regression analysis of the experi-
mental data. An example of this treatment is reported in Fig. S6, in
which the experimental pattern can be compared to the theoretical
one, calculated as a contribution of four molecules.
From the analysis of the spectra, we identiﬁed three principal com-
plexes, all mono-charged with the following stoichiometries: I)Fig. 4. ESI mass (+) spectra of cisplatin and 1 (A), cisplatin and 2 (B), cisplatin and C1
(C) (cisplatin 0.5 mM, copper complex 0.1 mM, 50:50 methanol/water with 0.05% of
triﬂuroacetic acid). In the spectra, copper complexes are marked with “*”.[CuPt(phen)(H2O)2(OH)Cl2]+ (m/z 561), II) [CuPt(phen)(H2O)(NH3)
(OH)Cl2]+ (m/z 560), and III) [CuPt(phen)(H2O)2Cl2]+ (m/z 544). To-
gether with I–III, nine other complexes were identiﬁed, but they turned
out to be adducts with TFA or products of exchange reactions with the
ﬂuorine carried out by the TFA. These nine complexes could be thought
as by-products (the complete list of these complexes is reported in the
Supplementary, Table S1). The assignments are tabulated with calculat-
ed m/z values in Table 2 (rows 27–29).
3.3.3.2. Tandem MS–MS. Tandem mass spectrometry was essential to
conﬁrm the proposed stoichiometry and to hypothesise the structure
of the formed complexes. A brief description of this technique is report-
ed in the caption of the Fig. S7.
The fragmentation proﬁles obtained for compounds I–III are reported
in Figs. 5–7. As can be seen in Fig. 5 for I, species with stoichiometries
[Cu(phen)]+ (m/z 243), [Cu(phen)Cl]+ (m/z 278), and [CuPt(phen)Cl2]+
(m/z 508) were visible as fragments of the parent compound
[CuPt(phen)(H2O)2(OH)Cl2]+ (m/z 561). The structures of the
[Cu(phen)]+, [Cu(phen)Cl]+ and [CuPt(phen)Cl2]+ ions were easily
proposed, as shown in the ﬁgure. To deﬁne the structure of the frag-
ment at m/z 544, it was convenient to consider it as (m/z 508 + m/z
2 × 18). Three possibilities were considered as two water molecules
linked to the copper (case i) or to the platinum (case ii) or one water
molecule linked to the copper and one to the platinum (case iii). If
one or two water molecules were linked to the copper, the resultingFig. 6. TandemMS–MS spectrum of the signals atm/z 560. The isotopic pattern was par-
tially lost for the low signal intensity and for the little range ofm/z isolated (collision en-
ergy 20 V, charges are omitted for clarity, the two nitrogen connected by a curved line
represent the phen molecule).
Fig. 7. Tandem MS–MS spectrum of the signals atm/z 544. The isotopic pattern was par-
tially lost for the low signal intensity and for the little range ofm/z isolated (collision en-
ergy 20 V, charges are omitted for clarity, the two nitrogen connected by a curved line
represent the phen molecule).
Scheme 1. Reactionmechanism between 1 and cisplatin (A) and 2 or C1 and cisplatin (B).
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were linked to the platinum the charge of the complex should have
been +1 (note that when copper is tetra-coordinated its oxidation
number is +1, if it is penta- or esa-coordinated its oxidation number
is +2). The fragment was mono-charged, then only the case ii was
considered. To deﬁne the structure of the parent compound at m/z
561, it was convenient to consider it as (m/z 544 + m/z 17). Ammo-
nia and hydroxide ions have anm/z of 17; therefore, the two possibil-
ities were considered as hydroxide or ammonia linked to the copper.
If OH- was linked to the copper, the resulting complex should have
had a +1 charge, whereas, if ammonia was present, the charge of
the complex should have been +2. The fragment was mono-
charged, then only the OH- ion was considered. Therefore, the struc-
ture of the parent ion was proposed as reported in the ﬁgure, that is,
[Cu(phen)(OH)μ-(Cl)2Pt(H2O)2]+.
The study of compound II appeared more complicated. As for I, the
structures of the [Cu(phen)]+, [Cu(phen)Cl]+, and [CuPt(phen)Cl2]+
were easily proposed, as shown in Fig. 6. As for the fragment at m/z
525, it was considered as (m/z 508 + m/z 17). Then, four possibilities
were considered, that is, hydroxide linked to platinum (i) or to copper
(ii) and ammonia linked to platinum (iii) or to copper (iv). If OH- or
NH3 were linked to platinum, the resulting complexes (cases i and iii)
should have had 0 or +1 as the charge, respectively. If OH- or NH3
were linked to copper, the resulting complexes (cases ii and iv) should
have had a +1 or +2 charge, respectively. As the fragment was
mono-charged, only cases ii and iii were considered. With regards to
the fragment at m/z 542, as before, it was considered as (m/z 525 +
m/z 17). Then, six possibilities were taken into account, starting from
the previous cases ii and iii, that is, ii+ OH- or NH3 linked to platinum
(cases v and vi), iii+ OH- or NH3 linked to copper (cases vi and ix), iii
+ OH- or NH3 linked to platinum (cases vii and viii). As the fragments
are mono-charged, the only possibilities that were considered were vi
and viii. The last fragment was considered as (m/z 525 + m/z 18), and
a water molecule was added to vi and viii, to obtain x (with +1 charge)
and xi (with +2 charge). Then, the most probable structure of the par-
ent ion was that of x, that is, [Cu(phen)(OH)μ-(Cl)2Pt(NH3)(H2O)]+.
The entire route is shown in Fig. S7. As far as compound III is concerned,
similar considerations were made to obtain as the most probable struc-
ture, [Cu(phen)μ-(Cl)2Pt(H2O)2]+, as shown in the Fig. 7. All of the re-
ported fragmentations were obtained with a CE of 20 V. To fragment
the [Cu(phen)]+ complex, a collision energy of 45 V was necessary,
but at this energy value, the other fragmentswere no longer observable.
Compound III can be considered as a fragment of I, which itself can
be considered as a hydrolysis product of II. A precursorwith the formula
[Cu(phen)(OH)μ-(Cl)2Pt(NH3)2)]+ can be hypothesised in solution;
however, this species was not detected in our experiments. Theproposed reaction between copper complexes and cisplatin is ﬁnally re-
sumed in Scheme 1. As can be seen, the same complex is formed, re-
gardless of the copper complex (1, 2 or C1) involved. In the reaction of
2 or C1 with cisplatin, one phen unit is released; in the case of C2, a
H2dit unit is also released. In the formed complex, copper and platinum
are linked by two bridging chlorides and the coordination spheres of
copper is completed by a phen and a hydroxide ion, and that of platinum
is completed by ammonia and water molecules. From themass spectral
evidence, the mixed copper–platinum complex was formed in aqueous
solution a fewminutes after themixing of the reagents, and itwas stable
for at least 1 week. The same reaction carried out in water–acetonitrile
required 3 weeks to be completed.
4. Conclusions
Binary combinations of cisplatin and the copper complex
[Cu(phen)2(OH2)](ClO4)2 present a synergistic antiproliferative ef-
fect against the cisplatin-resistant sublines of leukemic (CCRF-
CEM-res) and ovarian (A2780-res) cancer cells in vitro. Considering
that the synergy may arise from a chemical reaction between the
two metal complexes, solutions containing cisplatin and the copper
complex Cu(phen)(OH2)2(OClO3)2, [Cu(phen)2(OH2)](ClO4)2 or
[Cu(phen)2(H2dit)](ClO4)2 were studied by ESI–MS and tandem
MS–MS. A mixed complex containing copper and platinum with a
stoichiometry of [Cu(phen)(OH)μ-(Cl)2Pt(NH3)(H2O)]+ was detect-
ed. This complex was able to hydrolyse to form [Cu(phen)(OH)μ-
(Cl)2Pt(H2O)2]+ that was actually detected. Both the complexes
were formed, regardless of the copper complex used; then, in the re-
action of [Cu(phen)2(OH2)](ClO4)2 and [Cu(phen)2(H2dit)](ClO4)2
with cisplatin, one phen and/or one H2dit was released. Phen pre-
sents itself an IC50 value of approximately 2 μM towards the tested
cell lines, and it can contribute to the overall cytotoxic activity
shown by the mixtures, unlike H2dit, which is devoid of any biologi-
cal activity against the tested cells. The formation of the mixed cop-
per–platinum complex could be related to the synergistic effect of
the combination of the studied copper complexes with cisplatin
shown towards the tested cell line. Given that the synergy was also
observed against cisplatin-resistant cells, the formed copper–plati-
num complex is likely to interfere with one or more of the mecha-
nisms that lead to cisplatin resistance. Furthermore, considerations
about the reactivity can be made. In fact, it is accepted that the deter-
mining steps in the interaction of cisplatin with DNA are the hydrolysis
processes that are slow in saline solutions. Complexes [Cu(phen)(OH)μ-
(Cl)2Pt(NH3)(H2O)]+ and [Cu(phen)(OH)μ-(Cl)2Pt(H2O)2]+ are
formed within a few minutes and are already hydrolysed. They can
then react with DNA more readily than cisplatin. More experiments
114 T. Pivetta et al. / Journal of Inorganic Biochemistry 151 (2015) 107–114have to be carried out in order to obtainmore insights and possibly clar-
ify the underlying molecular mechanism(s). In this regards, as a future
perspective, we intend to extend these studies to other cisplatin-
resistant cell lines.
From the reported results, the ESI–MSand tandemMS–MSappear as
suitable tools for the study of the metal complexes formed in solution.
Of course, in the transition process from the solution to gas phase, the
structure of the complexes may be affected, and this is particularly rel-
evant for large molecules such as metal complexes with biomolecules.
In the case of themetal complexes, the electrochemical reactions occur-
ring at the capillary may also modify the valence state of the metal ion
inducing a structural change. Also the fragmentation products may re-
combine to form new species. Then, the species detected in ESI–MS
not necessarily correspond to those actually present in the sample solu-
tion. Nevertheless, relevant information on the solution stability and re-
activity of complexes that are not easily isolable in the solid state can
indeed be obtained under several experimental conditions such as dif-
ferent media, pH values and ionic buffers.
Abbreviations
ESI–MS electrospray ionisation mass spectroscopy
Phen 1,10-phenanthroline
CCRF-CEM human acute T-lymphoblastic leukaemia
CCRF-CEM-res cisplatin resistant human acute T-lymphoblastic
leukaemia
A2780 ovarian cancer
A2780-res cisplatin resistant ovarian cancer
MD multi-drug
MALDI matrix assisted laser desorption ionisation
LDI laser desorption ionisation
HTFA triﬂuoroacetic acid
TFA triﬂuoroacetate
H2dit imidazolidone-2-thione
FBS foetal bovine serum
MTT 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-tetrazolium
bromide
IC50 concentration required to inhibit cell proliferation by 50%
with respect to untreated cells
MS–MS tandem mass spectrometry
CE collision energy
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Fig. S1. Dose-response curves for 2 (A) and cisplatin (B) on leukemic cisplatin-resistant cancer 
cells (CCRF-CEM-res,●) and ovarian cisplatin-resistant cancer cells (A2780-res,▲). 
Antiproliferative effect is expressed as the percentage compared to untreated controls. 
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Fig. S2. Calculated (red line) and experimental (blue line) isotopic pattern for (A) 
[Cu(phen)(TFA)]
+
 (m/z 356), (B) [Cu(phen)2(TFA)]
+
 (m/z 536), (C) [Cu(phen)2(ClO4)]
+
 (m/z 522). 
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Fig. S3. ESI–MS (+) spectrum of cisplatin in the m/z 300-600 range; 0.5 mM, 50:50 methanol/water 
with 0.05% of trifluroacetic acid. 
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Fig. S4. Calculated (red line) and experimental (blue line) isotopic pattern for (A) [Pt(NH2)]
+
 (m/z 
211), (B) [Pt(NH3)Cl]
+
 (m/z 247), (C) [Pt(NH3)2Cl]
+
 (m/z 264), (D) [Pt(NH3)2Cl2+H]
+
 (m/z 300), 
(E) [Pt2(NH3)3Cl3]
+
 (m/z 546), (F) [Pt2(NH3)4Cl3]
+
 (m/z 563). Calculated pattern (G, black line) as a 
sum of [Pt(NH3)3(H2O)2Cl]
+
 (78%, red line) and [Pt(NH3)2(H2O)3Cl]
+
 (22%, orange line) and 
experimental data (H, blue line) in m/z range 314-320. 
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Fig. S5. ESI mass (+) spectra of cisplatin and 2 at 1:1 (A), 5:1 (B) and 10:1 (C) platinum/copper 
molar ratios (concentration of cisplatin is 0.5 mM, 50:50 methanol and water with 0.05% of 
trifluroacetic acid). In the spectra copper complexes are marked with “*”, polynuclear complexes 
containing two or more platinum ions and a variable number of chlorine, ammonia and water 
molecules are also pointed out. 
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 A         B 
Fig. S6. Theoretical (A) and experimental (B) isotopic pattern for signal centred at m/z 547. The 
signal is due to a mixture of [CuPt(phen)(H2O)FCl2]
+
 (46%, blue line), [CuPt(phen)(H2O)2F2Cl]
+
 
(28%, green line), [CuPt(phen)F2Cl2]
*+
 (24%, cyan line) and [CuPt(phen)(H2O)2Cl2]
+
 (2%, red 
line).  
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Fig. S7. A description of the possible structures as obtained from the tandem MS-MS experiments 
on the parent ion at m/z 560. 
Tandem MS–MS consists of multiple steps of mass spectrometry selection, and between these 
steps, several fragmentation processes occur. On a triple quadrupole Q1q2Q3 it is possible to select 
an ion of a certain mass (parent ion) in the first quadrupole Q1 and send it in the second quadrupole 
q2, which represents a collision cell. Here, the ion in the presence of an inert gas, such as Ar, He or 
N2, is fragmented. The resulting fragments are passed within the third quadrupole Q3, therein they 
are scanned and detected. The correct stoichiometry and structure of the parent ion can be deduced 
from the fragmentation profile. Furthermore, the energy required to fragment the ion gives 
information on its stability. In fact, when the MS–MS is applied to a metal complex, as in our case, 
the collision-induced dissociation determines the loss of neutral ligands such as water or ammonia 
at low collision energy (CE) (ca. 2–15 V), the breaking of bonds and aromatic-ring destruction at 
medium CE (ca. 15–30 V) and even the expulsion of the free metal ion at high CE (ca. 30–50 V). 
The necessary CE, which is strictly related to the strength of the bonds and the stability of the 
complex, is highly specific for each process and for each complex. Once obtained the fragmentation 
profile, the structure of the parent ion may be reconstructed, starting from the smallest fragments, 
whose structure could be easily hypothesised, as though the fragments were pieces of a puzzle. Of 
course, the fragment ions may rearrange in the gas phase, but this method generally leads to the 
most probable structure of the parent ion. 
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Table S1. Species containing copper and platinum as identified from the ESI-MS studies 
N° Ion Composition Exp. m/z
*
 Calc. m/z
*
 
1 [CuPt(phen)(H2O)FCl2]
+
 C12H10Cl2CuFN2OPt 544.96 544.91 
2 [CuPt(phen)F2Cl2]
+
 C12H8Cl2CuF2N2Pt 545.93 545.90 
3 [CuPt(phen)(H2O)2F2Cl]
+
 C12H12ClCuF2N2O2Pt 546.93 546.95 
4 [CuPt(phen)(TFA)(HO)3(H2O)]
+
 C14H13CuF3N2O6Pt 619.88 619.97 
5 [CuPt(phen)(TFA)(HO)2(H2O)2]
+
 C14H14CuF3N2O6Pt 620.99 620.97 
6 [CuPt(phen)(TFA)(HO)F(H2O)2]
+
 C14H13CuF4N2O5Pt 622.90 622.97 
7 [CuPt(phen)(TFA)(H2O)2F2]
+
 C14H12CuF5N2O4Pt 624.87 624.97 
8 [CuPt(phen)(TFA)(H2O)3Cl]
+
 C14H14ClCuF3N2O5Pt 639.92 639.95 
9 [CuPt(phen)(TFA)(H2O)2ClF]
+
 C14H12ClCuF4N2O4Pt 640.91 640.94 
* The experimental and calculated m/z values refer to the peak representative of the monoisotopic 
mass. 
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Chapter 3 
 
Cisplatin, glutathione and the third wheel 
 
 
 
 
 
This chapter reports the study of the synergistic effect of binary mixtures of GSH with 
[Cu(phen)(H2O)2(ClO4)2] or cisplatin, and ternary mixtures of GSH with 
[Cu(phen)(H2O)2(ClO4)2] and cisplatin.  
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Abstract  
The increase of intracellular levels of glutathione, able to bind cisplatin (CDDP) and deactivated 
it as drug, is one of the main mechanisms that cause the cisplatin-resistance. To overcome this 
issue, CDDP is often administered in combinations with other drugs, to exploit drug synergism.  
In a previous work (Chapter 2 – Article II) the cytotoxic activity of [Cu(phen)2(OH2)](ClO4)2 
(C0) and cisplatin, both alone and in binary combinations, were evaluate against cisplatin-resistant 
sublines of leukemic and ovarian cancer cell lines. Copper complex C0 shown an IC50 values of 
0.75 and 0.24 µM in CCRF-CEM-res and A2780-res, respectively, while CDDP shown values of 
6.98 and 5.3 µM in the same lines. The combinatorial treatment with C0 and CDDP against the 
cisplatin-resistant cell lines, gave rise to a synergistic effect in vitro.  
Taking into account that the possible deactivation of the CDDP may be due to the presence of 
GSH, I decided to study the cytotoxic activity of binary mixtures of GSH with C0 or CDDP and of 
ternary mixtures of GSH with C0 and CDDP against the wild type leukemic (CCRF-CEM) cancer 
cell lines and its cisplatin-resistant subline (Chapter 3 – Manuscript I). For the evaluation of the 
cytotoxic effects of the mixtures, I applied a method based on the use of experimental design for the 
choice of the mixtures and on artificial neural network for the evaluation of the experimental 
results.  
A synergistic effect was evidenced between C0 and cisplatin or GSH, while an antagonistic 
effect was shown by CDDP and GSH, for both the cell lines. The calculated synergistic surfaces for 
the binary systems CDDP-GSH, C0-GSH, and C0-CDDP, for CCRF-CEM-wt cell line are reported 
in Figure 13. 
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Figure 13. Synergistic surfaces for the binary systems of (A) CDDP and GSH, (B) C0 and GSH, 
(C) C0 and CDDP for CCRF-CEM-wt cell line. An antagonistic effect is shown by combinations of 
CDDP and GSH for concentration of GSH higher than 200 µM, a synergistic effect is shown by C0 
with CDDP and GSH for selected combinations. 
 
For the ternary systems it was observed that in presence of C0, the sensitivity of the cells, wild 
type and/or resistant ones, towards CDDP in presence of GSH was restored, i.e. the antagonistic 
effect of the GSH versus CDDP was prevented. Furthermore, a synergistic effect was found for 
selected combinations. The plots showing the influence of the concentration of C0 to the 
synergistic/antagonistic effect of mixtures CDDP-GSH for the CCRF-CEM-wt cells are reported in 
Figure 14. 
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Figure 14. Three-dimensional solid showing the synergistic effect for the ternary systems 
CDDP-GSH-C0 for CCRF-CEM-wt cell line (A), some selected planes of the solid (B); the color of 
the points is proportional to the synergistic effect, in particular red represents antagonistic effect, 
blue represents the synergistic effect, and white the additive effect). 
 
The selectivity of these cocktails of drugs was evaluated testing the compounds also against ex 
vivo cultures of human Peripheral blood Lymphocytes (PBLs). The drug combination was totally 
devoid of cytotoxicity on the PBLs cells after 24 h, 48 h and 72 h of incubation. If we consider the 
effects of the ternary combination vs. the single-drug treatments in the PBLs, the drug cocktail 
always showed a degree of cytotoxicity comparable to that of the CDDP alone, whereas in the 
CCRF-CEM cells the toxic effect of the combination was 7 fold greater than that of CDDP alone.  
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1. Introduction 
Cisplatin, [Pt(NH3)2Cl2] (CDDP), is a cytotoxic agent currently used in the clinic for many types of 
cancer, i.e. ovary, testicle, head and neck, bones, brain, lymph node and skin cancers (1) (2). In the 
bloodstream CDDP binds different plasmatic thiol-containing proteins (3) (4) and only free CDDP 
molecules can enter the cell. As [Pt(NH3)2(H2O)Cl]
+
 species, it reacts with a DNA base (5) (6) (7) 
leading to DNA distortions that, depending on the extent of the damages, activate DNA repair 
pathways or trigger the apoptotic cascade (8) (9) (10). Beside of the total lack of selectivity towards 
cancer cells, the real CDDP effectiveness in monotherapy, as well as in multidrug protocols, is yet 
limited by the selection of CDDP-resistant cancer cell populations during cycles of chemotherapy. 
Claimed mechanisms of CDDP-resistance include i) over-expression of drug-efflux pumps, ii) 
increased ability to repair and/or to tolerate damaged DNA, and iii) increased intracellular levels of 
thiol-containing molecules, particularly of glutathione (GSH) (8) (9). Although some authors 
associated CDDP-resistance with the formation of CDDP / GSH adducts, i.e. bis-(glutathionato)-
platinum [Pt(GS)2], preventing CDDP from binding DNA (11), others sustain that direct binding of 
Pt(II) of CDDP with GSH is not the most important cellular interaction (12). Actually, in some 
cases, CDDP-resistant cancer cells showed an increased intracellular levels of GSH (1), but given 
that higher GSH levels were not found to be correlated with lower Pt(II)-DNA adducts, it has been 
proposed that GSH might play a role in apoptotic regulatory pathways (13). Whatever is the 
mechanism(s) of CDDP resistance involving GSH, a reported feature of cancer cells is the presence 
of an increased ratio of the oxidized (GSSG) vs. the reduced (GSH) form of glutathione, which in 
physiologic conditions is maintained 1:10 by glutathione reductase (8) (9).   
In previous works, we have shown in a wide range of hematologic and solid tumor cell lines, the 
cytotoxic effects of a novel class of complexes of copper(II) with 1,10-phenantroline (phen); the 
most potent being the complex [Cu(phen)2(OH2)](ClO4)2  C0 (14) (15) (16).  In one of these studies 
we also reported that GSH, known to reduce free Cu(II) to Cu(I) thus increasing GSSG formation, it 
is not able to reduce Cu(II) to Cu(I) in the complex C0, likely by virtue of the stabilizing effect of 
phen ligand towards the bivalent form of the metal ion, as we observed the formation of two 
complexes with one or two molecules of GSH per metal ion (15).  Besides, in a more recent work 
we highlighted a strong synergic cytotoxic effect of C0 in dual-drug combinations with CDDP 
against human T-leukemia CCRF-CEM cells (17). The potential clinical relevance of our findings 
coupled with the literature data calling GSH into play in cancer cells and / or in resistance to CDDP, 
prompted us to widen further our studies by investigating the cytotoxic activity of binary mixtures 
of GSH with C0 or with CDDP, and of ternary mixtures of GSH, C0, and CDDP in populations of 
CCRF-CEM cells expressing phenotypes drug-sensitive, CEM wild type (CCRF-CEM-wt), or 
CDDP-resistant (CCRF-CEM-res). For the evaluation of types and degree of drug interactions in 
  
both the binary and ternary combinations, we applied the method detailed in our previous work 
(17), which is based on the use of Experimental Design (ED) for the choice of the drug mixtures, 
and on Artificial Neural Network (ANN) for the evaluation of the experimental results. The toxic 
effect of ternary mixture was investigate on ex vivo cultures of human Peripheral blood 
Lymphocytes (PBLs). 
 
2. Materials and Methods 
2.1 Reagents 
Copper(II) carbonate basic (Cu2(CO3)(OH)2), 1,10-phenanthroline monohydrate, cisplatin, 
perchloric acid, ethanol, ethyl ether, dimethyl sulphoxyde (DMSO), glutathione (GSH), acetonitrile, 
trypan blue, Staurosporine and Doxorubicin were purchased from Sigma-Aldrich (Milan, Italy) and 
used without any further purification. Interleukin 2 was purchased from Roche. Foetal bovine serum 
(FBS), Phytohemagglutinin (PHA) and kanamycin sulphate were purchased by Gibco-Invitrogen 
(Milan, Italy) and used without any further purification. RPMI 1640 with stable L-glutamine was 
purchased by EuroClone. Stock solutions of compound C0, CDDP and Staurosporine were prepared 
in DMSO, at 1000× of the highest concentration to be used on the cell culture and stored at 4 °C in 
the dark. CDDP stock solution, being stable only for few hours and showing a decreasing of the 
cytotoxic potency during the time, was prepared fresh each time immediately before the 
experiments.  GSH stock solution was prepared in RPMI medium and filtered.  
 
2.2 Synthesis 
The compound C0 was prepared as previously reported (15) (16).  
 
2.3 Cell lines 
The human acute T-lymphoblastic leukemia cells (CCRF-CEM) with its respective cisplatin-
resistant subline were used in the study. The CCRF-CEM human cell line was purchased from the 
American Type Culture Collection (ATCC-LGC; Milan, Italy). The CCRF-CEM-wt and CCRF-
CEM-res cell lines were maintained in culture between 1 × 10
5
 cells/ml and 1 × 10
6
 cells/ml in 
RPMI medium 10% foetal bovine serum (FBS) with 1% kanamycin (growth medium). To the 
growth medium for CCRF-CEM-res cell cultures, we also added cisplatin (5 μM). The cells were 
periodically checked for micoplasma contamination. For the experiments, the cell line was replaced 
every 3 months with freshly-towed cells from the cell stores in liquid nitrogen. 
 
 
 
  
2.4 Selection of the cisplatin-resistant CCRF-CEM subline 
A CCRF-CEM subline able to grow at the same extent in the absence and in the presence of 5 μM 
cisplatin (CCRF-CEM-res) was obtained by serial passages of wild-type cells in the presence of 
increasing cisplatin concentrations, starting from a sub-inhibitory concentration (0.5 μM). At each 
cell passage (every 3–4 days), the number of viable cells of cisplatin-treated cultures was compared 
to that of duplicate untreated cultures.  
Initially the CDDP concentration was increased by 0.25 μM at each cell passage up to 1.50 μM; 
from then on, cisplatin-treated cultures grew poorly and much slower than their untreated 
counterparts and had to be kept (5 consecutive passages) at the same CDDP concentration until the 
cell population had regained original growth timing and viability. After that the CDDP 
concentration was gradually increased. Given that cell cultures never survived at concentrations 
over 5 μM, the cell population was stabilised by 15 further passages at 5 μM CDDP. The number of 
viable cells was determined at each cell passage by the trypan blue exclusion method. At intervals 
during the selection process, the level of CDDP resistance was checked by the 3-(4,5- 
dimethylthiazol-2-yl)-2,5-diphenyl-tetrazolium bromide (MTT) method in cells that had grown 
without the drug for one passage. Resistance Index (RI) was calculated as ratio between IC50 in 
CCRF-CEM-res and CCRF-CEM-wt; Doxorubicin was used as a reference compound to evaluate 
the cisplatin-resistance specificity. 
 
2.5 Cytotoxic assay 
The biological stability of stocks solutions was checked verifying the cytotoxic activity measured 
by using the same solutions over more than 6 months. The tested compounds maintained the same 
IC50 (concentration of compound that reduce the viable cell by 50% with respect to untreated cells) 
in all the performed experiments. Dilutions of the drug stocks for biologic investigations were made 
in RPMI medium at 2x the final concentration for single drug evaluations, or at 4x the final 
concentration for evaluation of binary and ternary drug combinations. The concentration of DMSO 
in the cells was never higher than 0.1%. The effects of the drugs and drug combinations were 
evaluated in cultures of exponentially growing cells; for experiments in cisplatin-resistant cell 
cultures, were allowed to grow in the absence of the drug for 1 passage.  CCRF-CEM-wt and 
CCRF-CEM-res cells  were  seeded  at a density of 1 × 10
5
 cells/well of growth medium in flat-
bottomed 24-well plates and simultaneously exposed to the drugs or drug combinations. Cell 
growth in the absence and presence of drugs was determined after 96 h of incubation at 37 °C and 
5% CO2 (corresponding to three to four duplication rounds of untreated cells), through the viable 
cell counting with the trypan blue exclusion method. Values obtained in drug-treated samples were 
  
expressed as percentages of those of their respective controls. All experiments were repeated three 
times.  
 
2.6 Peripheral blood Lymphocytes (PBLs) separation  
Peripheral blood Lymphocytes from healthy donors were obtained by method of gradient separation 
Lympholyte-H (Cedarlane). After extensive washing, cells were resuspended (1 x10
6 
cells/ml) in 
RPMI-1640 with 10% FBS and incubated overnight.  
For evaluations in resting PBLs, 1 x 10
5
 cells/well were incubated in RPMI-1640 with 10% FBS in 
the absence or presence of the compounds at the indicate concentration in 24-well plat, at 37° C and 
5% CO2 , for 24 h, 48 h, 72 h.  
For experiments with proliferating PBLs, 1 x 10
5
 cells/well were incubated in RPMI-1640 with 
10% FBS supplemented with PHA (2.5 µg/ml) or supplemented with PHA (2.5 µg/ml) and 
interleukin 2 (5 U/mL) in the absence or presence of the compounds at the indicate concentration in 
flat-bottomed 24-well plates, at 37° C and 5% CO2.   
Cell growth in the absence and presence of drugs was determined after 24 h, 48 h and 72 h of 
incubation at 37 °C and 5% CO2 through the viable cell counting with the trypan blue exclusion 
method. Values obtained in drug-treated samples were expressed as percentages of those of their 
respective controls. All experiments were repeated three times using PBLs from three different 
healthy donors. 
 
2.7 Procedures of the applied method 
The used ED-ANNs method consists of the following steps: 
1. Set-up of the ED for the choice of the combinations to be evaluated 
2. Experimental determination of the cytotoxicity of the drugs alone and of the multidrug 
mixtures prepared according to the chosen ED 
3. Training and verification of the artificial neural network to plan and set up the prediction 
ability of the network 
4. Prediction of the response using the network according to a suitable grid that covers the 
whole working space 
5. Calculation of the non-algebraic additive effect (NAAE) (17) for each point of the used grid, 
i.e. for each combinations of the drugs 
6. Calculation of the Net Multi Drug Effect Index (NMDEI) (17) to determine the global effect 
(synergism, additive effect or antagonism) 
7. Test of the obtained results. 
  
2.8 Software 
ANNs computation was performed using EasyNN-plus (Neural Planner Software Ltd, Cheadle 
Hulme, UK). All computations were performed on a standard PC computer with Microsoft 
Windows Vista as operating system.  
 
3. Results and discussion 
3.1 Set up of the ED 
For the study of drug combinations, the concentrations of the drugs should be chosen in the range 
within 0 and twice the IC50 (the dose odf the drug which inhibits 50% of the cell proliferation). 
Then the knowledge of a simple estimation of IC50 is needed. To model the dose response curve of 
each drug and the cytotoxicity response surface an adequate number of experiments is required. A 
non-symmetrical experimental design has been used.  
The C0 and CDDP compounds were studied in the range of concentration of 0 -  2 µM while GSH 
in the interval 0 - 1000 µM.  
We prepared for CCRF-CEM-wt i) 6 combinations of GSH and C0; ii) 6 combinations of GSH and 
CDDP; iii) 7 combinations of C0 and CDDP; iv) 52 combinations of GSH, C0 and CDDP; v) 10 
solutions of CDDP alone, vi) 9 solutions of GSH alone and vii) 11 solutions of C0 alone; for 
CCRF-CEM-res i) 9 combinations of GSH and C0; ii) 9 combinations of GSH and CDDP; iii) 9 
combinations of C0 and CDDP; iv) 27 combinations of GSH, C0 and CDDP; v) 3 solutions of 
CDDP alone, vi) 3 solutions of GSH alone and vii) 3 solutions of C0 alone. 
Following the Experimental Design reported in Figures 1-2, solutions as i), vi) and vii) were used to 
study the binary system GSH-C0 (Figures 1A, 2A); solutions as ii), v) and vi) were used to study 
the binary system GSH-CDDP (Figures 1B, 2B); solutions as iii), v) and vii) were used to study the 
binary system CDDP-C0 (Figures 1C, 2C); solutions as iv), v), vi) and vii) were used to study the 
ternary system CDDP-GSH-C0 (Figures 1D, 2D). 
 
  
 
Figure 1. Concentration of combinations of (A) GSH and C0, (B) GSH and CDDP, (C) CDDP 
and C0, (D) GSH, C0 and CDDP for CCRF-CEM-wt cell line. 
 
 
Figure 2. Concentration of combinations of (A) GSH and C0, (B) GSH and CDDP, (C) CDDP 
and C0, (D) GSH, C0 and CDDP for CCRF-CEM-res cell line. 
 
 
  
3.2 Determination of the cytotoxicity of the drugs 
The experiments were carried out in three replicates. The vitality (% of living cells) after the 
treatment with the drugs was measured for each solution with respect to the control (untreated cells) 
and converted, for calculation purpose, into mortality (as 100% minus vitality). 
 
3.3 Training and verification of the artificial neural network 
The concentrations of drugs and the related mortality values were used to form the data matrix. 
Concentrations of drugs were used as input data and the experimental mortality as output ones. The 
standard back-propagation was used as training algorithm. The optimal neural network architecture 
was searched for using the criteria of lowest RMSE and it was found that a three layers structure 
with 4 (binary systems) and 5 (ternary system) neurons in the hidden layer was sufficient. The 
architecture of the network for the ternary system is shown in Figure 3. 
 
 
Figure 3. Architecture of the network used for the study of C0-CDDP-GSH ternary system. 
 
The network was trained and verified using the training and validation sets. All points lying on the 
borders of the experimental design were included in the training set. Validation points were chosen 
randomly on the working space. Among the prepared 101 solutions for CCRF-CEM-wt, 80 were 
used as training set, 9 as validation set and 12 as test set, among the prepared 63 solutions for 
CCRF-CEM-res, 40 were used as training set, 11 as validation set and 12 as test set. 
The generalization ability of the network was used to predict the cytotoxicity on the whole working 
space according to a bi-dimensional grid with 40 points per side for the binary systems and 
according to a cube with 20 points per side for the ternary system. At first, the data of binary 
systems were processed individually. Then, data of binary and ternary systems were processed 
together. The results for the binary systems obtained in the two processes were strictly comparable, 
proving the robustness and the reliability of the method. The agreement between calculated and 
experimental values for all the data for CCRF-CEM-wt cell line is shown in Figure 4 as example. 
  
 
 
Figure 4. Comparison between experimental and calculated mortality values (■  training set, ☆ 
validation set) for the ternary systems C0-CDDP-GSH for CCRF-CEM-wt cell line(linear fitting 
parameters for the equation y = mx+q are m = 0.9951, q = 0.007 with r = 0.9974 for training set,  m 
= 0.9536, q = 0.0038 with r = 0.9947 for validation set, m = 0.9912, q = 0.0092 with r = 0.9974 for 
all the data). 
 
3.4 CCRF-CEM-wt cell line 
3.4.1 Prediction of the response (cytotoxicity surfaces) 
The cytotoxicity of the mixtures and that of the drugs alone for the whole working space, were 
calculated by using the network. The dose-response curves for each compound and the cytotoxicity 
surface were then obtained.  
The calculated dose-response curves together with the experimental points for CDDP, GSH and C0 
for CCRF-CEM-wt cell line are reported in Figure 5A,B,C, respectively.  
 
 
Figure 5: Calculated dose-response curve (-•-) and experimental points (■) for (A) CDDP, (B) 
GSH and (C) C0, for CCRF-CEM-wt cell line. 
 
  
The different trends of the curves may suggest a different action mechanism inside the cells. The 
threshold doses (the minimum dose at which the drug presents an effect) for the three compounds 
are: 0.25 µM for CDDP, 150 µM for GSH and 0.5 µM for C0. The IC50 values are in the order 
CDDP (0.78 µM) < C0(1.05 µM) << GSH (332.1 µM).  
The cytotoxicity of C0 and CDDP are comparable. Also GSH presents a cytotoxic activity towards 
cancer cells. 
 
3.4.1.1 Binary mixtures 
The response surfaces calculated by the network (together with the experimental points) and the 
related contour plots for C0-CDDP, CDDP-GSH, and C0-GSH systems are shown in Figure 
6A,B,C. The calculated values are in good agreement with the experimental ones. The mortality 
increases with the concentrations of the two drugs, having similar trend to that one of the dose-
response curve. 
The areas of cytotoxicity iso-values of the contour plot for the binary mixtures can be explored to 
discover the combination with desired cytotoxicity and the related dose of both drugs. For example, 
if a toxicity of 50% is searched for, instead of choosing C0 alone at a concentration of 0.99 μM or 
CDDP alone at a concentration of 0.77 μM or GSH alone at a concentration of 403 μM, selected 
combination may be choosen, as: 
 C0 at 0.26 μM and CDDP at 0.40 μM (Figure 6A); 
 CDDP at 0.32 μM and GSH at 200 μM (Figure 6B); 
 C0 at 0.42 μM and GSH at 200 μM (Figure 6C). 
For a toxicity of 70%, instead of choosing C0 alone at a concentration of  1.20 μM or CDDP alone 
at a concentration of 1.13 μM or GSH alone at a concentration of 769 μM, selected combination 
may be choosen, as: 
 C0 at 0.32 μM and CDDP at 0.40 μM (Figure 6A); 
 CDDP at 0.63 μM and GSH at 240 μM (Figure 6B); 
 C0 at 0.47 μM and GSH at 200 μM (Figure 6C). 
The possibility to reach the same effect but with lower doses of the drugs gives the chance to 
minimize the side effects related to the doses.  
 
  
 
Figure 6. Calculated response surface and contour plot of cytotoxicity iso-values for the systems 
(A) C0-CDDP, (B) CDDP-GSH and (C) C0-GSH for CCRF-CEM-wt cell line; experimental points 
(■) are superimposed. 
 
3.4.1.2 Ternary mixtures 
The mortality surfaces calculated by the network for the ternary system CDDP-GSH-C0 is shown in 
Figure 7A (colour is proportional to the cytotoxic activity of the mixtures). To simplify the 
interpretation of the graph and to appreciate the trend of the cytotoxicity also in the core of the 
cube, only seven planes along the z axis have been reported in Figure 7B.  
 
 
Figure 7. Full calculated response surface for the ternary systems CDDP-GSH-C0 for CCRF-CEM-
wt cell line (A), some selected planes are reported for clarity (B); the colour of the point is 
proportional to the cytotoxic activity. 
 
  
As can be seen from the graph, a low value of cytotoxicity appears for low concentrations of all the 
compounds, while for concentration higher than 1 µM for C0 or CDDP the activity reaches quickly 
the highest value of 100%. Several combinations with a cytotoxic activity of 50% or 70% may be 
chosen, as for example: 
 C0 at 0.11 µM, CDDP at 0.21 µM and GSH at 250 µM (mortality values of 50%) 
 C0 at 0.32 µM, CDDP at 0.11 µM and GSH at 200 µM (mortality values of 50%) 
 C0 at 0.11 µM, CDDP at 0.63 µM and GSH at 200 µM (mortality values of 70%) 
 C0 at 0.11 µM, CDDP at 0.11 µM and GSH at 650 µM (mortality values of 70%) 
 C0 at 0.11 µM, CDDP at 0.42 µM and GSH at 400 µM (mortality values of 70%) 
 
3.4.2 Calculation of the non-additive effect and of the net multi drug effect index 
The non-algebraic additive effect (NAEE) of the combined drugs was calculated according to the 
equation already presented (17). The synergistic/antagonistic effect was evaluated calculating the 
net multi drug effect index (NMDEI) (17) for all the points of the used grid. The calculated surfaces 
show (Figure 8 for the binary systems and Figure 9 for the ternary system) the possible interactions 
occurring between two or among three drugs, allowing to determine if there is a synergistic or an 
antagonistic effect.  
 
 
Figure 8. Synergistic surfaces for the binary systems of (A) CDDP and GSH, (B) C0 and GSH, (C) 
C0 and CDDP for CCRF-CEM-wt cell line. 
 
  
 
Figure 9. Synergistic surfaces for the ternary systems CDDP-GSH-C0 for CCRF-CEM-wt cell line 
(A), some selected planes are reported for clarity (B); the color of the points is proportional to the 
synergistic effect. 
 
3.4.2.1. Binary mixtures of CDDP and GSH  
In the plot of the NMDEI as a function of CDDP and GSH concentrations (Figure 7A) a maximum 
(value is 42.0) is present for a concentration of CDDP 0.39 µM and of GSH 247 µM. At these 
concentrations both the two drugs, taken individually, present a mortality value of 10%, while their 
combination present a mortality value of 53.9% (Figure 6B). A synergistic effect is evident. 
In the plot there is a wide area of negative values, in particular in the region where 0.76 µM ≤ 
CDDP ≤ 1.48 µM and 384 µM ≤ GSH ≤ 684 µM, with a minimum (value is -12.4) at CDDP 1.14 
µM and GSH 533 µM. This combination presents a cytotoxicity value of 75.7% (Figure 6B), while 
the two drugs alone show at the same concentrations, a cytotoxicity of 69.6% and 65.0%, 
respectively. In this case an antagonistic effect is present. 
 
3.4.2.2 Binary mixtures of C0 and CDDP 
In Figure 8C is showed the plot of NMDEI as a function of the concentration of C0 and CDDP. 
There is a wide positive area that indicates a synergistic effect between the two drugs. A maximum 
of NMDEI (value is 91.9) appears for CDDP 0.34 µM and C0 0.54 µM. This combination shows a 
cytotoxicity of 96.7% (Figure 6A) while the two compounds alone show at the same concentration 
of the combination, a cytotoxicity values of 3% and 6%, respectively. The synergistic effect 
between C0 and CDDP is in agreement with my previous findings (17).  
 
3.4.2.3 Binary mixtures of C0 and GSH  
In Figure 8B is reported the plot of the NMDEI as a function of C0 and GSH concentrations. A 
maximum (value is 89.2) is present for C0 at 0.60 µM and GSH at 220 µM. At these concentrations 
  
the two drugs, taken individually, present a mortality value of 8% and 6% respectively, while their 
combination present a mortality value of 95.7% (Figure 6C). A clear synergistic effect is evident. 
 
3.4.2.4 Ternary mixtures of CDDP, GSH and C0 
For the evaluation of the three-drugs system, cubic surface has been build up, representing the 
NMDEI value with the colour of the points (Figure 9A). For clarity only 6 planes were represented 
in Figure 9B. It shows the influence of the concentration of C0 to the cytotoxicity of the mixtures. 
In absence of C0 (first plane from the bottom), for high concentrations of GSH, there is antagonism 
between CDDP and GSH. In presence of concentrations of C0 higher than 0.5 µM the antagonism 
between CDDP and GSH disappears. There is synergism between C0 and CDDP only at low 
concentration of GSH (for [C0]=[CDDP]= about 0.75 µM) (this could be explained by the 
formation of an adduct Pt-C0 and high concentration of GSH interfere with this reaction).  
Summarizing it’s possible to see that: 
- at low concentrations of C0, there is antagonism between GSH and CDDP; 
- at low concentrations of GSH, there is a good synergy between C0 and CDDP, for a 
combination in molar ration of about 1:1. 
 
3.5 CCRF-CEM-res cell line 
3.5.1 Selection of a cisplatin-resistant CCRF-CEM subline  
Given the potential relevance of this finding for the clinic of cancer, it was of primary importance to 
investigate the effect of such drug combinations in sub-populations of the same cell line that 
showed a phenotype of resistance to CDDP (CCRF-CEM-res). To this end, a parallel culture of 
CCRF-CEM cells was serially passaged in the presence of increasing concentrations of CDDP. The 
selection of a CCRF-CEM subline with a stable phenotype of CDDP resistance was a long 
procedure that took about 7 months as cell cultivation in the presence of increasing drug doses had 
to be alternate with several passages at a constant concentration in order to avoid total cell death.  
At first, cells were grown in the presence of a concentration of CDDP equal to 1/2 of the IC50, i.e. 
0.5 μM.  This CDDP concentration was initially increased by 0.25 μM doses at each passage, but 
once the concentration of 1.50 μM was reached, it was necessary to dwell for 5 consecutive 
passages at the same concentration. If further increased, in fact, the cells started growing with 
difficulty, the percentage of viability dropped, and the few viable cells showed the tendency to form 
clusters, an unusual feature for this type of cells. After that, the CDDP concentration could be 
increased to 1.75 μM for 2 passages, to 2 μM for 12 passages, then to 2.50 μM for 14 passages, and 
finally to 5μM, the maximum drug concentration at which cells seemed able to multiply; in our 
hands, in fact, CCRF-CEM cells were not able to adapt to CDDP concentrations higher than 5μM. 
  
The latter cell population was stabilized at 5μM CDDP by further 15 passages, then amplified, 
grown for one passage in the absence of the drug. Aliquots were stored in liquid nitrogen for 
experimental use. 
At different times during the selection procedure, the sensitivity of cells to CDDP was determined 
and compared to that of the wild type CCRF-CEM cells by the MTT method. As can be seen (Table 
1), only after 52 passages in the presence of CDDP it was possible to obtain a stable CCRF-CEM-
res subline showing a Resistance Index (RI) of about 6.  
It is worth mentioning that cell populations growing in the presence of CDDP, as well as the final 
one resistant to CDDP, never showed at any extent cross-resistance to the Cu(II) complex C0, 
indicating a different mechanism(s) of resistance of the two drugs, and thus also different molecular 
targets and modes of action. No modification in the cell sensitivity to the reference compound 
doxorubicin was ever observed. 
 
Table 1. Citotoxicity of CDDP and C0 against CCRF-CEM-wt and CCRF-CEM-res after 14, 26 
and 52 passages in the presence of CDDP. 
 CDDP C0 Doxorubicin 
CCRF-CEM-wt ± 1.12 µM 1 µM 0.02 µM 
CCRF-CEM-res 2.6 µM 0.8 µM 0.02 µM 
R.I.= 2.32 (14th passage) 
CCRF-CEM-wt ± 1.12 µM 1.1 µM 0.02 µM 
CCRF-CEM-res 2.52 µM 0.8 µM 0.02 µM 
R.I.= 2.25 (26th passage) 
CCRF-CEM-wt ± 1.12 µM 1 µM 0.02 µM 
CCRF-CEM-res 6.98 µM 0.74µM 0.02 µM 
R.I.= 6.23 (52th passage) 
 
Because cell resistance to CDDP has been reported to be multifactorial, i.e. reduced drug 
accumulation, increased drug inactivation, enhanced DNA-repair and increased DNA-damage 
tolerance, we deemed appropriate to obtain mechanistically homogenous cell clones from the mixed 
CDDP-resistant cell population in order to study them separately. However, despite of the several 
efforts made to grow cell clones by single-cell dilutions, an otherwise successful procedure to 
obtain cloned cell populations, in no case single-cell cultures were able to survive and multiply. 
Failed the separation of CDDP-resistant cells into different cloned populations, all studies implying 
CDDP-resistant CCRF-CEM cells had to be performed on the cell subline stabilized at 5µM CDDP.  
  
3.5.2 Calculation of the non-additive effect and of the net multi drug effect index 
The cytotoxicity of mixtures and drugs alone, together with the response surfaces, were calculated 
by using the network, for the case CCFR-CEM-res, following the same procedure adopted for the 
CCRF-CEM-wt. The calculated surfaces for the binary systems and that for the ternary system are 
reported in Figure 10 and Figure 11, respectively. 
 
 
Figure 10. Synergistic surfaces for the binary systems of (A) CDDP and GSH, (B) C0 and GSH, 
(C) C0 and CDDP for CCRF-CEM-res cell line. 
 
 
Figure 11. Synergistic surfaces for the ternary system CDDP-GSH-C0 for CCRF-CEM-res cell line 
(A), some selected planes are reported for clarity (B); the color of the points is proportional to the 
synergistic effect. 
  
3.5.2.1 Binary mixtures 
In the plot of the NMDEI as a function of CDDP and GSH concentrations (Figure 10A), there is a 
wide negative area that indicates an antagonistic effect between the two drugs. A minimum of 
NMDEI (value is -53.8) appears for CDDP 15 µM and GSH 950 µM. This combination shows a 
cytotoxicity of 42 %, while the two drugs alone show at the same concentrations, a cytotoxicity of 
94.4 % and 24.9 %, respectively. In the plot, there is a limited positive area, in particular in the 
region where 0.79 µM < CDDP < 3.95 µM and 50 µM < GSH < 300 µM, with a maximum of 4.1.  
In Figure 10B, is reported the plot of NMDEI as a function of the concentration of C0 and GSH. In 
all the studied region, a synergistic effect is evident. Two maximums (values are 70.9 and 65.4) 
appear for C0 0.42 µM and GSH 900 µM, and for C0 0.53 µM and GSH 350 µM. The second 
combination presents a cytotoxicity value of 95.6 %, while the two drugs alone show at the same 
concentrations, a cytotoxicity of 10.8 % and 21.8 %, respectively.  
In Figure 10C, is showed the plot of the NMDEI as a function of C0 and CDDP concentrations. The 
wide positive area indicates a synergistic effect between the two drugs. A maximum of NMDEI 
(value is 28.3) appears for C0 0.74 µM and CDDP 4.74 µM. This combination shows a cytotoxicity 
of 87.8 %, while the two compounds alone show at the same concentrations of the combination, a 
cytotoxicity values of 45.5 % and 25.7 %, respsectively. In the plot there is a limited negative area, 
in particular in the region where 0.11 µM < C0 < 0.52 µM and 0.78 µM < CDDP < 8.68 µM, with a 
minimum of -2.9. 
 
3.5.2.2 Ternary mixtures of CDDP, GSH and C0 
In Figure 11, the plots show the influence of the concentration of C0 to the cytotoxicity of the 
mixtures CDDP-GSH. As for CCRF-CEM-wt, in absence of C0 there is antagonism between 
CDDP and GSH. In presence of concentrations of C0 higher than 0.4 µM the antagonism between 
CDDP and GSH disappears.  
 
3.6 Test points 
The most relevant combinations of drugs were chosen as test point and the mixture were prepared 
and the corresponding cytotoxicity measured, to compare the experimental values with the ones 
calculated by the network. The mortality values calculated with the network are in good agreement 
with the experimental ones, confirming the predicting abilities of the network. 
 
 
  
3.7 Cytotoxic effects of the ternary drug combination in ex vivo cultures of 
human PBLs from healthy donors 
On the basis of the strong cytotoxic synergism shown by the CDDP-C0-GSH combination in 
CCRF-CEM-wt and CCRF-CEM-res tumour cell lines, either drug-sensitive and CDDP-resistant, it 
was of critical importance to investigate their toxic effect on normal cells so as to have an estimate 
of the selectivity of action of these cocktails of drugs. 
To this end, human peripheral blood lymphocytes (PBLs) freshly isolated from blood samples of 
healthy donors were seeded at the same cell density as such (i.e. resting PBLs), in the presence of 
the mitogen PHA (i.e. PHA-activated PBLs), or in the presence of both PHA and the growth factor 
Interleukin-2 (i.e. PHA/IL2-stimulated PBLs). Each of these cultures were then incubated in the 
presence of the most synergic three-drug combination in CCRF-CEM-wt cells and in the presence 
of the single drugs, each of them at the same concentrations present in the combination; i.e. 0.5µM 
CDDP, 0.5µM C0, and 300 µM GSH. The numbers of viable cells were determined by the trypan 
blue exclusion method and reported as percentage of untreated controls after 24 h (Figure 12A-C), 
48 h (Figure 13A-C) and 72 h (Figure 14A-C) of incubation in comparison to those of CEM cells 
incubated in parallel under the same drug conditions (Figs 12D,13D,14D). It has to be mentioned 
that the PBL values in Figures 12,13,14 are the mean data of independent experiments with PBLs 
isolated from three different donors, whereas in Figure 15 PBL growth curves and viable cell counts 
of untreated vs. drug combination treated PBLs isolated from one single donor are shown. 
 
Figure 12. Cytotoxic activity of C0, CDDP, and GSH, alone and in ternary combinations, in freshly 
isolated human PBLs and in CCRF-CEM-wt cells after 24 h of treatment. (A) resting PBLs, (B) 
PHA-stimulated PBLs, (C) PHA+ IL2- stimulated PBLs, (D) CCRF-CEM-wt. Values obtained in 
drug-treated samples were expressed as percentages of their respective controls. 
  
 
 
Figure 13.  Cytotoxic activity of C0, CDDP and GSH, alone and in ternary combinations, in freshly 
isolated human PBLs and in CCRF-CEM cells after 48 hours of treatment. (A) resting PBLs, (B) 
PHA-stimulated PBLs, (C) PHA+ IL2- stimulated PBLs, (D) CCRF-CEM-wt. Values obtained in 
drug-treated samples were expressed as percentages of their respective controls. 
 
 
Figure 14. Cytotoxic activity of C0, CDDP and GSH,  alone and in ternary combinations, in freshly 
isolated human PBLs and in CCRF-CEM-wt cells after 72 h of treatment. (A) Resting PBLs, (B) 
PHA-stimulated PBLs, (C) PHA+ IL2- stimulated PBLs, (D) CCRF-CEM-wt. Values obtained in 
drug-treated samples were expressed as percentages of their respective controls. 
 
  
 
Figure 15. Growth curves and cell numbers of untreated vs. ternary combination-treated CEM  and  
PBL cells. (A) Growth curves of CCRF-CEM-wt and PBLs. Viable cell numbers in untreated vs. 
ternary combination-treated CCRF-CEM-wt and PBLs after 24 h (B), 48 h (C), 72 h (D). 
 
 Single-drug treatments with 0.5µM CDDP showed a cytotoxic effect increasing over time only 
against active/proliferating cell cultures, i.e. against both PHA-activated and PHA/IL2-stimulated 
PBLs, and against CCRF-CEM cells, while, as expected, it had only negligible effects against non-
activated/non-proliferating cells (i.e. resting-PBLs). After 72 h of incubation, the degree of 
cytotoxicity of CDDP was comparable in PBLs and CEM cells, with an average of 60%-70% cell 
viability with respect to their respective untreated controls. In the PBL cultures, however, the 
CDDP effect was more precocious (i.e. in PHA/IL2-stimulated at 24 h; in PHA-activated at 48 h) 
than in the CCRF-CEM cultures; viable CCRF-CEM cells being still over 80% of controls at 24 h, 
and over 70% of controls at 48 h. 
The cytotoxic effect in PBLs of 0.5µM C0 appeared to better correlate with the activation stage of 
the cells; the viability of PHA/IL2-stimolated PBLs was reduced by 30% already after 24 h, while 
that of the PHA-activated PBLs by 25%-30% only after 48 h. Differently from CDDP, C0 seemed 
to affect the viability also of the resting PBLs as a slight toxic effect, i.e. a 10% to 20% mortality 
was observed in each PBL preparation of the three different donors. In CCRF-CEM cells, the 
cytotoxicity of C0 appeared to be even lower, if any, than in the resting PBLs: the viability of 
treated CCRF-CEM cells being over 90% of controls at all time points considered. 
Treatments with 300µM GSH were instead more toxic in CCRF-CEM cells than in PBLs, and 
among the latter, the PHA/IL2-stimulated were affected the most followed by the PHA-activated, 
whereas resting PBLs were not affected at all. Although GSH cytotoxicity was greater against the 
  
CEM cells (60%-70% mortality) than against PHA/IL2-stimulated PBLs (50% mortality), in both 
types of cell cultures the maximum effect was reached after 48 h of exposure to GSH. 
Compared to the single-drug treatments, in CCRF-CEM cells the drug cocktail confirmed the 
synergic effect showing a very strong toxic activity already in the first 24 h (over 80% mortality) 
which further increased at 48 h and 72 h with a mortality of 87% and 92%, respectively.   
As for the PBLs, the PHA/IL2-stimulated were the most sensitive of all PBL cultures to the toxic 
effect of the drug combination that was, however, both less potent and more delayed with respect to 
that exerted in the CCRF-CEM cells, i.e. a 50% mortality only after 48 h, which did not increase 
further with time. The toxic effect against the PHA-activated PBLs was even slower than that 
shown in the PHA/IL2-stimulated, 20%- 30% mortality at the first two time points, and comparable 
only after 72 h. The drug cocktail was totally devoid of cytotoxicity on the resting PBLs at any time 
points considered. 
Moreover, if we consider the effects of the ternary combination vs. the single-drug treatments in the 
PBLs, the drug cocktail always showed a degree of cytotoxicity comparable to that of the CDDP 
alone, whereas in the CCRF-CEM cells the toxic effect of the combination was 7 fold greater than 
that of CDDP alone. 
Taken together, these findings are very promising given that the ternary combination showed a 
selective cytotoxic effect for T-leukemia CEM cells with respect to proliferating normal T-cells. 
Beside of being more potent against the leukemic CEM cells (8% viability after 72 h) than against 
PHA/IL2-stimulated PBLs (50% viability at 72 h), the effect of the ternary combination against 
CEM cells appeared to be also very precocious, i.e. only 17% viability left at 24 h, compared to 
80% in the proliferating PBLs at the same time point. 
 
4. Conclusions 
CDDP was tested in combination with [Cu(phen)2(OH2)](ClO4)2 (C0) and GSH on wild type and 
cisplatin-resistant sublines of CCRF-CEM. A synergistic effect was evidenced between CDDP and 
C0, while an antagonistic effect was shown by CDDP and GSH. Combinations of C0 and GSH 
shown synergistic effect, then ternary mixtures of CDDP, C0 and GSH were tested. It was observed 
that in presence of C0, the sensitivity of the cells, wild type and/or resistant ones, towards CDDP in 
presence of GSH was restored, i.e. the antagonistic effect of the GSH versus CDDP was prevented. 
Furthermore, a synergistic effect was found for selected combinations.  
On the basis of the strong cytotoxic synergism shown by the ternary mixtures of CDDP- C0-GSH 
combinations in CCRF-CEM-wt and CCRF-CEM-res tumour cell lines, their toxic effect was 
investigated also on normal cells so as to have an estimate of the selectivity of action of these 
cocktails of drugs. The drug cocktail was totally devoid of cytotoxicity on the resting human 
  
peripheral blood lymphocytes (PBLs) at any time points considered. As for the PBLs, the PHA/IL2-
stimulated, i.e. the PBLs in the presence of PHA and growth factor Interleukin-2, were the most 
sensitive of all PBL cultures to the toxic effect of the drug combination that was, however, both less 
potent and more delayed with respect to that exerted in the CCRF-CEM cells, i.e. a 50% mortality 
only after 48 h, which did not increase further with time. The toxic effect against the PHA-activated 
PBLs, i.e. PBLs in the presence of the mitogen PHA, was even slower than that shown in the 
PHA/IL2-stimulated, 20%- 30% mortality at the first two time points, and comparable only after 72 
h. If we consider the effects of the ternary combination vs. the single-drug treatments in the PBLs, 
the drug cocktail always showed a degree of cytotoxicity comparable to that of the CDDP alone, 
whereas in the CCRF-CEM cells the toxic effect of the combination was 7 fold greater than that of 
CDDP alone.  
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Chapter 4 
 
Glutathione, cisplatin and copper-phenanthroline compounds: 
reactivity and complexation study 
 
 
 
 
 
 
This chapter reports the study of the reactivity of cisplatin, [Cu(phen)2(H2O)](ClO4)2, 
[Cu(phen)(H2O)2(ClO4)2], GSH and GSSG, in binary and ternary mixtures.  
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Abstract  
In previous studies, CDDP was tested in vitro with the copper complex [Cu(phen)2(H2O)](ClO4)2 
(C0) showing a synergistic effect not only towards the wild type leukemic (CCRF-CEM) and 
ovarian (A2780) cancer cell lines but also towards their cisplatin-resistant sublines (Chapter 2-
Article II). Considering that the cisplatin-resistance could be due to a reaction between CDDP and 
GSH and that in presence of C0 the sensibility of the resistant cell lines to CDDP is restored, I 
decided to study the reactivity of CDDP and C0 with GSH or GSSG with the aim to identify and 
characterize the possible formation of mixed complexes. I extended these studies also to GSSG, 
since it is in equilibrium with GSH, and to [Cu(phen)(H2O)2(ClO4)2] (C10), a copper complex that 
shows an antiproliferative activity versus the CCRF-CEM cells similar to that of C0 (Chapter 4 - 
Manuscript II). This study was carried out by Electro-Spray Ionisation at Atmospheric-Pressure 
Mass Spectrometry and tandem MS-MS of binary and ternary mixtures of the studied compounds. 
The formed complexes were identified by the fitting of the isotopic pattern and on the basis of the 
fragmentation pathways. The coordination mode around metal ions was assessed on the basis of the 
fragmentation pathways and quanto-mechanical calculations. In Figure 15 the formulas and 
acronyms of the molecules studied in this work are reported.  
Although several authors studied the mass spectra of GSH and GSSG with ESI-MS, only 
selected peaks were identified and few fragmentation pathways were discussed. I studied in deep 
the mass spectra of GSH and GSSG in order to interpret the mass spectra of their metal complexes.     
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Figure 15. Formulas and acronyms of the molecules studied in this work.  
 
CDDP reacts with GSH to form the complex [Pt(NH3)2Cl2(GSH+H)]
+
 (Figure 16), but with 
GSSG it forms the adduct [Pt(NH3)2Cl2+GSSG+H]
+
. Even in excess of thionic ligands, species 
containing more than one GSH or GSSG were not detected. 
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Figure 16. Coordination scheme (left) and optimized structure obtained by quanto-mechanical 
calculations (right) of [Pt(NH3)2Cl2(GSH+H)]
+
. 
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Copper complexes C0 and C10 react with GSH or GSSG to form complexes such as 
[Cu(phen)(GSH)-H]
+
 and [Cu(phen)(GSSG)(ClO4)]
+
. The two copper complexes form with CDDP 
mixed complexes where the two metal centers are linked by two bridging chloride (Chapter 2 – 
Article II). 
When the copper complexes were mixed with CDDP and GSH or GSSG, only copper-
glutathione complexes were detected. No peaks relative to platinum- and copper-containing ions or 
to platinum- and sulphur-containing ions were detected.   
Given that the cytotoxic activity of CDDP in presence of C0 against cisplatin-resistance cells 
was restored, C0 can be supposed to bind glutathione preventing in this way the deactivation of 
CDDP as anticancer agents.  
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ABSTRACT 
A large number of cancers are treated with cisplatin (CDDP). The effectiveness of CDDP therapy is 
limited by the drug resistance, often related to the intracellular levels of thiol-containing molecules, 
such as glutathione (GSH). Up to now, the role of GSH in cisplatin-resistant cancer cells is still 
unclear. GSH may form adducts with CDDP that results deactivated as drug, and, actually, a high 
intracellular level of GSH was observed in some cisplatin-resistant cancers. On the other hand, the 
increase of the GSH levels inside the cells could enhance the CDDP uptake by increasing the 
number of copper transporters. CDDP is often administered in combination with one or more drugs 
in order to exploit a possible synergistic effect and overcome the drug resistance. In previous 
studies, it was observed that the sensibility of leukemic and ovarian cisplatin-resistant cancer cell 
lines to CDDP, was restored in presence of [Cu(phen)2(H2O)](ClO4)2 (C0) (phen is 1,10-
phenathroline). In this work, the reactivity of CDDP, C0 and GSH, in binary and ternary mixtures, 
was studied. The investigation was extended also to [Cu(phen)(H2O)2(ClO4)2] (C10) and to GSSG, 
the oxidized form of GSH. It was observed that CDDP forms adducts with GSH or GSSG, but, in 
presence of C0 or C10, only copper-glutathione complexes were detected, while no platinum-
glutathione adducts were found. Glutathione shows towards copper(II) more affinity than towards 
platinum and the formation of mixed complexes between copper and platinum is discouraged in 
presence of glutathione. Then, it is possible to conclude that C0 or C10 are able to bind glutathione 
preventing the deactivation of CDDP as anticancer agent and restoring its cytotoxic activity also 
towards cisplatin-resistant cells.  
1. INTRODUCTION 
A large number of cancers in different organs like ovary, testicle, neck, head, bones, lymph nodes 
and skin are currently treated with cis-diammineplatinum(II) dichloride (cisplatin, CDDP) 
[1]–[5]
. 
CDDP exerts its antitumor activity binding DNA and triggering cellular apoptosis. It is 
administered by injection and, once in the bloodstream, is bound to different plasmatic proteins 
containing thiol groups 
[6],[7]
. The effectiveness of CDDP therapy is often limited by the 
development of resistance. Among the main identified mechanisms underneath this phenomenon, 
an important key role is played by the intracellular levels of thiol-containing molecules that, binding 
CDDP, form species without therapeutic efficacy 
[8],[9]
. One of the most abundant thiol-containing 
molecule in the human body is the glutathione (GSH), a γ-Glu-Cys-Gly tripeptide [4],[10],[11] 
ubiquitous in biological fluids, with concentration ranging from 1 to 10 mM. GSH is in equilibrium 
with its oxidized form, GSSG, formed by two glutathione molecules bound by a disulfide bridge 
between the cysteine residuals. The GSSG is reduced to GSH by the glutathione reductase, so that 
  
in physiological conditions the intracellular concentration of GSH is 1 to 10 of that of GSSG. When 
the ratio GSH/GSSG is lower than 10 the glutathione depletion, often correlated with cancer, arises. 
Pt(II) is a soft ion 
[12]
 and shows great affinity for the sulfur atom, then CDDP may form adducts 
with GSH, resulting deactivated as drug 
[13],[14]
. Actually, a high intracellular level of GSH was 
observed in some cisplatin-resistant cancers 
[4]
, even if, according to some authors, the increase of 
the GSH levels inside the cancer cells could enhance the sensibility of the cells to CDDP by 
increasing the number of copper transporters and then the drug uptake 
[15],[16]
. From these 
considerations, it appears evident that the role of GSH in cisplatin-resistant cancer cells is still 
unclear.  
CDDP is often administered in combination with one or more drugs in order to exploit a possible 
synergistic effect and overcome slow down the drug resistance. Basically, a combination of drugs 
may exhibit an increased (synergism), equal (additive effect) or lowered (antagonism) therapeutic 
effect with respect to the sum of the effects of the single drugs. If two or more drugs act 
synergistically, the drugs can be administered in reduced doses, weakening the side effects related 
to the doses and reducing the development of the drug resistance 
[17],[18]
. The synergism may arise 
from the simultaneous involvement of different targets or mechanisms, but also from a bio-chemical 
reaction among the combined drugs.  
In previous studies, CDDP was tested in vitro with the copper complex [Cu(phen)2(H2O)](ClO4)2 
(C0) showing a synergistic effect not only towards the wild type leukemic (CCRF-CEM) and 
ovarian (A2780) cancer cell lines but also towards their cisplatin-resistant sublines 
[19],[20]
. 
Considering that the cisplatin-resistance could be due to a reaction between CDDP and GSH and 
that in presence of C0 the sensibility of the resistant cell lines to CDDP is restored, we decided to 
study the reactivity of CDDP and C0 with GSH or GSSG with the aim to identify and characterize 
the possible formation of mixed complexes. We extended these studies also to GSSG, since it is in 
equilibrium with GSH, and to [Cu(phen)(H2O)2(ClO4)2] (C10), a copper complex that shows an 
antiproliferative activity versus the CCRF-CEM cells similar to that of C0 
[21]
. This study was 
carried out by Electro-Spray Ionisation at Atmospheric-Pressure Mass Spectrometry (ESI-MS) and 
tandem MS-MS of binary and ternary mixtures of the studied compounds. The formed complexes 
were identified by the fitting of the isotopic pattern and on the basis of the fragmentation pathways. 
In Fig. 1 formulas and acronyms of the molecules studied in this work are reported.  
  
 
Fig. 1. Formulas and acronyms of the molecules studied in this work.  
2. EXPERIMENTAL PART 
2.1. Reagents 
Methanol, oxidised glutathione (GSSG), sodium hydroxide, trifluoroacetic acid (HTFA) and 
reduced glutathione (GSH) were purchased from Sigma-Aldrich (Milan, Italy). Cis-
diammineplatinum(II) dichloride (CDDP) was purchased from Alfa-Aesar (Heysham, United 
Kingdom). The commercial reagents were used as received, without any further purification. Ultra-
pure water obtained with MilliQ Millipore was used for all the experiments. The copper complexes 
C0 and C10 were prepared as previously reported 
[21],[22]
.  
2.2. Preparation of solutions for ESI-MS 
Solutions containing CDDP, copper complexes, GSH, GSSG and the binary combinations of CDDP 
or copper complexes with GSH or GSSG in 1:0.5, 1:1, 1:2, 1:3, 1:4 and 1:100 metal:ligand molar 
ratios, were prepared by dissolving the appropriate amount of the compounds in water containing 
0.05% of HTFA (v/v). The concentrations of the reagents in the ternary mixtures were chosen on 
the basis of an experimental design (ED). In an ED experiment 
[23]
, two or more process variables 
(called factors) are changed together in order to observe the mutual effect on one or more response 
variables. The ED is opposite to the classical procedure of changing one variable at time (OVAT 
method) and provides more effective and unbiased conclusions.  The mixtures were prepared 
  
according to a cubic factorial ED with three factors, i.e. the analytical concentrations of C0, CDDP 
and GSH or GSSG and three levels of concentration, i.e. 1.00 (a), 0.66 (b) and 0.33 (c) mM. The 
used concentrations were the 27 permutations with repetition of a, b and c. Sample solutions were 
mixed with methanol in 1:1 H2O:CH3OH volume ratio in order to improve the quality of the 
spectra. So as not to alter the complex formation equilibria, methanol was added immediately 
before the mass spectra were recorded. 
2.3. Mass Spectrometry 
Mass spectra were recorded on a triple quadruple QqQ Varian 310-MS mass spectrometer using the 
Atmospheric-Pressure Electro-Spray Ionisation (ESI) technique. The mass spectra were recorded in 
positive ion mode in the m/z 100–1000 range. The experimental conditions were: needle voltage 
6000 V, shield voltage 800 V, housing temperature 60 °C, drying gas temperature 100 °C, nebuliser 
gas pressure 40 PSI, drying gas pressure 20 PSI, and detector voltage 2000 V. Tandem MS–MS 
experiments were performed with argon as the collision gas (1.8 PSI) using a needle voltage of 
6000 V, shield voltage of 800 V, housing temperature of 60 °C, drying gas temperature of 100 °C, 
nebuliser gas pressure of 40 PSI, drying gas pressure of 20 PSI, and a detector voltage of 2000 V. 
The isotopic patterns of the measured peaks in the mass spectra were analysed using mMass 5.5.0 
software package 
[24],[25]
. The assignments were based on the copper-63 and platinum-195 isotopes. 
The sample solutions were infused directly into the ESI source using a programmable syringe pump 
at a flow rate of 1.50 mL/h. A dwell time of 14 s was used and the spectra were accumulated for 10 
min in order to increase the signal-to-noise ratio.  
2.4.  Quantum chemical calculations 
The theoretical calculations were performed on an INTEL-i7 processor based system with 
Spartan’06 program (SPARTAN’06 , Wavefunction, Inc). The complex geometries were optimised 
using semi-empirical methods with PM3 basis set 
[26]
. Heat of formation, electron density surface, 
atomic, electrostatic 
[27],[28]
, natural 
[29]
 and Mulliken 
[30],[31]
 charges, HOMO and LUMO orbitals 
were obtained for each molecule, in order to evaluate the most stable conformers. 
2.5.  Synthesis of Cu(phen)(GSSG)(ClO4)2 
A propanolic solution (15 mL) containing GSSG (0.0775 g, 1.27x10
-4
 mol) and NaOH (0.0102 g, 
2.54x10
-4
 mol) was dropped into a propanolic solution of C10 (0.0604 g, 1.27x10
-4
 mol). The 
resulting solution was refluxed for 3 h, during this time the color of the solution turned from blue to 
dark green. The green solution was concentrated under vacuum and a violet solid product was 
recovered by filtration. Percentage yield 65%. Soluble in CH3OH and CH3CN. 
  
3. RESULTS AND DISCUSSION 
3.1.  ESI-MS experiments of pure compounds                     
The ESI-MS spectra of C0, C10 and CDDP were previously discussed 
[20]
. Regards GSH and 
GSSG, several authors studied their mass spectra with ESI-MS but only selected peaks were 
identified and few fragmentation pathways were discussed 
[32]–[37]
. Since the full knowledge of the 
fragmentation of GSH and GSSG is necessary to interpret the mass spectra of their metal complexes 
and to determine their molecular structure, we studied in deep the mass spectra of GSH and GSSG 
(Fig. S1). We recognized five fragmentation pathways for GSH, from the parent peak at m/z 308 to 
245, 233, 179, 144, 130; and nine for GSSG, from the parent peak at m/z 613 to 595, 538, 409, 355, 
288, 231, 211, 177, 130. These fragmentation pathways are depicted in the Supporting (Scheme S1 
for GSH and Scheme S2 for GSSG), while in Fig. 2 and 3 the most abundant fragments are shown 
for GSH and GSSG, respectively. 
 
 
Fig. 2. The most abundant fragments of [GSH+H]
+
 (m/z 308).  
  
 
Fig. 3. The most abundant fragments of [GSSG+H]
+
 (m/z 613) (G is C10H16N3O6).  
 
3.2. ESI-MS experiments of binary systems 
3.2.1. Copper complexes and GSH or GSSG 
In the ESI-MS spectra of binary mixtures of C0 or C10 with GSH or GSSG, characteristic peaks of 
copper- and sulphur-containing ions were detected. Three peaks corresponding to [Cu(phen)(GSH)-
H]
+
 (m/z 549.10, I), [Cu(GSSG)-H]
+
 (m/z 674.03, II), and [Cu(phen)(GSSG)-H]
+
 (m/z 854.10, III) 
were common in all the systems, while two peaks corresponding to [Cu2(phen)(GSSG)-3H]
+
 (m/z 
915.00, IV) and [Cu(phen)(GSSG)(ClO4)]
+
 (m/z 954.06, V) were observed in C0-GSH, C0-GSSG 
and C10-GSH systems. The assignments are tabulated in Table 1. 
 
  
Reagents 
Complex 
or adduct 
Stoichiometry Composition Exp. m/z* Calc. m/z* 
C0 + GSH or GSSG, 
C10 + GSH or GSSG 
I [Cu(phen)(GSH)-H]
+
 C22H24CuN5O6S 549.10 549.07 
C0 + GSH or GSSG, 
C10 + GSH or GSSG, 
CDDP + GSH + C0 
II [Cu(GSSG)-H]
+
 C20H31CuN6O12S2 674.03 674.07 
C0 + GSH or GSSG, 
C10 + GSH or GSSG, 
CDDP + GSH + C0 
III [Cu(phen)(GSSG)-H]
+
 C32H39CuN8O12S2 854.10 854.14 
C0 + GSH or GSSG, 
C10 + GSH 
IV [Cu2(phen)(GSSG)-3H]
+
 C32H37Cu2N8O12S2 915.00 915.06 
C0 + GSH or GSSG, 
C10 + GSH, 
CDDP + GSH + C0 
V [Cu(phen)(GSSG)(ClO4)]
+
 C32H40ClCuN8O16S2 954.06 954.10 
CDDP + GSH 
VI [Pt(NH3)2Cl(GSH)]
+
 C10H23ClN5O6PtS 571.09 571.07 
VII [Pt(NH3)2Cl2(GSH+H)]
+
 C10H24Cl2N5O6PtS 608.04 607.05 
CDDP + GSSG 
VIII [Pt(NH3)2Cl2+GSSG+2H]
+2
 C20H39Cl2N8O12PtS2 457.09 456.06 
IX [Pt(NH3)2Cl2+GSSG+H]
+
 C20H39Cl2N8O12PtS2 912.98 912.11 
CDDP + GSH + C0 X [Pt(NH3)2Cl]
+
 H6ClN2Pt 263.96 263.99 
CDDP + C0 or C10 
XI** [CuPt(phen)(H2O)2(OH)Cl2]
+
 C12H13Cl2CuN2O3Pt 560.90 560.92 
XII** [CuPt(phen)(H2O)(OH)(NH3)Cl2]
+
 C12H14Cl2CuN3O2Pt 559.90 559.94. 
XIII** [CuPt(phen)(H2O)2Cl2]
+
 C12H12Cl2CuN2O2Pt 543.95 543.92 
Table 1. Species identified from the ESI–MS studies. * The experimental m/z value is relative to the highest peak of the isotopic pattern while the 
calculated one refer to the monoisotopic mass, ** from ref. 
[20]
. 
  
It is interesting to remark that C0 and C10 form the same complexes I (Scheme 1) and III, and that 
a phen molecule is lost in the reactions involving C0.  
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Scheme 1. Reaction mechanism between C0 or C10 with GSH to form [Cu(phen)(GSH)-H]
+
, I.  
 
In all the detected complexes the copper ion has +2 as oxidation number. The tandem MS-MS 
spectra confirmed the elemental composition proposed, for the observed ions, on the basis of the 
isotopic patterns. The mass spectra of the studied systems at 1:2 copper:ligand molar ratio are 
reported in the Supporting (Fig. S2). The calculated and experimental isotopic patterns for selected 
peaks, are shown in Fig. S3.  
Species with more than one molecule of GSH or GSSG were not detected even in excess of the 
ligands. Species I and III were obtained also during fragmentation of V, species II was obtained 
also during fragmentation of III (Fig. 4). 
The coordination mode of GSH or GSSG to copper(II) was assessed on the basis of the MS-MS 
fragmentation pathways, and the most probable geometry of the complexes was obtained by quanto-
mechanical calculations. The hypothesized structures of I, II, III and V are shown in Fig. 5 while 
selected fragmentation pathways for II, III and V are shown in the Supporting (Schemes S3-S5).  
 
  
 
Fig. 4. MS-MS spectra of the signals at m/z 954 (A), 854 (B) and 674 (C) (collision energy 20 V,  
1:2 C10:GSH, GSH 0.5 mM, 50:50 methanol/water with 0.05% of HTFA). 
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Fig. 5. Coordination scheme (left) and optimized structure obtained by quanto-mechanical 
calculations (right) of [Cu(phen)(GSH)-H)]
+
 (I), [Cu(GSSG)-H)]
+
 (II), [Cu(phen)(GSSG)-H)]
+
 (III) 
and  [Cu(phen)(GSSG)(ClO4)]
+
 (V).  
 
  
The species V can exist in two different geometries, A and B, with similar formation enthalpies 
(kJ/mol -2195.0 and -2132.5 for A and B, respectively). In the first one, the metal ion is coordinated 
by the two phen nitrogen atoms, two aminic and one carboxylic groups of the glutamate residues, 
and a perchlorate anion. Three hydrogen bonds are present. In the second one, the copper(II) is 
coordinated, besides the two phen nitrogen atoms, by the two carboxylic groups of the glutamic 
residues and by the perchlorate anion. Five hydrogen bonds are present.  
In the most stable structure of species III, copper(II) is coordinated by the two phen nitrogen atoms, 
the aminic groups of the GSSG glutamic residues and the carboxylate group of one glutamic 
residue; two hydrogen bonds are present. In I, the metal ion is coordinated, besides the two phen 
nitrogen atoms, by the aminic, carboxylic and chetonic groups of the glutamic residue. The 
presence of a fragment with m/z 336 that retains carboxylic and aminic groups but not the thiolic 
one, and the absence of fragments in which carboxylic and aminic groups are missing, leads us to 
consider the tholic group as not involved in coordination. The coordination of a second amino group 
to copper in III and V, is endorsed by the presence in the MS-MS spectrum of a peak at m/z 289 
attributable to a unit of GSH which has lost one molecule of ammonia. The presence of the ion at 
m/z 181, due to the protonated phen, suggests that one carboxylic group of GSSG is involved in the 
coordination of copper in III and V or it is very close to phen to give it a proton. During collision, 
the species V gives III by losing perchloric acid and gives I by losing perchloric acid and a unit of 
GSH. The ion I is present also in the fragmentation of III. Species III results more stable than I, as 
shown by the greater abundance of the ion at m/z 549 compared to that at m/z 674. Moreover, 
species I is formed only at GSH:copper ratio ≥ 4:1. 
Apart from the ion at m/z 181, attributable to the protonated phen, the fragmentation of V and III 
differ significantly. This can be explained by assuming that the fragments with low m/z ratios 
present in the MS-MS spectrum of V, derive directly from it.  Both in the MS-MS spectra of V and 
III, the molecule of GSH, in fragments not containing the metal ion, lacks of carboxylic and aminic 
groups, suggesting that these groups are involved in coordination with the copper. Then a structure 
where copper ion is coordinated by carboxylic and aminic groups of the GSSG, the two 
phenanthrolinic nitrogen and the perchlorate anion, was supposed for V. The loss of perchloric acid 
from V leads to the more stable species III, which peak appears higher than that of V. II exists in 
ESI phase as a species and not only as a fragment of III. In fact, in the mass spectrum the intensity 
of the signal at m/z 674 appears not related with that of the signal at m/z 854. Moreover, the 
fragments of II are different from those of III for m/z lower than 674. Also in II, in fragments 
retaining copper, the metal ion is always bound to carboxylic and aminic groups, as shown by the 
  
presence of the carboxylic/carboxylate groups in all the fragments, regardless of the applied 
collision energy. 
During the reaction between C0 and GSH or GSSG a phen molecule is lost, due to the steric 
hindrance and to the strength of the bonds formed with glutathione, greater than that with the 
phenanthrolinic nitrogen atoms.   
 
3.2.2. Cisplatin and GSH 
Mass spectra of solutions containing CDDP and GSH in 1:0.5, 1:1, 1:2, 1:3, 1:4 and 1:100 molar 
ratios were measured. The mass spectrum of solution containing CDDP and GSH at 1:2 
platinum:GSH molar ratio, in the m/z 100-700 range is reported in Fig. 6 as an example.  
 
 
Fig. 6. ESI-MS (+) of solution containing CDDP (0.25 mM) and GSH (0.5 mM) (50:50 
methanol/water with 0.05% of HTFA); in the inset the signal centered at m/z 608 is shown.  
 
In all the recorded spectra, except in that of the 1:1 system, two signals centered at m/z 571 and 608 
with an isotopic patterns characteristic of platinum- and sulphur-containing ions were detected. The 
stoichiometries of the species [Pt(NH3)2Cl(GSH)]
+
 (m/z 571.09, VI) and [Pt(NH3)2Cl2(GSH+H)]
+
 
(m/z 608.04, VII), were assigned on the basis of the isotopic patterns and the tandem MS-MS 
spectra (Fig. S4). The assignments are tabulated in Table 1. 
The fragmentation of the peak at m/z 608 (Scheme S6) originates peaks at m/z 591 by loss of an 
ammonia molecule, at m/z 308 by loss of CDDP, at m/z 291, 233 and 179 by loss of CDDP and 
subsequent re-arrangement (note that the peak at m/z 608 could correspond to combinations of 
196
Pt-
35
Cl-
35
Cl or 
194
Pt-
35
Cl-
37
Cl).  
On the basis of the fragmentation pathways and quanto-mechanical calculations the coordination 
mode around platinum ion was assessed. Basically, in VII two hydrogen bonds are formed between 
  
i) an oxygen atom of the glycine residue and a proton of the ammonia of CDDP; ii) the oxygen 
atom of the carbonyl group of the glutamic residue and a proton of the second ammonia of CDDP. 
A third intramolecular hydrogen bond between the amino group of the glutamic residue and the 
cysteininc –NH group is also present. The hypothesized structures of VII is reported in Fig. 7. 
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VII, [Pt(NH3)2Cl2(GSH+H)]
+
, m/z 608 (E = -2328.6 kJ/mol) 
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VIII, [Pt(NH3)2Cl2+GSSG+2H]
2+
, m/z 457 (E = -3554.6 kJ/mol) 
Fig. 7. Coordination scheme (left) and optimized structure obtained by quanto-mechanical 
calculations (right) of [Pt(NH3)2Cl(GSH)]
+
 (VI), [Pt(NH3)2Cl2(GSH+H)]
+
 (VII) and 
[Pt(NH3)2Cl2+GSSG+2H]
2+
 (VIII).  
  
The CID of the peak at m/z 571 (Schemes S7) originates fragments at m/z 555, 554, 538, 479, 443, 
425, 390, 388 and 272 (note that the peak at m/z 571 could correspond to combinations of 
196
Pt-
35
Cl 
or 
194
Pt-
37
Cl).  In Fig. 7 the most probable structures of selected fragments originated by VI are 
reported. In VI, Platinum(II) ion is coordinated by the two ammonia molecules, one chloride and 
the amino group of the glutamic residue of the GSH.  
Considering that a Pt(GSH-H)2 complex was previously found 
[14]
, combinations of CDDP and 
GSH solutions in high excess of GSH (1:100 Pt/GSH) were prepared and analyzed but species 
containing more than one GSH molecule were not detected, neither after two days from the solution 
preparation. The different results may arise from the different experimental conditions used. 
 
3.2.3. Cisplatin and GSSG 
In the mass spectra of solutions containing cisplatin and GSSG, two peaks with characteristic 
isotopic pattern of platinum- and sulphur-containing ions were detected, the first at m/z 457 
corresponding to the doubly-charged ion (VIII) [Pt(NH3)2Cl2+GSSG+2H]
2+
 (separation between 
adjacent peaks was m/z 0.5) and the second at m/z ≈ 912 corresponding to the mono-charged ion 
(IX) [Pt(NH3)2Cl2+GSSG+H]
+
. A so called GSSG-CDDP composite was previously reported.
[38]
 
The experimental and calculated isotopic patterns for these two peaks are shown in Fig. S5.   
The assignments are tabulated with calculated and experimental m/z values in Table 1. On the basis 
of the fragmentation pathways (Scheme S8) and quanto-mechanical calculations, the most stable 
geometries for VIII was obtained (Fig. 7). In particular, since in the MS-MS spectra only fragments 
of GSSG not containing platinum were detected, the species VIII or IX can be considered as 
adducts between CDDP and GSSG, formed by hydrogen bonds.  
Differently from VIII and IX, the most of the fragments of VI and VII contain platinum ion, than it 
is possible to conclude that a complex is formed by reaction of CDDP and GSH, while an adduct is 
originated by weak interactions between CDDP and GSSG. 
 
3.2.4.  Copper complexes and cisplatin 
Compounds C0 or C10 form with CDDP the same complexes containing copper and platinum, i.e. 
[CuPt(phen)(H2O)2(OH)Cl2]
+
 (m/z 560.90, XI), [CuPt(phen)(H2O)(OH)(NH3)Cl2]
+
 (m/z 559.90, 
XII), and [CuPt(phen)(H2O)2Cl2]
+
 (m/z 543.95, XIII).
[20]
 
 
3.3. ESI-MS experiments of  ternary systems 
Twenty-seven solutions containing C0, CDDP and GSH were prepared and analyzed. In all the 
spectra, peaks corresponding to the copper complexes II, III and V were detected together with a 
  
peak relative to [Pt(NH3)2Cl]
+
 (m/z 263.96, X). No peaks relative to platinum- and copper-
containing ions or to platinum and sulphur-containing ions were detected.  
 
3.4. Identification  of Cu(phen)(GSSG)(ClO4)2 
Considering that unexpected species may be detected as formed in ESI phase but not necessarily 
present in solution, I deemed interesting to verify if the [Cu(phen)(GSSG)(ClO4)]
+
 species could be 
formed. As a matter of fact, a mixed complex with stoichiometry Cu(phen)(GSSG)(ClO4)2 was 
actually synthesized by reaction between C10 and the sodium salt of GSSG (C20H30N6 Na2O12S2), 
confirming the possible formation of such species. The formation of a complex between C0 and 
GSH with stoichiometry [Cu(phen)2(OH2)(GSH)-H]
+
 has been previously discussed.
[21]
  
4. CONCLUSIONS 
CDDP reacts with GSH to form the complex [Pt(NH3)2Cl2(GSH+H)]
+
, but with GSSG it forms the 
adduct [Pt(NH3)2Cl2+GSSG+H]
+
. As shown by MS-MS experiments, glutathione and CDDP are 
kept together by hydrogen bonds. Even in excess of thionic ligands, only a 1:1 cisplatin:ligand 
adduct was detected.  
Copper complexes C0 and C10 react with GSH or GSSG to form complexes such as 
[Cu(phen)(GSH)-H]
+
 and [Cu(phen)(GSSG)(ClO4)]
+
. The complexes formed with GSSG are more 
stable than the counterparts formed with GSH. The two copper complexes form with CDDP mixed 
complexes where the two metal centers are linked by two bridging chloride. 
When the studied copper complexes were mixed with CDDP and the thionic ligands, only copper-
glutathione complexes were detected. No platinum-glutathione adducts or copper-platinum 
complexes were found. These results show that i) glutathione has towards copper(II) more affinity 
than towards platinum, ii) the formation of the mixed complexes between copper and platinum is 
not observed in presence of glutathione. 
The previous cytotoxicity tests shown that the antiproliferative activity of CDDP in presence of C0 
against cisplatin-resistant cells was restored. C0 can be supposed to bind glutathione preventing in 
this way the deactivation of CDDP as anticancer agent . 
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SUPPLEMENTARY MATERIALS 
 
Fig. S1. ESI-MS (+) spectrum of GSH (A) and MS-MS spectrum of the parent peak at m/z 308 (B);  
ESI-MS (+) spectrum of GSSG (C) and MS-MS spectrum of the parent peak at m/z 613 (D) (0.5 
mM, 50:50 methanol/water with 0.05% of HTFA; collision energy 20 V).  
  
 
Fig. S2. ESI-MS (+) spectrum of solution containing (A) C0 and GSH, (B) C0 and GSSG, (C) C10 
and GSH, (D) C10 and GSSG (1:2 copper/ligand molar ratio, ligand 0.5 mM, 50:50 methanol/water 
with 0.05% of HTFA).  
  
 
 
Fig. S3. Experimental (black line) and calculated (red line) isotopic patterns of the peaks at m/z 954 
(A), 915 (B) and 854 (C) assigned to [Cu(phen)(GSSG)(ClO4)]
+
, [Cu2(phen)(GSSG)-3H]
+
 and 
[Cu(phen)(GSSG)-H]
+
, respectively. 
 
 
Fig. S4. Experimental (upper) and calculated (bottom) isotopic patterns of the peaks at m/z 571 (A, 
B) and 608 (C, D) for species with assigned stoichiometry [Pt(NH3)Cl2+GSH]
+
 and 
[Pt(NH3)2Cl2+GSH+H]
+
. 
  
 
Fig. S5. Experimental (black line) and calculated (red line) isotopic patterns of the peaks at m/z 457 
(A) and 912 (B) assigned to [Pt(NH3)2Cl2+GSSG+2H]
+2
 and [Pt(NH3)2Cl2+GSSG+H]
+
, 
respectively. 
 
 
Scheme S1. GSH: fragmentation pathways from m/z 308 to 245 (i), 233 (ii), 179 (iii), 144 (iv) and 
130 (v).                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     
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i) Fragmentation pathway (i) from m/z 308 (protonated GSH) to 245. 
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ii) Fragmentation pathway (ii) from m/z 308 (protonated GSH) to 233. 
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iii) Fragmentation pathway (iii) from m/z 308 (protonated GSH) to 179. 
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iv) Fragmentation pathway (iv) from m/z 308 (protonated GSH) to 144. 
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v) Fragmentation pathway (v) from m/z 308 (protonated GSH) to 130. 
 
 
Scheme S2. GSSG: fragmentation pathways from m/z 613 to (i) 130, (ii) 177,  (iii) 211, (iv) 231, (v) 
288, (vi) 355, (vii) 409, (viii) 538 and (ix) 595. 
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i) Fragmentation pathway (i) from m/z 613 (protonated GSSG) to 130. 
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ii) Fragmentation pathway (ii) from m/z 613 (protonated GSSG) to 177. 
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iii) Fragmentation pathway (iii) from m/z 613 (protonated GSSG) to 211. 
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iv) Fragmentation pathway (iv) from m/z 613 (protonated GSSG) to 231. 
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v) Fragmentation pathway (v) from m/z 613 (protonated GSSG) to 288. 
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vi) Fragmentation pathway (vi) from m/z 613 (protonated GSSG) to 355. 
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vii) Fragmentation pathway (vii) from m/z 613 (G is C10H16N3O6) to 409. 
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viii) Fragmentation pathway (viii) from m/z 613 (protonated GSSG) to 538 (G is 
C10H16N3O6). 
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ix) Fragmentation pathway (ix) from m/z 613 (protonated GSSG) to 595. 
 
 
Scheme S3. Selected fragmentation pathways of [Cu(phen)(GSSG)(OClO3)]
+
 (V, m/z 954).  
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i) Fragmentation pathway from m/z 954 to 918. 
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ii) Fragmentation pathway from m/z 954 to 854. 
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iii) Fragmentation pathway from m/z 854 to 549. 
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iv) Fragmentation pathway from m/z 954 to 423. 
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v) Fragmentation pathway from m/z 954 to 403. 
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vi) Fragmentation pathway from m/z 954 to 358 (2 resonance structures could be written, 
pentatomic (a) and triatomic (b) cycles formation is also possible) 
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vii) Fragmentation pathway from m/z 954 to 289. 
* All the fragments are monocharged (+1) even if not indicated. 
 
Scheme S4. Selected fragmentation pathways of [Cu(phen)(GSSG)-H)]
+
 (III, m/z 854) 
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i) Fragmentation pathway from m/z 854 to 674. 
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ii) Fragmentation pathway from m/z 854 to 549. 
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iii) Fragmentation pathway from m/z 549 to 369. 
NH
HN
COOH
O
O
HS
Cu
N
H2
O
O
H
N
N
H
COOH
NH2
O
OCu
(II)
H
N
N
H
COOH
NH2
O
O
Cu(I)
or
-SH
O
O
O
O
 
iv) Fragmentation pathway from m/z 369 to 336. 
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v) Fragmentation pathway from m/z 369 to 324. 
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vi) Fragmentation pathway from m/z 854 to 289. 
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vii) Fragmentation pathway from m/z 854 to 243. 
 
 
Scheme S5. Selected fragmentation pathways of [Cu(GSSG)-H)]
+
 (II, m/z 674) 
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i) Fragmentation pathway from m/z 674 to 369. 
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ii) Fragmentation pathway from m/z 674 to 323. 
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iii) Fragmentation pathway from m/z 674 to 306. 
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iv) Fragmentation pathway from m/z 369 to 277. 
OOC
N
H
NH2
O
O
NH
Cu
OOC
N
H
NH2
O
NH
Cu
 
v) Fragmentation pathway from m/z 277 to 249. 
 
 
 
  
Scheme S6. Fragments originated by the CID of the m/z 608 parent peak.  
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Scheme S7. Fragments originated by the CID of the m/z 571 parent peak.  
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ii) Fragmentation pathway from m/z 571 to 554 [PtC10H21N5O5ClS]
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iii) Fragmentation pathway from m/z 571 to 538 [PtC10H17N3O6ClS]
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iv) Fragmentation pathway from m/z 554 to 479 [PtC8H16N4O3ClS]
+ 
PtH3N NH2
NH
N
H
C
O
O
HO
O
HS
O
OH
Cl
NH3
H
PtH3N
NH2
N
H
O
HO
O
HS
Cl
NH3
 
v) Fragmentation pathway from m/z 571 to 443 [PtC5H16N4O3ClS]
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vii) Fragmentation pathway from m/z 571 to 390 [PtC5H12N3O3S]
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viii) Fragmentation pathway from m/z 571 to 388 [PtC5H12N3O3S]
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ix) Fragmentation pathway from m/z 571 to 272 [C10H14N3O4S]
+ 
* fragment containing 
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35
Cl; ** fragment containing 
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Pt and 
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Scheme S8. Fragments originated by the CID of the m/z 457 parent peak. 
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i) Fragmentation pathway from m/z 457 to 355* 
Pt
Cl
Cl
N
N
H
N
N
H
C
NH2
OH
O
NH
H
N
NH2
OH
O
OH
O
S
S
O
OH
HOOC
H
H
H
H
H
H
O
HO
HOOC
NH
H
N
NH2
O
OH
OH
O
H
SH
S
 
ii) Fragmentation pathway from m/z 457 to 340* 
Pt
Cl
Cl
N
N
H
N
N
H
C
NH2
OH
O
NH
H
N
NH2
O
O
OH
O
S
S
O
OH
HOOC
H
H
H
H
H
H
HOOC
H
N
N
H
C
NH2
OH
O
S
O
OH
H
H
HO
O
 
iii) Fragmentation pathway from m/z 457 to 308 
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iv) Fragmentation pathway from m/z 457 to 307 
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v) Fragmentation pathway from m/z 457 to 306 
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vi) Fragmentation pathway from m/z 457 to 269 
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vii) Fragmentation pathway from m/z 457 to 242.5 
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viii) Fragmentation pathway from m/z 457 to 231 
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ix) Fragmentation pathway from m/z 457 to 130 
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Chapter 5  
 
Identification of specific phospholipids to differentiate 
cisplatin-resistant and wild type cells in leukemic 
(CCRF-CEM) and ovarian cancer (A2780) 
 
 
 
This chapter reports the study of the phospholipid profile of 
wild type and cisplatin-resistance lines of CCRF-CEM and A2780 
cells.  
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Abstract 
Some of the proposed mechanisms for cisplatin resistance are the reduced influx and the 
increased efflux of cisplatin across the membrane transporters. The structure and the function of the 
cells are dependent on the membranes that consist of a lipid bilayer with inserted proteins. Changes 
in lipid composition and distribution on the cell membranes have been observed in cancer cells, 
then the conformation of the cell membrane could directly or indirectly be related also with the 
cisplatin resistance. On the bases of these considerations, I decided to study the qualitative 
phospholipid (PL) profile of wild type and cisplatin-resistant lines of acute T-lymphoblastic 
leukaemia (CCRF-CEM) and ovarian carcinoma (A2780) cells, to highlight possible differences 
and identify some specific PLs (Chapter 5 – Submitted manuscript I). I proposed an analytical 
procedure based on solid phase extraction (SPE) and Electro-spray Ionization Mass Spectrometry 
(Figure 17), that allowed to study the PL profile of cell lysates, obtaining reliable and reproducible 
results, preventing peptide and metabolite interferences.  
 
 
Figure 17. Experimental procedure to extract the PLs from the cell lysate.  
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From the analysis of supernatants and pellets fractions of cell lysate, a different PL profile was 
detected. These two fractions were taken into account simultaneously for a correct interpretation 
and a complete characterization of the PL profile. The PLs belonging to specific families were 
recognized and differentiate by the number of carbon atoms and double bonds. In some cases also 
the position of the double bonds was assigned (Figure 18).  
 
Figure 18. Tandem MS-MS(+) spectrum of m/z 786 peak (PC(20:2(11Z,14Z)/16:0)).  
 
In Figure 19 the total PL content identified with ESI(+) for the wild type and cisplatin-resistant 
lines of CCRF-CEM and A2780 cells is reported. Some phospholipids were identified to be specific 
components, and can be considered as “markers” to distinguish between wild type and cisplatin-
resistant cells. With respect to their parental counterparts, it was found that some 
glycerophosphocholines were strongly down-represented in the cisplatin-resistant CCRF-CEM 
cells, while some sphingomyelins were up-represented in the cisplatin-resistant A2780 cells. In both 
the resistant cell lines, dihydroxyacetone phosphate was found to be more up-represented. 
Considering that the different composition of the cell membranes could be related to cisplatin 
resistance, the presence of some lipids as “markers” for cisplatin-resistance cells could help to 
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clarify the mechanisms underlying the development of the resistance. Moreover, these “markers” 
could be used for a possible clinical application, as for example monitoring the onset of the 
resistance during cisplatin treatment by detecting those specific lipids.  
 
 
Figure 19. Phospholipids identified with ESI(+) in the lysate extract of CCRF-CEM wild type 
(CEM-wt) and cisplatin-resistant (CEM-res) cells (A), and A2780 wild type (A2780-wt) and 
cisplatin-resistant (A2780-res) cells (B). The phospholipids that are up-represented () or down-
represented () in the cisplatin-resistant cells with respect to the wild type ones, are marked.  
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Abstract 
Changes in lipid distribution and composition of the cellular membranes have been observed in 
cancer and several other pathologies. The conformation of the cell membrane could directly or 
indirectly be related with the cisplatin resistance. With the aim to highlight possible differences 
between wild type and cisplatin-resistant cells and to identify some specific phospholipids, we 
studied the phospholipid profile of wild type and cisplatin-resistant cells of two kinds of tumours, 
acute T-lymphoblastic leukaemia (CCRF-CEM) and ovarian carcinoma (A2780).The analytical 
procedure proposed in this work, based on solid phase extraction and mass spectrometry, allowed to 
identify specific components of the cisplatin-resistant cells. With respect to their wild type 
counterparts, it was found that some glycerophosphocholines were strongly down-represented in the 
cisplatin-resistant CCRF-CEM cells, while some sphingomyelins were up-represented in the 
cisplatin-resistant A2780 cells. In both the resistant cell lines, dihydroxyacetone phosphate was 
found to be more up-represented. The evidenced phospholipid changes play a key role in the 
detection of the transformation from wild type to cisplatin-resistance cells and can help to clarify 
the mechanisms underlying the development of the resistance. Moreover, the potential use of some 
lipids as “markers” for resistant cells could be important for a possible clinical application. In fact, 
the onset of the resistance during cisplatin treatment could be monitored by detecting those specific 
lipids. Under this perspective, the obtained findings represent an advancement of knowledge and 
can be exploited for the design of new strategies in cancer treatment. 
 
Introduction 
Cell membranes consist of a lipid bilayer with inserted proteins, whose content depends both on the 
cell type and on the cell compartment of the membrane itself. In the plasma membrane, for 
example, lipids and proteins are almost equally distributed, whereas in the inner membrane of 
mitochondria, a higher proportion of proteins is present (about 75%) [1]. Membranes can be 
considered as fluids in which lipids and proteins are free to rotate and shift laterally. The fluidity of 
the membranes depends principally on the lipid composition. Regions of membrane with long fatty 
acid residues are more rigid, since the interactions among long acyl chains are stronger than those 
among short ones, while the degree of unsaturation of the fatty acids increases the membrane 
fluidity as folds in the chains decrease interactions among them. The asymmetric distribution of 
lipids between the inner and the outer leaflets defines the characteristics of the cell membranes 
[1,2]. Three classes of lipids constitute the cell membrane: phospholipids (PLs), glycolipids and 
sterols. PLs are commonly present in the highest concentration and are considered the fundamental 
components of all the cell membranes. PLs are amphipathic molecules, consisting of two 
hydrophobic fatty acid chains linked to a hydrophilic phosphate-containing head group. The 
  
principal PLs present in the membranes are glycerophospholipids (GPLs), which contain a glycerol 
backbone with a fatty acyl or alkyl group at the sn-1 position, a fatty acyl group at the sn-2 position, 
and a phosphodiester moiety linked to a polar head-group at the sn-3 position [3]. GPLs are 
classified on the basis of the polar head: glycerophosphocholine (PC), glycerophosphoserine (PS), 
glycerophosphoethanolamine (PE), and glycerophosphoinositol (PI), in the presence of choline, 
serine, ethanolamine and inositol, respectively. PC derivatives represent more than 50% of the PLs 
in most eukaryotic membranes [4]. The second important family of structural polar lipids is 
represented by the sphingolipids (SLs), which consist of a ceramide unit with phosphocholine or 
phosphoethanolamine as a head group. In Fig. 1, the most important PLs are depicted.  
Changes in lipid distribution and composition of the cellular membranes have been observed in 
several pathologies and in cancer [5–8]. In neoplastic cells, alterations of the PL’s composition, [6] 
increases in the concentration of PI, PS, PE and PC derivatives, as well as increases in the level of 
esterified cholesterol were observed [6,9]. Moreover, considering that the mechanisms of transport 
through the plasma membrane depends on its assembly, particularly on its rigidity and permeability, 
and that these characteristics are determined by composition and structure of the membrane 
constituents, an alteration of the physiological membrane condition could readily affect drug influx 
and efflux across cell membrane. The conformation of the cell membrane could be then directly or 
indirectly also be related to the undesirable phenomena of drug resistance, such as cisplatin 
resistance. Cisplatin (CDDP) is used for the treatment of breast, ovarian [10], prostate [11], testes 
[12], and non-small cell lung cancer [13]. However, the administration of CDDP is limited by its 
side effects and the onset of inherited or acquired resistance. 
 
Fig. 1 Principal phospholipids contained in the cell membranes. For a complete description of the 
nomenclature of the phospholipids see ref. [1] and [14]. 
  
 
Cisplatin resistance is supposed to be related to its mechanism of action. Briefly, cisplatin enters the 
cells by passive diffusion or by active protein-mediated transport systems, i.e. human organic cation 
transporter (hOCT2) and copper transport protein (Ctr1). Once in cytoplasm, one of the two 
chloride ligands of CDDP is displaced by a water molecule to form the complex 
[PtCl(H2O)(NH3)2]
+
. This species binds DNA bases, mainly in the N7 position of guanine and 
adenine, and the N3 of cytosine, to form the monofunctional adduct [PtCl(DNA)(NH3)2]
+
. Also the 
second chloride ion can be displaced by a water molecule to form [Pt(H2O)(DNA)(NH3)2]
2+
. This 
last may bind DNA by crosslinking to form a bifunctional adduct that is responsible of the 
triggering of cell death [15–21]. The influx of the drug inside the cell and/or drug efflux outside the 
cell represent possible mechanisms for the onset of cisplatin resistance [22]. On the basis of these 
considerations, we decided to study the qualitative PL profile of two cancer cell lines and of their 
corresponding cisplatin-resistant sublines, to highlight possible differences and identify some cell-
line specific PLs. With this aim, we set up a procedure to analyse the PL content of the cell lysate 
sample in a fast, routine, accurate, and reproducible method, based on the solid phase extraction 
(SPE) and electrospray ionisation mass spectrometry (ESI-MS) and tandem mass spectrometry 
(MS-MS). In particular, the proposed method allows one to obtain mass spectra with high signal to 
noise ratio, preventing the interference of peptides that act as ionic suppressors and removing the 
metabolites that can be recovered for other uses. Moreover, we analysed both the supernatants and 
pellet of each cell lysate, finding interesting differences between the two lysate fractions. We 
studied the PL composition of i) the acute T-lymphoblastic leukaemia derived CCRF-CEM cell line 
(CCRF-CEM-wt), ii) the ovarian carcinoma derived A2780 cell line (A2780-wt), iii) the cisplatin-
resistant subline of acute T-lymphoblastic leukaemia cells (CCRF-CEM-res), and iv) the cisplatin-
resistant subline of ovarian carcinoma cells (A2780-res). The leukemic CCRF-CEM cells were 
selected since they represent a classical model widely used for studies in biochemistry and 
biomedicine, while the A2780 cells were selected because ovarian cancer is actually treated with 
cisplatin. 
 
Experimental 
Reagents 
Acetonitrile (CH3CN), ammonium hydroxide (NH4OH), formic acid (HCOOH), methanol 
(CH3OH), and trifluoroacetic acid (HTFA) were purchased from Sigma-Aldrich (Milan, Italy). 
Cisplatin was purchased from Alfa Aesar (Karlsruhe, Germany). Fetal Bovine Serum, Kanamycin, 
L-Glutamine medium, and RPMI medium were purchased from Euroclone (Milan, Italy). The 
  
commercial reagents were used as received. Ultra-pure water obtained with MilliQ Millipore was 
used for all the experiments. 
 
Cell culture  
The human acute T-lymphoblastic leukaemia cell line (CCRF-CEM-wt) was purchased from the 
American Type Culture Collection (ATCC, USA), whereas a subline cisplatin-resistant cells 
(CCRF-CEM-res), was obtained by us via serial passages of the CCRF-CEM cell line in the 
presence of increasing concentrations of cisplatin. The CCRF-CEM-res subline was stabilized at 5 
µM cisplatin (for details see ref. [23]).  The human ovarian carcinoma cell line (A2780-wt) and the 
cisplatin-resistant subline (A2780-res), were a generous gift by Dr. Eva Fischer (Tumor Biology 
Laboratory, The Ion Chiricuta Oncology Institute, Cluj-Napoca, Romania). CCRF-CEM cell lines 
were maintained in culture between 1×10
5
 cells/ml and 2×10
6
 cells/ml, in RPMI medium with 
stable L-Glutamine medium supplemented with 10% Fetal Bovine Serum and 1% Kanamycin 
(growth medium). A2780 cell lines were maintained in culture between 1.5×10
5
 cells/ml and 3×10
6
 
cells/ml (~70% confluency) in the same medium. Mycoplasma contamination was periodically 
monitored. All cell lines were replaced every 3 months with cells freshly thawed from liquid 
nitrogen. In addition, CCRF-CEM-res and A2780-res were treated with 5 µM (every passage) and 1 
µM (every two or three splits) cisplatin, respectively, in order to maintain the drug resistance. 
Cisplatin resistance was checked every month. All experiments with cisplatin-resistant sublines 
were performed using cell populations that were grown for one passage without cisplatin. 
 
Cell lysates 
Exponentially growing CCRF-CEM-wt/CCRF-CEM-res (2×10
7 
total) and A2780-wt/A2780-res 
(4×10
6
 total) cells were centrifuged at 1500 rpm for 5 minutes. Pellets were resuspended in 1 ml of 
deionized H2O. Cell lysates were obtained by using a 2 ml dounce tissue grinder set (Sigma 
Aldrich) followed by centrifugation at 4600 rpm for 2 minutes. PLs were extracted from 
supernatants and pellets and analysed by ESI-MS, immediately after the lysis in order to minimize 
the enzymatic activity. During manipulation, the samples were kept on ice. 
 
Extraction of phospholipids 
The SPE of PLs from the crude cell lysate was performed with the Visiprep
TM
 Solid Phase 
Extraction Vacuum Manifolds 12-Port Model and the SPE HybridSPE-Phospholipid Ultra Cartridge 
(Supelco). The cartridges were conditioned with 1 ml of CH3CN containing 1% of HCOOH, 
followed by 1 ml of water. The lysate pellets or 200 µl of each cell lysate supernatants,  was put 
into a cartridge with 600 µl of CH3CN containing 1% of HCOOH. To facilitate the protein 
  
precipitation, the mixture was mixed by repeated pipetting with a micropipette. The solution, 
containing almost metabolites, was extracted under vacuum and stored in freezer for other uses. The 
cartridge was washed with 1 ml of CH3CN containing 1% of HCOOH and afterwards the 
phospholipids were extracted with 1 ml of CH3OH containing 5% of NH4OH. The resulting 
solution was divided in two fractions: one was immediately used for negative ESI-MS 
spectrometry, the other one was evaporated under vacuum and the solid residue was dissolved in 1 
ml of H2O containing 0.5% HTFA and CH3OH (1:1) for positive ESI-MS. Five different lysate 
samples of each cell line were analysed and every extraction was repeated six times from every 
sample. The error percentage of the repeated measurements was always lower than 1%. 
 
Mass spectrometry 
Mass spectra were collected on a triple quadrupole QqQ Varian 310-MS mass spectrometer using 
the atmospheric-pressure ESI technique. 
The sample solutions were infused directly into the ESI source using a programmable syringe pump 
at a flow rate of 0.70 ml/h. A dwell time of 14 s was used and the spectra were accumulated for at 
least 10 minutes in order to increase the signal-to-noise ratio. Mass spectra were recorded in the m/z 
50–1000 range. The experimental conditions for positive- and negative-ion mode were: needle 
voltage 4500 V and −5500 V, shield voltage 600 V and −600 V, housing temperature 60 °C, drying 
gas temperature 100 °C and 120 °C, nebuliser gas pressure 40 PSI, drying gas pressure 20 PSI, and 
detector voltage 1600 V and −1800 V. Tandem MS-MS experiments were performed with argon as 
the collision gas (1.8 PSI). The collision energy was varied from 2 to 45 V. The isotopic patterns of 
the measured peaks in the mass spectra were analysed using mMass 5.5.0 software package [24–
26]. The assignment of the PLs to the spectral peaks was performed by using the human metabolite 
database HMDB (www.hmdb.ca) [27–29], on the basis of the MS-MS spectra. In case of ambiguity 
the human biofluid location of the chosen PL was also considered. Only peaks with intensities 
higher than 2107a.u. were considered. In some cases, due to the simultaneous presence of PLs with 
similar masses, convoluted signals were observed. In these cases, the experimental pattern was 
attributed to a weighted combination of the isotopic pattern of the different molecules [23]. The 
weights, that represent the percentage in which each molecule was present, were obtained by 
multivariate regression analysis of the experimental data. 
 
Results and discussion 
Sample preparation for ESI-MS spectrometry 
The PLs of the cellular lysate samples were extracted in a fast, routine, accurate, and reproducible 
method based on the solid phase extraction and analysed by mass spectrometry (Fig. 2).  
  
The mass spectrum of the cell lysate analysed without any pre-treatment is characterised by a high 
number of overlapped peaks of low intensity and a baseline with poor quality (Fig. 3A). The low 
intensity of the signals (10
8 
a.u.) is mainly due to the presence of proteins that act as ionic 
suppressors [30]. Following the procedure reported in Fig. 2, a reliable spectrum is instead obtained. 
Proteins are precipitated inside a cartridge (HybridSPE-Phospholipid Ultra Cartridge, Supelco, 
HybridSPE is a registered trademark of Sigma-Aldrich Co. LLC.) by addition of CH3CN and 
HCOOH. The resulting mixture is passed, under vacuum, through the cartridge to remove the liquid 
phase containing almost metabolites, while the precipitated proteins are retained in the upper frit of 
the cartridge. PLs are retained by the cartridge via a selective Lewis acid-base interaction between 
the proprietary zirconia ions, functionally bonded to the stationary phase, and the phosphate moiety 
of the PLs [31]. The PLs are then recovered by extraction with NH4OH in CH3OH. The resulting 
solution is divided in two fractions: one is used for negative ESI-MS spectrometry, the other one is 
evaporated under vacuum and the solid residue is dissolved in a proper amount of 1:1 H2O (0.5% 
HTFA) and CH3OH for positive ESI-MS spectrometry. The proposed procedure was followed for 
lysate samples of the four cell lines. Sixteen replicates for each cell line were analysed to check the 
reproducibility of the results and the robustness of the method. 
 
 
Fig. 2 Experimental procedure followed in this work to extract the phospholipids from the cell 
lysate. In the picture, the SPE extractor is shown (Visiprep Solid Phase Extraction Manifold - 12 
Port Model). 
  
Mass spectrometry 
Cell lysates were obtained by a mechanical method using a dounce homogenizer without detergents. 
The supernatant solutions containing cytoplasmic extracts and the respective pellets having nuclei 
and cell debris of the cell lysates were analysed by ESI-MS and different results were obtained for 
the two lysate fractions. The spectra recorded in positive ion mode for supernatant and pellet 
fractions and untreated lysate of CCRF-CEM-wt cells are reported in Fig. 3. The mass spectra 
recorded in positive, ESI(+), and negative, ESI(-), ion mode for all the samples are reported in the 
Supporting Information (Fig. S1-S4). 
 
Fig. 3 ESI(+) mass spectra of the lysate solutions of CCRF-CEM wild type cells without any 
pretreatment (A), after SPE extraction from the supernatant fraction (B), and from the pellet fraction 
(C). The intensities are reported in different scales; the intensity of the signals in the m/z 500–1000 
range was multiplied by a factor of 10 in B and C. 
  
The spectrum of the untreated lysate (Fig. 3A) is characterised by a very low intensity (10
8
 vs 10
9 
a.u. of 3B and 3C) and by the presence of many broad peaks due most probably to multi-charged 
protonated peptides. Comparing the spectrum of the lysate with those of the supernatant and pellet, 
it appears evident that the SPE treatment produces higher quality spectra. Signals of the PLs fall in 
the mass/charge ratio (m/z) 500–1000 range, while signals falling in the m/z 50–400 range are 
principally due to their fragment products, as confirmed by the MS-MS experiments. 
The PL peaks observed in the spectra were identified on the basis of the masses, isotopic 
distribution patterns and the structural information obtained from tandem MS-MS. PLs were 
assigned to a given family on the basis of characteristic peaks in the tandem MS-MS spectra and by 
precursor/product ion scan and neutral loss scan experiments. For example, the m/z 184 precursor 
ion scan gives the possibility to detect all the lipids containing the phosphocholine ion, while the 
neutral loss of phosphoethanolamine (m/z 141) helps in the identification of PEs. The collision-
induced fragmentation experiments were carried out varying the collision energy, in order to 
observe partial and complete fragmentation of the parent peaks. Considering the specific fragments 
and the common rules of fragmentation, in some cases it is possible to determine precisely the fatty-
acyl group and the structure of the long-chain base (number and position of the double bonds). 
Some MS-MS spectra of PLs with the corresponding assignment are reported in the Supporting 
Information (Fig. S5-S10). 
 
Phospholipid content 
The height of a mass peak is proportional to the concentration of the species that originated that 
signal but depends also on its ionisation efficacy. Therefore, the intensity of two or more signals 
originated by different species cannot be directly compared. Instead, providing that the 
experimental conditions are kept constant, the intensity of signals arising from the same species can 
be compared each other. The heights of the mass peaks for the studied samples, recorded in ESI(+) 
and ESI(-), are reported in Fig. 4-7 
 
 
 
 
 
 
 
  
  
 
 
 
Fig. 4 Phospholipids identified with ESI(+) in the lysate fractions of supernatant (S) and pellet (P) for the CCRF-CEM wild type (CEM-wt) and 
cisplatin-resistant (CEM-res) cells (charges of proton and sodium ions are omitted for clarity), the MS-MS spectra of the marked (*) PLs are presented 
and discussed in the supporting (Fig. S5-S7). The error percentage in intensity for repeated measurements was always lower than 1%. 
 
 
 
 
  
 
 
Fig. 5 Phospholipids identified with ESI(+) in the lysate fractions of supernatant (S) and pellet (P) for A2780 wild type (A2780-wt) and cisplatin-
resistant (A2780-res) cells (charges of proton and sodium ions are omitted for clarity), the MS-MS spectra of the marked (*) PLs are presented and 
discussed in the supporting (Fig. S5 and S7). The error percentage in intensity of the repeated measurements was always lower than 1%.  
 
 
 
 
 
  
 
 
Fig. 6 Phospholipids identified with ESI(-) in the lysate fractions of supernatant (S) and pellet (P) for the CCRF-CEM wild type (CEM-wt) and 
cisplatin-resistant (CEM-res) cells (charges of proton, sodium, potassium and formate ions are omitted for clarity), the MS-MS spectra of the marked 
(*) PLs are presented and discussed in the supporting (Fig. S8-S10). The species C37H72O7P was not distinguishable between PA(P-34:0) and PA(O-
34:1). The error percentage in intensity of the repeated measurements was always lower than 1%. 
  
 
 
Fig. 7 Phospholipids identified with ESI(-) in the lysate fractions of supernatant (S) and pellet (P) for the CCRF-CEM wild type (CEM-wt) and 
cisplatin-resistant (CEM-res) cells (charges of proton, sodium, potassium and formate ions are omitted for clarity), the MS-MS spectra of the marked 
(*) PLs are presented and discussed in the supporting (Fig. S9 and S10). The species C37H72O7P was not distinguishable between PA(P-34:0) and 
PA(O-34:1). The error percentage in intensity of the repeated measurements was always lower than 1%. 
  
The number of PLs detected in supernatant (S) and pellet (P) is different for each studied cell lines, 
as reported in Table 1. 
 
Table 1. Number of PLs detected in ESI(+) and ESI(-) in supernatant and pellet fractions of lysates 
of CCRF-CEM and A2780 cell lines in the chosen experimental conditions. 
 
Cell Line 
Number of detected phospholipids 
ESI(+) ESI(-) 
supernatant pellet supernatant pellet 
CCRF-CEM-wt 21 17 18 15 
CCRF-CEM-res 12 7 18 8 
A2780-wt 12 23 8 12 
A2780-res 14 22 9 15 
 
In ESI(+), the number of PLs detected in the supernatant fraction is higher than that of the pellet 
fraction in the CCRF-CEM lysate and lower in the A2780 lysate. In ESI(-), the number of PLs 
detected in the supernatant or pellet fractions is almost identical in the CCRF-CEM lysate, while is 
higher in the pellet fraction of A2780 lysate compared to the supernatant. Some PLs were detected 
only in one of the two fractions of the cell lysates.  
The intensities of the peaks recorded in ESI(+) are generally higher than those recorded in ESI(-), 
except for the signals of (DHAP+Na) and (LysoPA(18:2)+K-2H), where the presence of the metal 
ion increases the ionisation efficacy and originates a very high response. Regards the ESI(+) 
experiments, the PLs SM(d16:1/24:1), PC(P-34:0), PC(18:0/14:0), LysoPE(22:1), and 
LysoPE(20:1) are present only in the CCRF-CEM cells, in particular LysoPE(22:1) is present only 
in the CEM-resS, LysoPE(20:1) only in CEM-wtS, and SM(d16:1/24:1) only in CEM-wtP. The PLs 
PC(42:10), PE(40:8), PE(28:1), LysoPS(22:5), LysoPS(18:1), LysoPS(15:0), LysoPE(22:5), 
LysoPE(15:0) and S1P(d20:0) are detected only in A2780 cells. Regards the ESI(-) experiments, the 
PLs sphinganine 1-phosphate, LysoPC(18:1) and PC(P-34:0) are present only in the CEM cell 
lysate. PG(40:9) and SM(d18:0/22:2(13Z,16Z)(OH)) are present only in A2780 cell lysate.  
From the MS-MS experiments (precursor ion mode and parent ion mode), lysophospholipids were 
found to be present in the lysate but also formed by collision-induced fragmentation of PLs or by 
decomposition of precursor ions in ESI phase. LysoPE(15:0), for example, was derived from 
PE(36:3), PE(34:3) and PE(32:3).  
Considering the different results obtained for surpernatant and pellets, it follows that in the study of 
cell lysates, it is important to analyse both supernatant and pellet fractions and consider the total PL 
content. 
  
CCRF-CEM wild type and cisplatin-resistant cell lines 
The total PL content for CCRF-CEM-wt and CCRF-CEM-res is reported in Fig. 8. Intense changes 
between cisplatin-resistant and wild type cells are observable in the PL abundances and kinds. In 
particular, from ESI(+) results, in the resistant cells it appears that i) PC(20:2), PC(34:1), PC(P-
34:0), SM(d18:0/18:0), LysoPC(18:1), and LysoPC(16:0) are strongly down-represented, while ii) 
LysoPE(22:1) and DHAP(18:0e) are moderately up-represented. From ESI(-) results, it appears that 
i) PC(36:1), PC(18:1/16:0), PC(P-34:0), PC(32:1), LysoPC(18:1), LysoPC(16:0), LysoPA(18:2), 
DHAP(18:0e) are down-represented, while ii) SM(d18:0/14:1(9Z)(OH)), PA(O-
20:4(5Z,8Z,11Z,14Z)/2:0), LysoPE(15:0), LysoPA(P-16:0e/0:0) are up-represented. The PLs 
S1P(d19:1-P), LysoPE(14:1), LysoPE(O-16:0), PE(31:0), SM(d18:0/16:0), PE(34:3), PE(36:3) are 
almost retained from wild type to cisplatin-resistant cells. 
From the reported results, the principal outcome is that the PC content is strongly reduced in the 
cisplatin-resistant CCRF-CEM cells, with respect to the wild type ones. This could be due to 
increased PC catabolism or decreased PC biosynthesis. The biological turnover of PCs produces 
phosphatidic acid (PA) and choline, by the action of phospholipase D, and arachidonic acid and 
LysoPC, by the action of phospholipase A2. PA can be then converted in LysoPA, while 
arachidonic acid can be converted in prostaglandins and leukotriens. LysoPCs play an important 
role in lipid signaling by acting on the LysoPLs receptors. LysoPA stimulates proliferation, 
decreases apoptosis, platelet aggregation, smooth muscle contraction, and tumour cell invasion. PC 
biosynthesis is regulated by the cytidine 5'-diphosphocholine (CDP-choline), involved in the 
modulation of choline-phosphate cytidylyltransferase binding to membranes [32]. The CDP-choline 
reduces phospholipase A2 activity, increases the synthesis of S-Adenosyl methionine and 
glutathione, stimulates the glutathione reductase activity, and fixes the level of arachidonic acid 
[33–36]. DHAP(18:0e), moderately up-represented in the resistant cells, is the octadecanoyl 
derivative of the dihydroxyacetone phosphate (DHAP). DHAP is involved in the glycolysis 
metabolic pathway and it is produced by dehydrogenation of L-glycerol-3-phosphate (glycolytic 
pathway). DHAP(18:0e) or 1-octadecyl-glycerone-3-phosphate is converted from 1-octadecanoyl-
glycerone-3-phosphate via alkylglycerone phosphate synthase [37]. The alkyl derivatives of DHAPs 
are intermediates in the synthesis of ether phospholipids, molecules with one or more carbon atoms 
on a glycerol moiety bonded to the alkyl chain via ether linkage. If a vinyl ether group is present in 
the first position of the glycerol chain, these lipids are called plasmalogens (1-O-1'-alkenyl-2-
acylglycerophospholipids) [38]. 
 
  
 
Fig. 8 Phospholipids identified with ESI(+) (A) and ESI(-) (B) in the lysate extract of CCRF-CEM 
wild type (CEM-wt) and cisplatin-resistant (CEM-res) cells (charges of proton, sodium, potassium 
and formate ions are omitted for clarity). The species C37H72O7P was not distinguishable between 
PA(P-34:0) and PA(O-34:1). The phospholipids that are up-represented () or down-represented 
() in the cisplatin-resistant cells with respect to the wild type ones, are marked.  
 
A2780 wild type and cisplatin-resistant cell lines 
As shown in Fig. 9, from ESI(+) measurements, almost all the PLs are present to the same extent in 
the wild type and cisplatin-resistant cells, except SM(d34:1) which is slightly down-represented, 
and SM(d18:0/18:0) and PC(20:2(11Z,14Z)/16:0), which are slightly up-represented. On the 
contrary, the PLs detected in ESI(-) are all up-represented in resistant cells, and some of them are 
strongly up-represented. In particular, SM(d18:0/14:1(9Z)(OH)), C37H72O7P, PA(O-
  
20:4(5Z,8Z,11Z,14Z)/2:0), LysoPA(18:2), DHAP(18:0e) and LysoPA(P-16:0e/0:0) are up-
represented. 
SM(d18:0/14:1(9Z)) is a sphingolipid found in the membranous myelin sheath. The plasma 
membrane of cells is rich in sphingomyelin, in particular in the exoplasmic leaflet. Sphingomyelins 
(SMs) are important for signal transduction and are synthesized by the transfer of 
phosphorylcholine from phosphatidylcholine to a ceramide in a reaction catalyzed by 
sphingomyelin synthase. Sphingolipids are involved in the formation of rafts and caveolae (lipid 
raft of 50–100 nm in size), which are cellular domains involved in the regulation of cell function, 
transporters and proteins, and in the skin barrier permeability. Sphingomyelin turnover alters the 
structure of membrane domains [39,40]. 
 
Fig. 9 Phospholipids identified with ESI(+) (A) and ESI(-) (B) in the lysate extract of A2780 wild 
type (A2780-wt) and cisplatin-resistant cells (A2780-res) (charges of proton, sodium, potassium 
and formate ions are omitted for clarity). The species C37H72O7P was not distinguishable between 
PA(P-34:0) and PA(O-34:1). The phospholipids that are up-represented () or down-represented 
() in the cisplatin-resistant cells with respect to the wild type ones, are marked.  
  
Conclusions 
We studied the phospholipid profile of wild type and cisplatin-resistant cells of two kinds of 
tumour, T-lymphoblastic leukaemia (CCRF-CEM) and ovarian carcinoma (A2780), with the aim to 
highlight possible differences and identify some specific phospholipids between wild type and 
cisplatin-resistant cells. 
The analytical method proposed in this work is based on solid phase extraction and mass 
spectrometry and allowed us to study the phospholipidic (PL) profile of cell lysates, obtaining 
reliable and reproducible results and preventing peptide and metabolite interferences. A different 
phospholipidic profile was detected in supernatant and pellet fractions of the cell lysates, suggesting 
that these two fractions have to be taken into account simultaneously for a correct interpretation and 
a complete characterization of the phospholipidic profile. 
Comparing the PL profiles of wild type and cisplatin-resistant cells, the absence of PC(34:1), 
LysoPC(18:1), PC(20:2(11Z,14Z)/16:0) and PC(P-34:0) was observed as specific for cisplatin-
resistant CCRF-CEM cells, whereas the presence of PC(20:2(11Z,14Z)/16:0) and SM(d18:0/18:0) 
and the absence of SM(d34:1) were observed as specific for cisplatin-resistant A2780 cells. These 
lipids can be considered, within a specific line, as “markers” to distinguish between wild type and 
cisplatin-resistant cells.  
Considering that the PL composition influences the transport of drugs across the membrane, affects 
the activity of the drug transporters and the ability of the cells to load and accumulate drugs, it is 
evident that a change of the PL content is connected with the development of the resistance. 
However, from the obtained results, it is not possible to define if these changes are the cause or the 
consequence of the cisplatin-resistance occurrence. Nevertheless, the potential use of some lipids as 
“markers” for resistant cells could be important for a possible clinical application. In fact, the onset 
of the resistance during cisplatin treatment could be monitored by detecting those specific lipids. 
Under this perspective, the obtained findings represent an advancement of knowledge and can be 
exploited for the design of new strategies in cancer treatment. 
 
Abbreviations used 
A2780-res, cisplatin resistant sub-line of ovarian carcinoma cells; A2780-wt, wild type ovarian 
carcinoma cells; CCRF-CEM-res, cisplatin resistant sub line of acute T-lymphoblastic leukaemia 
cells; CCRF-CEM-wt, wild type acute T-lymphoblastic leukaemia cells; CDP-choline, cytidine 5'-
diphosphocholine; CID, collision-induced decomposition; DHAP, dihydroxyacetone phosphate; 
ESI(+), electrospray ionisation positive ion mode; ESI(-), electrospray ionisation negative ion 
mode; ESI-MS, electrospray ionisation mass spectrometry; FBS, foetal bovine serum; GPLs, 
glycerophospholipids; HTFA, trifluoroacetic acid; MS-MS, tandem mass spectrometry; P, pellet 
  
fraction; PA, phosphatidic acid; PC, glycerophosphocholine; PE, glycerophosphoethanolamine; PI, 
glycerophosphoinositol; PS, glycerophosphoserine; PLs, phospholipids; RPMI medium, Roswell 
Park Memorial Institute medium; S, supernatant fraction; SLs, sphingolipids; SMs, sphingomyelins; 
SPE, solid phase extraction; TFA, trifluoroacetate. 
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Fig. S1 ESI(+) mass spectra of the solution extracted from the supernatant fraction of CCRF-CEM-
wt (A), CCRF-CEM-res (B), A2780-wt (C) and A2780-res (D) in the m/z 50–1000 range. The 
intensity of the signals in the m/z 500–1000 range was multiplied by a factor of 10 for clarity.  
  
 
Fig. S2 ESI(-) mass spectra of the solution extracted from the supernatant fraction of CCRF CEM-
wt (A), CCRF-CEM-res (B), A2780-wt (C) and A2780-res (D) in the m/z 50–1000 range. The 
intensity of the signals in the m/z 500–1000 range was multiplied by a factor of 10 for clarity. 
  
 
Fig. S3 ESI(+) mass spectra of the solution extracted from the pellet fraction of CCRF-CEM-wt 
(A), CCRF-CEM-res (B), A2780-wt (C) and A2780-res (D) in the m/z 50–1000 range. The intensity 
of the signals in the m/z 500–1000 range was multiplied by a factor of 10 for clarity.  
  
 
Fig. S4 ESI(-) mass spectra of the solution extracted from the pellet fraction of CCRF-CEM-wt (A), 
CCRF-CCRF-res (B), A2780-wt (C) and A2780-res (D) in the m/z 50–1000 range. The intensity of 
the signals in the m/z 500–1000 range was multiplied by a factor of 10 for clarity. 
  
 
Fig. S5 Tandem MS-MS (+) spectrum of the m/z 496 peak. The structure of LysoPC(16:0) has been 
assigned based on the following considerations: i) correspondence between the molecular ion and 
the lipid present in the database; ii) loss of a water molecule resulting from the elimination of the 
free OH of the glycerol moiety and one of OH protons; iii) presence of phosphocholinic ion at m/z 
184 and cholinic ion at m/z 104 characteristicof this class of compounds; iv) the ions at m/z 381and 
m/z 285 generated by the loss of alkyl radicals are justified by the theory of charge-remote 
fragmentation [41]. The most probable structures of the fragments are reported in the Table S1. 
 
 
Fig. S6 Tandem MS-MS (+) spectrum of m/z 734 peak. Structure of PC(18:0/14:0) has been 
assigned based on the following considerations: i) correspondence among the molecular ion of the 
compound and those present in the database www.hmdb.ca; ii) peaks at m/z 379, 359, and 341 
indicate the presence of the carboxylic chain with 18 carbon atoms, therefore, according to the data 
  
base, this excludes the PC structure (16:0/16:0); iii) the peak at m/z 359 exclusively indicates the 
loss of the chain with 14 carbon atoms in the form of ketene, which is then eliminated more easily if 
it is in the sn-2 position [42]; iv) the presence of a phosphocholinic ion at m/z 184 is characteristic 
of this class of compounds. The most probable structures of the fragments are reported in the Table 
S3. 
 
 
Fig. S7 Tandem MS-MS (+) spectrum of m/z 786 peak. A structure of PC(20:2(11Z,14Z)/16:0) has 
been assigned on the basis of the following considerations: i) correspondence among the molecular 
ion of the compound and those present in the database www.hmdb.ca; ii) loss of a water molecule 
resulting from the elimination of the OH arising from the enolic form of carboxylic acid moiety and 
one of OH  protons. The abundance of this ion is lower than the corresponding one found in the 
fragmentation of the LysoPC(16:0), where the free OH alcoholic group is present; iii) the peak at 
m/z 697 is originated by the loss of the ethanol-aminic group after transposition of a methyl of the 
amino group on an oxygen phosphate group; iv) the ion at m/z 551 could be tilting the balance 
towards the assignment of this spectrum at one of the two PC(18-18) present in the data base, but 
the peaks at m/z 442 and 429 clearly indicate the presence of fatty acids with 16 and 20 carbon 
atoms, respectively. Furthermore, the ion at m/z 239 can be assigned to the group with 16 carbon 
atoms rather than to the less stable saturated alkyl ion with 18 carbon atoms; v) presence of 
phosphocholinic ion at m/z 184 characteristic of this class of compounds; vi) the ion at m/z 514 
generated by the loss of alkyl radicals from the ion at m/z 697 is justified by the presence of the 
chain with 16 atoms rather than 18 atoms due to the nearest charge being at the fragmentation point. 
The most probable structures of the fragments are reported in the Table S4. 
 
  
 
Fig. S8 Tandem MS-MS (-) spectrum of m/z 566 peak (LysoPC(18:1)+HCOO
-
). The peak at m/z 
506 allows us to identify the class of the lysoPC, while the peak at m/z 281 confirms the presence of 
the unsaturated acyl chain with 18 carbon atoms. The spectrum does not allow us to establish the 
position of the double bond. The most probable structures of the fragments are reported in the Table 
S2. 
 
 
Fig. S9 Tandem MS-MS (-) spectrum of m/z 540 peak (LysoPC(16:0)+HCOO
-
). The peak at m/z 
480 allows us to identify the class of the lysoPC, while the peak at m/z 255 confirms the presence of 
the saturated acyl chain of 16 carbon atoms. The most probable structures of the fragments are 
reported in the Table S5. 
 
  
 
Fig. S10 Tandem MS-MS (-) spectrum of m/z 804 peak (PC(18:1/16:0)+HCOO
-
). All the PC 
compounds in negative ionization mode and in the presence of formic acid exhibit the loss of 60 
due to the methyl formiate. This peak allows us to identify the phospholipid as PC(34:1). The peaks 
at m/z 281 and 255 allow us to identify acyl chains with 18 and 16 carbon atoms, the latter with an 
unsaturation. The greater abundance of the peak at m/z 255, assigned to the chain with 16 carbon 
atoms, allows us to put this chain in the sn-2 position of the glycerol units [43]. The peak at m/z 113 
allows us to tentatively assign the double bond position in the chain with 18 carbon atoms. In fact, 
its presence at position 9 favors the break between carbon atoms 6 and 7 due to the remote charge 
fragmentation. The most probable structures of the fragments are reported in the Table S6. 
 
 
Table S1. Most probable structures of the fragments originated by the parent peak at m/z 496. 
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Table S2. Most probable structures of the fragments originated by the parent peak at m/z 560. 
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Table S3. Most probable structures of the fragments originated by the parent peak at m/z 734. 
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Table S4. Most probable structures of the fragments originated by the parent peak at m/z 786. 
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Table S5. Most probable structures of the fragments originated by the parent peak at m/z 540. 
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Table S6. Most probable structures of the fragments originated by the parent peak at m/z 804. 
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Abstract 
The in vitro cultured cell lines are widely used as models in biomedical research. 
However, the research performed on cultured cell is dependent on proper cell identity 
and continuously faces to significant risk of misinterpretations due to cross 
contamination. The cell-line cross contamination consists in the inadvertent inoculation 
of the desired cell line with another one, arising from improper handling during cellular 
splitting, medium sharing for multiple cell lines, and also in storage. Mouse embryonic 
fibroblasts cells (mEFs) are often used as feeder cells for the culture of human 
embryonic stem cells (hESCs) and can accidentally contaminate them. For over 50 
years the problem of the cell-line cross-contamination has been underestimated and 
erroneous results and conclusions have been published. The ex-post discovery of such 
erroneous findings led to paper retraction, compromising both author’s and journal’s 
credibility. Although the issue of cell line misidentification is known for years in the 
scientific community, it is still a present matter. Nowadays, many high-impact journals 
started to adopt a zero-tolerance policy, requiring confirmation of cell line identity as 
prerequisite for publication. To check identity and cross-contamination of cell lines, 
methods such as DNA fingerprint analysis, karyotyping, isoenzyme analysis, 
immunotyping, human leukocyte antigen (HLA)-typing, and short tandem repeat (STR) 
profiling (this last accepted as international reference standard and used in the forensic 
field), are commonly used. However, all these methods do not allow the detection of 
interspecies contamination with a single technique able to provide all the information 
needed to completely identify a cell line. On the base of these considerations, a rapid 
and routinely applicable method for evaluation of cell culture cross contamination 
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levels, based on mass spectrometric fingerprints of intact mammalian cells coupled with 
artificial neural networks (ANNs), has been developed and validated (Figure 20) 
(Chapter 6 – Article III).   
 
 
Figure 20. The development and validation of a method for the evaluation of the cell culture 
cross-contamination levels based on mass spectrometric fingerprints of intact mammalian cells coupled 
with artificial neural networks.    
 
Human embryonic stem cells (hESCs) contaminated by either mouse embryonic 
stem cells (mESCs) or mouse embryonic fibroblasts (MEFs) have been used as a model. 
The contamination level has been determined using a mass spectra database of prepared 
calibration mixtures. The ANN was able to correct quantify the level of contamination 
of hESCs by mESCs or MEFs.  
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Abstract
Cross-contamination of eukaryotic cell lines used in biomedical research represents a
highly relevant problem. Analysis of repetitive DNA sequences, such as Short Tandem
Repeats (STR), or Simple Sequence Repeats (SSR), is a widely accepted, simple, and
commercially available technique to authenticate cell lines. However, it provides only quali-
tative information that depends on the extent of reference databases for interpretation. In
this work, we developed and validated a rapid and routinely applicable method for evalua-
tion of cell culture cross-contamination levels based on mass spectrometric fingerprints of
intact mammalian cells coupled with artificial neural networks (ANNs). We used human
embryonic stem cells (hESCs) contaminated by either mouse embryonic stem cells
(mESCs) or mouse embryonic fibroblasts (MEFs) as a model. We determined the contami-
nation level using a mass spectra database of known calibration mixtures that served as
training input for an ANN. The ANN was then capable of correct quantification of the level of
contamination of hESCs by mESCs or MEFs. We demonstrate that MS analysis, when
linked to proper mathematical instruments, is a tangible tool for unraveling and quantifying
heterogeneity in cell cultures. The analysis is applicable in routine scenarios for cell authen-
tication and/or cell phenotyping in general.
Introduction
In current biomedical research, cells cultured in vitro are irreplaceable experimental models
and biotechnological tools. However, the research performed on immortalized or tumor-
derived cell lines is dependent on proper cell identity and faces continuous significant risk of
data misinterpretations due to inadvertent cross-contamination by another cell line [1–4].
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Contamination can easily occur by improper passaging, sharing of culture media for multiple
cell lines, or inaccurate labeling and storage. Indeed, sophisticated techniques of cell culture
and tissue engineering, such as high-throughput reactors, microfluidics, and stem cell or tissue
cultures, require stringent monitoring of cell identity and phenotype stability [5–7]. The cur-
rent gold standard for authentication of individual cell lines is analysis of Short Tandem Repeat
sequences (STR) or Simple Sequence Repeats (SSR) widespread throughout the genome, since
each cell line theoretically has a unique STR-profile [1,2]. In specific scenarios, such as co-cul-
ture setups of two cell lines, use of various cell populations derived from a single individual or
from inbred strains, or the occurrence of phenotypic changes within STR- or otherwise stable
cell lines, STR analysis cannot provide sufficient discrimination. Furthermore, in cases of
intrinsic heterogeneity or impurity of cell cultures, co-culture setups, microsatellite instability,
phenotype shifts, or viral or mycoplasma infections, STR analysis can provide ambiguous
results, or, in the best case, allow only a qualitative assessment of cell identity without any
information on the extent of contamination or heterogeneity in cell populations. Techniques
that can complement STR authentication, such as identification of phenotype- or genotype-
related markers, e.g. karyotype, isoenzymes, surface markers, or single nucleotide polymor-
phisms (SNPs) [8,9], are nevertheless dependent on preceding knowledge of the biological
background of the model system used. Optimization of high-resolution methods common in
physical and analytical chemistry and advanced mathematical modeling can circumvent the
need for specific markers by analysis of global cellular or tissue patterns. Spectral techniques,
such as Raman near-infrared or mass spectrometry were recently demonstrated to provide
global fingerprints with sufficient capacity to distinguish diseased and normal tissues in models
of metabolic disorders, or even individual states of cell differentiation or metabolism [10–13].
Matrix-assisted laser desorption/ionization–time of flight mass spectrometry (MALDI-TOF
MS) has recently been used in fields beyond analytical and structural chemistry, such as bio-
medical research or clinical practice, and has been adapted for characterization of complex bio-
logical samples by peptide-mass-fingerprinting or peptide sequence tagging. Biotyping of non-
fractioned intact microorganisms by MS is now a fast, routine, and cheap technique in clinical
microbiology. Similarly, the concept of biotyping eukaryotic cells by intact cell (IC) MALDI-
TOF MS has been suggested to allow identification of cell lines [13–18] or to characterize of
physiological events occurring in the cells, such as terminal differentiation or programmed cell
death [19]. The IC MALDI-TOF MS technique allows for recording the characteristic profiles
of eukaryotic cells in quality sufficient for detailed analyses ranging from ultrastructural molec-
ular cytology, to deep cell phenotyping and tissue analyses [13,15,18–22], to species recognition
[23] and ecotoxicology [24,25].
However, a simple visual inspection of mass spectra is often not sufficient to establish an
unambiguous cell line-specific set of biomarker peaks. Moreover, specific signal intensity and
analytic concentration are not linear except in a narrow concentration range due to various sto-
chastic “MALDI effects,” such as variability in matrix/analyte interactions and energy dissipa-
tion or quenching or enhancing of ionization [26]. Mathematical methods that are successfully
used in chemometrics, such as bivariate regression, polynomial fitting, multiple linear regres-
sion, partial least squares, and artificial intelligence, must therefore be applied in MS analysis of
complex biological samples [27–29]. Artificial neural networks (ANNs) represent a robust and
versatile mathematical tool for many applications in various fields [30]. ANNs mimic the
“learning” and “generalization” abilities of human neural structures. ANNs are able to model
highly complex non-linear systems and are used for classification, pattern recognition, model-
ing, and multivariate data analysis [31]. The basic units of ANNs are “nodes” or “neurons.”
They are organized in one “input” layer, in one or more “hidden” layers, and in one “output”
layer. Each of the i-th neurons in a layer is linked to all the j-th neurons in the next layer. Each
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connection is weighted with a weight wij. The role of the neurons in the input layer is to receive
input data and transfer it to the neurons in the hidden layer through the weighted connections.
The neurons in the hidden layer(s) perform mathematical operations on the incoming data
(summation, addition of a “bias” term, and transformation by a suitable mathematical func-
tion). The result is then transferred to the neurons in the output layer where the ANN output is
calculated.
Here we study the possibility of using ANNs to determine a quantity of cells of a particular
cell line and/or type in two-component mixtures, mimicking a scenario of cell line cross-con-
tamination. To create such situations, we used: a) line CCTL14 of human embryonic stem cells
(hESCs), b) mouse embryonic fibroblasts (MEFs), and c) line R1 of mouse embryonic stem cell
(mESCs). The cells were arranged into two-component calibration mixtures of hESCs + MEFs
and hESCs + mESCs in various ratios. Line CCTL14 of hESCs has previously been thoroughly
characterized [32]. MEFs freshly isolated from connective tissue of 11.5 days old mouse
embryos are commonly used as a supportive feeder layer for hESCs in a routine co-culture
mode. Mouse ESCs [33] represent pluripotent and self-renewing cells that are developmentally
and functionally similar to hESCs.
The two-component cell suspensions were analyzed by ANN-coupled IC MALDI-TOF MS
in a multivariate calibration approach. We demonstrate that mass spectra contain sufficient
information to identify the presence of individual cell types in mixtures, and we report for the
first time that ANN analysis of mass spectra from two-component mixtures can correctly pre-
dict the level of cell cross-contamination in very complex microenvironment.
Material and Methods
Chemicals
Knockout Dulbecco’s modified Eagle’s medium (DMEM), DMEM/F12, knockout serum
replacement, fetal bovine serum, L-glutamine, minimum essential medium non-essential
amino acids, penicillin-streptomycin, and TrypLETM Select were purchased from Gibco, Life
Technologies Czech Republic Ltd. (Prague, Czech Republic). Ammonium bicarbonate, sinapi-
nic acid, trifluoroacetic acid, DMEM, 2-mercaptoethanol, phosphate buffered saline (PBS), and
gelatin were purchased from Sigma-Aldrich Ltd. (Prague, Czech Republic). MatrigelTM was
purchased from BD Bioscience, I.T.A.-Intertact Ltd. (Prague, Czech Republic). Fibroblast
growth factor-2 was purchased from PeproTech, Baria Ltd. (Prague, Czech Republic). Leuke-
mia Inhibitory Factor Protein was purchased from Chemicon, Merck Millipore (Prague, Czech
Republic). Acetonitrile was purchased from J.T. Baker, VWR International Ltd. (Prague, Czech
Republic). PepMix standard was purchased from Laser BioLabs (Sophia-Antipolis, France).
Tissue culture dishes were purchased from TPP (Trasadingen, Switzerland).
Cell cultures
Mouse embryonic fibroblasts derived from CF1-mouse embryos were cultured in tissue culture
dishes in medium consisting of Knockout DMEM supplemented with 10% fetal bovine serum,
2 mM L-glutamine, 1% minimum essential medium non-essential amino acids, 1% penicillin-
streptomycin, and 0.1 mM 2-mercaptoethanol as described previously [34,35]. Human embry-
onic stem cells [36,37] were cultured in the undifferentiated state in tissue culture dishes coated
with MatrigelTM in culture media conditioned by MEFs consisting of DMEM/F12 supple-
mented with 15% knockout serum replacement, 2 mM L-glutamine, 1% minimum essential
medium non-essential amino acids, 0.5% penicillin-streptomycin, 0.1 mM 2-mercaptoethanol,
and 4 ng/ml fibroblast growth factor-2. Mouse embryonic stem cells [33] were cultured in tis-
sue culture dishes coated with 0.1% gelatin in medium consisting of DMEM supplemented
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with 20% fetal bovine serum, 1% minimum essential medium non-essential amino acids, 1%
penicillin-streptomycin, 1 mM 2-mercaptoethanol and 5.5 μg/ml leukemia inhibitory factor
(LIF). All cell lines were maintained in an incubator at 37°C with a humidified atmosphere
containing 5% CO2, with daily media exchange.
Sample preparation
Cultured cells were washed with 1×PBS and enzymatically disaggregated to single cell suspen-
sion using TrypLE™ Select. After 2 min, the enzymatic activity was stopped by the respective
culture medium. Detached cells were pelleted by centrifugation at 200 g for 5 min and washed
once again with 1×PBS. Cell number was determined by CEDEX XS cell counter operated with
CEDEX Control Center software v. 1.0.3. from Innovatis AG, Roche Life Sciences (Prague,
Czech Republic).
Preparation of cell mixtures for MS analysis
hESCs + MEFs mixture. Cell suspensions containing a total of 1×106 hESCs and MEFs in
1×PBS in defined ratios were pelleted by centrifugation at 200 g for 5 min at 4°C and washed
three times with an aqueous solution of 150 mM ammonium bicarbonate. Then, the cell pellets
were resuspended in 10 μl of 150 mM ammonium bicarbonate and mixed with 5 μl of freshly
prepared sinapinic acid matrix (30 mg/ml in 70% acetonitrile and 7.5% trifluoroacetic acid).
Two microliters of sample/matrix mixture were immediately spotted in pentaplicates onto the
MALDI target and dried at room temperature.
hESCs + mESCs mixture. Aliquots of 1×106 mESCs or hESCs in 1×PBS were pelleted by
centrifugation at 200 g for 5 min at 4°C. Supernatant was discarded and pelleted cells were
washed three times with 150 mM ammonium bicarbonate solution. Resulting cell pellets were
then snap-frozen and stored until further processing. At the time of analysis, both mESCs and
hESCs aliquots were quickly thawed and reconstituted in 20 μl of 150 mM ammonium bicar-
bonate solution and sonicated briefly in a water ultrasound bath. Then, MEFs and hESCs were
mixed in given ratios to a total of 0.5×106 cells per sample and total volume was adjusted to
15 μl with 150 mM ammonium bicarbonate. Each cell suspension was mixed with 7.5 μl of
freshly prepared sinapinic acid matrix solution. Two microliters of sample/matrix mixture
were immediately spotted onto the MALDI target and dried at room temperature. Each sample
was spotted in five technical replicates.
Mass spectrometry
Mass spectra were recorded on an AXIMA CFR mass spectrometer from Kratos Analytical
(Manchester, UK) in linear positive ion mode. The instrument was equipped with a nitrogen
laser (337 nm) and delayed extraction was used. The laser energy was expressed in arbitrary
units from 0 to 180 a.u. The power of the laser at 180 a.u. was 6 mW, while the irradiated spot
size was approximately 150 μm in diameter. External mass calibration was done using the Pep-
Mix4 standard. The laser repetition rate was 5 Hz with a pulse time width of 3 ns. Each mass
spectrum was obtained by the accumulation of at least 5000 shots. In order to decrease the con-
tribution of chemical noise and possible errors on the baseline and in calibration, the raw mass
spectra were pre-processed, cleaned, transformed, and reduced in dimensionality before the
data analysis, as described elsewhere [38].
Mass spectra were analyzed using Launchpad Software (Kompact version 2.9.3, 2011) from
Kratos Analytical Ltd. Pre-processing of mass spectra and ANN computation were performed
using MATLAB 8.6. 2015 from The MathWorks Inc. (Natick, Massachusetts, USA) and Trajan
Neural Network Simulator, Release 3.0 D 1996–1998, from Trajan Software Ltd. (Durham, U.
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K.). Partial least squares projection to latent structures regression was performed with “leave-
one-out” cross-validated prediction in program R (www.r-project.org) using the external pls
library [39].
Artificial neural networks
We constructed an artificial neural network containing four neurons in one hidden layer. The
intensities of processed mass spectra served as the input, while the number of contaminating
cells in the two-component mixtures was the output. The “learning” of the ANN was per-
formed using the back-propagation training algorithm as described elsewhere [40,41]. The
back-propagation was achieved by iteratively adjusting the values of connection weights in
order to minimize the difference between the ANN calculated output value (opk) and the
experimental one (opk). After each iteration, the root mean square of the sum of (opk -opk)
2
residuals (RMS) was calculated according to Eq 1:
RMS ¼
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃPN
p¼1
PM
k¼1ðopk  opkÞ2
N M
s
ð1Þ
where N is the number of mass spectra,M is the number of outputs, opk is the ANN calcu-
lated, and opk is the experimental output value. The optimal ANN architecture was conﬁrmed
by plotting the RMS value against the number of neurons in the hidden layer(s) and number of
training cycles (epochs).
Results And Discussion
Preparation of two-component mixtures of different cell types and intact
cell MALDI-TOF mass spectrometry
We prepared calibration datasets consisting of twenty-eight defined two-component mixtures
of hESCs + MEFs, thirty-four mixtures of hESCs + mESCs (Fig 1A and 1D), and pure cell pop-
ulations, with total cell numbers of 1×106 (Fig 1B and 1E). We then recorded the mass spectra
of two-component cell mixtures and pure cell populations in the 2000–20000 m/z range with-
out previous fractionation or extraction. We pre-processed the mass spectra by (i) resampling
to 30000 m/z values (homogenizing in a chosen range and reducing the number of m/z values),
(ii) aligning (removing the systematic shifts in mass spectra of repeated experiments), (iii)
baseline subtraction, (iv) smoothing, and (v) normalization to a vector of unit length (SXi = 1),
where Xi are the intensities of the peaks of the mass spectrum) [42] (Fig 1C and 1F, S1 Fig).
Next, we organized the spectral data into a matrix with dimensionsm × n, wherem represents
the number of the mass spectrum of the particular cell mixture and n are the m/z values. The i-
th row of the matrix represents the mass spectrometric fingerprint of the i-thmixture. In order
to decrease the latent noise in pre-processed mass spectra, we selected only the peaks with
intensity higher than an arbitrarily set threshold (1×10−3) for further analysis. Thus, the data
matrices of hESCs + MEFs and hESCs + mESCs were reduced from the original n × 30000 to
n × 84 and n × 122, respectively. Next, we identified peaks with the highest intrinsic variability
in the datasets, as described elsewhere [43–46]. In brief, we selected informative peaks by
comparative determination of standard deviations of individual peaks normalized to the total
variance of the dataset, Lasso regression, and sparse partial least squares regression. The infor-
mative peaks are visualized in S3 Fig. That allowed us to finally reduce the data matrices of
hESCs + MEFs and hESCs + mESCs to n × 10 and n × 30, respectively (S1 Table).
Then, we used these datasets to perform principal component analysis aiming to discrimi-
nate the pure hESC and MEF cell populations and the cell mixtures containing 50% of each cell
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type. Eigenvalue analysis showed the presence of three factors contributing up to 94% of the
overall variability. Plotting the principal components revealed three clearly separated clusters
and provided proof of principle for the discriminative information of the MEF and hESC mass
spectra (Fig 2A and 2B). Similar discrimination was achieved for mESCs and hESCs (data not
shown).
Next, we visually compared mass spectra obtained from the pure hESCs and MEFs, and
their two-component mixtures. Despite the high similarity of the mass spectra, we identified
peaks unique to hESCs and MEFs (m/z 3992 and 9908) (Fig 2C) appearing reproducibly over
various mixtures. We presumed that if these two marker peaks are informative for MEFs, their
intensities should be proportional to the content of MEFs in the two-component mixtures.
However, we did not identify any linear trend between the normalized intensities of these two
marker peaks and the percentage of MEFs, especially in two-component mixtures with low
concentrations of MEFs (Fig 2D). In the case of highly similar pluripotent cell types, the mass
spectra of hESCs + mESCs mixtures lacked any spectral patterns specific for individual pure
cell lines (Fig 1F). Therefore, assessment of the individual biomarker peaks was not suitable for
precise and unambiguous quantification.
Fig 1. (A) Colony of human embryonic stem cells (hESCs) cultured on a feeder layer of mouse embryonic fibroblasts. (B) Experimental ratios of two-
component mixtures of hESCs + MEFs. (C) Representative mass spectra of selected two-component mixtures of hESCs + MEFs. (D) Colony of mouse
embryonic stem cells (mESCs) in a feeder-free culture. (E) Experimental ratios of two-component mixtures of hESCs + mESCs. (F) Representative mass
spectra of selected two-component mixtures of hESCs + mESCs.
doi:10.1371/journal.pone.0147414.g001
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Quantitative determination of contamination levels
Because of the data complexity, it was difficult to handle the mass spectral datasets by simple
linear analyses. We first examined the data by a method of partial least squares with projection
to latent structures regression (PLS) on the full data matrix of the complete mass spectra. PLS
has been developed and extended by Herman and Svante Wold, respectively, [47] for quantita-
tive analysis of highly complex multivariate data and is used preferentially in chemometrics.
Despite a correlation between predicted and actual cell percentages in the two-component mix-
tures, the prediction precision by PLS was rather low, with substantial root mean square error
Fig 2. (A) Principal component analysis of mass spectra dataset containing intensities of 84 m/z for pure MEF and hESC populations and their 1:1 mixture.
(B) Scree plot documenting the presence of three factors contributing predominantly to the overall variability in the analyzed dataset. (C) Pre-processed
MALDI-TOF mass spectra for pure hESCs and MEFs and a hESCs + MEFs two-component mixture containing 99% hESCs and 1%MEFs. The spectra were
normalized to vector of unit length (a.u.). Asterisks indicate peaks at m/z 3992 and 9908. (D) Surface plot of intensities of peaks at m/z 3992 and 9908 versus
the number of MEFs in hESCs + MEFs two-component mixtures.
doi:10.1371/journal.pone.0147414.g002
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(RMS) showing signs of systematic trends (Table 1, S3 Fig). Therefore, we asked whether non-
linear approaches and artificial intelligence methods, such as ANNs, could make predictions
with more precision. ANNs were previously reported to provide effective analysis and classifi-
cation of biological, clinical or bioanalytical, and chemometric non-linear data (for review see
[30]), and were found particularly suitable for analysis of MS data [28].
In our analysis the intensities of the selected peaks comprised the ANN-input data and the
number of MEFs and/or mESCs cells in the hESC calibration mixtures was the ANN-output
data. For the training step of the ANN, we tested several algorithms and found the back-propa-
gation algorithm to be the most suitable (data not shown). We determined the optimal archi-
tecture containing four neurons in one hidden layer (Fig 3A) by plotting the RMS against the
number of nodes (data not shown) and we validated over 100000 training cycles (epochs),
without overfitting the model (Fig 3B). We used the leave-one-out cross-validation method to
test the “generalization” ability of the designed network to predict the single cases excluded
Table 1. Values of RMS calculated as differences between predicted and observed values, k (regression coefficients), andR2 (determination
coefficient).
hESCs: MEFs hESCs: mESCs
PLS ANN PLS ANN
RMS 51.7×103 3.16×103 96.6×103 7.1×103
k 0.976 0.996 0.601 0.975
R2 0.9759 0.9992 0.6010 0.9822
doi:10.1371/journal.pone.0147414.t001
Fig 3. (A) Optimal ANN architecture (one Input layer, one Hidden layer with four neurons, and one Output
layer). (B) Training and leave-one-out verification plot of the RMS versus the number of training cycles
(epochs). First 50 000 iterations are shown. The inset shows a detailed plot for the first 10 000 training cycles.
doi:10.1371/journal.pone.0147414.g003
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from the training data set. We used the RMS as a measure of the prediction accuracy. The net-
work was able to evaluate the input data and correctly predict the number of MEFs (Fig 4A)
and mESCs (Fig 4C) in the hESC suspensions over the whole range of evaluated ratios.
Prediction by ANN was correct even at low percentages of contaminating cells in suspension.
To validate the model, the RMS was calculated as the differences between the predicted and
experimental values. The residuals reached significantly lower values than in PLS predictions
(Table 1). Moreover, the residual values were randomly distributed, and the absence of any sys-
tematic error or trend in residuals demonstrated correctness of the model (Fig 4B and 4D). To
perform further validation of the method, we analyzed an independent dataset of fifty hESCs
+ MEFs mixtures. Using a training set described above, the ANN correctly determined the
numbers of MEFs in hESCs suspension with high correlation between predicted and experi-
mental values (S4 Fig). In summary, multivariate calibration coupled with a correctly trained
ANN was able to determine the ratio of cell numbers in two-component mixtures.
We have identified the conditions and developed a step-by-step protocol for successful
quantitation of two distinct cell types in a single two-component mixture by a multivariate cali-
bration approach based on an ANN-coupled IC MALDI-TOF MS analysis. The major steps of
the method include:
1. a priori knowledge or identification of the contaminating cell line
2. construction of two-component calibration mixtures of the given cell lines
3. mass spectra pre-processing and m/z selection
4. parallel recording of mass spectra of pure cell populations and calibration mixtures and
building a library of spectral datasets for multivariate calibration
Fig 4. (A) Correlation between ANN-predicted number of cells and the experimental number of MEFs in two-
component mixtures of hESCs + MEFs. The inset shows the correlation between experimental and predicted
values in low concentration ranges of MEFs up to the 50×103 cells in the two-component mixtures. (B)
Overview of Residuals (difference between ANN-predicted number of cells and the experimental values)
versus the experimental number of MEF cells in two-component mixtures of hESCs + MEFs. (C) Correlation
between ANN-predicted number of cells and the experimental number of mESCs in two-component mixtures
of hESCs + mESCs. (D) Overview of Residuals (difference between ANN-predicted number of cells and the
experimental values) versus the experimental number of mESC cells in the two-component mixtures of
hESCs + mESCs.
doi:10.1371/journal.pone.0147414.g004
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5. estimation of the contamination levels in unknown samples using an ANNmodel trained
on the calibration datasets
The application of ANNs allowed us to overcome the unwanted inconsistency and non-lin-
earity of IC MALDI-TOF MS spectra and reveal hidden patterns in mass spectra to unambigu-
ously identify and quantify MEFs or mESCs in the hESC culture. However, a priori knowledge
of the contaminating cell line is a prerequisite for correct prediction and selection of the train-
ing dataset. The multivariate calibration-based ANN approach can be easily adapted to routine
protocols for quantitative determination of cell culture homogeneity and consistency and for
thorough MS analyses of cell parameters in various culture platforms, with all steps adaptable
for any experimental, routine, or high-throughput culture setup [48,49] (Figs 5 and 6). Cur-
rently, methods involving assessment of cell quality in clinical grade cultures, biomedical
research or bio-industry involve either genetic authentication confirming the cell identity or
functional assays documenting the phenotype. The intact cell mass spectrometry coupled with
ANN can reveal inconsistencies occurring in high-throughput or long-term cultures or co-cul-
tures, by monitoring spectral patterns and their alterations.
In conclusion, we demonstrated for the first time that the multivariate calibration approach
based on ANN-coupled IC MALDI-TOF MS analysis can provide quantitative information on
Fig 5. Overview for quantitative ANN-coupled MS-based analysis of cross-contamination.
doi:10.1371/journal.pone.0147414.g005
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cell culture heterogeneity and authenticity and thus complement the portfolio of techniques
that are available for characterization of mammalian cell cultures.
Supporting Information
S1 Fig. Comparison of raw (a) and pre-processed (b) mass spectra (five replicates) charac-
terizing human embryonic stem cells (hESCs). The pre-processed mass spectra were normal-
ized to a vector of unit length (SXi = 1), where Xi are the intensities of the peaks of the mass
spectrum).
(TIF)
S2 Fig. Standard deviations of the mean intensity of peaks of the particular m/z in the data-
set normalized to the standard deviation of the mean intensity of the hESCs + MEFs (a)
and hESCs + mESCs dataset (b). Peaks used in the further analyses are indicated by respective
m/z values.
(TIF)
S3 Fig. Correlation between PLS-predicted number of cells and the experimental number
of MEFs in two-component mixtures of (a) hESCs + MEFs and (b) hESCs + mESCs. Over-
view of Residuals (difference between PLS-predicted number of cells and the experimental
values) versus the experimental number of cells in the two-component mixtures of (c)
hESCs + MEFs and (d) hESCs + mESCs.
(TIF)
S4 Fig. Training and verification plot for an independent dataset of 50 cases of hESCs +
MEFs mixtures (a). Correlation between experimental and ANN-predicted numbers of MEFs
in hESCs suspension.
(TIF)
Fig 6. Experimental schematic of the multivariate calibration-based ANN spectral analysis.
doi:10.1371/journal.pone.0147414.g006
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S1 Table. Overview of normalized mass-to-charge ratios (m/z) of informative peaks used
for analysis.
(TIF)
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Abstract 
Zinc is an essential metal ion for living organisms, involved in a wide variety of metabolic 
processes, several proteins needs zinc for their proper functioning. A large number of structurally 
characterised Zn-catalytic sites are four-coordinated tetrahedra, where the zinc is bound to three 
histidine nitrogen atoms and to a water molecule, as found, for example, in carbonic anhydrases or 
phosphate esterases. The site occupied by the water molecule can be the target of anions, 
sulphonamides, and neutral organic molecules, that act as inhibitors. For these reasons, the exposure 
to coordinating drugs like methimazole (1-methyl-3H-imidazole-2-thione, MeImHS) (Figure 21) 
can potentially interact/interfere with zinc buffering systems and Zn-metalloenzyme activities, 
either causing zinc deficiency and/or potentially reducing the efficacy of the drug. MeImHS is 
currently the standard treatment for Graves’ disease, which is an autoimmune disease that affects 
the thyroid.  
 
 
Figure 21. Formulas and acronyms of studied ligands: methimazole (MeImHS), its anionic form 
(MeImS), S-methylmethimazole (MeImSMe), and 1-methylimidazole (MeIm). 
 
I synthesized and characterized zinc complexes with (N,S)-donor molecules to provide 
information about the coordination mode and reactivity of Zn-metalloproteins and -metalloenzymes 
(Chapter 7 - Article IV). In particular, zinc complexes of the drug methimazole (MeImHS) and its 
Chapter 7 
 
 
197 
 
anion (MeImS) have been synthesized, and structurally characterized
1
. The structures of the 
complexes have been optimized using DFT calculations.  
The complex [Zn(MeImS)2] has been studied also using Electro-Spray Ionisation at 
Atmospheric-Pressure Mass Spectrometry (Figure 22) and tandem MS-MS.  
 
 
Figure 22. Positive ion ESI-MS spectrum of [Zn(MeImS)2]; L = MeImS, L’ = methimazole-
disulfide (C8H10N4S2). 
 
A mononuclear ZnN4 model complex with the 1-methylimidazole (MeIm) ligands representing 
the histidine (His) amino acid residues has been selected to study the interaction of methimazole 
with a ZnN4 coordination sphere. The model complex [Zn(MeIm)4](ClO4)2 represents [Zn(His)4]
2+
 
and [Zn(His)3(H2O)]
2+
 protein sites. Spectrophotometric titrations showed methimazole displacing 
only one of the coordinated MeIm molecules (Figure 23). This evidence supports the possibility 
that methimazole, by blocking a histidine/water binding site, could interfere with the 
multifunctional roles of zinc atoms in proteins (e.g. the enzymatic activity of carbonic anhydrases). 
                                                 
1
 In collaboration with professor Francesco Demartin (Dipartimento di Chimica, Università degli Studi di Milano). 
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The anionic methimazole can effectively act as a (N,S)-bridging/chelating ligand to a variety of 
metal ions due to its N–C–S functional group.  
 
 
Figure 23. Selected spectra collected during the titration of [Zn(MeIm)4]
2+
 with MeImHS (left) and 
pure spectra of MeIm, MeImHS, [Zn(MeIm)4]
2+
, and [Zn(MeIm)3(MeImHS)]
2+
 (right). 
 
The synthesized complex [Zn(MeImS)2] featuring a ZnN2S2 core is of interest in the study of S-
alkylation of zinc-thiolates in biological processes. This complex reveals a different reactivity 
towards the electrophilic addition of CH3
+
 and H
+
. The MeImS moieties are N-protonated by HI to 
form the neutral complex [Zn(MeImHS)2I2]; conversely, the reaction of [Zn(MeImS)2] with methyl 
iodide leads to the formation of the complex [Zn(MeImSMe)2I2]. This evidence shows that Zn-
coordinated methimazole can markedly modify the coordination environment when changing from 
its thione to thionate form, and vice versa.  
Within the scope of the study on the interaction of molecules of pharmacological interest with 
zinc, these results underline that methimazole shows a reactivity and a variety of coordinating 
modes that may alter the biological processes that are based on the zinc ion. 
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Zinc(II)-methimazole complexes: synthesis
and reactivity†
Francesco Isaia,*a Maria Carla Aragoni,a Massimiliano Arca,a Alexandre Bettoschi,a
Claudia Caltagirone,a Carlo Castellano,b Francesco Demartin,b Vito Lippolis,a
Tiziana Pivettaa and Elisa Vallettaa
The tetrahedral S-coordinated complex [Zn(MeImHS)4](ClO4)2, synthesised from the reaction of [Zn-
(ClO4)2] with methimazole (1-methyl-3H-imidazole-2-thione, MeImHS), reacts with triethylamine to yield
the homoleptic complex [Zn(MeImS)2] (MeImS = anion methimazole). ESI-MS and MAS
13C-NMR experi-
ments supported MeImS acting as a (N,S)-chelating ligand. The DFT-optimised structure of [Zn(MeImS)2]
is also reported and the main bond lengths compared to those of related Zn-methimazole complexes.
The complex [Zn(MeImS)2] reacts under mild conditions with methyl iodide and separates the novel
complex [Zn(MeImSMe)2I2] (MeImSMe = S-methylmethimazole). X-ray diﬀraction analysis of the complex
shows a ZnI2N2 core, with the methyl thioethers uncoordinated to zinc. Conversely, the reaction of [Zn-
(MeImS)2] with hydroiodic acid led to the formation of the complex [Zn(MeImHS)2I2] having a ZnI2S2 core
with the neutral methimazole units S-coordinating the metal centre. The Zn-coordinated methimazole
can markedly modify the coordination environment when changing from its thione to thionate form and
vice versa. The study of the interaction of the drug methimazole with the complex [Zn(MeIm)4]
2+ (MeIm =
1-methylimidazole) – as a model for Zn-enzymes containing a N4 donor set from histidine residues –
shows that methimazole displaces only one of the coordinated MeIm molecules; the formation constant
of the mixed complex [Zn(MeIm)3(MeImHS)]
2+ was determined.
Introduction
Zinc is an essential metal ion for living organisms, its presence
being fundamental in catalytic, structural, and regulatory bio-
logical processes.1 Since the discovery in 1939 that the enzyme
carbonic anhydrase contains stoichiometric amounts of zinc,1c
more than 3000 proteins which must bind to zinc for proper
functioning have been identified.1d,e A wide variety of meta-
bolic processes which depend on zinc for activity have been
identified and studied, including the synthesis and degra-
dation of carbohydrates, lipids, nucleic acids and proteins.2
Flexibility in the choice of ligand (cysteine, histidine, aspartate
or glutamate) and coordination geometry leads to diverse
Zn(II) binding sites in zinc-metalloenzymes, rendering possible
a range of important biological roles.3 Zinc coordination sites
in proteins have been classified into four categories: catalytic,
cocatalytic, interface, and structural.4 In the former case, most
catalytic zinc sites contain at least one water molecule in
addition to three or four amino acid residues; the water mole-
cule site can be the target of inhibitors such as anions, sulpho-
namides, and neutral organic molecules.5 For these reasons,
the exposure to coordinating drugs like methimazole
(1-methyl-3H-imidazole-2-thione; MeImHS) (Fig. 1), which is
currently the standard treatment for Graves’ disease,6 can
potentially interact/interfere with zinc buﬀering systems and
Zn-metalloenzyme activities7 either causing zinc deficiency
Fig. 1 Ligands discussed in this paper: methimazole (MeImHS), its
anion form (MeImS), S-methylmethimazole (MeImSMe), and 1-methyl-
imidazole (MeIm).
†Electronic supplementary information (ESI) available: Electrospray Ionisation
Mass Spectrum (ESI-MS) data, DFT calculated bond lengths (Å) and angles (°)
for the complex [Zn(MeImS)2] and comments on the optimised structure and
MAS 13C-NMR spectrum of [Zn(MeImS)2]. CCDC 1051219 and 1051220. For ESI
and crystallographic data in CIF or other electronic format see DOI: 10.1039/
c5dt00917k
aDipartimento di Scienze Chimiche e Geologiche, Università degli Studi di Cagliari,
Cittadella Universitaria, 09042 Monserrato (CA), Italy. E-mail: isaia@unica.it;
Fax: +39 070 6754456; Tel: +39 070 6754496
bDipartimento di Chimica, Università degli Studi di Milano, via Golgi 19, 20133
Milano, Italy
This journal is © The Royal Society of Chemistry 2015 Dalton Trans.
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and/or potentially reducing the eﬃcacy of the drug.7 The rich
coordination chemistry of methimazole with transition metals
has previously been investigated in detail.8–10 Methimazole
can bind a metal ion as a neutral species (via the thione
sulphur atom) or in its anionic form (as a monodentate
species via either the thionate sulphur atom, the thioamido
nitrogen atom, or as an ambidentate ligand via a variety of
bonding modes) (Fig. 2).
In previous studies, we investigated the reactivity of methi-
mazole with liquid mercury and zinc powder obtaining
complexes of stoichiometry [Hg2(MeImHS)2I4] and
[Zn(MeImHS)2I2] whose X-ray crystal structures show the
neutral methimazole S-binding the metal centre and the for-
mation of intermolecular hydrogen bonding via C(4)H, N–H,
and N–Me groups.11
Although the drug methimazole has been marketed since
1950, its interaction with zinc ions has received little attention
to date. In this context, the synthesis and characterisation of
zinc complexes with (N,S)-donor molecules provide infor-
mation for the structure prediction and reactivity of Zn-metal-
loproteins and -metalloenzymes. In this study, the X-ray crystal
structures of the complexes [Zn(MeImHS)4](ClO4)2 and
[Zn(MeImSMe)2I2] are reported; the optimised structure of the
complex [Zn(MeImS)2] has been proposed on the basis
of density functional theory (DFT) calculations. The complex
[Zn(MeImS)2] featuring a ZnN2S2 core is of interest in the study
of S-alkylation of zinc-thiolates in biological processes: the
electrophilic addition of CH3
+ and H+ to the coordinated
MeImS anions is discussed. Moreover, the system methima-
zole-[Zn(MeIm)4](ClO4)2 (MeIm = 1-methylimidazole), where
the Zn-complex acts as a model for Zn-enzymes containing a
N4 donor set from histidine residues, has been investigated.
Results and discussion
Synthesis, structure characterization and reactivity of the
complexes [Zn(MeImHS)4](ClO4)2 and [Zn(MeImS)2]
A search in the Cambridge Structural Database shows that
only a limited number of zinc-methimazole complexes have
been structurally characterised to date (Table 1). In all of the
reported complexes but one, the methimazole acts as a neutral
ligand binding to the Zn(II) ion via the sulphur atom, whereas
in the case of the complex [Zn4O(MeImS)6] each anionic methi-
mazole ligand bridges two zinc ions via the sulphur atom and
the nitrogen atom. Metal complexes with MeImS in (N,S)-brid-
ging/chelating mode are quite scarce in the literature.8,9 Bell
et al. reported on the synthesis of the complex [Hg(MeImS)2],
15
failing, however, to obtain a crystalline sample. For the
synthesis of the homoleptic complex [Zn(MeImS)2] we further
simplified the synthetic procedure proposed by Bell15 for
the mercury analogue by reacting the cationic complex
[Zn(MeImHS)4]
2+ with a base.
The synthesis of the complex [Zn(MeImHS)4](ClO4)2 was
accomplished by reacting Zn(ClO4)2·6H2O with MeImHS
(1 : 4 molar ratio) in EtOH/H2O. X-ray diﬀraction analysis was
performed on a single crystal and data collection and refine-
ment parameters are summarised in Table 2. The Zn atom of
the [Zn(MeImHS)4]
2+ cation is located on a four-fold rotoinver-
sion axis whereas the chlorine atom of the perchlorate anion is
on a two-fold axis. The perchlorate oxygens are disordered over
two very close positions (see the Experimental section). Fig. 3
shows the structure of the complex [Zn(MeImHS)4]-(ClO4)2
with the expected four-coordinate tetrahedral geometry around
the zinc ion. It is quite evident from the bond angle values S–
Zn–Si of 103.47(1)° and S–Zn–Sii 122.28(3)° (i 0.75 + y, 1.25 − x,
0.25 − z; ii 2 − x, 0.5 − y, z) that deviation from the expected
109.5° is related to a compression along one of the S4 impro-
per rotation axes of the tetrahedron. Thus the coordination
sphere around zinc may be described as a flattened tetrahe-
dron with two longer non-bonding edges (S⋯Siii and Si⋯Siii
distances equal to 4.076(1) Å) and four shorter edges (3.655(1)
Å). Ligand bond distances and angles are comparable to those
previously observed for related compounds (see Table 1), and
to those observed in similar 1,3-dialkyl-imidazole-thione Zn
complexes.16 Each MeImHS molecule is involved in a N–H⋯O
Fig. 2 Main coordination mode of neutral MeImHS: (a) η1-S and of
anion MeImS: (b) η1-N; (c) η1-S; (d) μ-N,S (η1-N, η1-S); (e) η2-N,S.
Table 1 Structurally characterised metal complexes of methimazole with a zinc(II) ion
Complex Mean d(Zn–S) (Å) Geometry/core Reaction/solvent Ref.
[Zn(MeImHS)2Cl2] 2.3405(2) Td/ZnS2Cl2 ZnCl2 + MeImHS/MeOH 12
[Zn(MeImHS)2Br2] 2.340(2) Td/ZnS2Br2 ZnBr2 + MeImHS/MeOH 12
[Zn(MeImHS)2I2] 2.3581(5) Td/ZnS2I2 Zn + MeImHS + I2/CH2Cl2 11b
[Zn(MeImHS)3I]I 2.3746(3) Td/ZnS3I ZnI2 + MeImHS/MeOH 12
[Zn(MeImHS)4](NO3)]·H2O 2.3385(2) Td/ZnS4 Zn(NO3)2 + MeImHS/EtOH 13
[Zn(MeImHS)4](ClO4)2 2.3273(4) Td/ZnS4 Zn(ClO4)2 + MeImHS/EtOH-H2O
a
[Zn4O(MeImS)6]·CHCl3·3H2O
b 2.3375(3) Td/ZnN2OS–ZnOS3 Electrochemical oxidation of the zinc anode in the
presence of MeImHS/CH3CN
14
a This work. b d(Zn–N) = 2.003(10) Å.
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bond (interaction a in Fig. 4a) with perchlorate anions, thus
generating a highly symmetric network constructed by identi-
cal C22(12) chains running along both the [100] and [010] direc-
tions (Fig. 4a). Fig. 4b shows a lateral view of this network
(highlighted in red) sited in the crystal with a packing resem-
bling a bubble pack foil.
Despite the low solubility in water of the complex
[Zn(MeImHS)4](ClO4)2, it readily reacts in the heterogeneous
phase with a diluted aqueous solution of triethylamine to
form an insoluble powder which we failed to crystallise.
The ESI-MS spectrum of the isolated complex and the peak
assignments are shown in ESI-Fig. S1.† The characteristic iso-
topic peaks for zinc-containing ions are clearly identifiable in
the spectrum. The calculated and experimental isotopic
patterns for selected peaks are reported in ESI-Fig. S2.† The
signal with the highest intensity at m/z 291 is due to the
expected [Zn(MeImS)2H]
+ ion. Moreover, as shown by the
signals at m/z 405 and m/z 519, traces of complexes
[Zn(MeImS)3H2]
+ and [Zn(MeImS)4H3]
+, respectively, were
found. Fragmentation of the main species [Zn(MeImS)2H]
+
Table 2 Crystal data collection and reﬁnement parameters for the
compounds [Zn(MeImHS)4](ClO4)2 and [Zn(MeImSMe)2I2]
[Zn(MeImHS)4](ClO4)2 [Zn(MeImSMe)2I2]
Empirical formula C16H24Cl2N8O8S4Zn C10H16I2N4S2Zn
M 720.94 575.56
Crystal system Tetragonal Triclinic
Space group I41/a (no. 88) P1ˉ (no. 2)
a, b, c (Å) 12.3057(4), 12.3057(4),
20.5539(7)
8.9185(11), 9.1511(11),
11.8137(15)
α, β, γ (°) 90, 90, 90 88.66(2), 86.89(2),
71.16(2)
Volume (Å3) 3112.5(2) 911.2(2)
Z 4 2
Temperature (K) 294(2) 294(2)
Dcalc (Mg m
−3) 1.539 2.098
μ (mm−1) 1.280 4.958
θ min-max (°) 1.93–31.70 2.35–31.67
Refl. collected/
unique
16 439/2546
(Rint = 0.023)
9676/5494
(Rint = 0.016)
Data/restraints/
parameters
2546/0/89 5494/0/172
Refl. obs. (I > 2σI) 2085 4482
Final R indices
[I > 2σ(I)]
R1 = 0.0341,
wR2 = 0.1022
R1 = 0.0245,
wR2 = 0.0669
R indices (all data) R1 = 0.0434,
wR2 = 0.1090
R1 = 0.0324,
wR2 = 0.0702
Goodness-of-fit on
F2
1.066 1.050
Largest diﬀ. peak,
hole (e Å−3)
0.42, −0.41 0.89, −0.66
Fig. 3 Displacement ellipsoid model (obtained by Diamond 3.2k) of the
complex [Zn(MeImHS)4](ClO4)2 at the 20% probability level with the
numbering scheme. Only one of the two positions of the disordered
perchlorate anion (see the Experimental section) is shown for clarity.
Symmetry codes: i 0.75 + y, 1.25 − x, 0.25 − z; ii 2 − x, 0.5 − y, z; iii 1.25 −
y, −0.75 + x, 0.25 − z; iv 2 − x, −0.5 − y, z; v 0.25 − y, −0.75 + x, 0.25 − z.
Selected coordination-sphere bond distances (Å) and angles (°): Zn–S
2.3273(4), S–C1 1.712(2); S–Zn–S’ 103.47(1), S–Zn–S’’ 122.28(3); N1–
H1⋯O1’: H1⋯O1’ 2.100(8) Å, N1⋯O1’ 2.940(8) Å, N1–H1⋯O1’ 165.1(3)°.
Fig. 4 Packing views of the complex showing (a) identical C22(12) chains
running along both the [100] and [010] directions; (b) a 3D packing view
evidencing (red) the network depicted in (a). H-atoms have been
omitted for clarity reasons except for those involved in the interactions
shown: a, N1–H1⋯O1’: H1⋯O1’ 2.100(8) Å, N1⋯O1’ 2.940(8) Å, N1–
H1⋯O1’ 165.1(3)°; b, C3–H3⋯O2iv 2.82(1) Å, 3.54(1) Å, 135.9(3)°. Sym-
metry codes: i 0.75 + y, 1.25 − x, 0.25 − z; iv 2 − x, −0.5 − y, z.
Dalton Transactions Paper
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gives, besides the ligand, the [Zn(MeImS)(H2O)]
+ (m/z 195) and
[Zn(MeImS)]+ (m/z 177) species.
Useful information on the nature of the complex [Zn-
(MeImS)2] was also obtained from solid-state MAS
13C-NMR
spectroscopy (ESI-Fig. S3†). Deprotonation of the Zn-bound
methimazole produces the corresponding thionate species in
which the anionic charge is mainly localised on the N–C–S
thioamide fragment (see below). The spectrum of the complex
shows only four resonances showing the equivalence of the
MeImS molecules. As a consequence of (N,S)-coordination to
the Zn-centre, the thioamido carbon C(2) (δ = 145.6) proves to
be the most sensitive to complexation as confirmed by the sig-
nificantly high field shift observed (≈18 ppm) relative to that
of the free ligand. Conversely, carbons C(4) and C(5) are
slightly deshielded (3.1 and 1.0 ppm, respectively) compared
to free MeImHS (δC, 25 °C, MeImHS: CS 163.5, C5 120.0, C4
114.2, NMe 34.0, CHCl3/MeCN 4 : 1 v/v).
11 On the basis of
experimental evidence, it is therefore reasonable to hypo-
thesise for the homoleptic complex [Zn(MeImS)2] that each
MeImS unit binds the metal ion forming a four-membered
(N,S)-chelate.
Theoretical calculations
In recent years, theoretical calculations carried out at the
density functional theory (DFT)17,18 level have been widely
recognised as a reliable tool capable of providing very accurate
information at an acceptable computational cost. In particular,
some authors have exploited DFT calculations to investigate
the nature of diﬀerent ZnII complexes19 and the reactivity of
several systems based on imidazole-2-chalcogenone derivati-
ves.11a,20 Encouraged by these results, we have investigated the
donor properties of the anionic species MeImS by adopting
the well-known B3LYP21 functional along with the 6-31G* all-
electron basis set. Kohn–Sham (KS) HOMO calculated for the
donor is a π-orbital largely localised on the S and N atoms,
antibonding with respect to the CvS bond. KS-HOMO−1 and
HOMO−3 feature the largest contributions from the lone pairs
localised on the sulphur and nitrogen atoms, respectively
(ESI-Fig. S4†). An examination of the natural charges calcu-
lated for MeImS at the optimised geometry reveals that the
nitrogen atom in the 3-position and the exocyclic sulphur
atom display similar negative charges (−0.565 and −0.536 e,
respectively). The Kohn–Sham MO composition and the
charge distribution support the capability of both atoms to
behave as donors, as hypothesised for the complex [Zn-
(MeImS)2] (see above). A view of the optimised complex [Zn-
(MeImS)2] is presented in ESI-Fig. S5† (see ESI-Table S1† for a
list of selected bond lengths and angles). The zinc atom
adopts a distorted tetrahedral geometry with both anions
(N,S)-chelating.
The presented data suggest that the strained four-mem-
bered ring in Zn/MeImS aﬀects the electronic-donation from
the imido and thiocarbonyl groups to the hybrid orbitals of
the zinc ion, thus causing a lower orbital overlap.
The complex [Zn(MeImS)2]: reactivity at the zinc-coordinated
methimazole anion
Picot et al.22a recently reported biomimetics complex-models
featuring diﬀerent cores and charges to study the alkylation
reactions that occur at zinc-bound thiolate in a variety of zinc
sites of enzymes. The reactions of these biomimetic complexes
with methyl iodide led to the formation of thioethers and zinc
complexes containing iodide, allowing the authors to investi-
gate the mechanism of zinc-mediated alkyl group transfer to
thiols.22b–d
In this context, we have investigated the reactivity of the
complex [Zn(MeImS)2] with methyl iodide as the alkylating
agent. The [Zn(MeImS)2] complex may be subject to reactions
that can occur both at the coordinated methimazole and at the
metal centre. As zinc(II) is an ion of borderline hardness, nitro-
gen, sulphur, halogen, and oxygen donor atoms can all be
involved in coordination at the metal centre, with a coordi-
nation number of four, five, or six depending on the ligand
size and charge-transfer ability.8–11,22 Moreover, the lack in d10
metal ions of crystal field stabilisation energy (CFSE) enables a
facile change of the coordination sphere in a reaction.
The reaction between the complex [Zn(MeImS)2] and CH3I
(1 : 2 molar ratio) was carried out in a water/MeOH mixture for
five days. During this time, the suspended complex dissolved
completely with the formation of a clear solution by slow evap-
oration, allowing crystals of stoichiometry [Zn(MeImSMe)2I2]
to form. X-ray diﬀraction analysis was performed on a single
crystal; a displacement ellipsoid model view of the complex is
shown in Fig. 5 and data collection and refinement parameters
are summarised in Table 2.
The zinc(II) centre of the complex is coordinated by two
MeImSMe molecules acting as monodentate N-ligands and
two iodides in a slightly distorted tetrahedral geometry. The
Zn–N and Zn–I bond distances are similar to those in other
zinc complexes reported in the literature.23
Fig. 5 Displacement ellipsoid model (obtained by Diamond 3.2k) of the
complex [Zn(MeImSMe)2I2] at the 20% probability level with the number-
ing scheme. H-atoms are omitted for clarity reasons. Selected coordi-
nation sphere bond distances (Å) and angles (°): Zn–I1 2.5822(5), Zn–I2
2.5852(7), Zn–N1 2.018(2), Zn–N3 2.028(2), S1–C1 1.738(3); S2–C6
1.742(3); I1–Zn–I2 109.75(2), I1–Zn–N1 109.61(6), I1–Zn–N3 112.17(6),
N1–Zn–N3 103.14(8).
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The imidazole rings are planar and the S-Me groups are
oriented through the centre of opposite imidazole rings
with C–H⋯CntIm distances of 2.88 and 2.92 Å for C5–
H5c⋯CntIm(N3−N4) and C10–H10c⋯CntIm(N1−N2), respectively
(c and d interactions in Fig. 6a). Inter-molecular π⋯π inter-
actions between parallel facing Im rings pile up the molecules
in pillars developing along the [011] direction (Fig. 6a). Parallel
pillars weakly interact with each other through C–H⋯I con-
tacts as shown in Fig. 6b.
The interesting reactivity shown by the system
[Zn(MeImS)2]/CH3I led us to test the reaction of the complex
[Zn(MeImS)2] towards hydriodic acid (HI) with the aim of veri-
fying the site of protonation.
The complex [Zn(MeImS)2] was suspended in a water/
MeOH mixture with HI in a 1 : 2 molar ratio. The reaction pro-
ceeded with the complete dissolution of the powder and the
formation of a clear pale yellow solution. After slow evapor-
ation of the solution, white crystals of the complex
[Zn(MeImHS)2I2] were isolated. The X-ray crystal structure
which we recently reported11b features a tetrahedral zinc(II)
centre coordinated by two neutral methimazole units and two
iodides. Since the four-membered ring formed by (N,S)-chelat-
ing thionates is inherently strained,8,9 it is not surprising that
the products separated no longer feature the ZnNCS four-atom
ring. In the case of the reaction with HI we observe the proto-
nation of the imido-nitrogen atom along with the formation of
a Zn–S(thione) bond, leading to the formation of the neutral
complex [Zn(MeImHS)2I2]. In the case of the reaction with
MeI, the methylation reaction occurs on the thionate leading
to the formation of the organic moiety S-methylmethimazole
that binds the Zn centre via the imido-nitrogen atom only.
Being a neutral organic moiety, the charge is balanced by two
coordinating iodides. It is interesting to observe that the
thioether group is uncoordinated to zinc. On this matter, pre-
vious studies22,24,25 have shown that factors such as the charge
and structure at the Zn centre play an important role in
driving the coordinating ability of thioether groups; when
thioethers are part of neutral chelates they result in tetrahedral
complexes which are invariably uncoordinated since a nega-
tively charged ligand (i.e. I−) transfers more charge to Zn2+
than a neutral one.
Reactivity of methimazole towards the ZnN4 core
A large number of structurally characterised Zn-catalytic sites
are four-coordinated tetrahedra, with the zinc bound to three
histidine nitrogens and the fourth site occupied by a water
molecule, as found, for example, in carbonic anhydrases or
phosphate esterases.5c,d To study the interaction of methima-
zole with a ZnN4 coordination sphere, we selected a simple
mononuclear ZnN4 model complex with the 1-methylimidazole
(MeIm) ligands representing the histidine (His) amino acid
residues.26 The complex [Zn(MeIm)4](ClO4)2 was synthesised
according to Chen et al.27 The X-ray crystal structure of this
complex consists of tetrahedral monomeric [Zn(MeIm)4]
2+
cations and the Zn–NMeIm bond lengths (1.991(2) Å) are com-
parable to the Zn–N(His) average bond length found in Zn
proteins as determined by NMR spectroscopy28 (2.09 ± 0.14 Å).
The complex [Zn(MeIm)4](ClO4)2 shows good stability in water
since no relevant changes in its absorption spectrum were
found after 6 h at 25 °C. MeIm in aqueous solution shows a
Fig. 6 Packing views of the complex showing (a) pillars running along the [011] built up through a and b inter-molecular π⋯π interactions; (b)
aligned pillars interacting along the [100] direction. H-atoms have been omitted for clarity reasons except for those involved in the illustrated inter-
actions: a, CntIm(N1−N2)⋯CntIm(N1−N2)i, 3.50 Å, 0°; b, CntIm(N3−N4)⋯CntIm(N3−N4)ii, 3.61 Å, 0°; c, C5–H5c⋯CntIm(N3−N4) 2.88 Å; d, C10–H10c⋯CntIm(N1−N2)
2.92 Å; e, C4–H4a⋯I1iii 3.13 Å. Symmetry codes: i −x, 1 − y, 2 − z; ii −x, 1 − y, 1 − z; iii −1 − x, −y, 1 − z.
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broad absorption band located at 210 nm due to π–π* tran-
sitions of the imidazole ring (Fig. 7b).29 In the absorption
spectrum of [Zn(MeIm)4]
2+ the π–π* transitions are almost
unshifted (band at 212 nm), and a new band at 266 nm due to
the MeIm → Zn ligand-to-metal charge-transfer transition is
observed.31 The complex shows no appreciable absorption
in the region above 400 nm in water, in accord with the d10
electronic configuration of the zinc(II) ion.
The interaction of methimazole with the cationic complex
[Zn(MeIm)4]
2+ was assessed by spectrophotometric titration. By
adding increasing amounts of MeImHS, the band at 266 nm
related to [Zn(MeIm)4]
2+ shifts towards a shorter wavelength,
increasing its absorbance intensity (Fig. 7a), a feature consist-
ent with an interaction altering the ZnN4 core. An isosbestic
point is present at 277 nm, providing evidence for at least one
equilibrium. From eigenvalue analysis of the spectrophoto-
metric data in the 230–300 nm range, three significant eigen-
values were found, indicating that in solution three linearly
independent absorbing species were present (in the
230–300 nm range the absorption of MeIm is negligible),
namely [Zn(MeIm)4]
2+, MeImHS and a newly formed species
identified as the complex [Zn(MeIm)3(MeImHS)]
2+. By fitting
the experimental data considering the equilibrium as in
eqn (1),
½ZnðMeImÞ42þ þMeImHS Ð ½ZnðMeImÞ3ðMeImHSÞ12þ
þMeIm ð1Þ
the complex formation constant of [Zn(MeIm)3(MeImHS)]
2+
was calculated (Kf = 5.82 ± 0.02 M
−1). Any attempt to fit the
experimental data considering zinc complexes with more than
one MeImHS ligand led to unreliable results. The pure spectra
of MeIm, MeImHS, [Zn(MeIm)4]
2+, and [Zn(MeIm)3-
(MeImHS)]2+ are reported in Fig. 7b and the spectral para-
meters of all the absorbing species are reported in Table 3.
These results suggest that the electron-accepting ability of Zn
in the complex29 depends on the set of coordinating ligands.
In this case, the formation of [Zn(MeIm)3(MeImHS)]
2+ species
forecloses the entry of another unit of MeImHS.
Lim pointed out that the catalytic activity of the Zn-His3-
OH2 site is mainly due to the water ligand that transfers the
least charge to the zinc ion and is less bulky compared to the
protein residues.30 In this context, the marked diﬀerence in
charge-transfer ability between MeImHS and water supports
the possibility that MeImHS can interfere with the catalytic
activity of Zn-His3-OH2 metalloenzymes
31 by displacing the Zn-
bound water molecule from the active site.30 The promising
results obtained are a stimulus for further investigations
(beyond the scope of the present study) of the interaction of
methimazole, or of thioamide containing drugs in general,
with mononuclear models representative of [Zn-(XYZ)-(OH2)]
enzymes (where X, Y, Z = His, Asp, Cys, Glu).
Conclusions
New stable complexes of the drug methimazole (MeImHS) and
its anion (MeImS) with zinc ions have been separated and
Fig. 7 (a) Selected spectra collected during the titration of [Zn(MeIm)4]
2+ (8.53 × 10−5 M) with MeImHS (3.50 × 10−4 M) from 0 to 4 MeImHS/
[Zn(MeIm)4]
2+ molar ratio; (b) pure spectra of MeIm, MeImHS, [Zn(MeIm)4]
2+, and [Zn(MeIm)3(MeImHS)]
2+; [T = 25 °C, 0.1 M buﬀer solution pH 9
(borax/hydrochloric acid), 1 cm optical path length].
Table 3 Summary of UV/vis maximum absorption wavelength and
molar absorptivity values for ligands and complexes (aqueous solution,
25 °C, 0.1 M buﬀer solution, pH 9 (borax/hydrochloric acid), 1.0 cm
optical path length)
λmax/nm ε (M
−1 cm−1)
MeIm 210 3691
MeImHS 252 16 300
210 6600
[Zn(MeIm)4]
2+ 266 12 200
212 18 400
[Zn(MeIm)3(MeImHS)]
2+ 256 26 300
210 25 000
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structurally characterised. In the case of [Zn(MeImHS)4]-
(ClO4)2, four neutral ligands are S-coordinated in a distorted
tetrahedral coordination geometry; the Zn–S bond distances
are comparable to the average Zn–S(cysteine) bond lengths
(2.32 Å) found in zinc proteins. Solution studies on the
reaction of methimazole with [Zn(MeIm)4](ClO4)2, selected as
a model compound representing [Zn(His)4]
2+ and [Zn(His)3-
(H2O)]
2+ protein sites, show methimazole displacing only one
of the coordinated MeIm molecules. This evidence supports
the possibility that methimazole, by blocking a histidine/water
binding site, could interfere with the multifunctional roles of
zinc atoms in proteins (e.g. the enzymatic activity of carbonic
anhydrases).5c The anion methimazole can eﬀectively act as a
(N,S)-bridging/chelating ligand to a variety of metal ions due
to its N–C–S functional group. The synthesised homoleptic
complex [Zn(MeImS)2] reveals a diﬀerent reactivity towards the
electrophilic addition of H+ and CH3
+. The MeImS moieties
are N-protonated by HI to form the neutral complex
[Zn(MeImHS)2I2]; conversely, the reaction of [Zn(MeImS)2]
with methyl iodide leads to the formation of the complex
[Zn(MeImSMe)2I2]. This evidence shows that Zn-coordinated
methimazole can markedly modify the coordination environ-
ment when changing from its thione to thionate form, and
vice versa. Within the scope of the study on the interaction of
molecules of pharmacological interest with zinc, these results
underline that methimazole shows a reactivity and a variety of
coordinating modes that may in some way alter the biological
processes that are based on the zinc ion.
Experimental
Materials and instrumentation
Reagents were used as purchased from Aldrich or Fluka.
Elemental analyses were performed using a Fisons Instru-
ments 1108 CHNS elemental analyser. FT-infrared spectra of
powdered samples were recorded with a Thermo-Nicolet 5700
spectrometer from 4000 to 400 cm−1 in the form of pressed
KBr pellets. UV-vis spectrophotometric measurements were
carried out with a Varian Cary 50 spectrophotometer equipped
with a fiber optic dip probe (1 cm optical path length).
13C-NMR spectra were recorded on a Varian 400 MHz spectro-
meter. Chemical shifts are reported in ppm (δ) downfield
from TMS using the same solvent as the internal reference.
The MAS 13C-NMR spectrum was calibrated such that the
observed upfield peak in the spectrum of adamantane is set
to δ = 31.47. Mass spectra were obtained on a QqQ triple
quadrupole Varian 310-MS LC/MS mass spectrometer,
with electrospray ionisation at atmospheric pressure.
The complex tetrakis(1-methylimidazole-N3)zinc(II) diper-
chlorate [Zn(MeIm)4](ClO4)2 was synthesised according to
ref. 27.
Synthesis of complexes
Synthesis of complex [Zn(MeImHS)4](ClO4)2. A mixture of
methimazole (0.100 g, 0.88 mmol) dissolved in 5 mL of
ethyl alcohol and Zn(ClO4)2 hexahydrate (0.082 g,
0.22 mmol) dissolved in 5 mL of water was slightly heated
for 10 min and then stirred for 12 h. A white solid powder
was separated from the solution, washed with an ethyl
alcohol/n-hexane mixture (v/v 1 : 1) and dried in an oven at
50 °C. The filtered solution was slowly concentrated, and
cooled at 10 °C for two days to separate crystals of the
title compound. Yield C16H24Cl2N8O8S4Zn (720.94): calcd C
26.67, H 3.36, N 15.55, S 17.75; found: C 27.0, H 3.4,
N 15.6, S 17.7. δC (100.5 MHz, CDCl3-CH3CN 4 : 1 v/v)
150.7 (CS), 122.4 (C5), 118.0 (C4) 32.5 (N-CH3). IR (KBr, ν/
cm−1): 3127m, 1548m, 1532m, 1420w, 1289w, 1252w, 1235m,
1094s, 957w, 937m, 846w, 828w, 767m, 744m, 674w, 658m,
624m.
Synthesis of complex [Zn(MeImS)2]. The complex [Zn-
(MeImHS)4](ClO4)2 (0.200 g, 0.277 mmol) in 50 mL of water
was reacted with triethylamine (0.39 mL, 2.770 mmol) for 2 h
at room temperature. The solid powder was filtered and
washed several times with ethyl alcohol/water (1 : 1 v/v) to elim-
inate the triethylamine and then dried in an oven at 50 °C.
Yield: 0.066 g, 75%; C8H10N4S2Zn (291.53): calcd C 32.96,
H 3.46, N 19.21, S 21.93; found: C 33.2, H 3.5, N 19.3, S 21.8.
δC (100.5 MHz, solid state) 145.6 (CS), 123.1 (C5), 17.7 (C4),
31.4 (N-CH3). IR (KBr, ν/cm
−1): 3118w, 2940 m, 1536 m,
1456vs, 1414s, 1372vs, 1315s, 1284s, 1144s, 1084 m, 954 m,
732s, 697s, 688s, 517s.
Synthesis of the complex [Zn(MeImSMe)2I2]. The
complex Zn(MeImS)2 (0.100 g, 0.344 mmol) suspended in
20 mL of a water/MeOH mixture (1/1 v/v) and methyl iodide
(0.098 g, 0.688 mmol) were reacted at room temperature for
five days with continuous stirring. In the course of the reaction
the suspended complex dissolved with the formation of a clear
solution. It was filtered to remove traces of solids and allowed
to stand at 5° C. After two days white crystals were
collected and washed with n-hexane. Yield: 0.148 g, 75%;
C10H16I2N4S2Zn (575.41): calcd C 20.87, H 2.80, N 9.73,
S 11.37; found: C 21.0, H 2.9, N 9.9, S 11.4. δC (100.5 MHz,
CDCl3–CH3CN 4 : 1 v/v) 160.9 (C2S), 121.8 (C5), 128.5 (C4), 33.5
(N–CH3), 15.6(S–CH3). IR (KBr, ν/cm
−1): 3119w, 2919w, 1529w,
1462s, 1410s, 1338w, 1283s, 1148vs, 1080w, 970w, 953w, 764vs,
692vs.
Synthesis of the complex [Zn(MeImHS)2I2]. The complex
Zn(MeImS)2 (0.100 g, 0.344 mmol) suspended in 20 mL of a
water/MeOH mixture (1/1 v/v) and hydriodic acid (55 wt% in
water) (0.160 g, 0.688 mmol) dissolved in 5 mL of water were
reacted for two days at r.t. The clear pale yellow solution was
filtered and allowed to stand at 5 °C for three days. A pale
yellow powder was collected and washed with a 1 : 1 (v/v)
mixture of CH2Cl2/n-hexane and then dried in vacuo. Yield:
0.169 g, 90%; C8H12I2N4S2Zn (547.36): calcd C 17.54, H 2.21,
N 10.23, S 11.68; found: C 17.3, H 2.1, N 10.2, S 11.6. δC
(100.5 MHz, CDCl3–CH3CN 4 : 1 v/v) 152.5 (CS), 120.6 (C5),
115.4 (C4) 34.1 (N-CH3). IR (KBr, ν/cm
−1): 3287br,
3163m, 3133m, 1683w, 1573s, 1468s, 1450s, 1404 m, 1280 m,
1155m, 1086 m, 1015w, 920w, 733s, 685m, 667s, 627s, 595m,
510m.
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Spectrophotometric measurements
The complex formation constant of [Zn(MeIm)3(MeImHS)]
2+
was determined at 25 °C by spectrophotometric titration
of [Zn(MeIm)4]
2+ (8.53 × 10−5 mmoles) with MeImHS (3.50 ×
10−4 M) in 0.1 M buﬀer solution, pH 9 (borax/hydrochloric
acid). The number of linearly independent absorbing
species was obtained by applying eigenvalues analysis on the
absorbance data matrix.32 The complex formation constant
was obtained using the Hyperquad 2003 program.33
Mass spectrometry
Sample solutions (10 mg L−1) were prepared in CH3CN and
infused directly into the ESI source using a programmable
syringe pump, with a flow rate of 1.50 mL h−1. Needle, shield
and detector voltages were kept at 4500, 800 and 1450 V,
respectively. Pressures of nebulising and drying gas were both
15 psi, and housing and drying gas temperatures were 60 and
50 °C, respectively. The isotopic patterns of the signals in the
mass spectra were analysed using the mMass 5.5.0 software
package.34
X-ray structure determination of [Zn(MeImHS)4](ClO4)2 and
[Zn(MeImSMe)2I2]
A summary of the crystal data and refinement details is given
in Table 2. Intensity data were collected at room temperature
on a Bruker Smart CCD diﬀractometer using graphite-mono-
chromatised Mo-Kα radiation (λ = 0.71073 Å). Datasets were
corrected for Lorentz-polarisation eﬀects and for absorption
(SADABS35). All structures were solved by direct methods
(SIR-9736) and completed by iterative cycles of full-matrix
least-squares refinement on Fo
2 and ΔF synthesis using the
SHELXL-9737 program (WinGX suite).38 Hydrogen atoms
located on the ΔF maps were allowed to ride on their carbon
or nitrogen atoms. In [Zn(MeImHS)4](ClO4)2, the perchlorate
showed high anisotropic displacement parameters for the
oxygen atoms, thus indicating a situation of disorder, which
was subsequently modelled by spitting each oxygen atom
over two close positions, and refining them with an occupancy
factor of 0.5 each. Crystallographic data have been deposited
with the Cambridge Crystallographic Data Centre as sup-
plementary publication no. CCDC-1051219 and CCDC-
1051220.
Computational studies
Theoretical calculations were carried out at the DFT level on
MeImS and Zn(MeImS)2 using the software Spartan ‘10 v. 1.1.0
for Linux (parallel 64-bit version) with the B3LYP hybrid func-
tional.39 The all-electron 6-31G* was adopted for all atomic
species.
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Fig. S1 Positive ion ESI-MS spectrum of [Zn(MeImS)2], (3.45x10-5 M, CH3CN); L = MeImS, L’ = 
methimazole-disulfide (C8H10N4S2) (part of the released ligand from [ZnL2H]+, undergoes oxidation 
and formation of protonated methimazole-disulfide [(C4H5N2S)2H]+ (m/z 227). The signal at m/z 
114 corresponds to a convoluted signals of the radical [MeImSH]*+ (86%) and the [MeImHS+H+]+ 
(14%) species. In fact, the experimental pattern is due to a weighted combination of the isotopic 
pattern of the two molecules. The weights, namely the percentage in which each molecule is 
present, was obtained by multivariate regression analysis of the experimental data.  
 
 
                                                                                                                                                             S 3 
 
Fig. S2 Calculated (red) and experimental (black) isotopic patterns for [ZnL2H]+ (a),  [ZnL4H3] 
(b), [ZnL3H2]+ (c), [ZnL2(H2O)2H2]+ (d) ions, (L = MeImS). 
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Fig. S3 MAS 13C-NMR of complex [Zn(MeImS)2].1 
 
 
   
 
Fig. S4 Iso-surface drawings of Kohn–Sham HOMO (left), HOMO–1 (centre), and HOMO–3 
(right) calculated for anion methimazole (MeImS).  
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Fig. S5 Ball and stick representation of the structure of [Zn(MeImS)2] optimised at DFT level.  
 
 
Table S1 DFT calculated bond lengths (Å) and angles (°) for complex  [Zn(MeImS)2]; schematic 
structure and atom numbering of complex [Zn(MeImS)2]. 
Bond  Angle  
N1-C2  1.358 N1-C2-S 130.98 
N3-C2  1.345 N3-C2-S 119.34 
N1-C5 1.390 N1-C2-N3 109.69 
N2-C4  1.379 C5-N1-C2 107.58 
C4-C5  1.364 C4-N3-C2 107.27 
C2-S   1.746 N1-C5-C4 106.61 
N1-C5  1.390 N3-C4-C5 108.90 
 
 
 
 
Comments on the optimized structure of complex [Zn(MeImS)2]. 
The zinc atom adopts a distorted tetrahedral geometry with both anions (N,S)-chelating. An 
examination of the metric parameters at the Zn centre provide evidence for a strain in the 
metallacycle formed under coordination [Zn-N(3)-C and N(3)-C-S = 94.68° and 119.34°, 
respectively; Zn-S-C = 72.69°]. Due to the S-C-N(3) narrow bite, the calculated S-Zn-N(3) angle 
                                                                                                                                                             S 6 
(73.24°) shows a great departure from ideal tetrahedral coordination geometry; however, a similar 
extent of distortion was also found in the (N,S)-chelating pyridine-2-thionate (py2S) complexes 
[MeHg(py2S)],2a [Me2Sn(py2S)2],2b and [Me2Tl(py2S)],2b with thioamide angles of 58.5, 60.5, and 
54.2°, respectively. 
The calculated values of the bond lengths: d(Zn-N)  2.035 and d(Zn-S) 2.421 Å are consistent with 
those found in complex [Zn4O(MeImS)6],3 which features MeImS acting as a (N,S)-bridging ligand 
that binds pairs of non-interacting zinc atoms [average d(Zn-N)  2.003(10), d(Zn-S) 2.337(3) Å]. 
Moreover, a comparison of the Zn-NMeImS bond distance with those reported for tetrahedral Zn-
pyridine complexes2c,d (2.063-2.060 Å) shows that it is markedly shorter. Conversely, the calculated 
Zn-SMeImS bond distance is about 3% longer than the mean Zn-S bond distances reported for the 
neutral complexes listed in Table 1 [d(Zn-Sthione) in the range 2.340–2.3581 Å], possibly due to the 
overestimation of the metal-sulphur bond lengths previously observed for the B3LYP functional.4  
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Abstract 
Vanadium plays a number of roles in biological systems and has been found in many naturally 
occurring compounds. Vanadium compounds exhibit a wide variety of pharmacological properties. 
The first vanadium species that shown anticancer activity was vanadocene dichloride ([Cp2VCl2] or 
VDC), proposed in 1983 for the treatment of Ehrlich ascites tumour. Considering that the 
mechanism of action of VDC is closely related to the biotransformation in the blood plasma, I 
decided to study the speciation of VDC in the plasma under physiological conditions (Chapter 8 - 
Article V).  
The speciation of the potential antitumor agent VDC in the blood plasma was studied by 
instrumental (EPR, ESI-MS, MS-MS, and UV-vis spectroscopy) and computational (DFT) 
methods
1
. The complex VDC transforms at physiological pH to [Cp2V(OH)2] and only the 
bio-ligands oxalate, carbonate, hydrogen phosphate, and lactate are able to displace the two 
oxydrilic ions to yield [Cp2V(ox)], [Cp2V(CO3)], [Cp2V(lactH−1)], and [Cp2V(HPO4)] (Figure 24).  
 
 
Figure 24. Structure of [Cp2V(ox)] (a), [Cp2V(lactH–1)] (b), [Cp2V(CO3)] (c), and [Cp2V(HPO4)] 
(d). 
The formation of the complexes with oxalate, carbonate, lactate, and hydrogen phosphate was 
confirmed by ESI-MS and MS-MS spectra.  
                                                 
1
 In collaboration with professor Eugenio Garribba (Dipartimento di Chimica e Farmacia and Centro Interdisciplinare 
per lo Sviluppo della Ricerca Biotecnologica e per lo studio della Biodiversità della Sardegna, Università di Sassari).  
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It has been found that the affinity order of the four strongest bio-ligands is ox
2−
 ≫ CO3
2−
 > 
lactH−1
2−
 > HPO4
2−
. The complex [Cp2V(OH)2] does not interact with the plasma proteins 
transferrin and albumin under my experimental conditions (Figure 25).  
 
 
Figure 25. Scheme of interaction of the VDC with bioligands (oxalate, carbonate, phosphate, 
lactate, citrate, histidine, glycine, and trasferrrin and albumin) of the plasma. 
 
The VDC, after the oral administration, enters in the stomach, arrives in the small intestine and 
then in the bloodstream where reacts with the bio-ligands of the plasma. The concentration of VDC 
in the plasma does not correspond to the administered dose, but depends mainly on the 
gastrointestinal absorption. The speciation of VDC at the physiological conditions has been 
examined studying several model systems containing the bio-ligands in the same relative ratio as in 
the blood and, subsequently, carrying out experiments with plasma samples (Table 2). 
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V concentration in plasma  
< 10 µM  10-100 µM  > 100 µM  
[Cp
2
V(ox)] 
(main species) 
[Cp
2
V(ox)] 
(main species) 
[Cp
2
V(CO
3
)] 
(main species) 
[Cp
2
V(CO
3
)] 
(minor species) 
[Cp
2
V(CO
3
)] 
(main species) 
[Cp
2
V(ox)] 
(minor species) 
 [Cp
2
V(lactH
-1
)] 
(minor species) 
[Cp
2
V(lactH
-1
)] 
(minor species) 
Table 2. Speciation of VDC in the blood plasma as a function of its concentration.  
 
The obtained results show that the model systems behave in the same way as the blood plasma 
and if vanadium concentration is ≈ 10 μM, most of VDC administered is transported in the 
organism as [Cp2V(ox)], in fact the strongest bio-ligand, oxalate, binds the [Cp2V]
2+
 moiety. In 
contrast, if vanadium concentration is higher than 100 μM, VDC is complexed mainly by carbonate 
([Cp2V(CO3)] is the main species), and in minor quantity by oxalate and lactate ([Cp2V(ox)] and 
[Cp2V(lactH−1)] are the minor species). Finally, if vanadium concentration is in the range 10−100 
μM, [Cp2V]
2+
 distributes among the oxalate and carbonate (main species), and lactate (minor 
species). 
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ABSTRACT: The speciation of the potential antitumor agent vanadocene
dichloride ([Cp2VCl2], abbreviated with VDC) in the blood plasma was
studied by instrumental (EPR, ESI-MS, MS-MS, and electronic absorption
spectroscopy) and computational (DFT) methods. The behavior of VDC
at pH 7.4 in aqueous solution, the interaction with the most important
bioligands of the plasma (oxalate, carbonate, phosphate, lactate, citrate,
histidine, and glycine among those with low molecular mass and transferrin
and albumin between the proteins) was evaluated. The results suggest that
[Cp2VCl2] transforms at physiological pH to [Cp2V(OH)2] and that only
oxalate, carbonate, phosphate, and lactate are able to displace the two OH−
ions to yield [Cp2V(ox)], [Cp2V(CO3)], [Cp2V(lactH−1)], and [Cp2V-
(HPO4)]. The formation of the adducts with oxalate, carbonate, lactate,
and hydrogen phosphate was conﬁrmed also by ESI-MS and MS-MS
spectra. The stability order is [Cp2V(ox)] ≫ [Cp2V(CO3)] > [Cp2V-
(lactH−1)] > [Cp2V(HPO4)]. No interaction between VDC and plasma proteins was detected under our experimental
conditions. Several model systems containing the bioligands (bL) in the same relative ratio as in the blood samples were also
examined. Finally, the speciation of VDC in the plasma was studied. The results obtained show that the model systems behave as
the blood plasma and indicate that when V concentration is low (10 μM) VDC is transported in the bloodstream as [Cp2V(ox)];
when V concentration is high (100 μM) oxalate binds only 9.2 μM of [Cp2V]
2+, whereas the remaining part distributes between
[Cp2V(CO3)] (main species) and [Cp2V(lactH−1)] (minor species); and when V concentration is in the range 10−100 μM
[Cp2V]
2+ distributes between [Cp2V(ox)] and [Cp2V(CO3)].
■ INTRODUCTION
Vanadium plays a number of roles in biological systems and has
been found in many naturally occurring compounds.1 In
humans, vanadium compounds exhibit a wide variety of
pharmacological properties. In particular, the antidiabetic
activity has been extensively studied during the last 20 years;2
bis(maltolato)oxidovanadium(IV) (or BMOV) became the
benchmark complex for the new molecules with antidiabetic
action,3 and its derivative bis(ethylmaltolato)oxidovanadium-
(IV) (or BEOV) arrived to phase IIa of the clinical trials,4 even
if these have provisionally been abandoned due to renal
problems arising with several patients.5,6 Furthermore,
vanadium complexes have been tested as antiparasitic,
spermicidal, antiviral, anti-HIV, and antituberculosis agents.5,7
The ﬁrst report on the potential anticancer action of a
vanadium compound, bis(cyclopentadienyl)vanadium(IV) di-
chloride or vanadocene dichloride ([Cp2VCl2] abbreviated to
VDC, Scheme 1a), active in the treatment of Ehrlich ascites
tumor, dates back to 1983.8 Subsequently, VDC underwent the
same extensive preclinical testing against both animal and
human cell lines alongside the parent compound [Cp2TiCl2]
(TDC).9 The clinical test on TDC stopped at phase II of the
clinical trials, due to the low eﬃcacy in patients with metastatic
renal cell carcinoma or metastatic breast cancer.10 However, in
all the studies in vitro [Cp2VCl2] was found to be more active
than [Cp2TiCl2]; in particular, in a systematic study on the
activity of several metallocenes on the human testicular cancer
cell lines Tera-2 and Ntera-2, only vanadocene derivatives
exhibited signiﬁcant cytotoxicity leading the tumor cells to
apoptosis within 24 h.9a A very active derivative of VDC is bis-
[(p-methoxybenzyl)cyclopentadienyl]vanadium(IV) dichloride
(vanadocene Y, Scheme 1b), which exhibits an IC50 value of 3.0
μM against the LLC-PK (pig kidney epithelial) cell line (in
contrast, the value of titanocene Y is signiﬁcantly higher, 21
μM).11 This is a particularly encouraging datum, since
Received: March 18, 2015
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© XXXX American Chemical Society A DOI: 10.1021/acs.inorgchem.5b01277
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vanadocene Y is slightly more active against this cell line than
the “classic” cisplatin, which shows an IC50 value of 3.3 μM.
11
Recently, in vitro experiments on modiﬁed vanadocene Y
(diisoselenocyanate vanadocene Y, Scheme 1c) have shown
impressive cytotoxic eﬀects against the human renal cancer cells
CAKI-1, with an IC50 value reaching for the ﬁrst time the
nanomolar range for metallocene anticancer potential drugs.12
A comprehensive study of the cytotoxic activity of methyl- and
methoxy-substituted VDC toward T-lymphocytic leukemia cells
MOLT-4 has been recently reported.13 Under the physiological
conditions, the [Cp2V]
2+ moiety remains essentially intact,
while the auxiliary X ligand, chloride or isoselenocyanate, is
subject to substitution by H2O/OH
− that can further be
exchanged for functions provided by DNA. However, in
contrast with Pt(II), V(IV) is a particularly hard metal center
and thus should preferentially bind to phosphate residues of
DNA rather than N bases of guanosine.7a
The speciation of an active metal complex in the blood is an
important aspect of the drug metabolism, and the form
transported to the target organs signiﬁcantly aﬀects its
eﬃciency and mechanism of action. The assumption that the
V complexes (and metal complexes, in general) reach the target
cells in the same form as they are administrated can be
considered an oversimpliﬁcation.14 Indeed, in the blood ligand
exchange and complexation reactions by the components of the
plasma are possible; moreover, a V compound can distribute
between plasma and erythrocytes.15 All of the main proteins of
the plasma, such as transferrin (hTf), albumin (HSA), and
immunoglobulin G (IgG), and the low molecular mass (l.m.m.)
bioligands, such as oxalate, lactate, phosphate, citrate, and
amino acids, can interact with the V compound administered
and partly or fully displace the organic ligands.16,17 For
example, it has been recently demonstrated through an X-ray
determination that lysozyme replaces the water molecule
equatorially coordinated in the insulin-mimetic agent [VO-
(pic)2(H2O)] through the COO
− group of the Asp-52
residue.18 Unfortunately, the study of the speciation of a
metal complex in a complicated system such as the blood
plasma is not an easy task because plasma contains many
bioligands with very diﬀerent concentration and molecular
mass19 and many chemical reactionsas mentioned above
are possible. For this reason, in many cases model systems have
been investigated to infer indirect information on the biological
system.20 However, very often the results obtained in the
models are not fully in agreement with those observed in the
real systems and give only partial information.
In this work, the speciation of VDC in several model systems
and in blood plasma was studied and compared. It has been
noted recently that the paramagnetic nature of the V(IV)
center (electronic conﬁguration 3d1), which precludes the use
of classical NMR tools, makes the characterization of these
complexes and their biologically active species more diﬃcult
than the parent titanocene derivatives, and this slowed down
their analysis and the advances in this topic.21 However, EPR
spectroscopy is a valid tool to characterize V(IV) in solution;22
for example, nonoxido V(IV) complexes display distinctive
spectroscopic features, in particular, hyperﬁne coupling
constants A much smaller than those observed for V(IV)O
species.23 Herein, EPR characterization was supported by
electronic absorption spectroscopy24 and electrospray ioniza-
tion mass spectrometry (ESI-MS), which allows the detection
of metal complexes and adducts that readily fragment.25,26
Tandem mass spectrometry (MS-MS) was used to conﬁrm the
stoichiometry of the species. Computational methods based on
DFT (density functional theory) provide other valuable
information on the coordination mode of the bioligands on
and the environment of V(IV) species.27
The results reported in this study on the model systems
perfectly coincide with those observed in a complex real system
such as the plasma and allow the prediction of the speciation of
VDC in the blood as a function of the vanadium concentration
in the organism.
■ EXPERIMENTAL AND COMPUTATIONAL SECTION
Chemicals. Water was deionized prior to use through the
puriﬁcation system Millipore Milli-Q Academic. Vanadocene di-
chloride was a Sigma-Aldrich product. 4-(2-Hydroxyethyl)-1-piper-
azineethanesulfonic acid (HEPES), sodium hydrogen carbonate
(NaHCO3), sodium hydrogen phosphate (Na2HPO4), citric acid
(H3citr), lactic acid (Hlact), oxalic acid (H2ox), histidine (His), and
glycine (Gly) were Sigma-Aldrich, Merck, or Carlo Erba products of
the highest grade available and used as received. Human serum apo-
transferrin (98%, T4283) and human serum albumin (97−99%,
A9511) were purchased from Sigma-Aldrich with a molecular mass of
76−81 and 66 kDa, respectively.
Methanol (CH3OH) for LC-MS and triﬂuoroacetic acid (TFA)
used in the ESI-MS and MS-MS experiments were purchased from
Sigma-Aldrich.
Preparation of the Solutions for Spectroscopic Measure-
ments. The solutions were prepared by dissolving in ultrapure water,
obtained through the puriﬁcation system Millipore Milli-Q Academic,
weighted amounts of VDC and bioligands.
In the binary systems VDC concentration was 1.0 × 10−3 M, and
the VDC to bioligand (NaHCO3, Na2HPO4, oxalic acid, lactic acid,
citric acid, histidine, glycine) molar ratio was 1/10 (Figures S5−S9 of
Supporting Information). In all systems the pH was adjusted to 7.4,
and spectra were immediately recorded. Argon was bubbled through
the solutions during their preparation to ensure the absence of oxygen
and avoid oxidation of the V(IV) ion. The eventual oxidation of V(IV)
to V(V), therefore, could start only during the spectroscopic
measurements.
In the multicomponent systems containing VDC and the bioligands
(NaHCO3, Na2HPO4, oxalic acid, lactic acid) three types of
Scheme 1. Structure of Vanadocene Dichloride (VDC) (a) and Its Derivatives Vanadocene Y (b) and Diisoselenocyanate
Vanadocene Y (c)
Inorganic Chemistry Article
DOI: 10.1021/acs.inorgchem.5b01277
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experiments were carried out: (i) in the ﬁrst experiment the VDC and
bioligands concentration was 1.0 × 10−3 M and 1.0 × 10−2 M and the
molar ratio VDC/bL was 1/10 (Figures 3 and S11 and S12 of the
Supporting Information); (ii) in the second one VDC concentration
was 4.0 × 10−4 M and the ratio VDC/ox/NaHCO3/lact/Na2HPO4 1/
1/2706.5/164.1/119.6 (Figures 4−6); (iii) in the third one VDC
concentration was 4.0 × 10−4 M and the ratio VDC/ox/NaHCO3/
lact/Na2HPO4 1/0.1/270.7/16.4/12.0 (Figures 5, 7, and S13 of the
Supporting Information). In all experiments the pH was brought to 7.4
and argon was bubbled through the solutions to avoid oxidation of the
V(IV) ion.
EPR spectra with the physiological concentrations of the bioligands
(and metal ion) cannot be measured because very low intensity signals
would be detected. To overcome this problem we used higher
concentrations of the metal ion (4.0 × 10−4 M) and bioligands but
maintaining the same ratio as in a blood plasma. The same strategy
was previously used when studying the distribution of insulin-
enhancing V(IV)O2+ complexes between the high and low molecular
mass components of the plasma, with the extrapolation to low
concentrations being a normal procedure used in the literatur-
e.17c,20,28,29
In the experiments involving apo-hTf a concentration of VDC of 5.0
× 10−4 M was used. The pH was raised to ca. 4.0, and NaHCO3 and
HEPES were added in appropriate amounts in order to have a
concentration of 2.5 × 10−2 and 1.0 × 10−1 M, respectively.
Subsequently, pH was brought to ca. 5.0, and apo-hTf was added to
the solution to obtain a ﬁnal concentration of 2.5 × 10−4 M. Finally,
pH was increased to 7.40. In the experiments involving HSA the
concentration of VDC was 1.0 × 10−3 M. The pH was raised to ca. 5.0,
and HEPES and HSA were added to have a concentration of 1.0 ×
10−1 and 2.5 × 10−4 M. Then the pH was brought to 7.40. In all
systems, the spectra were immediately measured to minimize the
possible oxidation of V(IV) to V(V).
Experiments with Blood Plasma. Blood samples were obtained
from Servizio Trasfusionale Aziendale (ASL of Sassari). Blood samples
were centrifuged for 10 min at 3000 rpm, and the plasma was
separated from buﬀy coat and red blood cells. The plasma was
subsequently incubated for 30 min at 37 °C with a solution of VDC to
have a ﬁnal concentration of 4.5 × 10−5 M. The EPR spectrum was
immediately measured.
Spectroscopic Measurements. EPR spectra were recorded at
room temperature (298 K) or on frozen solutions (120 K) using an X-
band (9.4 GHz) Bruker EMX spectrometer equipped with an HP
53150A microwave frequency counter. When the signal-to-noise ratio
was low due to the low V(IV) concentration, signal averaging was
used.30 Electronic absorption spectra were obtained with a
PerkinElmer Lambda 35 spectrophotometer.
Mass Spectrometry. The aqueous sample solutions containing
VDC or the adducts with oxalate, lactate, carbonate, and hydrogen
phosphate were prepared in ultrapure water obtained with Milli-Q
Millipore. To improve the quality of the spectra, all solutions were
mixed in a 1:1 v/v ratio with methanol containing 1% of TFA. These
solutions were infused in the ESI chamber immediately after their
preparation in order not to modify the aqueous solution equilibria.
Mass spectra in positive- and negative-ion mode were obtained on a
triple-quadrupole QqQ Varian 310-MS mass spectrometer using the
atmospheric-pressure technique. The sample solutions were infused
into the ESI source using a programmable syringe pump at a ﬂow rate
of 1.00 mL/h. A dwell time of 14 s was used, and the spectra were
accumulated for at least 10 min in order to increase the signal-to-noise
ratio. Mass spectra were recorded in the m/z range 50−500 at a ﬁnal
concentration of 5.0 × 10−4 M. The experimental conditions used for
the measurements were: needle voltage 4500 V, shield voltage 600 V,
housing temperature 60 °C, drying gas temperature 100 °C, nebulizer
gas pressure 40 PSI, drying gas pressure 20 PSI, and detector voltage
1450 V. MS-MS experiments were performed with argon as collision
gas (1.8 PSI) using a needle voltage of 6000 V, shield voltage of 800 V,
housing temperature of 60 °C, drying gas temperature of 120 °C,
nebulizer gas pressure of 40 PSI, drying gas pressure of 20 PSI, and
detector voltage of 2000 V. Collision energy was varied from 2 to 50
eV. The isotopic patterns of the experimental peaks were analyzed
using the mMass 5.5.0 software package.31
DFT Calculations. DFT (density functional theory) calculations
were performed with the software Gaussian 03 (revision C.01)32 and
ORCA.33
The geometry of V(IV) complexes was optimized with Gaussian at
the B3P86/6-311g level of theory with the procedure reported in the
literature.34 This choice ensures a good degree of accuracy in the
prediction of the structures of ﬁrst-row transition metal complexes35
and, in particular, of vanadium species.34 For all structures, minima
were veriﬁed through frequency calculations.
On the optimized structures, the 51V hyperﬁne coupling tensor A
was calculated with Gaussian software using the hybrid functional half-
and-half BHandHLYP and the basis set 6-311g(d,p) and with ORCA
software using the hybrid functional PBE0 and the basis set VTZ,
according to the procedures previously published.36 It must be taken
into account that for a V(IV) species A is usually negative, but in the
literature its absolute value is often reported; this formalism was also
used in a number of points of this study. The 51V A tensor has three
contributions: the isotropic Fermi contact (AFC), the anisotropic or
dipolar hyperﬁne interaction (AD), and one second-order term that
arises from spin−orbit (SO) coupling (ASO):33b A = AFC1 + AD + ASO,
where 1 is the unit tensor. The values of the 51V anisotropic hyperﬁne
coupling constants along the x, y, and z axes are as follows: Ax = A
FC +
Ax
D + Ax
SO, Ay = A
FC + Ay
D + Ay
SO, and Az = A
FC + Az
D + Az
SO. From these
equations, the value of Aiso is Aiso = (1/3)(Ax + Ay + Az) = A
FC + (1/
3)(Ax
SO + Ay
SO + Az
SO) = AFC + APC, where the term (1/3)(Ax
SO + Ay
SO +
Az
SO) is named isotropic pseudocontact, APC.33b Gaussian neglects the
second-order term represented by ASO; thus, APC = 0 and Aiso = A
FC.
The theory background was described in detail in ref 37. The percent
deviation from the experimental value |Ai|
exptl, where i = iso, x, y, was
calculated as 100 × [(|Ai|
calcd − |Ai|exptl)/|Ai|exptl].
■ RESULTS AND DISCUSSION
1. Behavior of VDC in Aqueous Solution. The behavior
of VDC in aqueous solution has been investigated through the
combined application of EPR, UV−vis spectroscopy, ESI-MS,
MS-MS, and DFT methods. The structure of VDC has been
already solved by X-ray diﬀraction analysis:38 it is tetrahedral
with two sites occupied by the cyclopentadienyl rings and the
other two sites by the ions Cl−. The geometry of VDC has been
optimized with Gaussian 03 software through DFT methods,
which give good results in the optimization of the structure of
transition metal complexes35 and of vanadium complexes in
particular.34 The structure of VDC is shown in Figure S1a of
the Supporting Information, and a comparison between the
bond distances and angles is given in Table S1.
The behavior of [Cp2VCl2] in aqueous solution has been
examined by Toney and Marks and, subsequently, by Pavliḱ
and Vinklaŕek.39−41 The results indicate that the two Cp−V
bonds are more resistant to hydrolysis than the analogous
compounds of titanium and zirconium, [Cp2TiCl2] and
[Cp2ZrCl2], and the stability order is V > Ti > Zr. When
[Cp2MCl2] (M = V, Ti, Zr) are dissolved in water the
dissociation of both the Cl− ions is revealed, with the
dissociation of the ﬁrst chloride being too fast to be observed
and the half-life time for the dissociation of the second one
being 50 (M = Ti), 30 (M = Zr), and 24 min (M = V). The
dissociation constant for the loss of the ﬁrst Cl− is very large
and cannot be measured; that for the second Cl− is 4.2 × 10−2
(M = Ti) and 2.7 × 10−3 M (M = V).40 In the system with
VDC, the species formed at acid pH is [Cp2V(H2O)2]
2+, whose
structure has been determined by X-ray diﬀraction analysis39
and simulated in this study (Table S1 and Figure S1b of the
Supporting Information). The two water molecules bound to
vanadium(IV) in [Cp2V(H2O)2]
2+ are strongly acid (pKa =
Inorganic Chemistry Article
DOI: 10.1021/acs.inorgchem.5b01277
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4.73 and 5.15).40 Pavliḱ and Vinklaŕek demonstrated that
[Cp2V(H2O)2]
2+ is stable in aqueous solution for several days.
They also proved that at pH 7.4 the only species present in
solution is [Cp2V(OH)2], whose EPR signal disappears after
exposition to air for 72 h.41
The behavior of VDC in aqueous solution has been re-
examined in this work through EPR and UV−vis spectroscopy
and the ESI-MS technique as the basis for the study of its
speciation in the blood plasma under the physiological pH. EPR
spectra recorded as a function of pH on a solution containing
VDC 1.0 × 10−3 M (Figure S2 of Supporting Information)
show, according to the results reported in the literature, the
presence of [Cp2V(H2O)2]
2+ in acid solution (pH < 4.0) and of
[Cp2V(OH)2] in neutral and basic solution (pH > 6.0). The
intermediate species [Cp2V(H2O)(OH)]
+ is not observable
because the two deprotonations of the water molecules overlap
for the very close values of pKa.
40 Room-temperature EPR
spectra are characterized by a signiﬁcant variation of giso and Aiso
from [Cp2V(H2O)2]
2+ (giso = 1.980 and Aiso = 73.5 × 10
−4
cm−1) to [Cp2V(OH)2] (giso = 1.985 and Aiso = 58.4 × 10
−4
cm−1), see Figure S3 of the Supporting Information.
The mass spectrum of VDC (Figure 1) shows, in particular,
the peaks of [Cp2VCl]
+ (m/z 216) and [Cp2V(OH)]
+ (m/z
198). Other peaks were also identiﬁed, such as those of
[Cp2V(TFA)]
+ (m/z 294), [Cp2VF]
+ (m/z 200), [2Cp+3H]+
(m/z 133), and [Cp2V]
2+ (m/z 90), but they were recognized
as products of the fragmentation−recombination reactions
occurring in ESI phase. All identiﬁed signals are listed in Table
4, together with the fragmentation products of the most intense
peaks. Calculated and experimental isotopic patterns for
selected peaks are reported in Figure S4 of the Supporting
Information. The stoichiometry of the hypothesized species was
conﬁrmed by MS-MS experiments.
The Aiso values were calculated by DFT methods, which are a
good tool to predict the hyperﬁne coupling constants between
the unpaired electron with 51V nucleus measured in an EPR
spectrum.42,43 According to the procedures established in the
literature,37c the calculations were performed with Gaussian 03
(which does not include the spin−orbit coupling) using the
half-and-half functional BHandHLYP and the basis set 6-
311g(d,p) and ORCA (which takes into account the second-
order spin−orbit contribution) with the functional PBE0 and
the basis set VTZ. To the best of our knowledge, no systematic
study on the prediction of the EPR parameters (tensors g and
A) for nonoxido vanadium(IV) complexes was published, but
recent results indicate that ORCA performs slightly better than
Gaussian because the percent contribution of the spin−orbit
coupling to Aiso is larger than in the case of V(IV)O
2+
complexes,44 i.e., the pseudocontact term APC = (1/3)(Ax
SO +
Ay
SO + Az
SO) is not negligible with respect to Fermi contact, AFC
(see Experimental and Computational Section). The results
obtained for VDC and the V(IV) species formed in solution,
including those with the bioligands, are listed in Table 1.
From the data reported in Table 1, it emerges that ORCA
performs better than Gaussian in the prediction of Aiso. This
diﬀerence can be attributed to the term APC (considered by
ORCA and not by Gaussian), which contributes for 8−10% to
Aiso. On the basis of the results, it can be argued that a DFT
calculation with ORCA can be used to predict the Aiso value of
a V(IV) complex; in particular, a calculation performed at the
level of theory PBE0/VTZ allows one to predict Aiso with a
mean deviation from the experimental value of 3.1% (Table 1).
2. Interaction of VDC with the l.m.m. Bioligands of
the Blood Serum. Among the low molecular mass bioligands
of the blood serum (bL), oxalate (ox), lactate (lact), citrate
(citr), hydrogen phosphate (HPO4
2−), glycine (Gly), histidine
(His), and carbonate (CO3
2−) are the most likely potential
V(IV) binders.16a,20 In this work, the systems VDC/bL were
studied at the physiological pH using a ratio of 1/10 and VDC
Figure 1. Positive ESI mass spectrum of VDC (5.0 × 10−4 M),
recorded in H2O/CH3OH 1:1 v/v (1% TFA).
Table 1. Experimental (exptl) and Calculated (calcd) Isotropic Hyperﬁne Coupling Constants (Aiso) for VDC, Its Hydrolytic
Products, and Ternary Complexesa
exptl calcd (Gaussian)b calcd (ORCA)c
complex giso Aiso Aiso dev. %
d Aiso dev. %
d
[Cp2VCl2] 1.978 −69.1 −59.6 −13.7 −64.0 −7.4
[Cp2V(H2O)2]
2+ 1.980 −73.5 −71.6 −2.6 −78.3 6.5
[Cp2V(OH)2] 1.985 −58.4 −52.6 −9.9 −60.0 2.7
[Cp2V(ox)] 1.983 −63.5 −56.1 −11.7 −63.8 0.5
[Cp2V(CO3)] 1.985 −58.3 −51.8 −11.1 −59.6 2.2
[Cp2V(lactH−1)] 1.984 −63.6 −58.1 −8.6 −65.7 1.7
[Cp2V(citrH−1)]
3− 1.987 −65.4 −62.8 −4.0 −67.2 2.8
[Cp2V(HPO4)] 1.993 −63.3 −55.9 −11.7 −63.4 0.2
MADe 9.5 3.1
aAiso value measured in 10
−4 cm−1. bValues calculated at the level of theory BHandHLYP/6-311g(d,p). cValues calculated at the level of theory
PBE0/VTZ. dPercent deviation from the experimental value, |Aiso|
exptl, calculated as 100 × [(|Aiso|
calcd − |Aiso|exptl)/|Aiso|exptl]. eMean of the absolute
percent deviations (MAD) from the experimental values.
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concentration of 1 × 10−3 M. EPR and UV−vis spectra were
compared with those of [Cp2V(OH)2], whichas mentioned
aboveis the only species existing at pH 7.4 when VDC is
dissolved in aqueous solution. ESI-MS, MS-MS spectra, and
DFT calculations were carried out to conﬁrm the results (see
below). The oxidation of V(IV) to V(V) is negligible at the
experimental conditions used in this study, and EPR and UV−
vis data support this conclusion: indeed, the spectroscopic
signals of the main V(IV) species existing at pH 7.4 do not
change signiﬁcantly as a function of time.
The formation of the ternary species in the solid state
between the moiety [Cp2V]
2+ and mono- and bidentate ligands
was demonstrated in the literature. In particular, Vinklaŕek and
co-workers prepared solid samples upon reaction of VDC with
amino acids with noncoordinating45 and coordinating side-
chain groups,46 with phosphate,47 oxalate,48 and carbonate.49
The results of the spectroscopic measurements revealed in this
study on the systems VDC/oxalate, VDC/lactate, VDC/citrate,
VDC/HCO3
−, VDC/HPO4
2−, VDC/Gly, and VDC/His
showed that only oxalate, lactate, carbonate, and hydrogen
phosphate are able to replace the two OH− ions of
[Cp2V(OH)2] to yield mixed species (Figure S5 of Supporting
Information). Glycine and histidine, in contrast with what was
observed in the solid state, do not form ternary complexes in
solution, whereas in the system with citrate the amount of
mixed compound is signiﬁcantly lower than that of [Cp2V-
(OH)2] (Figure S6 of the Supporting Information).
In the system with oxalate, the formation of a neutral species
[Cp2V(ox)] was detected. Oxalate binds vanadium(IV) with
the two oxygen atoms of carboxylate groups forming a ﬁve-
membered chelate ring (Scheme 2a). The concentration of this
species is close to 100% (Figure S5, trace b). The structural
details calculated by DFT methods for the species [Cp2V(ox)]
are compared with those determined in the solid state through
X-ray diﬀraction analysis by Honzićěk et al. (Table S2 of the
Supporting Information).48 Another aspect to be noticed is the
small line width of the eight resonances (ΔH1 = 6.5 × 10−1 mT
and ΔH8 = 9.3 × 10−1 mT); here, we would like to stress that
this observation will be very important when the distribution of
[Cp2V]
2+ between the bioligands of the blood serum will be
discussed. The formation of [Cp2V(ox)] from [Cp2V(OH)2] is
also demonstrated by examination of the electronic absorption
spectra reported in Figure S7 of the Supporting Information
(traces black and red).
Scheme 2. Structures of [Cp2V(ox)] (a), [Cp2V(lactH−1)] (b), [Cp2V(CO3)] (c), and [Cp2V(HPO4)] (d)
Table 2. Experimental (exptl) and Calculated (calcd) Anisotropic Hyperﬁne Coupling Constants (Ai) for Ternary Complexes
Formed by VDCa
calcd (Gaussian)b calcd (ORCA)c exptld % (Gaussian) % (ORCA)
Ax Ay Az Ax Ay Az Ax Ay % |Ax|
e % |Ay|
e % |Ax|
e % |Ay|
e
[Cp2V(ox)] −91.7 −74.9 −1.6 −98.4 −85.4 −7.5 −102.1 −77.9 −10.2 −3.9 −3.7 9.7
[Cp2V(CO3)] −87.9 −70.8 3.3 −95.5 −79.9 −3.3 −94.5 −75.9 −7.0 −6.7 1.0 5.3
[Cp2V(lactH−1)] −94.9 −78.7 −0.7 −101.9 −88.0 −7.2 −101.7 −79.1 −6.7 −0.5 0.2 11.3
MADf 8.0 3.7 1.6 8.8
aAll values measured in 10−4 cm−1. bValues calculated at the level of theory BHandHLYP/6-311g(d,p). cValues calculated at the level of theory
PBE0/VTZ. dAz not measurable.
ePercent deviation from the experimental value, |Ai|
exptl (i = x, y), calculated as 100 × [(|Ai|
calcd − |Ai|exptl)/|Ai|exptl].
fMean of the absolute percent deviations (MAD) from the experimental values.
Scheme 3. Possible Coordination Modes of Hydrogen Phosphate (a−c) and (bi)Carbonate (d−f) to the [Cp2V]2+ Moiety of
VDC
Inorganic Chemistry Article
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The frozen solution EPR spectrum of [Cp2V(ox)] is
reported in trace a of Figure S8 of Supporting Information,
whereas the values of Ax, Ay, and Az calculated with Gaussian
and ORCA are listed in Table 2. Also, in the case of the
anisotropic hyperﬁne constants, the prediction of ORCA is
slightly better than that of Gaussian.
To the best of our knowledge, the system VDC/lactate was
never studied up to now. The room-temperature EPR spectrum
recorded at pH 7.4 is shown in Figure S5, trace a, and the
frozen solution spectrum in Figure S8, trace b. The
spectroscopic data (Tables 1 and 2) show that a mixed species
with composition [Cp2V(lactH−1)] is formed (the structure is
represented Scheme 2b), in which lactate binds V(IV) with the
donor set (COO−, O−). This species is present in solution with
a small amount of the bis-chelated V(IV)O2+ complex,
[VO(lactH−1)2]
2−, in which lactate in the doubly deprotonated
form binds vanadium with the coordination mode 2 × (COO−,
O−).50 The line width of the eight resonances of the room-
temperature spectrum (ΔH1 = 8.1 × 10−1 mT and ΔH8 = 12.0
× 10−1 mT) is larger than that of the analogous species of
oxalate, [Cp2V(ox)]. The electronic absorption spectrum of
[Cp2V(lactH−1)] (Figure S7, green) diﬀers signiﬁcantly from
that of [Cp2V(OH)2] (Figure S7, black).
The room-temperature EPR spectrum recorded at the
physiological pH in the system with hydrogen phosphate is
reported in Figure S5, trace c. It is possible to observe that
instead of the eight transitions expected for a mononuclear
V(IV) species, 16 resonances are revealed. This is due to the
coupling of the unpaired electron with the nucleus of 31P (I =
1/2) and is in agreement with the results in the literature.47
Concerning the species formed under these experimental
conditions, three possibilities for coordination of the HPO4
2−
ion must be taken into account: in the ﬁrst it is bidentate and
forms a four-membered chelated cycle (Scheme 3a), in the
second one it is monodentate and replaces only one OH− ion
(Scheme 3b), and in the third one two HPO4
2− anions replace
both OH− ligands in [Cp2V(OH)2] (Scheme 3c).
Some years ago, Vinklaŕek and co-workers demonstrated
through the combined application of spectroscopic and
computational methods that [Cp2V(HPO4)] exists in sol-
ution.47 Here, we repeated the DFT calculations: the values of
Aiso for the coupling between the unpaired electron and the
nuclei of 51V and 31P were calculated with the software
Gaussian and ORCA for [Cp2V(HPO4)], [Cp2V(HPO4)2]
2−,
and [Cp2V(HPO4)(OH)]
− and are reported in Table 3. In
agreement with the results reported,47 the best agreement with
the experimental data is obtained for [Cp2V(HPO4)] with a
bidentate coordination mode of hydrogen phosphate (Scheme
3a). In particular, the high value of Aiso (
31P) is compatible only
with this species. The electronic spectrum of [Cp2V(HPO4)] is
represented in Figure S7, purple, and is diﬀerent from those of
the other mixed complexes and of [Cp2V(OH)2].
In the system with the ion HCO3
− the formation of only one
species is observed in the room-temperature spectrum (Figure
S5, trace d) with giso = 1.985 and Aiso = 58.3 × 10
−4 cm−1.
These parameters are very similar to those of [Cp2V(OH)2], in
agreement with what is predicted by DFT calculations (Table
1). The anisotropic EPR spectrum recorded at 120 K in the
system VDC/HCO3
− at pH 7.4 with a ratio 1/10 is shown in
Figure S9, trace b, and is compared with that expected for
[Cp2V(CO3)] on the basis of the calculations with ORCA
software. From an examination of Figure S9, it can be observed
that the agreement between the two spectra is rather good. The
formation of [Cp2V(CO3)] was demonstrated in the literature
by Vinklaŕek et al.45,49 Another conﬁrmation of the formation
of [Cp2V(CO3)] is the signiﬁcant diﬀerence in the electronic
absorption spectra recorded at pH 7.4 in the systems containing
only VDC and VDC/HCO3
− (cfr. traces black and blue in
Figure S7).
As for hydrogen phosphate, carbonate could bind to the unit
[Cp2V]
2+ in three diﬀerent modes represented in Scheme 3d−f.
In this case too, the comparison between the experimental
values of Aiso (
51V) and Aiso (
13C) allowed us to demonstrate
that the correct coordination mode for CO3
2− ligand is the
bidentate one. For example, the values of Aiso (
51V) predicted
for structures d, e, and f of Scheme 3 are 59.6, 70.6, and 66.3 ×
10−4 cm−1 (with ORCA), respectively, to be compared with
58.3 × 10−4 cm−1 experimentally measured. These results are in
agreement with those obtained by Vinklaŕek and co-work-
ers.45,49
The formation of the mixed species revealed by EPR and
UV−vis spectroscopy and DFT calculations was conﬁrmed by
ESI-MS and MS-MS spectrometry preparing solutions
containing VDC and the bioligand in 1/1−1/10 ratios. These
two techniques are suitable tools for the study of metal
complexes in solution.25 Of course, in the transfer from
solution to gas phase, two important phenomena may happen:
(i) the redox reactions occurring at the capillary may alter the
valence state of the metal ion inducing a coordination change
and a structural rearrangement; (ii) the fragmentation products
may themselves recombine forming new species. The mass
spectra of solutions containing VDC and oxalate, lactate, or
carbonate show the peaks of the corresponding adducts, i.e.,
[Cp2V(ox)+H]
+ (m/z 270), [Cp2V(lactH−1)+H]
+ (m/z 270),
Table 3. Experimental (exptl) and Calculated (calcd) Isotropic Hyperﬁne Coupling Constants (Aiso) with the Nuclei of
51V, 31P,
and 13C for the Possible Ternary Complexes Formed by VDC with HPO4
2− and CO3
2− Anionsa
Aiso (
51V)b Aiso (
31P)c Aiso (
13C)d
species calcd (Gaussian) calcd (ORCA) calcd (Gaussian) calcd (ORCA) calcd (Gaussian) calcd (ORCA)
[Cp2V(HPO4)] −55.9 −63.4 33.2 45.3
[Cp2V(HPO4)2]
2− −56.6 −64.7 1.5 2.6
[Cp2V(HPO4)(OH)]
− −55.7 −64.1 4.9 5.7
[Cp2V(CO3)] −51.8 −59.6 10.5 17.4
[Cp2V(HCO3)2] −64.3 −70.6 1.7 6.1
[Cp2V(HCO3)(OH)] −60.6 −66.3 1.1 3.5
aAll values measured in 10−4 cm−1. bThe experimental value of Aiso (
51V) for the ternary complex formed in the system VDC/HPO4
2− is −63.3 ×
10−4 cm−1, while that for the ternary complex formed in the system VDC/HCO3
− is −58.3 × 10−4 cm−1. cThe experimental value of Aiso (31P) for
the ternary complex formed in the system VDC/HPO4
2− is 27.5 × 10−4 cm−1 (ref 47). dThe experimental value of Aiso (
13C) for the ternary complex
formed in the system VDC/HCO3
− is 8.0 × 10−4 cm−1 (ref 49).
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and [Cp2V(CO3)+H]
+ (m/z 242). In Figure 2a, the mass
spectrum of the system VDC/oxalate is reported as an example.
In the case of phosphate, due to the suppression eﬀect of this
ion,51 a reliable spectrum was obtained only working with high
voltages at needle (6000 V) and shield (800 V). At these
conditions, a peak attributable to [Cp2V
V(PO4)+Na]
+ was
found (m/z 299), together with peaks indicating the formation
of polynuclear species. However, some of the detected species
could have been formed in ESI phase for the severe
experimental conditions used and then do not reﬂect the
composition of the solution.
The stoichiometry hypothesized for the adducts formed with
oxalate, lactate, and carbonate was conﬁrmed by MS-MS
experiments. The fragmentation proﬁle obtained for the peak at
m/z 270 for the system VDC/oxalate is reported in Figure 2b
as an example. As it can be seen, the MS-MS is identical to the
ESI-MS spectrum, indicating that the species with stoichio-
metry [Cp2V(OH)]
+ (m/z 198) is a recombined fragment of
the parent compound [Cp2V(ox)+H]
+ (m/z 270). Therefore,
the results conﬁrm that [Cp2V(ox)] is the predominant species
in solution. Analogous results were obtained in the systems
with lactate and carbonate. The comparison between the
calculated and the experimental isotopic pattern for [Cp2V-
(ox)+H]+, [Cp2V(lactH−1)+H]
+, and [Cp2V
V(PO4)+Na]
+ is
shown in Figure S4 of the Supporting Information. In Table 4
the experimental and calculated m/z values for the detected
species are reported.
In contrast with the ligands discussed above, in the system
with citrate [Cp2V(citrH−1)]
2− is a minor species (Figure S6 of
Supporting Information, trace c). The major complex is
[Cp2V(OH)2], whereas the resonances of two V(IV)O
2+
species, [VO(H2O)5]
2+ (giso = 1.968 and Aiso = 106.9 × 10
−4
cm−1) and [VO(citrH−1)]
2− (giso = 1.970 and Aiso = 98.0 × 10
−4
cm−1), in which citrate in the fully deprotonated form binds
vanadium with the donor set (COO−, O−), are also
detected.50a,52
Among the amino acids of the blood serum, in this study
glycine (as an example of an amino acid without coordinating
side-chain group) and histidine (as an example of an amino acid
with coordinating side-chain group) were examined. The team
of Vinklaŕek synthesized several complexes in the solid state
formed by amino acids (a.a.) with structure [Cp2V(a.a.)]
+.45
When such species are dissolved in an organic solvent such as
MeOH, the resonances of [Cp2V(a.a.)]
+ can be revealed. The
data obtained in this study indicate that the behavior in aqueous
solution is diﬀerent. In the system with glycine (Figure S6 of
the Supporting Information, trace b) the only species is
[Cp2V(OH)2]; the value of Aiso measured (58.3 × 10
−4 cm−1)
is signiﬁcantly diﬀerent from that of the species formed by the
amino acids, [Cp2V(a.a.)]
+ (62.2−62.9 × 10−4 cm−1 45), and
Figure 2. (a) Positive ESI mass and (b) tandem MS-MS spectrum of the solution containing VDC and oxalate (5.0 × 10−4 M, 1/1 molar ratio),
recorded in H2O/CH3OH 1:1 v/v (1% TFA).
Table 4. Species Identiﬁed from the ESI-MS Studies and MS-
MS Fragmentation Products
ion composition
exptl
m/za
calcd
m/za
I [Cp2V]
2+ (originated from
XI and XIII)
C10H10V 90.90 90.51
II [C5H6 + C3H3]
+ (originated
from XIV)
C8H9 104.92 105.07
III [CpV]+ (originated from
VIII and XVI)
C5H5V 115.85 115.98
IV [2Cp + 3H]+ (originated
from IX, XIV and XVIII)
C10H13 132.90 133.10
V [CpVIIIF]+ (originated from
X)
C5H5FV 134.91 134.98
VI [CpVN2]
+ (originated from
VIII)
C5H5N2V 143.87 143.98
VII [Cp2V
III]+ (originated from
XI, XV and XVI)
C10H10V 180.95 181.02
VIII [Cp2VH]
+ (MS-MS
fragments: m/z 144, 116)
C10H11V 181.98 182.01
IX [Cp2V(OH)]
+ (MS-MS
fragment: m/z 133)
C10H11OV 197.94 198.00
X [Cp2VF]
+ (MS-MS
fragment: m/z 135)
C10H10FV 199.97 200.00
XI [Cp2VCl]
+ (MS-MS
fragments: m/z 181, very
low, 91)
C10H10ClV 215.98 216.00
XII [Cp2V(OH)N2]
+ (originated
from XIV)
C10H11N2OV 225.94 226.03
XIII [Cp2V(CO3)+H]
+ (MS-MS
fragments: m/z 198, 91)
C11H11O3V 242.03 242.00
XIV [Cp2V(OH)(H2O)N2]
+
(MS-MS fragments: m/z
226, 133, 105)
C10H13N2O2V 243.98 244.03
XV [Cp2V(lactH−1)+H]
+ (MS-
MS fragments: m/z 198,
181)
C13H15O3V 269.99 270.00
XVI [Cp2V(ox)+H]
+ (MS-MS
fragments: m/z 198, 181,
116)
C12H11O4V 270.01 270.00
XVII [Cp2V(TFA)]
+ C12H10F3O2V 294.04 294.00
XVIII [Cp2V
V(PO4)+Na]
+ (MS-
MS fragment: m/z 133)
C10H10NaO4PV 299.00 299.00
aThe experimental and calculated m/z values refer to the peak
representative of the monoisotopic mass.
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that calculated with ORCA for [Cp2V(Gly)]
+ (62.8 × 10−4
cm−1). In the system with histidine the major species is
[Cp2V(OH)2], whereas the resonances of [Cp2V(His)]
+ (giso =
1.984 and Aiso = 62.4 × 10
−4 cm−1) are much less intense,
suggesting that the mixed complex is present at the
physiological pH in a very low amount. Therefore, at the
experimental conditions of this study, it can be aﬃrmed that the
aﬃnity of the amino acids for the moiety [Cp2V]
2+ is much
lower than that of other l.m.m. bL. This may be due to the low
aﬃnity of [Cp2V]
2+ for the nitrogen with respect to that for the
oxygen donors. A demonstration of this ﬁnding is the behavior
of 1-methylimidazole (that has been used over the last years by
our team as a model for the coordination of an imidazole
nitrogen of a histidine residue to the insulin-mimetic V(IV)O2+
complexes16b−i), which does not form mixed complexes and
conﬁrms the poor aﬃnity of [Cp2V]
2+ ion toward the nitrogen
donors.
3. Interaction of VDC with Blood Serum Proteins. The
interaction of the insulin-mimetic V(IV)O2+ complexes with
the blood serum proteins has been widely studied by our
team.16b−i The results demonstrated that both hTf and HSA
bind vanadium(IV) complexes with a nitrogen donor of an
accessible histidine residue, probably exposed on the protein
surface. Recently, it was proved that also carboxylate of an
aspartate residue is able to coordinate V(IV)O2+ ion.18 Some
years ago, the interaction of VDC with apo-transferrin (apo-
hTf) has been studied through the combined application of
EPR, electronic absorption, CD, and ﬂuorescence spectrosco-
py.53,54 In particular, Nishida et al. in the system VDC/apo-hTf
observed two sets of isotropic resonances with giso = 1.985 and
Aiso = 95.9 × 10
−4 cm−1 (species a) and giso = 1.984 and Aiso =
58.0 × 10−4 cm−1 (species b). These two signals were
incorrectly attributed to the species in which V(IV)O2+ ion is
bound to the Fe sites in the N- and C-terminal regions of the
protein and to the species derived from VDC in which the two
Cl− ions are replaced by O and N donors of the side chains of
transferrin.54 It is well known that EPR spectra recorded at
room temperature in the systems containing proteins can be
characterized by two types of signals: isotropic signals
belonging to species in which V(IV) is bound to the l.m.m.
ligands and anisotropic signals for the binary or ternary species
in which V(IV) is bound to the proteins.16f,17d,28,55 The
detection of anisotropic signals at room temperature is due to
slow tumbling motion, in the time scale of an EPR experiment,
of the complexes formed by the proteins which behave as a
solid or a frozen solution. In contrast, the signals revealed by
Nishida et al. are completely isotropic, and this induces us to
believe that apo-transferrin did not interact with VDC under
their experimental conditions. On the basis of the results
discussed above, species b observed by Nishida et al. is the
complex in which two OH− ions bind [Cp2V]
2+ forming
[Cp2V(OH)2] (Aiso = 58.0 × 10
−4 cm−1), whereas species a is,
without any doubt for the large value of Aiso (95.9 × 10
−4
cm−1), a V(IV)O2+ complex; in addition, the intensity of the
signal of [Cp2V(OH)2] decreases as a function of the time and
that of V(IV)O2+ species increases signiﬁcantly, indicating a
V(IV)−V(IV)O transformation. Du et al., instead, proposed
that the interaction between [Cp2VCl2] and apo-hTf is similar
to [Cp2TiCl2],
53 which loses the two cyclopentadienyl rings
forming Ti2(apo-hTf);
56 this result appears to be in contrast
with the fact that the fragment [Cp2V]
2+ is much more stable
than [Cp2Ti]
2+ and that EPR data do not show the formation
of (VO)2(apo-hTf), whose spectrum is well known.
17b,30,55,57,58
In this study, the system VDC/apo-hTf has been re-
examined and the EPR spectrum recorded at pH 7.4 is
shown in Figure S10 of the Supporting Information, trace b.
Our data are in agreement with those of Nishida et al., even if
the interpretation of the data is diﬀerent; in particular, it
emerges that the spectrum at the physiological conditions is
superimposable with that of [Cp2V(OH)2] (see traces a and b
of Figure S10).
Nishida et al. also examined the system VDC/HSA. EPR
signals at room temperature are isotropic with giso = 1.984 and
Aiso = 58.0 × 10
−4 cm−1.54 On the basis of this result, the
authors concluded that albumin interacts with [Cp2V]
2+
through surface sites of the protein, analogously to what was
observed for TDC.59 Our data conﬁrm what was detected by
Nishida et al.,54 but in this case too the detection of isotropic
signals (Figure S10 of Supporting Information, trace c) allowed
us to rule out that the albumin interacts with [Cp2V]
2+ ion. The
eight resonances (which do not change as a function of the
time) and the spectral parameters (giso = 1.985 and Aiso = 58.3
× 10−4 cm−1) can be attributed to [Cp2V(OH)2] (spectrum
shown in trace a of Figure S10 of Supporting Information).
Moreover, in both systems with apo-hTf and HSA no decrease
of the isotropic signals, attributable to an interaction with the
proteins such as to broaden the resonances, is observed.
In conclusion it can be argued that, under the experimental
conditions used in this study, the blood plasma proteins do not
interact with VDC. At the moment the reasons of this behavior
are not known, but it can be hypothesized that several factors
contribute to disfavor the formation of the possible ternary
species formed upon interaction of the moiety [Cp2V]
2+ with
the proteins: (i) as mentioned above, the aﬃnity of [Cp2V]
2+
toward the nitrogen donors is rather poor, and this would
preclude the bonding with His-N, which instead appears to be
very important for the insulin-mimetic V(IV)O2+ complex-
es;16b−i (ii) the protein surface is rich of polar residues such as
aspartate, glutamate, tyrosine, and threonine, and this could
hinder their interaction with the [Cp2V]
2+ moiety, in which the
two cyclopentadienyl rings are strongly apolar; (iii) as noticed
for citrate, the presence of the two bulky cyclopentadienyls may
hinder the interaction with the side chains of the amino acids of
apo-hTf and HSA.
4. Speciation of VDC in Blood Plasma Model
Solutions. After the examination of the binary systems formed
by VDC and the main blood plasma components (bL and
proteins), in this section the behavior of several model systems
of the blood plasma will be discussed. In particular, the
multicomponent system formed by VDC and the bioligands
with higher aﬃnity for [Cp2V]
2+ (i.e., oxalate, carbonate,
lactate, and hydrogen phosphate, see above) was studied. For
all systems, room-temperature and frozen solution EPR spectra
and electronic absorption spectra were recorded at pH 7.4.
Initially, the molar ratio between VDC and the bioligands bL
was set at 1/10, whereas subsequently it was brought to the
physiological value using the relative concentration of oxalate,
carbonate, lactate, and hydrogen phosphate in the plasma as
reported by Harris ([ox] = 9.2 μM, [HCO3
−] = 24.9 mM,
[lact] = 1.51 mM, [HPO4
2−] = 1.10 mM);19 in particular, the
ratios [HPO4
2−]/[ox], [lact]/[ox], and [HCO3
−]/[ox] were
119.6, 164.1, and 2706.5, respectively.
The room-temperature EPR spectrum recorded at pH 7.4 in
the system VDC/ox/NaHCO3/lact with molar ratio 1/10/10/
10 is shown in Figure 3b. It can be noticed that in the
quaternary system the main species is [Cp2V(ox)] and
Inorganic Chemistry Article
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[Cp2V(CO3)] is a minor species. Even if [Cp2V(ox)] and
[Cp2V(lactH−1)] are characterized by similar EPR parameters,
the signals can be attributed without ambiguity to [Cp2V(ox)]
for the small experimental line width (ΔH1 = 6.2 × 10−1 mT
and ΔH8 = 9.0 × 10−1 mT, to be compared with ΔH1 = 6.5 ×
10−1 mT and ΔH8 = 9.3 × 10−1 mT for [Cp2V(ox)] and ΔH1 =
8.1 × 10−1 mT and ΔH8 = 12.0 × 10−1 mT for
[Cp2V(lactH−1)], see above). This result suggests that the
aﬃnity of [Cp2V]
2+ for oxalate is much higher than that for
carbonate and lactate.
In Figure S11 of the Supporting Information (trace b) the
room-temperature EPR spectrum of the system VDC/
NaHCO3/lact/Na2HPO4 with ratio 1/10/10/10 and VDC
concentration 1.0 × 10−3 M is reported. In this system the two
species [Cp2V(CO3)] (spectrum shown in trace a) and
[Cp2V(lactH−1)] (spectrum in trace c) are formed in
comparable amounts, with the concentration of the mixed
complex with carbonate slightly larger than that with lactate.
The possible formation of [Cp2V(HPO4)] can be excluded
because this species would be countersigned by the character-
istic coupling between the unpaired electron and the 31P
nucleus (Figure S5, trace c).
The behavior of the ternary system VDC/lact/Na2HPO4
with molar ratio 1/10/10 is represented in Figure S12 of the
Supporting Information (trace b). In such a system [Cp2V-
(lactH−1)] is the main species, and [Cp2V(HPO4)] (which can
be distinguished very well for the 16-line spectrum) is the
minor species. This indicates that the aﬃnity of lactate for
[Cp2V]
2+ ion is slightly higher than that of phosphate.
On the basis of these results, it can be aﬃrmed that the
aﬃnity order of the four blood plasma bL ligands for the moiety
[Cp2V]
2+ is ox2− ≫ CO32− > lactH−12− > HPO42−.
The systems discussed above (see Figure 3 and Figures S11
and S12 of Supporting Information), even if they allow us to
demonstrate the relative strength of the bL bioligands for
[Cp2V]
2+, are not good models of the blood plasma because the
relative concentrations of bL must be considered; for example,
the higher aﬃnity of oxalate may be compensated by the larger
concentration of the other three components. To throw light
on this point, the quinary system VDC/ox/NaHCO3/lact/
Na2HPO4 has been studied at pH 7.4 with the bioligands at the
same concentration ratio as in the blood plasma. Concerning
the concentration of VDC in the blood necessary to display a
pharmacological eﬀect, no decisive datum was published in the
literature, but it seems to be reasonable assume that,
analogously to what was reported for the insulin-mimetic
vanadium compounds, the value must be in the range 10−100
μM.1b,60 Therefore, the system VDC/ox/NaHCO3/lact/
Na2HPO4 was examined at molar ratio 1/1/2706.5/164.1/
119.6 and 1/0.1/270.7/16.4/12.0 with a concentration of VDC
of 4 × 10−4 M. The ﬁrst model system “simulates” the situation
in which the concentration in the plasma of the containing-V
drug is close to that of oxalate (9.2 μM19), whereas in the
second system the concentration is 10 times that of oxalate
(92.0 μM). With this approach, the concentration range 9.2−
92.0 μM of the pharmacologically active VDC can be explored.
The room-temperature spectrum recorded on the system
VDC/ox/NaHCO3/lact/Na2HPO4 with molar ratio 1/1/
2706.5/164.1/119.6 is shown in Figure 4b. It can be observed
that the main species is [Cp2V(ox)] (Figure 4a), whereas
[Cp2V(CO3)] (Figure 4c) is formed only in a very small
amount. Therefore, when the ratio VDC/ox is 1/1, almost all
[Cp2V]
2+ ion is bound by oxalate and the participation of the
other bL is negligible. Analogous results are expected when the
ratio VDC/ox is <1, i.e., when the concentration of VDC at
physiological conditions is lower than 9.2 μM.
The behavior of the quinary system VDC/ox/NaHCO3/
lact/Na2HPO4 with ratio 1/0.1/270.7/16.4/12.0 is reported in
Figure S13 of the Supporting Information, trace b. In such a
system the main species is [Cp2V(CO3)] (Figure S13, trace a),
whereas two minor species are observable, [Cp2V(ox)] and
probably [Cp2V(lactH−1)] (Figure S13, traces c and d).
[Cp2V(HPO4)], instead, is not formed. This behavior can be
rationalized in the following way: when VDC is present in
solution in excess with respect to oxalate (i.e., when it is present
in the blood plasma with a concentration higher than 9.2 μM),
Figure 3. Room-temperature (298 K) EPR spectra recorded at pH 7.4
in aqueous solution in the systems containing (a) VDC/ox 1/10, (b)
VDC/ox/NaHCO3/lact 1/10/10/10, and (c) VDC/NaHCO3 1/10.
VDC concentration was 1.0 × 10−3 M. With the dotted lines the
resonances MI = −7/2, 7/2 of the complexes [Cp2V(ox)] (trace a)
and [Cp2V(CO3)] (trace c) are shown.
Figure 4. Room-temperature (298 K) EPR spectra recorded at pH 7.4
in aqueous solution in the systems containing (a) VDC/ox 1/10, (b)
VDC/ox/NaHCO3/lact/Na2HPO4 1/1/2706.5/164.1/119.6, and (c)
VDC NaHCO3 1/10. The concentration of VDC was 4.0 × 10
−4 M
(b) or 1.0 × 10−3 M (a and c). With the dotted lines the resonances
MI = −7/2, 7/2 of the complexes [Cp2V(ox)] (trace a) and
[Cp2V(CO3)] (c) are shown.
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7
the latter binds the maximum possible amount of [Cp2V]
2+,
whereas the remaining part of VDC distributes between the
carbonate ion (mainly) and lactate (in much smaller
concentration). The exact amount of the mixed complex with
lactate cannot be determined because the resonances of
[Cp2V(ox)] and [Cp2V(lactH−1)] fall in the same region of
the EPR spectrum.
The electronic absorption spectra recorded in the two
quinary systems VDC/ox/NaHCO3/lact/Na2HPO4 with ratio
1/1/2706.5/164.1/119.6 and 1/0.1/270.7/16.4/12.0 (Figure
5) allowed us to conﬁrm this ﬁnding. It can be noticed that in
the ﬁrst case (VDC and oxalate at the equimolar ratio) the
electronic absorption spectrum is comparable to that of
[Cp2V(ox)] (in blue in Figure 5), whereas when an excess of
VDC is present (for example, when it is 10 times more
concentrated than oxalate) the spectrum closely resembles that
of [Cp2V(CO3)] (in black in Figure 5) with an absorption band
at 575 nm.
The behavior at low temperature of the two systems VDC/
ox/NaHCO3/lact/Na2HPO4 at molar ratio 1/1/2706.5/164.1/
119.6 and 1/0.1/270.7/16.4/12.0 is the same as described at
room temperature. Frozen solutions EPR spectra are reported
in Figures 6 and 7 and, as usual, are better resolved than the
room-temperature ones. It can be observed that when the ratio
VDC/ox is 1/1, the main species is [Cp2V(ox)], whereas
[Cp2V(CO3)] is the minor species; the spectrum recorded in
the system with ratio 1/1/2706.5/164.1/119.6 can be
reproduced postulating 70% of [Cp2V(ox)] and 30% of
[Cp2V(CO3)] in aqueous solution (Figure 6c). When the
ratio VDC/ox is 10/1, instead, the main species is [Cp2V-
(CO3)], whereas [Cp2V(ox)] and [Cp2V(lactH−1)] are the
minor species; in this case the spectrum was simulated
considering in aqueous solution 80% of [Cp2V(CO3)], 10%
of [Cp2V(ox)], and 10% of [Cp2V(lactH−1)] (Figure S14 of the
Supporting Information).
5. Speciation of VDC in the Blood Plasma. After the
investigation of the behavior of VDC in the blood model
solutions, the speciation in the plasma was evaluated. To carry
out these experiments, a blood sample was centrifuged to
separate plasma from buﬀy coat and red blood cells (see
Experimental and Computational Section). The plasma was
subsequently incubated for 30 min at 37 °C with a solution of
VDC with a concentration of 4.5 × 10−5 M, and the EPR
spectrum at 120 K was immediately measured. As pointed out
in the literature,37b the analysis of a frozen solution EPR
spectrum is preferred to that of room-temperature one because
it allows one to get more detailed information on (i) the type of
V(IV) species (nonoxido or oxido), (ii) the coordination mode,
geometry, and distortion of V(IV) species, since the values of Ai
Figure 5. Electronic absorption spectra recorded in aqueous solution
at pH 7.4 in the systems containing VDC/ox/NaHCO3/lact/
Na2HPO4 1/1/2706.5/164.1/119.6 (green), VDC/ox 1/10 (blue),
VDC/ox/NaHCO3/lact/Na2HPO4 1/0.1/270.7/16.4/12.0 (red), and
VDC/NaHCO3 1/10 (black). VDC concentration was 4.0 × 10
−4
(green and red) and 1.0 × 10−3 M (blue and black). Spectra of
[Cp2V(CO3)] and [Cp2V(ox)] are indicated by the two arrows.
Figure 6. EPR spectra recorded at 120 K and pH 7.4 in aqueous
solution in the systems containing (a) VDC/ox 1/10, (b) VDC/ox/
NaHCO3/lact/Na2HPO4 1/1/2706.5/164.1/119.6, (c) spectrum
obtained in aqueous solution 70% of [Cp2V(ox)] (trace a) and 30%
of [Cp2V(CO3)] (trace d) and (d) VDC/NaHCO3 1/10. The
concentration of VDC was 4.0 × 10−4 (b) and 1.0 × 10−3 M (a and c).
With the dotted lines the resonances MI = −7/2, 7/2 of the complexes
[Cp2V(ox)] (a) and [Cp2V(CO3)] (d) are shown.
Figure 7. EPR spectra recorded at 120 K in aqueous solution at pH 7.4
in the systems containing (a) VDC/NaHCO3 1/10, (b) VDC/ox/
NaHCO3/lact/Na2HPO4 1/0.1/270.7/16.4/12.0, (c) VDC/ox 1/10,
and (d) VDC/lact 1/10. The concentration of VDC was 4.0 × 10−4 M
(b) and 1.0 × 10−3 M (a, c, and d). With the dotted lines the
resonances MI = −7/2, 7/2 of the complexes [Cp2V(CO3)] (a),
[Cp2V(ox)] (c), and [Cp2V(lactH−1)] (d) are shown.
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(i = x, y, z) are more sensitive to the identity of the donors than
Aiso, and (iii) the presence of minor species in solution, which
usually are not detectable from the examination of a room-
temperature spectrum. The EPR spectrum recorded in the
blood plasma is shown in Figure 8a, together with the spectra of
the system VDC/ox/NaHCO3/lact/Na2HPO4 at ratio 1/0.1/
270.7/16.4/12.0 (Figure 8b). The results are very surprising:
the behavior revealed in the blood plasma is perfectly
superimposable to that observed in the model system,
demonstrating that the study of a good model can give
valuable information on the behavior of a more complicated
system such as a biological one. From an examination of Figure
8, it can be observed that V(IV) distributes between oxalate and
carbonate ion: in particular, the strongest ligand, oxalate (9.2
μM), binds 9.2 μM of VDC to form [Cp2V(ox)], whereas the
remaining part of [Cp2V]
2+ (35.8 μM) is complexed by
carbonate as [Cp2V(CO3)]. The predicted ratio between the
amounts of [Cp2V(CO3)] and [Cp2V(ox)] should be ca. 4:1, in
very good agreement with what was observed in the spectrum
reported in Figure 8a.
Some years ago, Vinklaŕek and co-workers dissolved VDC in
the blood plasma and recorded room-temperature EPR spectra;
they found two sets of isotropic signals attributed to
[Cp2V(CO3)] and an unspeciﬁed species with an amino acid,
[Cp2V(a.a.)].
45 The results of this study indicate that their
results are partially correct: whereas [Cp2V(CO3)] iswithout
any doubtformed, the other species was confused with
[Cp2V(a.a.)] (not formed) because its spectrum is charac-
terized by an Aiso value similar to that of [Cp2V(ox)].
On the basis of the results discussed in this study, the
speciation of [Cp2VCl2] in the blood plasma can be illustrated
in Scheme 4. After the oral administration VDC passes in
solution at the acid pH of the stomach (where the two Cl− ions
are probably replaced by two H2O ligands). When [Cp2V-
(H2O)2]
2+ arrives in the small intestine and then in the
bloodstream at pH 7.4, [Cp2V(OH)2] is formed and can react
with the bioligands of the plasma (in particular, oxalate,
carbonate, and lactate, see above). The concentration of VDC
in the plasma does not correspond to the administered dose; in
fact, usually only 1−10% of orally ingested V compound is
absorbed in the gastrointestinal tract, the real percent amount
being inﬂuenced by several factors such as the chemical form
(inorganic salt or complex), the charge, and the polarity of the
species.61 A total concentration in the range 10−100 μM is
plausible for an orally administered active V compound,1b,60 the
exact value depending mainly on the gastrointestinal tract
absorption. If V concentration is around 10 μM, most of VDC
administered is transported to the target organs in the organism
as [Cp2V(ox)], i.e., the moiety [Cp2V]
2+ is bound by the
strongest bL bioligand, oxalate. If V concentration is 10 times
higher, 100 μM, only 9.2 μM of [Cp2V]
2+ is complexed by
oxalate, whereas the remaining part distributes between
carbonate which forms the main species [Cp2V(CO3)] and
lactate which forms the minor species [Cp2V(lactH−1)]. When
V concentration is in the intermediate concentration range,
10−100 μM, [Cp2V]2+ distributes between oxalate and
carbonate, with the role of the latter being more important
with increasing concentration with respect to the lowest limit of
10 μM.
■ CONCLUSIONS
It is now demonstrated that many vanadium compounds have
antitumor activity. [Cp2VCl2] or VDC has been the ﬁrst V
species with anticancer activity and has been proposed in 1983
in the treatment of Ehrlich ascites tumor. All VDC derivatives
studied subsequently induce apoptosis in human cancer cells,
but their mode of action remains elusive. The mechanism of
VDC is closely related to the biotransformation in the blood
plasma because the latter determines which species arrives to
the target cells in the organism.
Therefore, in this study the speciation of VDC in the plasma
under physiological conditions was studied. The results indicate
that in an aqueous solution the two Cp−V bonds are very
resistant to the hydrolysis, whereas both Cl− ions dissociate to
form at acid pH of the stomach [Cp2V(H2O)2]
2+, which at
physiological pH deprotonates quantitatively to [Cp2V(OH)2].
In contrast with what was found for other pharmacologically
active V compounds, such as antidiabetic V(IV)O2+ species,
[Cp2V(OH)2] does not interact with the plasma proteins
(transferrin and albumin) and undergoes displacement
reactions with the low molecular mass bioligands. The
bioligands with highest aﬃnity for [Cp2V]
2+ moiety are oxalate,
carbonate, lactate, and hydrogen phosphate, whereas other
candidates to V binding such as citrate and amino acids do not
show any aﬃnity for it. On the basis of EPR, UV−vis, ESI-MS,
MS-MS, and DFT results, it has been found that the aﬃnity
Figure 8. EPR spectra recorded at 120 K at pH 7.4 in the systems
containing (a) blood plasma incubated with VDC for 30 min and (b)
VDC/ox/NaHCO3/lact/Na2HPO4 1/0.1/270.7/16.4/12.0. The con-
centration of VDC was 4.5 × 10−5 M (a) and 4.0 × 10−4 M (b). With
the dotted lines the resonances MI = −7/2, 7/2 of the complexes
[Cp2V(ox)] (I) and [Cp2V(CO3)] (II) are indicated.
Scheme 4. Speciation of VDC in the Blood Plasma as a
Function of Its Concentrationa
aWith high, intermediate, and low the relative amount of each species
is shown.
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order of the four strongest bioligands is ox2− ≫ CO32− >
lactH−1
2− > HPO4
2−. The speciation of VDC at the
physiological conditions has been examined studying several
model systems containing the bioligands with the same relative
amount as in the blood and, subsequently, carrying out
experiments with plasma samples. The results obtained show
that the model systems behave in the same way as the blood
plasma, demonstrating that the choice of a good model is
essential to get information on more complicated systems, such
as the biological ones.
The speciation of VDC in the blood plasma can be
summarized as follows: if V concentration is low (10 μM),
most of VDC administered is transported in the organism as
[Cp2V(ox)], i.e., the strongest bioligand, oxalate, binds the
[Cp2V]
2+ moiety. In contrast, if V concentration is high (100
μM) oxalate binds only 9.2 μM of [Cp2V]
2+ (9.2 μM is the
oxalate concentration in the plasma), whereas the remaining
90.8 μM of [Cp2V]
2+ distributes between carbonate to form
[Cp2V(CO3)] (main species) and lactate to yield [Cp2V-
(lactH−1)] (minor species). Finally, if V concentration is in the
range 10−100 μM, [Cp2V]2+ distributes between [Cp2V(ox)]
and [Cp2V(CO3)], with the role of carbonate being more and
more important with increasing V concentration with respect to
10 μM.
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I.; Šiman, P.; Řezaćǒva,́ M. Inorg. Chim. Acta 2011, 373, 1−7.
(14) Yoshikawa, Y.; Sakurai, H.; Crans, D. C.; Micera, G.; Garribba,
E. Dalton Trans. 2014, 43, 6965−6972.
(15) (a) Sanna, D.; Serra, M.; Micera, G.; Garribba, E. Inorg. Chem.
2014, 53, 1449−1464. (b) Sanna, D.; Serra, M.; Micera, G.; Garribba,
E. Inorg. Chim. Acta 2014, 420, 75−84. (c) Sanna, D.; Fabbri, D.;
Serra, M.; Buglyo,́ P.; Bíro,́ L.; Ugone, V.; Micera, G.; Garribba, E. J.
Inorg. Biochem. 2015, 147, 71−84. (d) Levina, A.; McLeod, A. I.; Pulte,
A.; Aitken, J. B.; Lay, P. A. Inorg. Chem. 2015, 54, 6707−6718.
(e) Levina, A.; McLeod, A. I.; Gasparini, S. J.; Nguyen, A.; De Silva, W.
G. M.; Aitken, J. B.; Harris, H. H.; Glover, C.; Johannessen, B.; Lay, P.
A. Inorg. Chem. 2015, 54, 7753−7766.
(16) (a) Sanna, D.; Micera, G.; Garribba, E. Inorg. Chem. 2009, 48,
5747−5757. (b) Sanna, D.; Micera, G.; Garribba, E. Inorg. Chem. 2010,
49, 174−187. (c) Sanna, D.; Buglyo,́ P.; Micera, G.; Garribba, E. JBIC,
J. Biol. Inorg. Chem. 2010, 15, 825−839. (d) Sanna, D.; Micera, G.;
Garribba, E. Inorg. Chem. 2011, 50, 3717−3728. (e) Sanna, D.; Biro,
L.; Buglyo, P.; Micera, G.; Garribba, E. Metallomics 2012, 4, 33−36.
(f) Sanna, D.; Ugone, V.; Micera, G.; Garribba, E. Dalton Trans. 2012,
41, 7304−7318. (g) Sanna, D.; Bíro,́ L.; Buglyo,́ P.; Micera, G.;
Garribba, E. J. Inorg. Biochem. 2012, 115, 87−99. (h) Sanna, D.;
Micera, G.; Garribba, E. Inorg. Chem. 2013, 52, 11975−11985.
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2 
Table S1. Experimental (exptl.) and calculated (calcd.) structural parameters for VDC and its 
hydrolysis products in aqueous solution.
a
 
 Exptl.
b
 Calcd.
c
  Exptl.
d
 Calcd.
c
  Calcd.
c
 
Distance or angle
e
 [Cp2VCl2]  [Cp2V(H2O)2]
2+
  [Cp2V(OH)2] 
VCl or VO 2.408 2.410  2.056 2.109  1.874 
VCl or VO 2.411 2.410  2.070 2.109  1.874 
VCg 1.968 1.980  1.963 1.978  2.071 
VCg 1.977 1.983  1.964 1.978  2.071 
ClVCl or OVO 87.2 88.9  83.9 79.9  84.9 
ClVCg or OVCg 107.2f 105.9f  107.1 107.8  108.0 
CgVCg 131.9 134.8  133.3 133.0  130.4 
a
 Distances in Å and angles in degrees (°). 
b
 Experimental structure reported in ref. 1. 
c
 Structure 
calculated at the level of theory B3P86/6-311g. 
d
 Experimental structure reported in ref. 2. 
e
 Cg 
indicates the centroid of the cyclopentadienyl ring. 
f
 Mean values. 
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Table S2. Structural parameters calculated by DFT methods for the mixed complexes formed by 
VDC.
a
 
 Exptl.
b
 Calcd.
c
   Calcd.
c
  
Distance or angle
d
 [Cp2V(ox)]  [Cp2V(lactH1)] [Cp2V(CO3)] [Cp2V(HPO4)]
 
VO 2.021 1.950  1.878 1.973 1.986 
VO 2.038 1.950  1.953 1.974 1.988 
VCg 1.959 1.998  2.021 1.986 1.989 
VCg 1.961 1.998  2.038 1.989 1.993 
OVO 78.6 79.4  80.5 67.2 72.7 
OVCg e 107.8 107.2  107.6 108.2 107.9 
CgVCg 133.5 134.8  133.3 136.0 135.2 
a
 Distances in Å and angles in degrees (°). 
b
 Experimental structure reported in ref. 3. 
c
 Structures 
calculated with Gaussian at the level of theory B3P86/6-311g. 
d
 Cg indicates the centroid of 
cyclopentadienyl ring. 
e
 Mean values. 
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Figure S1. Structure of the complexes [Cp2VCl2] (a), [Cp2V(H2O)2]
2+
 (b) and [Cp2V(OH)2] (c) 
optimized by DFT methods at the level of theory B3P86/6-311g. 
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Figure S2. Room temperature (298 K) EPR spectra recorded as a function of pH dissolving VDC 
(1.0103 M) in water. With I and II [Cp2V(H2O)2]
2+
 and [Cp2V(OH)2] are indicated. The asterisks 
denote the resonances of the species [Cp2V(H2O)(OH)]
+
, present in a small amount around pH 5. 
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Figure S3. Room temperature (298 K) EPR spectra obtained dissolving VDC (1.0103 M) in 
water: (a) spectrum of [Cp2V(H2O)2]
2+
 (pH 2.10) and (b) spectrum of [Cp2V(OH)2] (pH 7.40).  
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Figure S4. Calculated (red line) and experimental (blue line) isotopic pattern for (A) [Cp2VCl]
+
 
(m/z 216); (B) [Cp2V(OH)]
+
 (m/z 198); (C) [Cp2V(lactH1)+H]
+
 (m/z 270); (D) [Cp2V(ox)+H]
+
 (m/z 
270) and (E) [Cp2V
V
(PO4)+Na]
+
 (m/z 299).  
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Figure S5. Room temperature (298 K) EPR spectra recorded in aqueous solution at pH 7.4 in the 
systems containing: (a) VDC/lactate 1/10 (spectrum of [Cp2V(lactH–1)]); VDC/oxalate system 1/10 
(spectrum of [Cp2V(ox)]); (c) VDC/HPO4
2
 1/10 (spectrum of [Cp2V(HPO4)]) and (d) VDC/HCO3

 
1/10 (spectrum of [Cp2V(CO3)]). VDC concentration was 1.010
3
 M. With I the species 
[VO(lactH–1)2]
2–
 is indicated.  
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Figure S6. Room temperature (298 K) EPR spectra recorded in aqueous solution at pH 7.4 in the 
systems containing: (a) VDC; (b) VDC/glycine 1/10 and (c) VDC/citrate 1/10. VDC concentration 
was 1.0103 M. The MI = -7/2, 7/2 resonances of [Cp2V(OH)2] are shown with a dotted line. With 
I and II the species [VO(H2O)5]
2+
 and [VO(citrH1)]
2
 are indicated.  
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Figure S7. Electronic absorption spectra recorded in aqueous solution at pH 7.4 in the systems 
containing: (trace black) VDC (spectrum of [Cp2V(OH)2]); (trace red) VDC/oxalate 1/10 (spectrum 
of [Cp2V(ox)]; (trace blue) 1/10 VDC/HCO3

 (spectrum of [Cp2V(CO3)]); (trace green) 
VDC/lactate 1/10 (spectrum of [Cp2V(lactH–1)]) and (trace purple) VDC/HPO4
2
 1/10 (spectrum of 
[Cp2V(HPO4)]). VDC concentration was 1.010
3
 M. 
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Figure S8. EPR spectra recorded at 120 K and pH 7.4 in aqueous solution in the systems 
containing: (a) VDC/oxalate 1/10 (spectrum of [Cp2V(ox)]); (b) VDC/lactate 1/10 (spectrum of 
[Cp2V(lactH–1)]) and (c) VDC/HCO3

 1/10 (spectrum of [Cp2V(CO3)]). VDC concentration was 
1.0103 M. With I the species [VO(lactH–1)2]
2–
 is indicated.  
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Figure S9. Experimental EPR spectrum recorded at 120 K and pH 7.4 in aqueous solution in the 
system VDC/HCO3
–
 with VDC concentration of 1.0103 and ratio 1/10 (b) and comparison with 
those calculated by ORCA software for [Cp2V(OH)2] (a) and [Cp2V(CO3)] (c). For [Cp2V(OH)2] 
were used gx = 1.968, gy = 1.975, gz = 1.981, Ax = -117.1×10
4
 cm
1
, Ay = -50.9×10
4
 cm
1
, Az = -
12.1×10
4
 cm
1
 and for [Cp2V(CO3)] gx = 1.976, gy = 1.979, gz = 1.997, Ax = -95.5×10
4
 cm
1
, Ay = 
-79.9×10
4
 cm
1
, Az = -3.3×10
4
 cm
1
.  
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Figure S10. Room temperature (298 K) EPR spectra recorded in aqueous solution at pH 7.4 in the 
systems containing: (a) VDC; (b) VDC/apo-hTf 2/1 and (c) VDC/HSA 4/1 (c). VDC concentration 
was 1.0103 (traces a and c) and 5.0104 (trace b). The MI = -7/2, 7/2 resonances of [Cp2V(OH)2] 
are shown with a dotted line.  
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Figure S11. Room temperature (298 K) EPR spectra recorded in aqueous solution at pH 7.4 in the 
systems containing: (a) VDC/NaHCO3 1/10; (b) VDC/NaHCO3/lact/Na2HPO4 1/10/10/10 and (c) 
VDC/lact 1/10. VDC concentration was 1.0103 M. With the dotted lines the resonances MI = -7/2, 
7/2 of the complexes [Cp2V(CO3)] (trace a) and [Cp2V(lactH1)] (trace c) are shown.  
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Figure S12. Room temperature (298 K) EPR spectra recorded in aqueous solution at pH 7.4 in the 
systems containing: (a) VDC/lact 1/10; (b) VDC/lact/Na2HPO4 1/10/10 and (c) VDC/Na2HPO4 1/10 
(c). VDC concentration was 1.0103 M. With the dotted lines the resonances MI = -7/2, 7/2 of the 
complexes [Cp2V(lactH1)] (trace a) and [Cp2V(HPO4)] (trace c) are shown. 
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Figure S13. Room temperature (298 K) EPR spectra recorded in aqueous solution at pH 7.4 in the 
systems containing: (a) VDC/NaHCO3 1/10; (b) VDC/ox/NaHCO3/lact/Na2HPO4 
1/0.1/270.7/16.4/12.0; (c) VDC/ox 1/10 and (d) VDC/lact 1/10. The concentration of VDC was 
4.0104 M. With the dotted lines the resonances MI = -7/2, 7/2 of the complexes [Cp2V(CO3)] 
(trace a) and [Cp2V(ox)] (trace c) and [Cp2V(lactH1)] (trace d) are shown. 
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Figure S14. (a) EPR spectrum recorded at 120 K and at pH 7.4 in aqueous solution in the systems 
containing VDC/ox/NaHCO3/lact/Na2HPO4 1/0.1/270.7/16.4/12.0 and (b) spectrum obtained 
considering in aqueous solution 80% of [Cp2V(CO3)] (trace a of Figure 7 of the main text), 10% of 
[Cp2V(ox)] (trace c of Figure 7 of the main text) and 10% of [Cp2V(lactH1)] (trace d of Figure 7 of 
the main text). The concentration of VDC was 4.0104 M. With the dotted lines the resonances MI 
= -7/2, 7/2 of the complexes [Cp2V(ox)] (external lines) and [Cp2V(CO3)] and [Cp2V(lactH1)] 
(internal lines) are shown.  
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Synthesis, protonation constants, spectral characterization, 
biological activity and theoretical studies of salicylaldehyde-
derived Schiff bases 
 
 
This chapter reports the synthesis, characterization, solution equilibria, antitumour 
activity, and DNA affinity of a group of Schiff bases ligands derived from salicyladehyde 
and six natural amino acids. 
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Abstract 
Schiff bases represent a class of biological active molecules widely studied in organic synthesis, 
coordination  and pharmaceutical chemistry. They are also used in the preparation of β-lactam 
family of antibiotics. Besides β-lactams, other Schiff bases show biological activity against fungi, 
bacteria and viruses. The potential development of pharmaceutical applications of these 
compounds, requires a proper knowledge of the chemical and biological reactions in which they are 
involved, and of their toxicological profiles. Despite the great amount of studies reported in 
literature on chemical and biological properties of the Schiff bases, the different experimental 
conditions often chosen, prevent a comparison to investigate the structure-activity correlation. This 
problem is relevant in particular for the solution equilibria study, since protonation constants of 
Schiff bases belonging to the same family are often determined in different solvents, temperatures, 
and ionic buffers. For these reasons, I decided to study a group of Schiff bases ligands derived from 
salicyladehyde and six natural amino acids, keeping constant the experimental conditions, in order 
to obtain comparable information and find useful insights about the relationship existing between 
their structure and their biological activity (Chapter 9 – Manuscript III).  
The use of ATR-IR spectroscopy, together with NMR, UV-vis and potentiometric 
measurements, was investigated on the Schiff bases with the aim to collect useful information on 
the species actually formed. Theoretical studies were also performed. In particular, I studied the 
solution equilibria, the antiproliferative activity and the DNA-binding ability of L-
Salicylidenealanine (1), L-Salicylidenevaline (2), L-Salicylidenecysteine (3), L-Salicylideneserine 
(4), L-Salicylidenearginine (5), and L-Salicylidenehistidine (6). The formulas, names and 
abbreviations of the studied molecules are reported in Figure 26.  
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Figure 26. Formulas, names and abbreviations of the studied Schiff bases. 
 
The chosen compounds have been synthesised
1
 through optimization of previously reported 
methods, and they have been characterized by elemental analysis, Nuclear Magnetic Resonance 
(NMR) and Infrared (IR) Spectroscopy techniques.  
The protonation constants of the studied compounds have been determined by potentiometric 
and spectrophotometric titrations carried out simultaneously in aqueous solution at 25 °C in 0.1 M 
ionic strength (NaCl). ATR-IR spectra at variable pH of the six Schiff bases were interpreted with 
the aid of simulated spectra obtained by quantum mechanical calculations.  
The interaction of the six Schiff bases with calf thymus DNA (ct-DNA) and the cytotoxic 
activity against a panel of human tumour cell lines SK-MES-1 (squamous cell lung carcinoma), 
                                                 
1
 In collaboration with professor C. Fattuoni (Dipartimento di Scienze Chimiche e Geologiche, University of Cagliari). 
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DU-145 (prostate carcinoma), Hep-G2 (hepatocellular carcinoma), CCRF-CEM (acute T-
lymphoblastic leukemia), CCRF-SB (acute B-lymphoblastic leukemia) have been also studied. 
The studied ligands do not show cytotoxic activity, however they are able to interact with DNA, 
showing DNA binding constant in the 48–447 M-1 range. The absence of cytotoxicity and the poor 
reactivity with DNA, confirm the feasibility of these compounds for pharmaceutical applications, 
also in complexes with metal ions to exploit their unique properties. In fact, although the ligands are 
devoid of significant activity, it is not untypical that the derived complexes show antitumor activity. 
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ABSTRACT 
Schiff bases represent a class of biological active molecules widely studied for their importance in 
organic and coordination chemistry. They are also used in the preparation of β-lactam family of 
antibiotics. Despite the great amount of studies on the chemical and biological properties of Schiff 
bases, the different experimental conditions prevent a useful comparison to investigate the 
structure-activity correlation. For this reason, we decided to study a group of Schiff bases derived 
from salicyladehyde and six natural amino acids, keeping constant the experimental conditions, in 
order to obtain comparable information and find useful insights about the relationship existing 
between their structure and activity. Interestingly, accurate NMR characterization for these 
compounds has not been yet reported. In particular, solution equilibria, antiproliferative activity and 
DNA-binding activity were studied. These compounds show DNA-binding constants in the 48-447 
M
-1
 range, depending on the different amino acid side-chain, and exert no significant cytotoxic 
activity against the human tumour cell lines SK-MES-1, DU-145, Hep-G2, CCRF-CEM, CCRF-
SB. Finally, the studied Schiff bases were synthesized through optimized methods, and all products 
were fully characterized by NMR spectroscopy. 
 
KEYWORDS 
Schiff bases; DNA binding; cytotoxicity; spectrophotometric titration  
 
1. INTRODUCTION 
 
Schiff bases, also known as imines or azomethines and named after their discoverer Hugo Schiff, 
are condensation products of primary amine and aldehydes or ketones. Schiff bases are represented 
by the general formula R1N=CR2R3, where R1, R2 and R3 may be alkyl, aryl or hydrogen [1]. Schiff 
bases are important intermediates in bio-processes such as the transamination reaction or the protein 
glycation, and are involved in racemization and decarboxylation reactions [2–4]. This class of 
compounds is important in organic synthesis and pharmaceutical chemistry. In organic synthesis, 
Schiff bases are used in nucleophilic addition, hetero Diels-Alder [5] and Staudinger [6] reactions. 
The latter process is widely used for the preparation of the β-lactams by reaction of a Schiff base 
with a ketene. The β-lactams constitute an important class of antibiotics such as penams, cephems, 
penems, monobactams, carbapenems, and trinems. The interest of pharmaceutical companies in the 
study of new derivatives of this family is kept alive by the onset of antibiotic resistance in some 
microorganisms such as Staphylococcus aureus, Streptococcus, Pseudomonas aeruginosa, and 
others. Besides β-lactams, other Schiff bases show biological activity against fungi, bacteria and 
  
viruses [7–10]. In addition, some derivatives have been recently proposed for the treatment of 
Alzheimer's disease, as metal binding agents able to promote the disaggregation of β-amyloid 
plaques [11]. Thanks to their soft-hard donor character, Schiff bases are commonly used as ligands 
for several metal ions. They are used to recognize anions and cations and their application in 
biochemical and environmental fields has been proposed [12]. Moreover, complexes formed by 
Schiff bases with metals such as Cu(II) [13], Cd(II) [14], Ru(II) [15], Zn(II) [16], and lanthanides 
[17], show antitumor activity. The potential development of pharmaceutical applications of these 
compounds, requires a proper knowledge of the chemical and biological reactions in which they are 
involved, and their toxicological profile. Despite the high level of interest among the scientific 
community for these molecules, scientific literature highlights an overall lack of consistency. In 
fact, although Schiff bases are widely studied from different points of view, a direct comparison of 
the reported data is not possible because different experimental conditions have been used. This 
problem is relevant in particular for the solution equilibria study, since protonation constants of 
Schiff bases belonging to the same family are often determined in different solvents, temperatures, 
and ionic buffers [3,18–20]. Being the knowledge of the protonation constants fundamental for the 
study of the complex formation constants, it is suitable that the experiments are carried out in the 
same conditions at least for homologous series of compounds. For these reasons, we decided to 
study a group of Schiff bases derived from salicyladehyde and six natural amino acids, in the same 
experimental conditions in order to have comparable information on their chemical and biological 
behaviour. In particular, we studied the solution equilibria, the cytotoxic activity and the DNA 
binding ability of L-Salicylidenealanine (1), L-Salicylidenevaline (2), L-Salicylidenecysteine (3), L-
Salicylideneserine (4), L-Salicylidenearginine (5), and L-Salicylidenehistidine (6). Formulas, names 
and abbreviations of the studied molecules are reported in Figure 1. The chosen compounds have 
been synthesised through optimization of previously reported methods, and they have been 
characterized by elemental analysis, Nuclear Magnetic Resonance (NMR) and Infrared (IR) 
Spectroscopy techniques. The protonation constants of the compounds have been determined by 
potentiometric and spectrophotometric titrations, carried out simultaneously in aqueous solution at 
25 °C in 0.1 M ionic strength (NaCl). The interaction of the six Schiff bases with calf thymus DNA 
(ct-DNA) and the cytotoxic activity against a panel of human tumour cell lines (SK-MES-1, DU-
145, Hep-G2, CCRF-CEM, CCRF-SB) have been also studied. 
 
  
 
Figure 1. Formulas, names and abbreviations of the studied Schiff bases. 
2. EXPERIMENTAL 
2.1 Reagents 
 
Calf thymus DNA sodium salt, hydrochloric acid standard solutions, diethyl ether, 
dimethylsulfoxide-d6 (DMSO-d6), ethanol, L-aniline, L-arginine, L-cysteine, L-histidine, L-serine, 
L-valine, methanol, 1,4-piperazinediethanesulfonic acid, potassium bromide, salicylaldehyde, 
sodium bromide, sodium chloride, sodium hydroxide pellets, sodium hydroxide standard solution, 
sodium sulfate were purchased from Sigma-Aldrich and used without any further purification.   
 
2.2 Characterization 
 
Infrared spectra were recorded using a Bruker Equinox 55 spectrophotometer, in KBr medium 
(pellets). 
1
H and 
13
C NMR spectra were recorded on Varian 400 and 500 spectrometers. Proton and 
carbon chemical shifts in DMSO-d6 were referenced to the residual solvent signals (
1
H NMR,  = 
2.60 ppm; 
13
C NMR,  = 39.6 ppm). Melting points (mp) were measured using a Kofler hot stage 
microscope and are uncorrected. 
  
2.3 Synthesis 
2.3.1 Synthesis of L-Salicylidenealanine (1) 
Compound 1 was prepared according to the literature method [21]. A mixture of L-alanine (0.8 g, 9 
mmol), salicylaldehyde (1 ml, 9 mmol) and Na2SO4 (4 g) in methanol (150 mL) was stirred under 
reflux for 12 h. The solid was filtered, the solvent was removed under reduced pressure to give 1.6 
g (90% yield) of light brown solid, mp 138-142 °C (dec).
1
H NMR (400 MHz, DMSO-d6):  8.59 (s, 
1H, CH=N), 7.46 (m, 1H, Ar-H), 7.35 (m, 1H, Ar-H), 6.90 (m, 2H, Ar-H), 4.21 (q, 1H, CH-CO2H, 
J=6.7), 1.44 (d, 3H, CH3, J=6.7). 
13
C NMR (125 MHz, DMSO-d6):  19.48, 64.79, 116.60, 117.36, 
118.69, 131.93, 132.69, 160.62, 166.61, 173.29. IR (KBr): /cm-1 3418, 3090, 2604, 1630, 1595, 
1452, 1409, 1356, 1309, 1117, 853, 542. Elemental analysis found (calc. for C10H11NO3): C% 61.80 
(62.17), H% 5.64 (5.74), N% 7.21 (7.25). 
2.3.2 Synthesis of L-Salicylidenevaline (2) 
Compound 2 was prepared according to the literature method [21]. A mixture of L-valine (1.05 g, 9 
mmol), salicylaldehyde (1 ml, 9 mmol) and Na2SO4 (4 g) in methanol (150 mL) was stirred under 
reflux for 12 h. The solid was filtered, the solvent was removed under reduced pressure to give 1.22 
g (62% yield) of light yellow solid, mp 162-164 °C. 
1
H NMR (500 MHz, DMSO-d6):  0.89 (d, 3H, 
CH3, J=4 Hz), 0.91 (d, 3H, CH3, J=4.5 Hz), 2.26 (m, 1H, CH-CH3), 3.82 (m, 1H, CH-CO2H), 6.89 
(m, 2H, Ar-H), 7.35 (t, 1H, Ar-H, J=7.6 Hz), 7.45 (d, 1H, Ar-H, J=7.6 Hz), 8.53 (s, 1H, CH=N). 
13
C 
NMR (100 MHz, DMSO-d6):  17.8, 19.3, 31.1, 75.9, 116.6, 118.6, 118.7, 132.0, 132.7, 160.8, 
167.4, 172.4. IR (KBr): /cm-1 3430, 2961, 2626, 1648, 1589, 1511, 1394, 1330, 757, 541. 
Elemental analysis found (calc. for C12H15NO3): C% 64.98 (65.14), H% 6.84 (6.83), N%6.21 
(6.33). 
2.3.3 Synthesis of L-Salicylidenecysteine (3) 
A mixture of L-cysteine (1.09 g, 9 mmol) and salicylaldehyde (1 ml, 9 mmol) in ethanol (50 mL) 
was stirred under reflux for 12h. The solid product was filtered, washed with ethanol and dried. The 
white solid obtained (1.75 g, 86% yield) resulted at the NMR analysis to be formed by two isomers 
(E and Z) of compound 3, mp 166-167 °C. 
1
H NMR (500 MHz, DMSO-d6):  (E) 2.97 (dd 
unresolved, 1H, CH2, J= 9.5 Hz), 3.34 (dd, 1H, CH2, J=7 and 9.5 Hz), 4.20 (m, 1H, CH-CO2H), 
5.65 (s, 1H, CH=N), 6.81 (t, 2H, Ar-H, J=7 Hz), 7.13 (t, 1H, Ar-H, J=7.5 Hz), 7.34 (d, 1H, Ar-H, 
J=7 Hz);  (Z) 3.03 (dd, 1H, CH2, J=5 and 10 Hz), 3.20 (dd, 1H, CH2, J=7 and 10 Hz), 3.82 (m, 1H, 
CH-CO2H), 5.85 (s, 1H, CH=N), 6.76 (m, 2H, Ar-H), 7.06 (t, 1H, Ar-H, J=7.5 Hz), 7.30 (d, 1H, Ar-
H, J=7.5 Hz). 
13
C NMR (100 MHz, DMSO-d6):  (E) 37.11 (CH2), 64.85 (CH-C=O), 65.69 
(CH=N), 115.15 (CAr-H), 118.81 (CAr-H), 127.67 (CAr-C), 126.16 (CAr-H), 128.16 (CAr-H), 155.23 
  
(CAr-OH), 172.98 (C=O);  (Z) 38.21 (CH2), 65.26 (CH-C=O), 67.73 (CH=N), 115.74 (CAr-H), 
119.10 (CAr-H), 124.30 (CAr-C), 127.94 (CAr-H), 129.09 (CAr-H),154.65 (CAr-OH),172.51 (C=O). 
IR (KBr): /cm-1 3438, 3100, 2701, 2578, 1622, 1598, 1577, 1457, 1384, 1334, 1283, 760, 679. 
Elemental analysis found (calc. for C10H11NO3S): C% 53.64 (53.32), H% 5.06 (4.92), N% 6.31 
(6.22), S% 13.87 (14.23). 
2.3.4 Synthesis of L-Salicylideneserine (4) 
A mixture of L-serine (0.95 g, 9 mmol) and salicylaldehyde (1 ml, 9 mmol) in ethanol (50 mL) was 
stirred under reflux for 2.5 h, then kept in the refrigerator overnight. The solid product was filtered, 
washed with ethanol, and dried. Product 4 was obtained as a light brown solid (1.00 g, 53% yield), 
mp 220 °C (dec). 
1
H NMR (500 MHz, DMSO-d6):  3.69 (dd, 1H, CH2, J=7.5 and 11 Hz), 3.86 (dd, 
1H, CH2, J=4 and 11 Hz), 4.09 (dd, 1H, CH-CO2H, J=4 and 7.5 Hz), 6.90 (m, 2H, Ar-H), 7.35 (t, 
1H, Ar-H, J=7.5 Hz), 7.46 (d, 1H, Ar-H, J=7.5 Hz), 8.53 (s, 1H, CH=N). 
13
C NMR (125 MHz, 
DMSO-d6):  62.7, 72.5, 116.7, 118.5, 118.7, 132.0, 132.7, 160.9, 167.6, 171.4. IR (KBr): /cm
-1 
3444, 3054, 2947, 1635, 1618, 1603, 1507, 1472, 1416, 1348, 1313, 1125, 1015, 615, 527. 
Elemental analysis found (calc. for C10H11NO4): C% 57.46 (57.41), H% 5.25 (5.30), N% 6.31 
(6.70). 
2.3.5 Synthesis of L-Salicylidenearginine (5) 
A mixture of L-arginine (1.57 g, 9 mmol) and salicylaldehyde (1 ml, 9 mmol) in ethanol (50 mL) 
was stirred under reflux for 12 h. The solid product was filtered, washed with ethanol and dried. 
Product 5 was obtained as a bright yellow solid (2.45 g, 98% yield), mp 200-202 °C. 
1
H NMR (500 
MHz, DMSO-d6):  1.58 (m, 2H, CH2CH2CH2), 1.83 (m, 1H, CHCH2), 2.01 (m, 1H, CHCH2), 3.18 
(m, 2H, CH2-NH), 3.88 (m, 1H, CH-COOH), 6.86 (m, 2H, Ar-H), 7.36 (t, 1H, Ar-H, J=8 Hz), 7.45 
(d, 1H, Ar-H, J=8 Hz), 8.52 (s, 1H, CH=N), 9.60 (s, broad, 1H, NH). 
13
C NMR (100 MHz, DMSO-
d6):  26.0, 31.6, 41.4, 71.3, 117.4, 118.2, 119.4, 133.2, 134.5, 157.5 (NH2-C=NH), 165.3, 166.8, 
174.8. IR (KBr): /cm-1 3407, 3315, 3078, 2965, 2865, 1662, 1650, 1634, 1591, 1474, 1377, 1343, 
1192, 1149, 777, 536. Elemental analysis found (calc. for C13H18N4O3): C% 56.16 (56.10), H% 6.59 
(6.52), N% 20.08 (20.13). 
2.3.6 Synthesis of L-Salicylidenehistidine (6) 
A mixture of L-histidine (0.7 g, 4.5 mmol) and salicylaldehyde (1 ml, 9 mmol) in ethanol (50 mL) 
was stirred under reflux for 24 h. The solid product was filtered, washed with ethanol and dried. 
Product 6 was obtained as a bright yellow solid (0.9 g, 77% yield), mp 174-180 °C. 
1
H NMR 
(400MHz, DMSO-d6):  3.00 (dd, 1H, CH2, J=8.4 and 14.6 Hz), 3.18 (dd, 1H, CH2, J=4.8 and 14.6 
Hz), 4.32 (dd, 1H, CH-CO2H, J=4.8 and 8.4 Hz), 6.77 (s, 1H, C=CH-N), 6.85 (m, 2H, Ar-H), 7.34 
  
(m, 2H, Ar-H), 7.59 (s, 1H, NH-CH=N), 8.32 (s, 1H, CH=N). 
13
C NMR (125 MHz, DMSO-d6):  
31.22, 70.19, 116.57, 118.59, 119.49, 129.28, 131.86, 132.63, 134.84, 136.46, 160.62, 166.93, 
172.38. IR (KBr): /cm-1 3422, 3122, 3018, 2879, 1638, 1531, 1470, 1416, 1341, 1267, 1149, 838, 
624, 535. Elemental analysis found (calc. for C13H13N3O3): C% 60.19 (60.22), H% 4.97 (5.05), N% 
16.24 (16.21). 
2.4 Potentiometric and spectrophotometric titrations 
Potentiometric titrations were performed in a thermostated vessel with a Mettler-Toledo Seven 
Compact pH/Ion-meter, equipped with a Mettler-Toledo InLab Micro Pro combined glass electrode 
with an integrated temperature probe. Potentiometric titrations were performed at 25 °C in 0.1 M 
ionic strength (NaCl) under N2 atmosphere. The glass electrode was calibrated daily by titration of a 
known amount of HCl with carbonate-free NaOH standard solution. Electrode standard potential 
(E
0
), water ionic product (pKw), electrode response and carbonate content of the titrant solution 
were checked with Gran’s procedure [22] using the Glee software [23]. The UV-visible (UV–vis) 
measurements were carried out with a Varian Cary 60 spectrometer equipped with an optical fiber 
dip probe with a 1 cm optical path length. 
2.5 Protonation constants 
Protonation constants of compounds 1-6 were determined by spectrophotometric and potentiometric 
titrations, at 25 °C in 0.1 M ionic strength (NaCl), following the spectral variations due to the 
additions of the titrant. Solutions of ligand were prepared daily by dissolving the proper amount of 
the compound in freshly distilled water. Concentrations of compounds 1-6 ranged from 2.8 x 10
-4
 M 
to 1.0 x 10
-3
 M, according to their absorptivity and solubility. Solutions containing a known amount 
of compound and HCl (necessary to fully protonate the molecule) were titrated with NaOH standard 
solution. The reversibility of the involved equilibria was checked by back-titration with standard 
HCl. The overall stability constants were determined with the Hyperquad 2003 software [24]. 
2.6 DNA binding 
The binding constants (Kb) between ct-DNA and compounds 1-6 were determined at 25 °C by 
spectrophotometric titrations in PIPES buffer 0.01 M at pH 7.0. A stock solution of ct-DNA in 0.01 
M PIPES buffer at pH 7.0 was prepared and stored at 4 °C. This solution was used within four days. 
The concentration of DNA per nucleotide was determined by UV absorption at 260 nm using its 
molar absorption coefficient (6600 M
-1
cm
-1
) [25]. The purity of the DNA was checked by 
monitoring the ratio of the absorbance at 260 nm to that at 280 nm. A ratio higher than 1.8 indicates 
a DNA sufficiently protein-free [26]. Twenty solutions containing a fixed amount of the compounds 
(ranging from ≈ 2.03 x 10-4 to ≈ 6.07 x 10-4 mmol, according to the absorptivity) and variable 
  
amounts of DNA (ranging from 6.09 x 10
-4
 to 1.82 x 10
-3 
mmol) were prepared. The stock solution 
of 3 was prepared at least 39 h before the experiment due to its slow hydrolysis in PIPES. Since the 
interactions between DNA and compounds 1-6 are slow processes, spectra in the 200–500 nm range 
were recorded when equilibration was reached (15 h). All the solutions were stored meanwhile in 
the dark at room temperature. The DNA binding constants were obtained by using the Hyperquad 
2003 software [24]. 
2.7 Cell lines 
 
Cell lines were purchased from the American Type Culture Collection (ATCC) and were derived 
from: lung squamous carcinoma (SK-MES-1); prostate carcinoma (DU-145); hepatocellular 
carcinoma (Hep-G2); acute T-lymphoblastic leukaemia (CCRF-CEM); acute B-lymphoblastic 
leukaemia (CCRF-SB). All cell lines were grown at 37 °C in a 5% CO2 atmosphere, in their specific 
media according to ATCC instructions, in presence of 5–10% foetal bovine serum (FBS), antibiotic 
and, unless otherwise indicated, sodium pyruvate. All cell cultures were maintained in exponential 
growth by periodically splitting high density suspension cultures (i.e. 10
6
 cell/mL) or when cell 
monolayers reached sub-confluence. The absence of mycoplasma contamination was checked 
periodically by the Hoechst staining method [27]. 
2.8 Cytotoxic assays 
The cytotoxic effect of the compounds 1-6 was evaluated in cell lines during exponential growth 
stage. Stock solutions of compounds were stored at 4 °C in the dark. For the evaluation of 
cytotoxicity, solutions of compounds 1-6 were serially diluted in growth medium specific for the 
different cell lines. Suspension cell lines were seeded in 96-well plates at an initial density of 1 x 
10
5
 cells/mL in specific growth medium, with or without serial dilutions of each compound. 
Adherent cell lines were seeded at an initial density of 1 x 10
4
 cells per well and incubated 
overnight before adding serial dilutions of the test compound. Cell viability was determined after 96 
h at 37 °C, 5% CO2, by the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-tetrazolium bromide (MTT) 
method as previously described [28]. Cell growth at each drug concentration was expressed as the 
percentage of untreated controls. The results were expressed as IC50, i.e. the concentration of 
compound required to reduce the viability of the tested cells by 50%. 
 
  
3. RESULTS AND DISCUSSION 
3.1. Synthesis 
Literature reports many different synthetic methods to prepare amino acid-derived Schiff bases [29–
32]. The classic method to synthetize Schiff bases consists of simple mixing equimolar amounts of 
amine and aldehyde in ethanol, and refluxing the mixture for some hour: the readily formed product 
can be filtered and isolated. When the amine role is played by an α-amino acid, the synthetic 
procedure may not be so straightforward: the amino acid zwitterionic character is responsible for a 
weaker nucleophilic amino-group. Several modifications of the classic method are then reported. 
For example, potassium [33] or sodium hydroxide [34] is added to an aqueous or methanolic 
solution of the amino acid to enhance its nucleophilic character. An analogous effect is obtained 
with a bicarbonate buffer [30]. On the other hand, the effect of the added base is also to promote the 
aldehyde self-reaction, leading to lower yield of the desired Schiff base. We found that the simple 
mixing-reflux method works well only for cysteine and arginine derivatives. To obtain a 
satisfactory yield for the other four amino acid based compounds, the classic method has been 
modified as follows: i) for histidine derivative, a double amount of aldehyde was used; ii) for 
alanine and valine derivatives, anhydrous sodium sulfate was added to the reaction mixture (as also 
reported by Hsieh [21]) to obtain the two Schiff-bases in satisfactory yield; iii) for serine derivative, 
an equimolar mixture of amino acid and aldehyde was refluxed in ethanol for 2 h and the resulting 
solution was kept in the refrigerator overnight. It is noteworthy the high reactivity of cysteine in the 
reported condition: in fact, after only an hour at the reflux temperature a thick white precipitate was 
formed. The NMR analysis revealed it was constituted by the two geometric isomers E and Z. The 
E isomer, which was found as the most abundant, was identified due to the correspondence of the 
CH=N chemical shift value with those reported [35]. All attempts to prepare only one isomer, as 
lowering the reaction temperature or increasing the solvent amount, were unsuccessful. 
 
3.2 Protonation constants 
The protonation constants of the studied Schiff bases were determined by a basic titration, 
measuring simultaneously the electrochemical potential and the UV-vis absorption. The absorbance 
values measured during the potentiometric titrations of the six Schiff bases are reported as a 
function of wavelength and pH, in Figure 2. The functional groups involved in the protonation and 
the protonation sequence were determined by comparing the pure UV-vis spectra of the formed 
species and ATR-IR spectra at variable pH of the studied compounds. No reliable NMR spectra in 
water solution were obtained due to the low water solubility of the compounds (<1 mM). 
  
 
Figure 2. Absorbance as a function of wavelength and pH measured during the titrations of 0.0240 
mmol of 1 (A), 0.0178 mmol of 2 (B), 0.0141 mmol of 3 (C), 0.00058 mmol of 4 (D), 0.00401 
mmol of 5 (E) and 0.00061 mmol of 6 (F); 25 °C, 0.1 M NaCl ionic buffer, 1 cm optic path length. 
 
3.2.1 Spectral evidences 
Compound 1 
During the titration of compound 1 with NaOH, three equilibria are spectrally evidenced in the 
pH range 2-11.4 (Figure 3A). At pH 2, two peaks and a shoulder are present at 325, 257 and ≈ 280 
nm, respectively. Increasing the pH, the absorbance of the peaks slightly decreases, not for the 
dilution as it can be seen in the inset of the Figure 3B, where the absorbance at 325 nm is corrected 
for the dilution. The observed spectral variation is caused by the deprotonation of the H3L
+
 species 
to form the H2L one. These two species appear spectrally not well distinguishable. Increasing the 
pH value to 8.8, the intensity of the peaks at 325 and 257 nm decreases, while two new peaks 
appear at 378 nm and 266 nm due to the formation of the HL
-
 species (Figure 3C). Four isosbestic 
points are present at 340, 300, 265 and 247 nm. At pH higher than 8.8, the intensity of the peak at 
  
378 raises while that of the peak at 265 diminishes, and a shoulder is observed at ≈ 300 nm because 
of the formation of the L
2-
 species (Figure 3D). Two isosbestic point are present at 283 and 259 nm.  
 
 
Figure 3. Selected spectra recorded during the potentiometric titration of 1 (9.01  10-4 M, 25 °C, 
0.1 M NaCl, 1 cm optical path length) from pH 2.0 to 11.4 (A), from pH 2.0 to 4.5 (B), from pH 4.5 
to 8.8 (C) and from pH 8.9 to 11.4 (D). 
 
Compound 2 
The analysis of the spectra recorded during the titration of 2 gives evidence of three equilibria 
(Figure 4A). At acidic pH two peaks are present at 252 and 325 nm. Increasing the pH till 8, the 
intensity of these two peaks decreases, while two new peaks appear at 264 and 378 nm (Figure 4B). 
Four isosbestic points are present at 342, 292, 265 and 245 nm. After pH 8, the maximum of 
intensity shifts at 380 nm and three isosbestic points are present at 342, 292 and 265 nm (Figure 
4C). After pH 9, the peaks shifts at 374 nm with larger width, a poor resolved isosbestic point is 
present at 332 nm (Figure 4D).  
 
  
 
Figure 4. Selected spectra recorded during the potentiometric titration of 2 (9.32  10-4 M, 25 °C, 
0.1 M NaCl, 1 cm optical path length) from pH 2.6 to 10.9 (A), from pH 2.6 to 8.0 (B), from pH 8.0 
to 9.5 (C) and from pH 9.5 to 10.9 (D).  
 
Compound 3 
The analysis of the spectra recorded during the titration of 3, gives evidence of four equilibria 
(Figure 5A). At pH 2.7 two bands at 324 and ≈ 260 nm and a shoulder at 280 nm are present. 
Increasing the pH, the intensity of the band centered at 324 nm rises while that of the shoulder at 
280 nm decreases (Figure 5B). An isosbestic point is present at 290 nm. At pH values higher than 
5.9, a new band forms at 378 nm, while the intensity of the band at 324 nm decreases (Figure 5C). 
An isosbestic point is present at 339 nm. At pH higher than 8, the band at 378 nm grows with a 
different shape while the shoulder at ≈ 300 nm decreases. An isosbestic point is present at 326 nm 
(Figure 5D). At pH > 9.5, the width of the band centered at 378 nm continues to increase.  
 
  
 
Figure 5. Some spectra recorded during the potentiometric titration of 3 (7.07  10-4 M, 25 °C, 0.1 
M NaCl, 1 cm optical path length) from pH 2.7 to 11 (A), from pH 2.7 to 5.7 (B), from pH 5.9 to 
8.5 (C) and from pH 8.9 to 11.0 (D). 
 
Compound 4 
As for 3, during the titration of 4, four protonation equilibria are evidenced by spectral variations 
(Figure 6A).  At acidic pH, two peaks at 256 and 325 nm are present, which absorbance rises till pH 
6.1 (Figure 6B).  At pH > 6.1, the intensity of these two peaks decreases while two new peaks are 
formed at 263 and 377 nm (Figure 6C). Three isosbestic points are present at 264, 289 and 340 nm. 
At pH > 9, the peak at 377 nm increases in intensity but with different shape, while that at 265 nm 
does not vary significantly (Figure 6D). Two isosbestic points are present at 336 and 264 nm.  
 
  
 
Figure 6. Some spectra recorded during the potentiometric titration of 4 (2.9  10-4 M, 25 °C, 0.1 M 
NaCl, 1 cm optical path length)  from pH 2.3 to 11.1 (A), from pH 2.3 to 6.1 (B), from pH 6.3 to 9.0 
(C) and from pH 9.1 to 11.1 (D). 
 
Compound 5 
The analysis of the spectra recorded during the titration of 5, gives evidence of four equilibria 
(Figure 7A). At pH 3, two absorption peaks, at 255 and 325 nm, are present. Increasing the pH till 
3.3, the intensity of these peaks increases slightly (Figure 7B). At pH > 3.3, the intensity of the 
peaks at 255 and 325 nm decreases while two peaks at 265 and 377 nm appear (Figure 7C). Four 
isosbestic points are present at 244, 264, 290 and 340 nm. At pH > 8, the intensity of the peak at 
265 nm increases while that of the peak at 377 nm decreases (Figure 7D). An isosbestic point is 
present at 344 nm. At pH values higher than 9, the width of the peak centred at 377 nm continues to 
increase.  
 
  
 
Figure 7. Some spectra recorded during the potentiometric titration of 5 (2.01  10-4 M, 25 °C, 0.1 
M NaCl, 1 cm optical path length) from pH 2.9 to 11.0 (A), from pH 2.9 to 3.3 (B), from pH 4.5 to 
7.8 (C) and from pH 7.9 to 11.0 (D). 
 
Compound 6 
During the titration of 6, three protonation equilibria are evidenced by the spectral variations 
(Figure 8A). At acidic pH, two peaks are present at 256 and 325 nm. Increasing the pH to the value 
of 6.1, the intensity of both the peaks decreases while a shoulder is form at ≈ 280 nm (Figure 8B). 
Two isosbestic points are present at 270 and 291 nm. At pH > 6.1 two peaks at 265 and 377 nm are 
formed (Figure 8C). Four isosbestic points are present at 244, 265, 289 and 341 nm. At pH > 9.4, 
the peaks at 265 and 377 nm decrease in intensity, while a little band appear at ≈ 300 nm (Figure 
8D). Two isosbestic points are present at 286 and 309 nm. 
 
  
 
Figure 8. Some spectra recorded during the potentiometric titration of 6 (2.78  10-4 M, 25 °C, 0.1 
M NaCl, 1 cm optical path length) from pH 2.0 to 11.4 (A), from pH 2.0 to 6.1 (B), from pH 6.4 to 
9.3 (C) and from pH 9.4 to 11.4 (D). 
 
3.2.2 Calculation of the protonation constants 
From the eigenvalue analysis of the spectrophotometric data, the significant eigenvalues, 
interpreted as the number of linearly independent absorbing species, were found.
[1]
 The 
concentration profile as a function of pH, and the pure UV-vis spectra of all the absorbing species 
were then calculated without model assumptions. The results are shown in Figures 9-10 for all the 
studied compounds.  
Three significant eigenvalues were found for 1, four for 2, 4 and 6, and five for 3 and 5. Four 
eigenvalues were expected for 1 and 2 and five for the other compounds. Any attempt to fit the 
experimental data taking into account four eigenvalues for 1 or five for 4 and 6 led to negative 
calculated pure spectra. These results show that H3L
+
 and H2L species for 1, and H4L
+
 and H3L 
species for 4 and 6 were not spectrally distinguishable. The potentiometric and spectrophotometric 
data were fitted simultaneously supposing a model considering three protonation equilibria (from 
L
2-
 to H3L
+
) for 1 and 2, and four protonation equilibria (from L
3-
 to H4L
+
) for 3, 4, 5, and 6. The 
protonation constants and the refined pure spectra were calculated. The protonation constants are 
  
reported in Table 1. The pK values related to the formation of the H3L
+
, H4L
+
, and H4L
2+ 
species for 
1, 4 and 6, respectively, are outside the experimental pH range. 
 
 
Figure 9. Model free concentration profile calculated with eigenvalues analysis of the 
spectrophotometric data collected during the potentiometric titration of 1-6 (1 9.01  10-4 M, 2 9.32 
 10-4 M, 3 7.07  10-4 M, 4 2.9  10-4 M, 5 2.01  10-4 M, 6 2.78  10-4 M) at 25 °C, 0.1 M NaCl, 1 
cm optical path length. 
  
 
Figure 10. Pure spectra calculated with eigenvalues analysis of the spectrophotometric data 
collected during the potentiometric titration of  1-6 (1 9.01  10-4 M, 2 9.32  10-4 M, 3 7.07  10-4 
M, 4 2.9  10-4 M, 5 2.01  10-4 M, 6 2.78  10-4 M) at 25 °C, 0.1 M NaCl, 1 cm optical path length. 
Overall Stability Constants 
Compound Species Log β pK 
1 
HL
-
 10.2(1) 10.2 
H2L 18.30(5) 8.1 
H3L
+
 19.8(2) < 2 
  
2 
HL
-
 9.40(2) 9.4 
H2L 18.2(1) 8.8 
H3L
+
 21.5(1) 3.3 
3 
HL
2-
 10.14(1) 10.14 
H2L
-
 18.72(1) 8.58 
H3L 26.72(1) 8.00 
H4L
+
 29.80(4) 3.08 
4 
HL
2-
 11.0(5) 11.0 
H2L
-
 20.3(1) 9.3 
H3L 27.8(1) 7.5 
H4L
+
 28.5(5) < 2 
5 
HL
-
 9.81(3) 9.81 
H2L 18.52(3) 8.71 
H3L
+
 26.09(4) 7.57 
H4L
2+
 28.2(4) ≈ 2 
6 
HL
-
 10.7(2) 10.7 
H2L 20.15(2) 9.45 
H3L
+
 27.33(2) 7.18 
H4L
2+
 29.3(3) < 2 
Table 1. Protonation constants of the compounds 1-6 at 25 °C and 0.1 M NaCl ionic strength. 
 
3.2.1 Protonation sequence 
The assignment of the protonation sequence is straightforward for compounds 1 and 2. In fact, the 
first pK is related to the protonation of the oxygen atom of the ring, the second one to the iminic 
nitrogen, and the third one to the carboxylate group. Protonation sequence for compounds 1 and 2 is 
reported in Scheme 1.  
To define the order in which the functional groups of 3 are protonated, the absorptivity spectra of 
the different species of 3 were compared with those of 1. The spectra of the HL species (charges are 
omitted for simplicity) of 1 and 3 are similar for position and absorptivity ratio of the bands. This 
suggests that the same group is protonated in both the species, i.e. the oxygen atom on the aromatic 
ring. The spectrum of the H2L species of 3 is different from that of the H2L species of 1, where the 
iminic group is protonated, and is similar to that of the HL species of 1, where the iminic group is 
still not protonated. Then the second protonation in 3 involves the sulphur atom. Being the spectra 
of the H3L species of 3 and that of the H2L species of 1 similar, it can be deduced that the third 
  
protonation in 3 involves the nitrogen atom. Finally, the fourth protonation occurs on the 
carboxylate group of 3 (see Scheme 2).  
 
 
Scheme 1. Protonation sequence for compound 1 and 2. 
 
 
Scheme 2. Protonation sequence for compound 3.  
 
For the compound 4, by comparison of the pure spectra of all the species formed by the studied 
compounds, it follows that the protonations occurs in the order: the oxygen of the side chain, the 
oxygen of the ring, the iminic group, and the carboxylate group (Scheme 3).  
For compound 5, considering the absorptivity spectra of the formed species and the pK 12.48 of the 
–NH2 group in the arginine side chain
[2]
, the first protonation appears to involve the –NH2 group. 
The second protonation involves the oxygen atom of the aromatic ring, the third one the –C=N 
group and the last one the carboxylate group (Scheme 4).  
Regarding compound 6, comparing the spectra of the absorbing species of all the studied 
compounds, and taking into account the protonation constants of histidine
[3]
, the protonations occur 
in the order: the oxygen of the ring, the nitrogen atom of the histidine residue, the iminic group and 
finally the carboxylate group (Scheme 5). 
 
  
 
Scheme 3. Protonation sequence for compound 4. 
 
 
Scheme 4. Protonation sequence for compound 5. 
 
 
Scheme 5. Protonation sequence for compound 6. 
 
  
All the proposed protonation sequences have been confirmed by the ATR-IR spectra at variable 
pH of the studied compounds. For each sample, the transition from the aqueous phase to the solid 
film was followed. In Figure 11, ATR-IR spectra of 2 recorded at a different time period are 
reported as example.  
The spectra show changes due to water evaporation and once the solid film is formed, sharp and 
distinguishable vibration bands are visible. During the evaporation, the shape of the vibration bands 
changes, but the peak positions remain constant.
[4]
 This means that the same species in aqueous 
phase are found in the solid film.  
All the attributions of the peaks were based on quantomechanical calculations. In Figures 12-13, 
the spectra of the compounds 1 and 3 and relative attribution are reported as example.   
 
 
Figure 11. ATR-IR spectra of 2. Each spectrum was collected at a different time period after 
depositing the solution on the ATR crystal, showing changes due to water evaporation. 
Concentration of the compounds 2 was 1.108  10-3 M, according to its solubility. 
  
 
Figure 12. ATR-IR spectra of 1 at different pH ranging from pH 1 to 11. Concentration of the 
compounds 1 in each sample was 5.072  10-4 M, according to its solubility. 
 
  
 
Figure 13. ATR-IR spectra of 3 at different pH ranging from pH 1 to 11. Concentration of the 
compounds 3 in each sample was 1.021  10-3 M, according to its solubility. 
 
  
3.3. DNA-binding study  
The ability of the compounds 1-6 to bind DNA has been studied by UV-vis titration with ct-
DNA. The interaction of a molecule with DNA is known to result in a modification of its UV-vis 
spectrum. The type of changes (red or blue shift, and hyper- or hypochromism) gives information 
on the binding mode.
[5]
 All the studied compounds show, in the chosen experimental conditions, a 
peak at ≈ 325 nm. After each addition of DNA, the band decreases in intensity for compounds 2-6 
whereas for the compound 1 only slight variations of the absorbance are present. No significant 
shift of the maximum is observed. The formation of another small band around 400 nm is also 
observed for all the compounds. Selected spectra collected during the titrations with ct-DNA are 
reported in Figure 14 for all the compounds. The spectral evidences suggest that compounds 2-6 
slightly interact with DNA thorough intercalation between base pairs. 
The equilibrium reaction involved in DNA binding is described by the equation (L + D ↔ LD), 
where L is a generic molecule interacting with DNA, D is the DNA and LD is the formed adduct. 
The DNA binding constants, defined as Kb=[LD]/[L][D], have been calculated by fitting the 
experimental absorbance data supposing the formation of the 1:1 compound-DNA adduct, 
according to 
[6]
. The Kb values range from 48 to 447 (Table 2), and vary along the series 6 > 3 > 5 > 
4 > 2 > 1.  
The affinity with the DNA appears related to the substituents present in the side chain. In fact, 
the lowest values (48 and 69 M
-1
) are observed for 1 and 2, that have a methyl and a iso-propyl as 
substituents. The presence in the side-chain of the imidazole or of the thiolic group increases the Kb 
by ≈ 10 and ≈ 5 times, respectively, with respect to the compound 1. Our Kb values are lower to 
those reported in literature for similar Schiff bases.
[7],[8]
 The difference is probably due to the 
presence of other substituents that can participate to the DNA interaction. The experimental 
evidences show that the amino acid moiety present in our compounds contributes, but not heavily, 
to the DNA binding. 
 
  
 
Figure 14. Selected UV-vis spectra collected during the titration of 1-6 with ct-DNA (5.02  10-4 
mmol of 1 with DNA 3.44  10-3 M; 4.88  10-4 mmol of 2 with DNA 3.10  10-3 M; 2.10  10-4 
mmol of 3 with DNA 1.24  10-3 M; 6.07  10-4 mmol of 4 with DNA 3.32  10-3 M; 2.03  10-4 
mmol of 5 with DNA 2.07  10-3 M; 3.03  10-4 mmol of 6 with DNA 1.95  10-3 M) in PIPES 
buffer 0.01 M at pH 7.0, 1 cm optical path length, 25 °C. The arrows show the change in 
absorbance due to the DNA addition. 
 
 
 
  
Compound Kb (M
-1
) 
1 48 
2 69 
3 229 
4 110 
5 148 
6 447 
Table 2. DNA-binding constants of the studied Schiff bases. 
 
3.3 Cytotoxicity 
An evaluation of the cytotoxic activity of the synthetized compounds has been carried out in 
order to study the influence of the introduction of the phenolic ring on the cytotoxicity of the amino 
acids. In fact, phenolic compounds are known to be toxic due to ROS formation.
[9]
 The 
antiproliferative activities of the six studied compounds have been tested against three human solid 
tumour cell lines (SK-MES-1, DU-145, and Hep-G2), and two human haematological tumour cell 
lines (CCRF-CEM, and CCRF-SB). All the studied compounds show IC50 values higher than 100 
µM against all the tested tumour cell lines, and are then devoid of a significant cytotoxic activity. 
 
4. Conclusions 
The compounds L-Salicylidenealanine, L-Salicylidenevaline, L-Salicylidenecysteine, 
L-Salicylideneserine, L-Salicylidenearginine, and L-Salicylidenehistidine have been synthesized 
through optimization of previously reported methods: reduced reaction time (for L-
Salicylidenecysteine and L-Salicylideneserine), doubled amount of salicyladehyde (for L-
Salicylidenehistidine) and sodium sulphate addition (for L-Salicylidenealanine and L-
Salicylidenevaline) were needed for the synthesis of the compounds according to the different 
reactivity of amino acids. The synthesized Schiff bases were characterized by means of elemental 
analysis, NMR and IR spectroscopy. The protonation and DNA-binding constants and the cytotoxic 
activity have been determined. The protonation of the carboxylate group occurs at around pH 3 for 
compounds L-Salicylidenevaline and L-Salicylidenecysteine whereas for all the other compounds 
around 2 or lower. The protonation of the iminic group occurs between pH 7.2 and 8.8, while that of 
the oxygen of the phenolic group between pH 8.7 and 10.7. The protonation of the amino acid side 
chain occurs before the protonation of the phenolic oxygen only for compounds L-
Salicylideneserine and L-Salicylidenearginine. Afterwards, in all the compounds the iminic group is 
protonated after the carboxylic group. The studied compounds do not show cytotoxic activity, 
  
however they are able to interact with DNA, showing DNA binding constant in the 48–447 M-1 
range. The absence of cytotoxicity and the poor reactivity with DNA, confirm the feasibility of 
these compounds for pharmaceutical applications, also in complexes with metal ions to exploit their 
unique properties. In fact, although the ligands are devoid of significant activity, it is not untypical 
that the derived complexes show antitumor activity. 
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Conclusions  
In this work my attention was focused on the study of copper, zinc and vanadium complexes 
with biological activity and on the application of experimental design and artificial neural networks 
to the collected biochemical data. Moreover, I used the artificial neural networks to evaluate the cell 
culture cross-contamination. 
A new family of copper(II) complexes with phen, phendione, and phendiol was prepared and 
studied towards the HEP-G2, SK-MES-1, CCRF-CEM, and CCRF-SB human tumour cell lines. 
This family presents an antiproliferative effect higher than that of cisplatin. In particular, 
[Cu(phen)2(OH2)](ClO4)2 and [Cu(phendione)2(OH2)(OClO3)](ClO4) are promising for the 
treatment of SK-MES-1 and HEP-G2 cell lines, respectively. These two compounds, in fact, show 
an IC50 value 37 and 18 times lower than that of cisplatin. 
The cytotoxic activity of the ligands was found to be correlated to the cellular microenvironment. 
Compound phendiol, the less lipophilic compound, appears as the most active ligand on cells 
surrounded by a hydrophilic environment, while phendione, the most lipophilic, is more effective 
against cells in a lipophilic environment. 
The studied copper(II) complexes interact with DNA mainly by groove binding or electrostatic 
interactions. The DNA binding constants resulted directly correlated with the IC50 values and then 
inversely correlated with the antitumour activity, in fact, the complexes with the highest DNA 
affinity show the lowest cytotoxicity. This behavior can be explained assuming that the copper 
complexes exhibit their antiproliferative activity with mechanisms different from the DNA binding.  
Binary combinations of cisplatin and the copper complex [Cu(phen)2(OH2)](ClO4)2 were tested 
and resulted to present a synergistic antiproliferative effect against the cisplatin-resistant sublines of 
leukemic (CCRF-CEM) and ovarian (A2780) cancer cells in vitro. A mixed complex containing 
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copper and platinum with a stoichiometry of [Cu(phen)(OH)μ-(Cl)2Pt(NH3)(H2O)]
+
 was detected, 
and, considering that this complex is able to hydrolyze to form [Cu(phen)(OH)µ-(Cl)2Pt(H2O)2]
+
 
species, this complex could be responsible of the synergistic effect shown by the studied mixtures 
and it is likely to interfere with one or more of the mechanisms that lead to cisplatin resistance. 
Given that the determining step in the interaction of cisplatin with DNA are the slow hydrolysis 
processes and considering that the hydrolyzed complexes [Cu(phen)(OH)µ-(Cl)2Pt(NH3)(H2O)]
+
 
and [Cu(phen)(OH)µ-(Cl)2Pt(H2O)2]
+
 are formed within a few minutes, this mixed copper-platinum 
complex is supposed to be able to react with DNA more readily than cisplatin. 
I tested the cytotoxicity activity of binary mixtures of GSH with [Cu(phen)2(OH2)](ClO4)2 or 
cisplatin and ternary mixtures of GSH with [Cu(phen)2(OH2)](ClO4)2 and cisplatin against the wild 
type CCRF-CEM cancer cell line and its cisplatin-resistant subline, finding a synergistic effect 
between [Cu(phen)2(OH2)](ClO4)2 and cisplatin or GSH, and an antagonistic effect between 
cisplatin and GSH. In particular, in the ternary systems, in absence of [Cu(phen)2(OH2)](ClO4)2 
there is antagonism between cisplatin and GSH, while at increasing concentrations of 
[Cu(phen)2(OH2)](ClO4)2 the antagonism between cisplatin and GSH disappears. The ternary 
combination shows a selective cytotoxic effect for T-leukemia CEM cells with respect to 
proliferating normal T-cells.  
Cisplatin reacts with GSH to form the complex [Pt(NH3)2Cl2(GSH+H)]
+
, but with GSSG it 
forms the adduct [Pt(NH3)2Cl2+GSSG+H]
+
. Even in excess of thionic ligands, only a 1:1 
cisplatin:ligand adduct was detected in the chosen experimental conditions. The copper complexes 
[Cu(phen)2(H2O)](ClO4)2 and [Cu(phen)(H2O)2(ClO4)2] react with GSH or GSSG to form 
complexes such as [Cu(phen)(GSH)-H]
+
 and [Cu(phen)(GSSG)(ClO4)]
+
. The copper complexes 
form with cisplatin mixed complexes where the two metal centers are linked by two bridging 
chloride. When the copper complexes were mixed with cisplatin and the thionic ligands, only 
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copper-glutathione complexes were detected. No platinum-glutathione adducts or copper-platinum 
complexes were found. Given that the antiproliferative activity of cisplatin in presence of 
[Cu(phen)2(OH2)](ClO4)2 against cisplatin-resistant cells was restored, [Cu(phen)2(OH2)](ClO4)2 
can be supposed to bind glutathione preventing in this way the deactivation of cispaltin as 
anticancer agent.  
Regarding the study of the phospholipid profile of wild type and cisplatin-resistant cells of 
CCRF-CEM and A2780, some phospholipids were identified to be specific components, and can be 
considered as “markers” to distinguish between wild type and cisplatin-resistant cells. Considering 
that the PL composition influences the transport of drugs across the membrane, affects the activity 
of the drug transporters and the ability of the cells to load and accumulate drugs, it is evident that a 
change of the PL content is connected with the development of the resistance. However, from the 
obtained results, it is not possible to define if these changes are the cause or the consequence of the 
cisplatin-resistance occurrence. Nevertheless, the potential use of some lipids as “markers” for 
resistant cells could be important for a possible clinical application. In fact, the onset of the 
resistance during cisplatin treatment could be monitored by detecting those specific lipids.  
A step-by-step protocol for successful quantitation of two distinct cell types in a single two-
component mixture by a multivariate calibration approach based on an ANN-coupled IC MALDI-
TOF MS analysis has been developed and tested.  
Solution studies on the reaction of the drug methimazole with [Zn(MeIm)4](ClO4)2, selected as a 
model compound representing [Zn(His)4]
2+
 and [Zn(His)3(H2O)]
2+
 protein sites, show that 
methimazole displaces only one of the coordinated MeIm molecules. This evidence supports the 
possibility that methimazole, by blocking a histidine/water binding site, could interfere with the 
multifunctional roles of zinc atoms in proteins (e.g. the enzymatic activity of carbonic anhydrases). 
The anion methimazole can effectively act as a (N,S)-bridging/chelating ligand to a variety of metal 
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ions due to its N–C–S functional group. Moreover, Zn-coordinated methimazole can markedly 
modify the coordination environment when changing from its thione to thionate form, and vice 
versa.  
The vanadocene dichloride, [Cp2VCl2], transforms at physiological pH to [Cp2V(OH)2] and only 
the bio-ligands oxalate, carbonate, hydrogen phosphate, and lactate are able to displace the two 
oxydrilic ions to yield [Cp2V(ox)], [Cp2V(CO3)], [Cp2V(lactH−1)], and [Cp2V(HPO4)]. The complex 
[Cp2VCl2] does not interact with the plasma proteins transferrin and albumin under my 
experimental conditions.  
The  Schiff bases ligands L-Salicylidenealanine, L-Salicylidenevaline, L-Salicylidenecysteine, 
L-Salicylideneserine, L-Salicylidenearginine, and L-Salicylidenehistidine, do not show 
cytotoxic activity towards SK-MES-1, DU-145, Hep-G2, CCRF-CEM and CCRF-SB human 
tumour cell lines, however they are able to interact with DNA, showing DNA binding constant in 
the 48–447 M-1 range. The absence of cytotoxicity and the poor reactivity with DNA, confirm the 
feasibility of these compounds for pharmaceutical applications, also in complexes with metal ions 
to exploit their unique properties. In fact, although the ligands are devoid of significant activity, it is 
not untypical that the derived complexes show antitumor activity.
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Perspectives 
On the basis of the obtained results, it would be interesting to continue the study of copper 
complexes and to test in vivo the most effective combinations of drugs.  
Given the importance to monitor the onset of the resistance during cisplatin treatment, the 
extension of the study of the phospholipid markers to other cell lines, could be important for a 
possible clinical application.   
In order to complete the study on the Schiff base ligands, it would be necessary to synthesize 
complexes with different metal ions. 
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